MX2008013191A

MX2008013191A - Lysobactin amides.

Info

Publication number: MX2008013191A
Application number: MX2008013191A
Authority: MX
Inventors: Franz Von Nussbaum; Nina Brunner; Rainer Endermann; Jacques Ragot; Guido Schiffer; Joachim Schuhmacher; Joachim Telser; Sonja Anlauf; Yolanda Cancho-Grande; Hans-Christian Militzer; Johannes Koebberling; Hartmut Beck; Susanne Greschat
Original assignee: Aicuris Gmbh & Co Kg
Priority date: 2006-04-13
Filing date: 2007-04-13
Publication date: 2009-01-12
Also published as: JP2009533371A; AU2007237431A1; KR20080110902A; BRPI0709507A2; DE102006018080A1; US8076285B2; ZA200809686B; WO2007118691A1; IL194353A0; CN101466729A; RU2008144660A; US20090203582A1; UA95630C2; CA2648164A1; ATE524488T1; EP2007794B1; RU2441021C2; EP2007794A1

Abstract

The invention relates to lysobactin amides, methods for the production thereof, and the use thereof for producing medicaments utilized for treating and/or preventing diseases, particularly bacterial infectious diseases.

Description

LISOBACTINA AMIDAS FIELD OF THE INVENTION The invention relates to lisobactin amides and methods for their preparation, as well as their use in the preparation of medicaments for the treatment and / or prophylaxis of diseases, in particular bacterial infectious diseases.

BACKGROUND OF THE INVENTION The bacterial cell wall is synthesized by a number of enzymes (biosynthesis of the cell wall) and is essential for the survival and reproduction of microorganisms. The structure of this macromolecule, as well as the proteins related to the synthesis thereof, is highly conserved among bacteria. Due to its essential nature and uniformity, the biosynthesis of the cell wall constitutes an ideal point of attack for new antibiotics (DW Green, Expert Opin. Ther. Targets, 2002, 6, 1 -19). Vancomycin and penicillins are inhibitors of bacterial cell wall biosynthesis and represent successful examples of the antibiotic potency of this principle of action. They have been used clinically for several decades for the treatment of bacterial infections, especially with Gram-positive pathogens. Due to the increasing appearance of resistant microbes, for example methicillin-resistant staphylococci, penicillin-resistant pneumococci and vancomycin-resistant enterococci (F. Baquero, Gram-positive resistance: challenge for the development of new antibiotics, J. Antimicrob. Chemother., 1997, 39, Supl A: 1-6, AP Johnson, DM Livermore, GS Tillotson, Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated ?, J. Hosp. Infect, 2001, (49), Supl A: 3-11) and recently also for the first time vancomycin-resistant staphylococci (B. Goldrick, First reported case of VRSA in the United States, Am. J. Nurs., 2002, 102, 17) these substances are increasingly losing their therapeutic efficacy. The present invention describes a new class of inhibitors of wall biosynthesis Cell without cross-resistance with known classes of antibiotics. It has been described that the natural product lysobactin and some derivatives have antibacterial activity in US 4,754,018. The isolation and antibacterial activity of lysobactin are also described in EP-A-196 042 and JP 01132600. WO04 / 099239 discloses lisobactin derivatives having antibacterial activity. The antibacterial effect of lysobactin and katanosin A is further described in O'Sullivan, J. ef al., J. Antibiot. 1988, 41, 1740-1744, Bonner, D. P. ef al., J. Antibiot. 1988, 41, 1745-1751, Shoji, J. et al., J. Antibiot. 1988, 41, 713-718 and Tymiak, A. A. er a /., J. Org. Chem. 1989, 54, 1149-1 157.

The stability of an active ingredient constitutes an important parameter due to its convenience as a medicine. Stability is important, among others, in the storage and administration of medications. Many natural products show a stability that is insufficient for medicines. The deisopeptide lysobactin having antibacterial activity is hydrolyzed in a neutral to basic aqueous medium (pH > 7) over a period of days. The result of this is an "open lysobactin" that is opened by the lactone and has no antibacterial activity. It is therefore desirable to obtain active analogs of lysobactin with greater stability in the ring. An object of the present invention comprises providing alternative compounds of lysobactin having a comparable or improved antibacterial effect, greater tolerability, for example lower nephrotoxicity, and greater stability in a neutral to basic aqueous medium for the treatment of diseases by bacteria in humans and animals. It has surprisingly been found in the context of this invention that lysobactin amides (nonapeptide cyclic amides) have an antibacterial effect analogous to lysobactin and are stable to hydrolysis in a neutral to basic aqueous medium. The lysobactin amides are aza lisobactin analogues that have not been described so far, where the central lactone functionality is replaced by a lactam functionality. The invention relates to compounds of formula wherein R 1 represents 2-methylprop-1-ylo, 2,2-dimethylprop-1-yl, 2,2-d-methylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl , 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1,3-thiazol-4-ylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, R2 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl , trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1,3-thiazol-4-ylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, R3 represents hydrogen, Cr C ^ alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl or 5- or 6-membered heteroarylmethyl, where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, Ci-C4-alkoxy, CrC4-alkylaryriin, hydroxycarbonyl, CrC4-alkoxycarbonyl, aminocarbonyl, CrC ^ alkylaminocarbonyl, and 5- or 6-membered heterocyclyl which bind via nitrogen, represents ( VCValkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, where alkyl may be substituted by between 1 and 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where Cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents selected independently from each other from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, CV Valky, CrC-a lcoxy, CrC4-alkylamino, hydroxycarbonyl, C4-alkoxycarbonyl, aminocarbonyl and C1-C4-alkylaminocarbonyl, represents Ci-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, heteroaryl of 5 or 6 members, 5 or 6 membered heteroarylmethyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, wherein alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto , 1, 4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with from 1 to 4 independently selected substituents between the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, (VCalkyl, C1-C4-alkoxy, CC ^ alkylamino, hydroxycarbonyl, Ci-C4-alkoxycarbonyl, aminocarbonyl and C1-C4- alkylaminocarbonyl, represents CrCe-alkyl, wherein alkyl is substituted with a substituent selected from the group consisting of amino, 1, 4,5,6-tetrahydropyrimidin-2-ylamino, [amino- (imino) methyl] amino, 2-pyridyl , 3-pyridyl and 4-pyridyl, represents C Ce-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, wherein alkyl may be be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylammon and [amino (imino) methyl) ] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C- | -C4-alkyl, CrC4-alkoxy, (-Vd-alkylamino, hydroxycarbonyl, d-C4-alkoxycarbonyl, aminocarbonyl and C, -C4-alkylaminocarbonyl, represents d-Ce-alkyl, C3-C7-cycloalkyl, C3 -C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, where alkyl may be substituted with 1 to 3 substituents independently selected from each other between the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl they can be replaced with ent 1 and 4 substituents selected independently from each other from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C 1 -C 4 -alkyl, C C -alkoxy, Crd-alkylamino, hydroxycarbonyl, CC ^ alkoxycarbonyl, aminocarbonyl and C4-4alkylaminocarbonyl, represents hydrogen, C Ce-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl , trimethylsilylmethyl or 2-amino-2-oxoethyl, where alkyl may be substituted with 1 to 3 substituents inddently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6- tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents inddently selected from the group consisting of halogen , cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, CVC-alkyl, CVC4-alkoxy, CVCalkylamino, hydroxycarbonyl, C-Gt-alkoxycarbonyl, aminocarbonyl and Ci-C-alkylaminocarbonyl, represents hydrogen, CrCe-alkyl , C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1-hydroxy-2 -oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (C1-C4-alkylamino) -2-oxoethyl or 2- (C-C4-alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents inddently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, CrCt-alkoxy, C4-alkylamino, hydroxycarbonyl, CrC ^ alkoxycarbonyl, aminocarbonyl and CC - alkylaminocarbonyl, R11 represents (VCe-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, heteroaryl of 5 or 6 members, heteroarylmethyl of 5 or 6 members, trimethylsilylmethyl, 2-amino-2-oxoethyl, -amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (C1-C4-alkylamino) -2-oxoethyl or 2- (C4-alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where Cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents inddently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, VGt-alkyl, (- Vd-alkoxy, C 1 -C 4 -alkylamino, hydroxycarbonyl, aminocarbonyl and Ct-C4-alkylaminocarbonyl, and the salts thereof, the solvates thereof and the solvates of the salts thereof, except co (the), wherein R 1 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1,3-thiazol-4-ylmethyl they can be substituted with 1 or 2 substituents inddently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, R2 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2, 2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2 -thienylmethyl, 3-thienylmethyl and 1,3-thiazol-4-ylmethyl may be substituted with 1 or 2 substituents inddently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, and R 2 represents hydrogen no or methyl, and the salts thereof, the solvates thereof and the solvates of the salts thereof. The compounds of the invention are the compounds of the formula (I) and the salts, solvates, solvates of the salts and prodrugs thereof, wherein said compounds are comprised by the formula (I) and are of the formulas mentioned below, and the salts, solvates, solvates of the salts and prodrugs thereof, as well as the compounds which are comprised by the formula (I) and which are mentioned below as examples of embonts, and the salts, solvates, solvates of the salts and prodrugs thereof, provided that the compounds are comprised by the formula (I) and are not mentioned below are no longer salts, solvates, solvates of the salts and prodrugs. Depending on their structure, the compounds of the invention may exist in stereoisomeric forms (enantiomers, diastereomers). Therefore, the invention relates to the enantiomers or the diastereomers, and their respective mixtures. The uniform stereoisomeric constituents can be isolated in a known manner from said mixtures of enantiomers and / or diastereomers When the compounds of the invention can exist in tautomeric forms, all of these tautomeric forms will be included in the present invention. Preferred salts for the purposes of the present invention are salts acceptable for physiological use of the compounds of the invention. However, salts which alone are not suitable for pharmaceutical applications but which can be used, for example, for the isolation or purification of the compounds of the invention or mixed salts are also included. A mixed salt i means, in the context of the present invention, an additional salt comprising two or more different acids or bases, such as, for example, a trifluoroacetate-mesylate salt. Salts acceptable for physiological use of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid. Salts acceptable for physiological use of the compounds of the invention also include conventional base salts, such as, by way of example and preferably, alkali metal salts (eg, sodium and potassium salts), alkaline earth metal salts (for example, calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having between 1 and 16 carbon atoms, such as, by way of example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, W-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine. For the purposes of the present invention, the solvates refer to those forms of the compounds of the invention that form a complex in the solid or liquid state through coordination with the solvent molecules. Hydrates are a special form of solvates in which coordination takes place with water. For the purposes of the present invention, the substituents have the following meaning, unless otherwise specified: Alkyl, per se and "alk" and "alkyl" in alkoxy, alkylamino, alkoxycarbonyl and alkylaminocarbonyl represents a straight or branched chain alkyl radical which is generally between 1 and 6, preferably between 1 and 4, particularly preferably between 1 and 3 carbon atoms, by way of example and preferably methyl, ethyl, n-propyl, isopropyl, tert-butyl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1 -yl, n-pentyl and n-hexyl. Alkoxy, by way of example and preferably, represents methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy. Alkoxycarbonyl, by way of example and preferably, represents methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl. "Alkylamino" represents an alkylamino radical having one or two alkyl substituents (selected independently from each other), by way of example and preferably methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino, A /, / Vo methylamino, W, W-diethylamino, W-ethyl-W-methylamino, W-methyl-Wn-propylamino, A / -isopropyl-A / -n-propylamino, / V-tert-butyl- / V -methylamino, / V-ethyl-Wn-pentylamino and Wn-hexyl-W-methylamino. A CVCa-alkylamino, for example, represents a monoalkylamino radical having between 1 and 3 carbon atoms or a dialkylamino radical having 1 to 3 carbon atoms each per alkyl substituent. Alkylaminocarbonyl. represents an alkylaminocarbonyl radical having one or two alkyl substituents (independently selected from each other), by way of example and preferably methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, tert-butylaminocarbonyl, n-penti-aminocarbonyl, n-hexylaminocarbonyl, N, N-dimethylaminocarbonyl, A /, / / / diethylaminocarbonyl, / V- ethyl-A / -methylaminocarbonyl, W-methyl-Wn-propylaminocarbonyl, W-isopropyl-Wn-propylaminocarbonyl, / V-tert-butyl-N-methylaminocarbonyl, Ne \ \ -Nn-pentylaminocarbonyl and / Vn-hexyl-A -methylaminocarbonyl . A CVCa-alkylamino, for example, represents a monoalkylaminocarbonyl radical having between 1 and 3 carbon atoms or a dialkylamino radical having 1 to 3 carbon atoms each per alkyl substituent. Cycloalkyl represents a cycloalkyl group which generally has between 3 and 7 carbon atoms carbon, by way of example and preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Heterocyclyl represents a monocyclic, heterocyclic radical having 5 or 6 ring atoms and up to 3 heteroatoms and / or hetero groups of the series N, O, S, SO, S02, wherein a nitrogen atom can also form an N- oxide. The heterocyclyl radicals may be saturated or partially unsaturated and, by way of example and preferably, represent pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolinyl, tetrahydrofuranyl, tetrahydrothienyl, pyranyl, piperidin-1-yl, piperidin-2-yl , piperidin-3-yl, piperidin-4-yl, thiopyranyl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl. Heteroaryl represents a monocyclic aromatic radical having 5 or 6 ring atoms and up to 4 heteroatoms of the S, O and N series, by way of example and preferably thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl and pyridazinyl. Halogen, represents fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine. Preference is given to compounds of formula (I) wherein R 1 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl. or 3-pyridylmethyl, wherein benzyl, 2-pyridylmethyl and 3-pyridylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, R2 represents 2-methylprop-1-yl , 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl or 3-pyridylmethyl, where benzyl, 2-pyridylmethyl and 3-pyridylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, R3 represents Crd-alkyl, phenyl, benzyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, where phenyl, benzyl, 2- pyridyl, 3-pyridyl and 4-pyridyl can be substituted with 1 to 4 substituents independently selected between the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, C1-C4-alkyl, CVGt-alkoxy and C4-alkylamino, represents Ci-C6-alkyl, C3-C7-cycloalkylmethyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, wherein alkyl may be substituted with a hydroxy substituent, and wherein cycloalkylmethyl, benzyl and heteroarylmethyl may be substituted with 1 and 4 substituents selected independently from each other from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C C4-alkyl, CVC ^ alkoxy, CVGt-alkylamino, hydroxycarbonyl, CrC ^ alkoxycarbonyl, aminocarbonyl and CrC ^ alkylaminocarbonyl , represents Ci-C6-alkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, wherein alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1, 4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkylmethyl, phenyl, benzyl and heteroarylmethyl may be substituted with 1 and 4 substituents selected independently from each other from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, C 1 -C 4 -alkyl, CrC ^ alkoxy and CVC ^ alkylamino, represents (.VCe-alkyl, where alkyl is substituted with a substituent selected from the group consisting of amino, 1,4,5,6-tetrahydropyrimidin-2-ylamino, [amino- (.lamino) methyl] amino, 2-pyridyl, 3-pyridyl and 4-pyridyl, represents CVCe-alkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, wherein alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4, 5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkylmethyl, phenyl, benzyl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, C C4-alkyl, (VQ-alkoxy and (-VGt-alkylamino, represents C Ce-alkyl, C3-C7-cycloalkylmethyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, where alkyl may be substituted with a hydroxy substituent, and wherein cycloalkylmethyl, benzyl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C4-alkyl , C ^ -CValkoxy, CVC ^ alkylamino, hydroxycarbonyl, CVC ^ -alkoxycarbonyl, aminocarbonyl and CVC ^ alkylaminocarbonyl, represents hydrogen, CrCValkyl, C3-C7-cycloalkyl, phenyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, where methyl can be substituted with a substituent selected from the group consisting of hydroxy, amino and mercapto, and wherein cycloalkyl and phenyl may be substituted with from 1 to 4 substituents selected in independently from each other between the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, CrC4-alkyl, CVC-alkoxy and CpCValkylamino, represents hydrogen, CrC6-alkyl, C3-C7-cycloalkyl, phenyl, trimethylsilylmethyl, -amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (C1-C4-alkylamino) -2-oxoethyl or 2- (C1-C-alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1, 4,5,6- tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl and phenyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl , trifluoromethoxy, Cd-alkyl, (C4-alkoxy and CrC4-alkylamino, R11 represents methyl or ethyl, where methyl and ethyl can be substituted with a substituent selected from the group consisting of hydroxy, amino, mercapto, 1,4, 5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and the salts thereof, the solvates thereof, and the solvates of the salts thereof, except the compounds of the formula (Ia) , wherein R 1 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl or 3-pyridylmethyl, wherein benzyl, 2- pyridylmethyl and 3-pyridylmethyl can be substituted with 1 or 2 substituents independently selected e between the group consisting of halogen, trifluoromethyl and methyl, R2 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, -pyridylmethyl or 3-pyridylmethyl, wherein benzyl, 2-pyridylmethyl and 3-pyridylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, and R 12 represents hydrogen or methyl, and the salts thereof, the solvates thereof and the solvates of the salts thereof. Also preferred are compounds of formula (I), wherein R 1 represents 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, R 2 represents 2,2-dimethylprop-1. -yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, R3 represents CrC-alkyl, 3-pyridyl or phenyl, where 3-pyridyl or phenyl may be substituted with a substituent selected from the group consisting of halogen, cyano, methyl, methoxy, dimethylamino and diethylamino, R4 represents -CH (OH) -C C5-alkyl or -CH (OH) phenyl, where -CH (OH) phenyl may be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, CVCValkyl , Ci-C4-alkoxy and CG'-dialkylamino, R5 represents CrC6-alky, C3-C7-cycloalkylmethyl, benzyl or trimethylsilylmethyl, R6 represents C2-C4-linear alkyl, where alkyl is substituted with a substituent selected from the group which consists of amino, 1, 4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, R7 represents CVCValkyl, C3-C7-cycloalkylmethyl, benzyl or trimethylsilylmethyl, R8 represents CVCValkyl, -CH2-OH , -CHÍOHJ-C Cs-alkyl or -CH (OH) phenyl, where -CH (OH) pheny it can be substituted with between 1 and 3 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, C C4-alkyl, f-VCalkoxy and C1-C4-dialkylamino, R9 represents hydrogen, C CValkyl, hydroxymethyl or 2-amino-2-oxoethyl, R 0 represents hydrogen, C C 4 -alkyl, 2-amino-2-oxoethyl or 2-amino-1-hydroxy-2-oxoethyl, where CVC 4 -alkyl can be substituted with a substituent selected from the group consisting of amino and hydroxy, with the exception that R 0 is not 4-aminobut-1-yl, R 11 represents methyl, where methyl is substituted with a substituent selected from the group consisting of hydroxy and amino, and the salts thereof, the solvates thereof and the solvates of the salts thereof, except the compounds of formula (la), wherein R represents 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, R2 represents 2,2-dimethylprop-1-; it, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, and R12 represents hydrogen or methyl, and the salts thereof, the solvates thereof and the solvates of the salts thereof. Also preferred are compounds of formula (I) wherein R 1 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or benzyl, where benzyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. Also preferred are compounds of the formula (I) wherein R 1 represents 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl or trimethylsilylmethyl, or one of the salts thereof, the solvates of the same or the solvates of the salts thereof. Also preferred are compounds of formula (I) wherein R 2 represents 2,2-dimethylprop-1-yl or 3-pyridylmethyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. same. Also preferred are compounds of formula (I) wherein R3 represents phenyl, benzyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, wherein phenyl, benzyl, 2-pyridyl, 3-pyridyl and 4-pyridyl may be substituted with between 1 and 4 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, CrC4-alkyl, CrC4-alkoxy and Crd-alkylamino, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. Also preferred are compounds of formula (I) wherein R3 represents phenyl, wherein phenyl may be substituted with a substituent selected from the group consisting of halogen, cyano, methyl, methoxy, dimethylamino and diethylamino, or one of the salts of the same, the solvates thereof or the solvates of the salts thereof. Also preferred are compounds of formula (I), wherein R8 represents -CH (OH) -CrC5-alkyl or -CH (OH) phenyl, where -CH (OH) phenyl may be substituted with from 1 to 3 substituents selected from independently from each other between the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, CrC4-alkoxy and Ci-C dialkylamino, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. Also preferred are compounds of formula (I) wherein R10 represents CrC6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (C -C 4 -alkylamide) -2-oxoethyl or 2- (C -C 4) -alkylamino) -1-hydroxy-2-oxoethyl, wherein alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, CrC 4 -alkyl, C 1 -C -alkoxy, C d-alkylamino, hydroxycarbonyl, Ci-C 4 -alkoxycarbonyl, aminocarbonyl and C 1 -C 4 -alkylaminocarbonyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. Also preferred are compounds of formula (I) wherein R10 represents (VCe-alkyl, C3-C7-cycloalkyl, phenyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, ( aminosulfonyl) (hydroxy) -methyl, 2- (C-4-alkylamino) -2-oxoethyl or 2- (C 1 -C 4 -alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl and phenyl may be substituted with 1 and 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, CrCValkyl, C 1 -C 4 -alkoxy and CrC 4 -alkylamino, or one of the salts thereof, the solvates of the same or the solvates of the salts thereof The compounds of the formula (I) wherein R 10 represents methyl, ethyl, 2-amino-2 are also preferred. -oxoethyl or 2-amino-1-hydroxy-2-oxoethyl, where methyl and ethyl can be substituted with a hydroxy substituent, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof . The invention also relates to a method for preparing the compounds of formulas (I), wherein [A] compounds of formula wherein R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings indicated, are first reacted with compounds of formula wherein R1 and R2 have the meanings indicated, Y1 represents io-butoxycarbonyl or benzyloxycarbonyl, and X1 represents halogen, preferably bromine, chlorine or fluorine or hydroxy, and then with an acid and / or hydrogenolysis, or [B] compounds of formula wherein R 4, R 5, R 6, R 7, R 8, R 9, R 10 and R 11 have the meanings indicated, are first reacted with compounds of formula wherein R1, R2 and R3 have the meanings indicated, and Y1 represents fer-butoxycarbonyl or benzyloxycarbonyl, and then in a 4-step synthesis a) with a fluoride reagent such as tetrabutylammonium fluoride, b) with an acid, c) with a dehydrating reagent, when appropriate in the presence of a base, and d) by hydrogenolysis.

Method [A]: If X1 is halogen, the reaction in the first stage generally takes place in inert solvents, when appropriate in the presence of a base, preferably in a temperature range between -30 ° C and 50 ° C under atmospheric pressure. Examples of inert solvents are tetrahydrofuran, methylene chloride, pyridine, dioxane, dimethylacetamide, N-methylpyrrolidine or dimethylformamide, preferably pyridine or dimethylformamide. Examples of bases are triethylamine, diisopropylethylamine or / v-methylmorpholine, preferably diisopropylethylamine. If X1 is hydroxy, the reaction in the first stage generally takes place in inert solvents, in the presence of a dehydrating reagent, where appropriate in the presence of a base, preferably in a temperature range between -30 ° C and 50 ° C. ° C under atmospheric pressure. Examples of inert solvents are halohydrocarbons, such as dichloromethane or trichloromethane, hydrocarbons, such as benzene, nitromethane, dioxane, dimethylformamide or acetonitrile. In the same way, it is possible to use mixtures of these solvents. Dichloromethane or dimethylformamide is particularly preferred. Examples of suitable dehydrating reagents are then carbodiimides such as, for example,? /,? / '- diethyl-,? /,? /' - dipropyl-,? /,? / '- diisopropyl-,?, Hydrochloride. '-dicyclohexylcarbodiimide, A / - (3-dimethylaminoisopropyl) -W-ethylcarbodiimide (EDC), N-cyclohexylcarbodiimide-W-propyloxymethylpolystyrene (PS-carbodiimide) or carbonyl compounds such as carbonyldiimidazole or 1,2-oxazolium compounds such as 3-sulfate of 2-ethyl-5-phenyl-1,2-oxazolium or 2-tert-butyl-5-methylisoxazole perchlorate, or acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1, 2- dihydroquinoline or propanphosphonic anhydride or isobutyl chloroformate or bis (2-oxo-3-oxazolidinyl) phosphoryl chloride or benzotriazolyloxytri (dimethylamino) phosphonium hexafluorophosphate or 0- (benzotriazol-1-yl) hexafluorophosphate -A /, / V, A / ', A /' - tetramethyluronium (HBTU), tetrafluoroborate 2- (2-OXO-1 - (2H) -pyridyl) -1, 1, 3,3-tetramethyluronium (TPTU), tetrafluoroborate 0- (1 H- 6-chlorobenzotriazol-1-yl) -1, 1, 3,3-tetramethyluroni or (TCTU) or 0- (7-azabenzotriazol-1-yl) - / V, A /, A / ', A / -tetramethyluronium (HATU), or 1-hydroxybenzotriazole (HOBt) or hexafluorophosphate hexafluorophosphate benzotriazol-1-yloxytris (dimethylamino) phosphonium (BOP) or benzotriazol-1-yloxytris (pyrrolidino) phosphonium hexafluorophosphate (PyBOP) or W-hydroxysuccinimide or mixtures thereof, with bases. Examples of bases are alkali metal carbonates, such as, eg, sodium or potassium carbonate, or bicarbonate, or organic bases, such as trialkylamines, e.g., triethylamine, W -methylmorpholine, W-methylpiperidine, 4-dimethylaminopyridine or düsopropylethylamine. Condensation is preferably conducted with HATU or with EDC in the presence of HOBt. The reaction with an acid in the second stage of the method preferably takes place in a temperature range between 0 ° C and 40 ° C at atmospheric pressure. Here, suitable acids are hydrogen chloride in dioxane, hydrogen bromide in acetic acid or trifluoroacetic acid in methylene chloride. The hydrogenolysis in the second stage of the method generally takes place in a solvent, in the presence of hydrogen and palladium on activated carbon, preferably in a temperature range between 0 ° C and 40 ° C at atmospheric pressure. Examples of solvents are alcohols such as methanol, ethanol, n-propanol or isopropanol, in a mixture with water and acetic acid or aqueous hydrochloric acid, preferably a mixture of ethanol, water and acetic acid or a mixture of isopropanol and aqueous hydrochloric acid. Method [B]: The reaction of the compounds of the formula (IV) with compounds of the formula (V) generally takes place in inert solvents in the presence of a dehydrating reagent, when appropriate in the presence of a base, preferably in a temperature range between -30 ° C and 50 ° C under atmospheric pressure. Examples of inert solvents are halohydrocarbons, such as dichloromethane or trichloromethane, hydrocarbons, such as benzene, nitromethane, dioxane, dimethylformamide or acetonitrile. In the same way, it is possible to use mixtures of the solvents. Dichloromethane or dimethylformamide is particularly preferred.

Examples of suitable dehydrating reagents are then carbodiimides such as, for example,? /,? / '- diethyl-,? /, /' - dipropyl-,? /,? / '- diisopropyl-,?,? -dicyclohexylcarbodumide, N- (3-dimethylaminoisopropyl) - / V'-ethylcarbodiimide (EDC), N-cyclohexylcarbodiimide-A / -propyloxymethylpolystyrene (PS-carbodiimide) or carbonyl compounds such as carbonyldiimidazole or 1,2-oxazolium compounds such as 2-Ethyl-5-phenyl-1,2-oxazolium 3-sulfate or 2-phenyl-butyl-5-methyl isoxazolium perchlorate, or acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline or anhydride propanphosphonic or isobutyl chloroformate or bis (2-oxo-3-oxazolidinyl) phosphoryl chloride or benzotriazolyloxytri (d -methyl-amino) phosphonium hexafluorophosphate or 0- (benzotrazole-1-yl) -W, W hexafluorophosphate W ', W'-tetramethyluronium (HBTU), tetrafluoroborate 2- (2-oxo-1- (2H) -pyridyl) -1, 1, 3,3-tetramethyluronium (TPTU), tetrafluoroborate 0- (1 H -6-chlorobenzotriazol-1-yl) -1, 1, 3,3-tetramethyl ronio (TCTU) or 0- (7-azabenzotriazol-1-yl) - / V, A /, / \ / ', / / -tetramethyluronium (HATU) hexafluorophosphate, or 1-hydroxybenzotriazole (HOBt) or benzotriazole hexafluorophosphate 1-yloxytris (dimethylamino) phosphonium (BOP) or benzotriazol-1-yloxytris (pyrrolidino) phosphonium hexafluorophosphate (PyBOP) or W-hydroxysuccinimide or mixtures thereof, with bases. Examples of bases are alkali metal carbonates, such as, for example, sodium or potassium carbonate, or bicarbonate, or organic bases, such as trialkylamines, for example, triethylamine, A / -methylmorpholine, AZ- methylpiperidine, 4-dimethylaminopyridine or diisopropylethylamine. The condensation is preferably conducted with HATU or with a mixture of EDC and HOBt. The reaction with tetrabutylammonium fluoride in the first step (a) of the additional method generally takes place in inert solvents, preferably in a temperature range between 0 ° C and 40 ° C under atmospheric pressure. Examples of inert solvents are halohydrocarbons such as dichloromethane or trichloromethane, or ethers such as tetrahydrofuran or dioxane. Tetrahydrofuran is particularly preferred. The reaction with an acid in the second stage (b) of the method preferably takes place in a temperature range between 0 ° C and 40 ° C at atmospheric pressure.

Here, suitable acids are hydrogen chloride in dioxane, hydrogen bromide in acetic acid or trifluoroacetic acid in methylene chloride. The reaction in the third step (c) of the method takes place analogously to the reaction of the compounds of the formula (IV) with the compounds of the formula (V). The hydrogenolysis in the fourth stage (d) of the method generally takes place in a solvent, in the presence of hydrogen and palladium in activated carbon, preferably in a temperature range between 0 ° C and 40 ° C at atmospheric pressure. Examples of solvents are alcohols such as methanol, ethanol, n-propanol or isopropanol, in a mixture with water and acetic acid or aqueous hydrochloric acid, preferably a mixture of ethanol, water and acetic acid or a mixture of isopropanol and hydrochloric acid aqueous. The compounds of the formula (II) are known or can be prepared by reacting compounds of the formula wherein R 4, R 5, R 6, R 7, R 8, R 9, R 10 and R 11 have the meaning indicated above, First with compounds of the formula wherein R 3 has the meaning indicated above, and R 13 represents cyanomethyl, p-nitrophenyl, o-nitrophenyl, 2,4-dinitrophenyl, 2,4,5-trichlorophenyl, pentachlorophenyl, pentafluorophenyl (Pfp), N-hydroxyphthalimidyl, N-hydroxysuccinimidyl (O-Su), 1-hydroxypiperidinyl or 5-chloro-8-hydroxyquinolinyl, and then in a 3-step synthesis a) with an acid, b) with a dehydrating reagent, when appropriate in the presence of a base, and ) by hydrogenolysis. The reaction of the compounds of the formula (VI) with compounds of the formula (VII) in general takes place in inert solvents, when appropriate in the presence of a base, preferably in a temperature range between -30 ° C and 50 ° C under atmospheric pressure. Examples of inert solvents are tetrahydrofuran, methylene chloride, pyridine, dioxane, dimethylacetamide, W-methylpyrrolidine or dimethylformamide, preferably pyridine or dimethylformamide. The reaction with an acid in the first step (a) of the method preferably takes place in a temperature range between 0 ° C and 40 ° C at atmospheric pressure. Here, suitable acids are hydrogen chloride in dioxane, hydrogen bromide in acetic acid or trifluoroacetic acid in methylene chloride. The reaction in the second step (b) of the method takes place analogously to the reaction of the compounds of the formula (IV) with the compounds of the formula (V). Hydrogenolysis in the third stage (c) of the method generally takes place in a solvent, in the presence of hydrogen and palladium in activated carbon, preferably in a temperature range between 0 ° C and 40 ° C at atmospheric pressure. Examples of solvents are alcohols such as methanol, ethanol, n-propanol or isopropanol, in a mixture with water and acetic acid or aqueous hydrochloric acid, preferably a mixture of ethanol, water and acetic acid or a mixture of isopropanol and hydrochloric acid aqueous. The compounds of formulas (III), (V) and (VII) are known or can be synthesized by known methods or with the methods that will be described below, from the corresponding starting materials. The compounds of formulas (IV) and (VI) are known or can be synthesized in solution using appropriate protective groups or on solid phase by methods of synthesis of known peptides or by the methods to be described below, from the corresponding materials of departure. The preparation of the compounds of the invention can be illustrated by the following synthesis schemes.

?? Synthesis scheme 2: Synthesis scheme 3: The compounds of the invention exhibit a valuable range of pharmacological effects that could not have been predicted. They have an antibacterial effect. Therefore, they are suitable for use as medicaments for the treatment and / or prophylaxis of diseases in humans and animals. The compounds of the invention are distinguished by a lower nephrotoxicity compared to lysobactin. The compounds of the invention are distinguished by improved stability in a neutral to basic aqueous medium. This property improves the storage of the compounds of the invention and its administration as medicines. The described nonadepsipeptides act as inhibitors of bacterial cell wall biosynthesis. The preparations of the invention are particularly effective with bacteria and bacterioid microorganisms. They are therefore particularly suitable for the prophylaxis and chemotherapy of local and systemic infections caused by these pathogens in human and veterinary medicine. The preparations of the invention can be used in principle against all bacteria and bacterioid microorganisms that possess a bacterial cell wall (murein sacculus) and the relevant enzyme systems, for example against the following pathogens or mixtures of the following pathogens: Gram cocci -negatives (Neisseria gonorrhoeae) as well as Gram-negative bacilli such as Enterobacteriaceae, for example Escherichia coli, Haemoph Hus influenzae, Pseudomonas, Klebsiella, Citrobacter (C. freundii, C. divernis), Salmonella and Shigella; also Enterobacter (E. aerogenes, E. agglomerans), Hafnia, Serratia (S. marcescens), Providence, Yersinia, as well as the genus Acinetobacter, Branhamella and Chlamydia. The antibacterial range further includes strictly anaerobic bacteria such as, for example, Bacteroides fragilis, representative of the genus Peptococcus, Peptostreptococcus, as well as of the genus Clostridium; other mycobacteria, for example M. tuberculosis. The compounds of the invention show a particularly pronounced effect on Gram-positive cocci, for example staphylococci (S. aureus, S. epidermidis, S. haemolyticus, S. carnosus), enterococci (E. faecalis, E. faecium) and streptococci ( S. agalactiae, S. pneumoniae, S. pyogenes). The above list of pathogens is offered merely by way of example, and under no circumstances should it be construed restrictively. Examples that can be mentioned of diseases that can be caused by the aforementioned pathogens or mixed infections and that can be prevented, improved or cured with the preparations of the invention are: Infectious diseases in humans such as, for example, uncomplicated infections and Complications of the urinary tract, cutaneous and superficial uncomplicated infections, complicated skin and soft tissue infections, community-acquired pneumonia, nosocomial pneumonias, acute exacerbations and secondary bacterial infections of chronic bronchitis, acute otitis media, acute sinusitis, streptococcal pharyngitis, bacterial meningitis, urethritis / gonococcal and uncomplicated gonococcal cervicitis, acute prostatitis, endocarditis, uncomplicated and complicated intra-abdominal infections, gynecological infections, pelvic inflammatory disease, bacterial vaginosis, acute and chronic osteomyelitis, acute bacterial arthritis, empirical therapy in patients with febrile neutropenia, besides bacteremias, MRSA infections, acute infectious diarrhea, Helicobacter infections pylori, postoperative infections, odontogenic infections, ophthalmological infections, postoperative infections (including periproctal abscess, wound infections, biliary infections, mastitis and acute appendicitis), cystic fibrosis and bronchiectasis. Apart from humans, bacterial infections can also be treated in other species. Examples that may be mentioned are: Pigs: diarrhea, enterotoxemia, sepsis, dysentery, salmonellosis, metritis-mastitis-agalactia syndrome, mastitis; Ruminants (cattle, sheep, goats): diarrhea, sepsis, bronchopneumonia, salmonellosis, pasteurellosis, genital infections; Horses: bronchopneumonia, joint diseases, puerperal and post-operative infections, salmonellosis; Dogs and cats: bronchopneumonia, diarrhea, dermatitis, otitis, urinary tract infections, prostatitis; Poultry (chickens, turkeys, quail, pigeons, ornamental birds and others): E. coli infections, chronic respiratory disorders, salmonellosis, pasteurellosis, psittacosis. In the same way, it is possible to treat bacterial diseases in the breeding and management of productive and ornamental fish, in which case the antibacterial spectrum extends beyond the aforementioned pathogens to reach other pathogens, such as, for example. , Pasteurella, Brucella, Campylobacter, Listeria, Erysipelothris, corynebacteria, Borellia, Treponema, Nocardia, Rikettsia, Yersinia. The present invention also relates to the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, in particular of bacterial infectious diseases. In addition, the present invention relates to the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, especially the diseases mentioned previously. In addition, the present invention relates to the use of the compounds of the invention in the preparation of a medicament for the treatment and / or prophylaxis of diseases, especially the diseases mentioned previously. The compounds of the invention are preferably used for the preparation of medicaments suitable for the prophylaxis and / or treatment of bacterial diseases. In addition, the present invention relates to a method for the treatment and / or prophylaxis of diseases, especially the aforementioned diseases, using an antibacterially effective amount of the compounds of the invention. The present invention also relates to medicaments comprising at least one compound of the invention and at least one or more additional active ingredients, in particular for the treatment and / or prophylaxis of the diseases mentioned. The preferred active ingredients for the combination are compounds having an antibacterial activity and having a range of different effects, in particular a range of supplementary effects, and / or which are synergistic with the compounds of the invention. The compounds of the invention can act systemically and / or locally. For this purpose, they can be administered in an appropriate manner, such as, for example, orally, parenterally, pulmonally, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally or otically, or as an implant or a stent. For these routes of administration, the compounds of the invention can be administered in appropriate administration forms. Those suitable for oral administration are the administration forms that work according to the prior art and which allow the compounds of the invention to be delivered rapidly and / or in a modified manner, and which contain the compounds of the invention in a crystalline and / or amorphous and / or dissolved form, such as, for example, , tablets (tablets not coated or coated, for example having enteric coatings or coatings that dissolve with delay or that are insoluble and control the release of the compound of the invention), tablets or films / wafers that disintegrate rapidly in the oral cavity , films / freeze-dried, capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. Parenteral administration can take place by avoiding an absorption step (e.g., intravenous, intraarterial, intracardiac, intraspinal or intralumbar), or with the inclusion of an absorption step (e.g., intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). The administration forms suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders. For the other routes of administration are appropriate, eg, the pharmaceutical forms for inhalation (among others, powders for inhalers, nebulizers), nasal drops, solutions, sprays; tablets, films / plates or capsules for lingual, sublingual or buccal administration, suppositories, preparations for the ears or eyes, vaginal capsules, aqueous suspensions (lotions, stirring mixtures), lyophilic suspensions, ointments, creams, transdermal therapeutic systems (such as as, eg, patches), milk, pastes, foams, dusting powder, implants or stents. The compounds of the invention can be converted into the aforementioned administration forms. This can take place in a way known per se, through a mixture with inert, non-toxic excipients, suitable for pharmaceutical use. These excipients include, but are not limited to, vehicles (eg, microcrystalline cellulose, lactose, mannitol), solvents (eg, liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (eg, sodium dodecylsulfate, polyoxysorbitan oleate), binders ( for example, polyvinylpyrrolidone), synthetic and natural polymers (e.g., albumin), stabilizers (e.g. antioxidants, such as, for example, ascorbic acid), colorants (for example, inorganic pigments, such as, for example, iron oxides), and flavor and / or aroma correctors. In addition, the present invention relates to medicaments comprising at least one compound of the invention, commonly together with one or more inert, non-toxic excipients, acceptable for pharmaceutical use, and with their use for the purposes mentioned above.

In general, it has proven advantageous to administer with intravenous administration amounts of between 0.001 and 100 mg / kg approximately, preferably between 0.1 and 10 mg / kg approximately, of body weight to obtain effective results, and with an oral administration the dosage it comprises between 0.01 and 50 mg / kg approximately, preferably between 0.5 and 10 mg / kg, of body weight. However, it may be necessary when it is appropriate to deviate from the established amounts, in particular according to the body weight, the route of administration, the individual response to the active ingredient, the nature of the preparation and the time or interval over which it takes place. the administration. Therefore, in some cases it may be sufficient to use amounts lower than the minimum amount mentioned above, while in other cases it may be necessary to exceed the established maximum limit. In the case in which larger quantities are administered, it will be advisable to divide them into a plurality of individual doses during the day. The percentages data in the following tests and examples are, unless otherwise indicated, percentages by weight; The parts are parts by weight. The relationships between solvents, dilution ratios and concentration data for liquid / liquid solutions are based on volume in each case. The attached figures show the stability diagrams for examples of selected compounds, and lysobactin as a comparative example. They show: Fig. 1: A graph of the change in the concentration of lisobactin and a degradation product of lisobactin over time in an aqueous, slightly alkaline solution. Fig. 2 A graph of the change in concentration of the compound of example 19 over time in an aqueous, slightly alkaline solution.

Fig. 3 A graph of the change in concentration of the compound of Example 23 over time in an aqueous, slightly alkaline solution. Fig. 4 A graph of the change in concentration of the compound of Example 25 over time in an aqueous, slightly alkaline solution. Fig. 5 A graph of the change in concentration of the compound of Example 40 over time in an aqueous, slightly alkaline solution. A. Examples Abbreviations abs. absolute ac aqueous BHI brain-heart infusion Boc rt-butoxycarbonyl conc. DCC concentrate dicyclohexylcarbodiimide. DCI direct chemical ionization (in MS) DCM dichloromethane DIEA A ./V- diisopropylethylamine DMAP 4-A /, / V-dimethylaminopyridine DMSO dimethyl sulfoxide DMF N, N-dimethylformamide EA ethyl acetate EDC 1-ethyl-3- (3-dimethylaminopropyl carbodiimide (also EDCI) EDCxHCI 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride EDTA ethylenediaminetetraacetic acid Electron impact ionization (in MS) eq. equivalent (s) ESI ionization by electroatomization (in MS) Eg example h hour (s) HATU 0- (7-Azabenzotriazol-1-yl) -A /, / V, / V ', A / - tetramethyluronium HOBt 1-hydroxybenzotriazole HPLC High-performance liquid chromatography, high-performance LC-MS coupled mass spectroscopy to liquid chromatography LDA Lithium diisopropylamide LHMDS lithium hexamethyldisilazide LLA (3-cyclohexyl D-Leu-Leu- (3-cyclohexyl) Ala) LLF D-Leu-Leu-Phe MALDI ionization / attrition with matrix-assisted laser MIC minimum inhibitory concentration Min minute / minutes MRSA Staphilococcus aureus resistant to methicillin MS mass spectroscopy MTBE methyl tertiary butyl ether NCCLS National Committee for Clinical Laboratory Standards neg. negative NMM W-methylmorpholine NMR nuclear magnetic resonance spectroscopy: org. organic p.a. pro palladium Pd analysis Pd-C palladium on carbon pos. positive PTFE polytetrafluoroethylene quant. quantitative RP-HPLC reverse phase HPLC RT room temperature Rf retention factor (in thin layer chromatography) R, retention time (in HPLC) sat. saturated TBAF tetrabutylammonium fluoride TBTU O-benzotriazol-1-yl- / S /, A /, A / 'tetrafluoroborate, V -tetramethyluronium TCTU 0- (- 6-chlorobenzotriazol-1-yl) -1 tetrafluoroborate, 1, 3,3-tetramethylurea TFA trifluoroacetic acid TFE 2,2,2-trifluoroethanol THF tetrahydrofuran TMG W, N, A /, / V-tetramethylguanidine TMSE (2- (trimethylsilyl) ethyl) TOF ultraviolet UV flying time VRSA Staphylococcus aureus vancomycin-resistant XPHOS dicyclohexyl (2 ', 4' > 6'-triisopropylbiphenl-2-yl) phosphine Z, Cbz benzyloxycarbonyl References Regarding the nomenclature of peptides and cyclodepsipeptides, compare: 1. A Guide to IUPAC Nomenclature of Organic Compounds (Recommendations 1993), 1993, Blackwell Scientific publications. 2. Nomenclature and symbolism for amino acids and peptides. recommendations 1983. IUPAC-IUB Joint Commission on Biochemical Nomenclature, United Kingdom. Biochemical Journal 1984, 219, 345-373, and the literature cited therein.

Materials and methods Analytical methods Method 1: Type of HPLC instrument: HP 1100 Series; UV DAD; column: Phenomenex Synergy 2μ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 minutes of 90% A - > 2.5 minutes of 30% A - 3.0 minutes of 5% A - 4.5 minutes of 5% A; Flow rate: 0.0 minutes at 1 ml / minute, 2.5 minute / 3.0 minute / 4.5 min. at 2 ml / minute; oven: 50 ° C; UV detection: 210 nm. Method 2: Type of HPLC instrument: HP 1050 Series; UV DAD; column: Phenomenex Synergy 2μ Max-RP Mercury 20 mm x 4 mm; eluent A: 1 I of water + TFA 0.05%; eluent B: 1 I of acetonitrile; gradient: 0.0 minutes 90% A - 2.5 minutes 30% A 3.0 minutes 5% A - 4.5 minutes 5% A; Flow rate: 0.0 minutes at 1 ml / minute, 2.5 minute / 3.0 minute / 4.5 min. at 2 ml / minute; oven: 50 ° C; UV detection: 210 nm. Method 3: Type of HPLC instrument: HP 1100 Series; UV DAD; column: Kromasyl C18, 60 x 2.1 mm, 3.5 pm; eluent A: water / perchloric acid 0.5%; eluent B: acetonitrile; gradient: 0-0.5 min of 2% B, 0.5-4.5 min of 2-90% B, 4.5-6.5 min of 90% B, 6.5-6, 7 min of 90-2% of B, 6.7-7.5 min of 2% of B; flow rate: 0.75 ml / minute, oven: 30 ° C, UV detection at 210 nm. Method 4: Instrument: HP 1100 with DAD detection; column: Kromasyl 100 RP-18, 60mm x 2.1mm, 3.5pm; eluent A: 5 ml of perchloric acid (70%) / l of water, eluent B: acetonitrile; gradient: 0 minutes of 2% B, 0.5 minutes of 2% B, 4.5 minutes of 90% B, 9 minutes of 90% B, 9.2 minutes of 2% B, 10 minutes of 2% of B; flow rate: 0.75 ml / minute; Column temperature: 30 ° C; Detection: UV at 210 nm. Method 5: Instrument: Agilent 1100 with DAD (G1315B), binary pump (G1312A), automatic dispenser (G1313A), solvent degasser (G1379A) and column thermostat (G1316A); column: Agilent Zorbax Eclipse XDB-C8 4.6 x 150 x 5 mm; Column temperature: 30 ° C; eluent A: perchloric acid 0.05% -70% in water; eluent B: acetonitrile, flow rate: 2.00 ml / min; gradient: 0-1 min of 10% B, ramp, 4-5 min of 90% B, ramp, 5.5 min of 10% of B. Method 6: Instrument: Agilent 1100 with DAD (G1315B), binary pump (G1312A), automatic dispenser (G1313A), solvent degasser (G1379A) and column thermostat (G1316A); column: Agilent Zorbax Eclipse XDB-C8 4.6 x 150 x 5 mm; Column temperature: 30 ° C; eluent A: TFA 0.01% in water; eluent B: TFA 0.01% in acetonitrile; flow rate: 2.00 ml / min; gradient: 0-1 min of 10% B, ramp, 4-5 min of 90% B, ramp, 5.5 min of 10% of B. Method 7: Agilent 1100 with DAD (G1315B), binary pump ( G1312A), automatic dispenser (G1313A), degasser (G1379A) and column thermostat (G1316A); column: Synergy 4? Hydro-RP 80A, 4.6 x 150 x 5 mm; Oven temperature: 30 ° C; eluent A: water + perchloric acid 0.05% -70%; eluent B: acetonitrile, flow rate: 2.00 ml / min; gradient: 0-1 min of 10% B, ramp, 4-5 min of 90% B, ramp, 5.5 min of 10% of B. Method 8: Instrument: Agilent 1100 with DAD (G1315B), pump binary (G1312A), automatic dispenser (G1313A), solvent degasser (G1379A) and column thermostat (G1316A); column: Agilent Eclipse XDB-C8 4.6 x 150 x 5 mm; column temperature: 40 ° C; eluent A: perchloric acid 0.05% -70% in water; eluent B: methanol; flow rate: 2.00 ml / min; Socratic: 0-7 min with 55% of B. Method 9: Type of HPLC instrument: HP 1050 Series; UV DAD; column: Zorbax 300 mSB-C18 3.5 μ, 4.6 mm x 150 mm; eluent A: 1 I of water + 0.1% TFA; eluent B: 400 ml of acetonitrile / 600 ml of water + 0.1% TFA; gradient: 0.0 min to 100% A, 1.3 min to 10% B, 18.0 min to 80% B, 20.0 min to 80% B, 21.0 min to 100% B, 25.0 min at 100% B, 26.0 min at 0% B, 30.0 min at 0% B. Flow rate: 1 ml / minute; homo: 40 ° C; UV detection: 210 nm. Method 10: Type of HPLC instrument: HP 1050 Series; UV DAD; column: Zorbax 300 mSB-C18 3.5 μ, 4.6 mm x 150 mm; eluent A: 1 I of water + 0.1% TFA; eluent B: acetonitrile; gradient: 0.0 min at 100% A, 15.0 min at 100% B, 17.0 min at 100% B, 18.0 min at 100% A. Flow rate: 1 ml / minute; oven: 40 ° C; UV detection: 210 nm. Method 11: Type of HPLC instrument: HP 1050 Series; UV DAD; column: Zorbax 300 mSB-C18 3.5 μ, 4.6 mm x 150 mm; eluent A: 1 I of water + 0.1% TFA; eluent B: 400 ml of acetonitrile / 600 ml of water + 0.1% TFA; gradient: 0.0 min to 100% A, 2.0 min to 10% B, 50.0 min to 80% B, 52.0 min to 100% B, 55.0 min to 100% A, 60.0 min at 100% A. Flow rate: 1 ml / min; oven: 40 ° C; UV detection: 210 nm. Method 12: Type of HPLC instrument: HP 1050 Series; SymmetryPrep ™ C 8 column, Waters, 50 x 2, 1 mm, 3.5 pM; eluent A: water / 0.1% TFA; eluent B: acetonitrile; gradient: 0-3 min at 0% B, 3.01-9 min at 100% B, 9.01-11 min at 100% B, 11, 01-12 min at 0-100% A; oven: 40 ° C; flow rate: 0.4 ml / minute; UV detection: 210 nm. Method 13: Type of HPLC instrument: HP 1 100 Series; UV DAD; column: Chromolith Speed ROD RP18; eluent A: 1 I of water + TFA 0.05%; eluent B: 1 I of acetonitrile; gradient: 0.0-0.5 min at 95% A, 0.51-3.0 min at 5-95% B, 3.01-3.80 min at 95% A; flow rate: 5 ml / min; oven: 40 ° C; UV detection: 210 nm. Method 14: column (steel column, dimensions 250 x 4.6 mm); stationary phase (silica / chiral composite polyamide KBD 5326, based on the poly (/ V-methacryloyl-leucine dicyclopropylmethylamide) selector, eluent: ethyl acetate, socrático, flow rate: 1 ml / min, temperature: 25 ° C, UV detection: 220 nm, sample: 10 μm injection .. Method 15: stationary phase (Chiralcel OD), eluent: i-hexane / i-PrOH: 9/1, Socratic, flow rate: 2 ml / min; temperature: 25 ° C; UV detection: 254 nm Method 16: HPLC instrument type: HP 1100 Series; column: Chiralpack AD-H, 250 mm x 4.6 mm, eluent A: isohexane, eluent B: ethanol + 0.2% TFA + 1% H20; Socratic; flow rate: 1 ml / minute; oven: 40 ° C; UV detection: 230 nm Method 17: Daicel Chiralpak AD-H 5 pm 250 mm x 4.6 mm, hexane / 2-propanol / methanol 85/6/9, flow rate: 2.0 ml / min, UV detection at 254 nm Method 18: Type of MS instrument: Micromass ZQ; Type of HPLC instrument: Waters Alliance 2795 / HP 1 100, column: Phenomenex Synergy 2μ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 minutes 90% A - 2.5 minutes 30% A - 3.0 minutes 5% A - > 4.5 minutes of 5% of A; flow rate: 0.0 min at 1 ml / min, 2.5 min / 3.0 min / 4.5 min at 2 ml / min; oven: 50 ° C; UV detection: 210 nm.

Method 19: Type of MS instrument: Micromass ZQ; Type of HPLC instrument: Waters Alliance 2795 / HP 1100; column: Phenomenex Gemini 3 μ C-18 100 A, 30 mm? 3 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 minutes of 90% A - > 2.5 minutes of 30% of A - > 3.0 minutes of 5% A - 4.5 minutes of 5% A; flow rate: 0.0 min at 1 ml / min, 2.5 min / 3.0 min / 4.5 min at 2 ml / min; oven: 50 ° C; UV detection: 210 nm. Method 20: UV detection: 210 nm. Type of MS instrument: Micromass ZQ; Type of HPLC instrument: Waters Alliance 2795; column: Phenomenex Synergy 2μ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 minutes 90% A - 2.5 minutes 30% A - > 3.0 minutes of 5% A - 4.5 minutes of 5% A; flow rate: 0.0 min at 1 ml / min, 2.5 min / 3.0 min / 4.5 min at 2 ml / min; oven: 50 ° C; UV detection: 210 nm. Method 21: Instrument: Micromass Quattro LCZ with Agilent HPLC 1100 series; column: Phenomenex Synergy 2μ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 minutes of 90% A - > 2.5 minutes of 30% A - 3.0 minutes of 5% A - > 4.5 minutes of 5% of A; flow rate: 0.0 min at 1 ml / min, 2.5 min / 3.0 min / 4.5 min at 2 ml / min; oven: 50 ° C; UV detection: 208-400 nm. Method 22: Instrument: Micromass Platform LCZ with Agilent HPLC 1100 series; Column: Thermo Hypersil GOLD 3μ 20 mm x 4 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 minutes of 100% A - 0.2 minutes of 100% A - > 2.9 minutes of 30% A - > 3.1 minutes of 10% A - 5.5 minutes of 10% A; oven: 50 ° C; flow rate: 0.8 ml / minute; UV detection: 210 nm. Method 23: Type of MS instrument: Micromass LCT (ESI pos./neg.); HPLC instrument type: HP 1100 Series; UV DAD 1100 Series; Symmetry-Prep ™ C18 column, Waters, 50 x 2.1 mm, 3.5 μ? t ?; eluent A: water / formic acid 0.1%; eluent B: acetonitrile / formic acid 0.1%; gradient: 0-1 min at 0% B, 1-6 min at 0-90% B, 6-8 min at 90-100% B, 8-10 min at 100% B, 10-10, 1 min to 100-0% of B, 10.1-12 min to 0% of B, then regeneration of the chromatography column. Oven: 40 ° C; flow rate: 0.5 ml / min (briefly up to 1 ml / min at 10, 1 min), UV detection: 210 nm. Method 24: The TOF-HR-MS-ESI + spectra were recorded with a Micromass LCT instrument (capillary voltage: 3.2 KV, cone voltage: 42 V, source temperature: 120 ° C, desolvation temperature: 280 ° C). A syringe pump (Harvard Apparatus) is used to distribute the sample for this purpose. Leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) is used as standard. Method 25: Investigations with MALDI-MS / MS were conducted with a 4700 Proteomics Analyzer (Applied Biosystems, Framingham, MA, USA) which is equipped with TOF / TOF ion optics and a 200 Hz Nd: YAG laser (355 nm). The quasi-molecular ions are accelerated at the source of ions with 8 kV, selected with an electric baffle (MS1) and made to collide with argon atoms in a collision cell disposed between MS1 and MS2. The resulting fragment ions are re-accelerated with 15 kV and are characterized with the second mass analyzer with time of flight (MS2). Preparative Chromatography Method 26: Instrument: Gilson Abimed HPLC; binary pump system; column: Nucleodur C18 Gravity, Macherey-Nagel, 5 μ? t ?; 250 x 21 mm; eluent A: water + TFA 0.05% -0.1%; eluent B: acetonitrile; gradient: 0-8 min at 5% B, 8-40 min at 5-60% B, 40-60 min at 60% B, 60-75 min at 60-100% B, 75-80 min to 100% B, then regeneration of the chromatography column; flow rate: 7-15 ml / min; UV detector at 210 nm. Method 27: Instrument: Gilson Abimed HPLC; binary pump system; column: Nucleodur C18 Gravity, Macherey-Nagel, 5 μ? t ?; 250 x 21 mm; eluent A: water + TFA 0.05% -0.1%; eluent B: acetonitrile; gradient: 0-8 min at 5% B, 8-40 min at 5-60% B, 40-60 min at 60% B, 60-75 min at 60-100% B, 75-80 min to 100% B, then regeneration of the chromatography column; flow rate: 7-15 ml / min; UV detector at 210 nm. Method 28: Instrument: Gilson Abimed HPLC; binary pump system; column: Nucleodur Cie Gravity, Macherey-Nagel, 5 μ? t ?; 250 * 40 mm; eluent A: water / TFA 0.05-0, 1%; eluent B: acetonitrile / TFA 0.05-0.1%; Gradient: 0-10 min to 10% B, 10-24 min to 10-30% of B, 24-28 min at 30-50% B, 28-35 min 50% B, 35-45 min at 50-60% B, 45-53 min at 60-70% B, 53- 60 min to 60-90% B, 60-70 min to 100% B, then regeneration of the chromatography column; flow rate: 15-45 ml / min; UV detector at 210 nm. Method 29: Instrument: Gilson Abimed HPLC; binary pump system; column: Nucleo-dur C18 Gravity, Macherey-Nagel, 5 pm; 250 x 21 mm; eluent A: water / acetic acid 0.2%; eluent B: acetonitrile / acetic acid 0.2%; gradient: 0-10 min at 10% B, 10-24 min at 10-30% B, 24-28 min at 30-50% B, 28-35 min at 50% B, 35-45 min at 50-60% B, 45-53 min at 60-70% B, 53-60 min at 60-90% B, 60-70 min at 100% B, then regeneration of the chromatography column; flow rate: 7-15 ml / min; UV detector at 210 nm. Method 30: Instrument: Gilson Abimed HPLC; binary pump system; column: Nucleodur C18 Gravity, Macherey-Nagel, 5 pm; 250 * 40 mm; eluent A: water / acetic acid 0.2%; eluent B: acetonitrile / acetic acid 0.2%; gradient: 0-10 min at 10% B, 10-24 min at 10-30% B, 24-28 min at 30-50% B, 28-35 min at 50% B, 35-45 min at 50-60% B, 45-53 min at 60-70% B, 53-60 min at 60-90% B, 60-70 min at 100% B, then regeneration of the chromatography column; flow rate: 15-45 ml / min; UV detector at 210 nm. Method 31: Instrument: Gilson Abimed HPLC; binary pump system; column: Kromasyl-100A C18, 5 pM; 250 * 30 mm; eluent A: water / acetic acid 0.25%; eluent B: acetonitrile; gradient: 0-3 min to 5% B, 3-30 min to 5-100% B, 30-38 min 100% B, then regeneration of the chromatography column; flow rate: 25 ml / min; UV detector at 210 nm. Method 32: Instrument: Gilson Abimed HPLC; binary pump system; column: KromasyMOOA C18, 5 pm; 250 * 30 mm; eluent A: water / TFA 0.05-0.5%; eluent B: acetonitrile; gradient: 0-5 min at 5% B, 5.01-10 min at 10% B, 10.01-20 min at 40% B, 20.01-27 min at 50% B, 27.01- 40 min to 60% B, 40.01-45 min to 90% B, 45.01-60 min to 100% B; flow rate: 15-60 ml / min; UV detector at 210 nm. Method 33: Gilson Abimed HPLC; 210 nm UV detector; column: Kromasyl RP-18 5 p.m., 100 A, 250 x 20 mm; eluent A: water + 0.05% TFA; eluent B: acetonitrile + TFA 0.05% Flow rate: 10 ml / min; 0-3 min of 10% B, ramp, 30-38 min of 90% B, 38-45 min of 10% of B. Method 34: Gilson Abimed HPLC; 210 nm UV detector; column: Gromsilo ODS-4HE 10 μ ??, 250 x 40 mm; eluent A: water + 0.05% TFA; eluent B: acetonitrile + TFA 0.05% Flow rate: 20 ml / min; 0-3 min of 10% B, ramp, 30-35 min of 90% B, 35-40 min of 90% of B. Method 35: Instrument: Gilson Abimed HPLC; binary pump system; column: Waters Symmetry-PrepTM C18, 7 pm, 300 * 19 mm; eluent A: water / glacial acetic acid 0.2%; eluent B: acetonitrile; gradient: 0-8 min at 5% B, 8-25 min at 5-100% B, 25.01-40 min at 100% B, then regeneration of the chromatography column; flow rate: 15 ml / min; UV detector at 210 nm. Method 36: Instrument: Gilson Abimed HPLC; binary pump system; column: Waters Symmetry-PrepTM C18, 7 pm, 300? 19 mm; eluent A: water / 0.1% TFA; eluent B: acetonitrile; gradient: 0-5 min at 5% B, 5.01-32 min at 5-100% B, 32.01-35 min at 100% B, then regeneration of the chromatography column; flow rate: 15 ml / min; UV detector at 210 nm. Method 37: Column: Kromasyl-100 C18, 5 pM; 250 * 20 mm; eluent A: 25% water + 0.2 TFA / 75% acetonitrile; Socratic 0-8.5 min; flow rate: 25 ml / min; UV detector at 220 nm; temperature 30 ° C. Method 38: column (steel column, dimensions 250 x 30 mm); stationary phase (silica / polyamide chiral compound KBD 5326, based on the poli selector (/ V-methacryl-L-leucine dicyclo-propylmethylamide), eluent of ethyl acetate, Socrates, flow rate: 25 ml / min temperature: 24 ° C, UV detection: 225 nm, sample: repetitive injection of 2000 μ .. Method 39: column (steel column, dimensions 430 x 75 mm), stationary phase (silica / chiral polyamide based on poly selector) (/ \ / - methacryloyl-D-leucine dicyclopropylmethylamide), eluent of isohexane (80%) / THF (20%), Socratic, flow rate: 200 ml / min, temperature: 24 ° C, UV detection: 254 nm; sample: repetitive injection of 10000 μ .. Method 40: column (steel column, dimensions 250 x 20 mm), stationary phase (Daicel Chiralpak AD-H, 5 pm), eluent: isohexane (70%) / 2-propanol + 0.2% acetic acid + 1% water (30%), Socratic, flow rate: 15 ml / min, temperature: 29 ° C, UV detection: 220 5 nm; sample: 750 μ ?. repetitive injection. Method 41: Gilson Abimed HPLC; column: Daicel Chiralpak AD-H 5 μ ??; 250 x 20 mm; eluent A: sohexane, eluent B: 0.2% acetic acid / 1% water / 2-propanol; Socratic flow rate: 15 ml / min; UV detector at 212 nm. Method 42: column (steel column, dimensions 500 x 40 mm); Stationary phase (Daicel Chiralpak AD 20 pm), isohexane / isopropanol / methanol 95/2/3, flow rate: 100 ml / minute; UV detection: 230 nm. Method 43: Instrument: Gilson Abimed HPLC; 210 nm UV detector; binary pump system; column: SymmetryPrep ™ Ci8, Waters, 7 pm; 300 mm x 19 mm; flow rate: 25 ml / min; eluent A: water / 0.2% TFA; eluent B: acetonitrile; gradient: 0-10 min at 15-65% B, then regeneration of the chromatography column. Method 44: Gilson Abimed HPLC; 210 nm UV detector; column: Waters Symmetry-PrepTM C-18, 7 pm, 300 * 19 mm; eluent A: water + 0.05% TFA; eluent B: acetonitrile + TFA 0.05% Flow rate: 10 ml / min; 0-3 min of 10% B, ramp, 30-38 min of 90% B, 38-45 min of 10% of B. Method 45: Gel chromatography is performed without pressure on Sephadex LH-20 (Pharmacia ). The fractions are taken according to UV activity (UV detector for 254 nm, Knauer) (ISCO Foxi 200 fraction collector). Dimensions of the column: 32? 7 cm (scale 1000-100 pmol); 30? 4 cm (scale 100-10 pmol); 25 * 2 cm (10-1 pmol scale). Methanol is used as eluent. Method 46: Gilson Abimed HPLC; 210 nm UV detector; column: Biotage Flash40 RP-18 or compatible module Varian Metaflash C18 40M, 35 pm, 150? 40 mm; eluent A: water + 0.05% TFA; eluent B: acetonitrile + TFA 0.05% Flow rate: 40 ml / min; 0-3 min of 10% B, ramp, 30-38 min of 90% B, 38-45 min of 10% of B. Method 47: The preparative separation of fragments 1-3 and 4-1 1 by cleavage by dihydrolisobactin chymotrypsin by reverse phase chromatography. Column: Source 15-RPC (GE-Health-Care), 5 cm in diameter, 12 cm in length, 235 ml in volume. Eluent A: 0.1% formic acid in water Eluent B: 0.1% formic acid in methanol. Flow rate: 30 ml / minute; UV detection: 215 nm, 280 nm. Load: approximately 6-7 mg of total protein / ml of resin. Loading of the sample: The column is equilibrated with the eluent A, the filtration mixture solution filtered by 0.2 μm is placed on the column, which is then washed with the eluent A. Elution: 0-45% in approximately 18 volumes of column, subsequent washing with approximately 1.3 column volumes of 100% B. Fractionation: fractions of 50 ml are collected from the beginning of the elution. CIP: The column is washed with 2 column volumes of a 1 N sodium hydroxide solution at a reduced flow rate (5 ml / min). Specific methods for analyzing amino acids and peptides Method 48: The amino acid analyzes are carried out using an amino acid analyzer LC 3000 from Eppendorf / Biotronik. A slightly modified standard Eppendorf / Biotronik separation program is used. The separation programs and the function of the analyzer are described in detail in the instrument manual (Handbuch des Aminosáurenanalysators LC 3000, Wissenschaftliche Geráte GmbH Biotronik, Maintal, 1996). Method 49: Capillary electrophoresis allows the separation of peptides and proteins on the basis of their charge in the electric field. The quality of the separation then depends on the buffer solution, the pH, the temperature and the additives used. The capillaries used are the so-called fused silica columns with an internal diameter of 50-100 μm. This method is a very good criterion to evaluate the purity of a peptide and to monitor the formation of enzymatic cleavage products. The peptides dihydrolisobactin and octahydrolisobactin elute at about 21 min, fragment 4-11 at about 18 min, 1-3 (LLF) at about 24 min, 1-3 (ALL (3-cyclohexyl)) at 22 min approximately, the deamidated forms as a double peak approximately at 30 min (1-1 1) and 24 min (4-11) of the capillary column. A large increase in the deamidated products after 24 h in the buffer solution is clearly observed. About 4 ng of the enzymatic cleavage products or of the starting compounds dihydrolisobactin and octahydrolisobactin or of the mixture are investigated by capillary electrophoresis on a glass column (length 72 cm, internal diameter 50 μm). Conditions: 90 μm current, column temperature 25 ° C, 100 mM phosphate buffer pH 3.0, detection of.

UV at 210 nm, load under pressure in 3 seconds. Method 50: 3 nmol of dissolved fragments in 60% acetonitrile / 0.1% TFA are loaded onto a sequencer sheet pre-incubated with Polibren®. The proteins are sequenced using the normal sequencer cycle. PTH amino acids are identified by on-line HPLC with the help of a PTH standard of 40 pmol. The non-proteinogenic amino acids are identified by their relative position with respect to the amino acid standard. The purity of the peptides is estimated according to the amino acid of the 1st cycle of PTH. The various peptides are sequenced over 4 to 12 stages. Other analytical methods and preparations Method 51: Instrument: Micromass Quattro LCZ with Agilent HPLC 1100 series; column: Phenomenex Onyx Monolithic C18, 100 mm x 3 mm. Eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 min of 90% A - > 2 min of 65% A - 4.5 min of 5% A - 6 min of 5% A; flow rate: 2 ml / minute; homo: 40 ° C; UV detection: 208-400 nm. Method 52: Type of MS instrument: Micromass ZQ; Type of HPLC instrument: Waters Alliance 2795; column: Phenomenex Synergy 2μ Max-RP Mercury 20 mm x 4 mm; eluent A: 1 I of water + 0.5 ml of formic acid 50%, eluent B: 1 I of acetonitrile + 0.5 ml of formic acid 50%; gradient: 0.0 min 90% A - 0.1 min 90% A - 3.0 min 5% A - 4.0 min 5% A 4.01 min 90% A; Flow rate: 2 ml / minute; oven: 50 ° C; UV detection: 210 nm. Method 53: Instrument: Agilent 1100 with DAD (G1315B), binary pump (G1312A), automatic dispenser (G1313A), solvent degasser (G1379A) and column thermostat (G1316A); column: Agilent Zorbax Eclipse XDB-C8 4.6 x 150 x 5 mm; Column temperature: 30 ° C; eluent A: TFA 0.01% in water; eluent B: TFA 0.01% in acetonitrile; flow rate: 2.00 ml / min; gradient: 0-1 min of 10% B, ramp, 10-14 min of 90%, reconditioning. Method 54: Instrument: Agilent 1100 with DAD (G1315B), binary pump (G1312A), automatic dispenser (G1313A), solvent degasser (G1379A) and column thermostat (G1316A); column: Agilent Zorbax Eclipse XDB-C8 4.6 x 150 x 5 mm; column temperature: 30 ° C; eluent A: TFA 0.01% in water; eluent B: TFA 0.01% in acetonitrile; flow rate: 1.40 ml / min; gradient: 0 min of 10% of B, ramp, 2.5-5 min of 90%, reconditioning. Method 55: Column (steel column, dimensions 250 x 20 mm); Stationary phase (Daicel Chiralpak AD-H, 5 pm); eluent: isohexane (90%) / ethanol + 0.2% AcOH + 1% H20 (10%), Socratic; flow rate: 15 ml / min; temperature: 30 ° C; UV detection: 220 nm; sample: repetitive injection of 500 pl. Method 56: Column (steel column, dimensions 250 x 4.6 mm); Stationary phase (Daicel Chiralpak AD-H, 5 pm); eluent: isohexane (90%) / ethanol + 0.2% AcOH + 1% H20 (10%), Socratic flow rate: 1.0 ml / min; temperature: 30 ° C; UV detection: 220 nm; sample: injection of 10 μ ?. Method 57: Column: Column: Kromasyl 100 C18, 60 x 2.1 mm, 3.5 pM, oven for column at 30 ° C, flow rate: 0.75 ml / min, detector: 210 nm, run time : 15 min; eluent A: water with 5 ml of HCl04 / liter of water), eluent B: acetonitrile; Gradient: 0-1 min 2% of B, ramp, 9-13 min of 98% of B, reconditioning. Method 58: (Chiral preparative HPLC, Chiralpak AD-H 40-60); column (steel column, dimensions 250 x 20 mm); stationary phase (Daicel Chiralpak AD-H, 5 pm); eluent: isohexane (40%) / ethanol + 0.2% AcOH + 1% H20 (60%), Socratic; flow rate: 15 ml / min; temperature: 30 ° C; UV detection: 220 nm; sample: repetitive injection of 500 μ ?. Method 59: (Chiral analytical HPLC, Chiralpak AD-H 40-60); column (steel column, dimensions 250 x 4.6 mm); stationary phase (Daicel Chiralpak AD-H, 5 pm); eluent: isohexane (40%) / ethanol + 0.2% AcOH + 1% H20 (60%), Socratic; flow rate: 1.0 ml / min; temperature: 30 ° C; UV detection: 220 nm; sample: injection of 10 μ ?. General Procedures Procedure 1 (removal of Boc protective groups with TFA): The Boc-protected compound is suspended in dichloromethane (1 / 5-1 / 10 of the reaction solution) and then, under a protective atmosphere of argon gas, is added 30% TFA in dichloromethane (approximately 1 ml / 10 mg starting material in 100-1 millimolar scale, approximately 1 ml / 1 mg in 100-1 micromolar scale), and the mixture is stirred at room temperature until the HPLC chromatogram shows a complete conversion (for example method 1). The solvent is then removed by vacuum distillation, the temperature of the bath not exceeding 30 ° C. The crude product is suspended in toluene, concentrated again on a rotary evaporator, and dried under high vacuum. This procedure is repeated several times (between two and five times). If the purity of the product is insufficient, it is purified where appropriate by chromatography, for example by preparative HPLC or by gel chromatography. Procedure 2 (removal of Boc protecting group with 30% TFA in dichloromethane): The starting material is taken up in 30% TFA (dichloromethane solution) and stirred at room temperature for 30 min. The solvent is then removed by vacuum distillation, the temperature of the bath not exceeding 30 ° C. The product is then dried to constant weight under vacuum by oil pump. Process 3 (removal of Boc protecting group with 4N hydrochloric acid in dioxane): The N- (tert-butoxycarbonyl) protected compound - (1 mmol) is provided in dioxane (2-3 ml) under a protective atmosphere of argon gas. At room temperature or by cooling with ice and under vigorous stirring, 4N hydrochloric acid in dioxane (30 ml) is added dropwise. Stirring is continued until analysis by analytical HPLC (Method 1) indicates complete conversion (approximately between 30 min and 2 h). The reaction mixture is evaporated in vacuo at room temperature. The crude product is collected in a small amount of dichloromethane and the solvent is again removed in vacuo. This procedure is repeated several times with toluene (twice) and with dichloromethane (twice). Finally the crude product is lyophilized or reacted immediately after drying under high vacuum. If the purity of the product is insufficient, it is purified where appropriate by chromatography, for example by preparative HPLC or by gel chromatography. Procedure 4 (hydrogenolysis of ester 1): The peptide benzyl ester is dissolved in methanol or dioxane (approximately 3-10"4-2-10" 3 mol / l), then 0.1% aqueous TFA or 0 hydrochloric acid is added. , 1N (6-10 eg.), And, under a protective atmosphere of argon gas, 10% palladium-carbon (10 mol%) is added. The hydrogenation is carried out at room temperature under atmospheric pressure until analysis by analytical HPLC (for example method 1) indicates the conversion 5 complete The reaction mixture is filtered (for example through kieselguhr, Celite), concentrated in vacuo and dried under high vacuum. If the purity of the product is insufficient, it is purified where appropriate by chromatography, for example by preparative HPLC or by gel chromatography. Procedure 5 (ester hydroquinolysis 2): The peptidyl benzyl ester is dissolved in methanol (approximately 3-10'4 - 2 0"3 mol / l) and, under a protective atmosphere of argon gas, 10% palladium-carbon is added ( 2-10 mol%) The hydrogenation is carried out at room temperature under atmospheric pressure until analysis by analytical HPLC (for example method 1) indicates the complete conversion.The reaction mixture is filtered (for example through kieselguhr , Celite®), concentrated under vacuum and dried under high vacuum.If the purity of the product is insufficient, it is purified where appropriate by chromatography, for example by preparative HPLC or by gel chromatography .. Procedure 6 (ester hydrolysis) : The carboxylic ester (3 mmol) is supplied under a protective atmosphere of argon gas in THF / water / DMF 200/100 / 2.5 (20 ml) At 0 ° C, strictly controlling the temperature, lithium hydroxide is added powder (3.6 mmol, 1, 2 eq.) in portions to the solution Vigorously stirred ion If it is observed that the conversion is not completed after 2 h according to analytical HPLC (method 13), solid lithium hydroxide (3.3 mmol, 1.1 eq.) is added again. This procedure is repeated until the conversion is completed, after which the reaction mixture is adjusted to pH 3-4 at 0 ° C using 0.1 N aqueous hydrochloric acid, concentrated in vacuo and then freeze-dried. The crude product can then be subjected to gel chromatography (for example method 45) and / or refining the purification by preparative HPLC (for example method 31). Procedure 7 (peptide coupling on resin): The amino acid protected with Fmoc bound to chlorotryril resin is mixed with a piperidine solution in D F 20% and stirred for 30 min. The solution is then filtered off with suction through a fritted disk, piperidine solution is added again, and stirring is continued for another 30 min. The solution is filtered off with suction, and the resin is washed with DMF, methanol, THF and dichloromethane. The deprotected polymer is suspended in DMF (1 ml of solvent per 100 mg of resin) and the amino acid protected with Fmoc (1.3-2.0 eq.), DIEA (2.0-3.0 eq. ) and TBTU (1, 5-2.0 eq.) dissolved in DMF. The resin is stirred at room temperature overnight. For further treatment, the polymer is collected by suction filtration on a fritted disk and then washed with DMF, THF and dichloromethane. After separating a sample in acetic acid / trifluoroethanol / dichloromethane 1: 1: 3, the obtained peptide can be confirmed by analysis. Procedure 8 (automatic solid phase synthesis with Chemspeed robot): Instrument: Chemspeed ASW 2000, equipped with 75 ml reactors and direct filtration with suction of the solvent waste. Mix by vertex. Reagents: Amino acids are used with the protective group W - [(9H-fluoren-9-ylmethoxy) carbonyl] (Fmoc group) in the? / 2 position. In addition to the Fmoc protecting group in the? / 2 position, an additional protective group is used in the side chain of the following amino acids: arginine and D-arginine each carrying a group [(2,2,5,7, 8- pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl (PMC group) in the guanidine function; serine and threonine are protected in their side chain as 03-fer-butylserine and -treonine, respectively. The amino groups of the side chains of lysine, ornithine, 2,4-diaminobutyric acid and 2,3-diaminobutyric acid are protected with benzyloxycarbonyl groups (Cbz groups). Procedure: 1.7 g of 2-chlorotryl chloride resin (Iris Biotech, No. CAS 42074-68-0) (pre-charged with an α-amino acid protected with Fmoc, 0.85 mmol / g) dry in each reactor, 17 ml of DMF are added and the mixture is stirred for 30 min. The DMF is removed by suction filtration. In order to synthesize the described octapeptides, 7 cycles of deprotection-coupling are carried out, where each consists of the following steps: 1.) Removal of Fmoc - 12.75 ml of DMF and 4.25 ml of piperidine are added. .

- The mixture is stirred for 30 min. - The mixture in DMF / piperidine is removed by filtration with suction. - 12.75 ml of DMF and 4.25 ml of piperidine are added. - The mixture is stirred for 10 min. - The mixture in DMF / piperidine is removed by filtration with suction. 2.) Washing step (repeated 5 times) - 17 ml of DMF are added. - The mixture is stirred for 30 min. - The DMF is removed by suction filtration. 3.) Amino Acid Coupling - 10.2 ml of the corresponding Fmoc-amino acid (1.5 equivalents) dissolved in DMF are added. - 6.8 ml of TBTU (2 equivalents) dissolved in DMF are added. - Diisopropylethylamine (3 equivalents) is added. - The reaction mixture is stirred for 2 h and then filtered off with suction. 4.) Washing step (repeated 3 times) - 17 ml of DMF are added. - The mixture is stirred for 30 min. - The DMF is removed by suction filtration. After the last reaction step, the product resins which are collected by suction filtration are transferred with 10 ml of dichloromethane to a filter, collected by filtration and washed twice with 5 ml of dichloromethane each time. Method 9 (elimination with complete deprotection): The resin with the peptide is mixed in a reaction vessel with a fritted base with 50% TFA in DCM (20 ml of the solution for a mixture of the size described in procedure 8), add triisopropylsilane (100 μl) and water (100 μl) and the mixture is stirred at room temperature overnight. The dark solution is then removed by suction filtration, the resin is washed with 4 portions of DCM, stirred for 2 min each time, and again collected by suction filtration. The filtrates are combined and the solvent is distilled off. The residue is stirred with MTBE, collected by filtration with suction and collected in methanol. Finally, the methanol is distilled off under vacuum. Procedure 10 (coupling with active bridgehead ester): The octapeptide and the active ester (compound 17A or compound 277A (1.1 equivalents) are dissolved in DMF (20-40 μ? / Μ? Octapeptide) to 0 ° C, and DIEA (4-5 eq.) Is added.The reaction mixture is further stirred at room temperature for between 90 min and 2 h.The mixture is taken up in acetonitrile and purified by chromatography. The product is combined and lyophilized Procedure 11 (cyclization): The starting compound is dissolved in DMF (approximately 50 μm / pmol) and the solution is cooled to 0 ° C. 4-Methylmorpholine (6 equivalents) and HATU are added. (3 equivalents), and the mixture is stirred at 0 ° C for 2 hrs. Subsequent treatment is carried out by directly charging the entire reaction mixture and separating according to method 45 or one of the aforementioned HPLC methods. fractions containing product are combined and lyophilized or concentrated in evaporation Revolving agent: Procedure 12 (elimination of the Fmoc group using piperidine): The peptide is mixed at 0 ° C with a mixture of THF and piperidine (4 + 1, approximately 20 μ? / μ ??). The mixture is then stirred at this temperature for 1 h. The reaction mixture is purified directly according to method 45, and the product-containing fractions are combined and concentrated. Method 13 (peptide coupling using HATU in the liquid phase): A cyclic peptide with an N-deprotected term (e.g. the compound of example 407, 408, 409, etc.) and a dipeptide (e.g., compound 8A, 10A, etc.) (1.5 equivalents) are dissolved in DMF (approximately 30-80 μ? / μ? t? of cyclopeptide) and the solution is cooled to 0 ° C. 4-Methylmorpholine (4 equivalents) and HATU (1.6 equivalents) are added and the mixture is stirred at room temperature for 2 h. The reaction is then quenched with 3 ml of methanol and purified by chromatography according to method 45. The fractions containing product are combined and concentrated. Starting compounds Example 1A D-Leucyl-L-leucyl-L-phenylalanyl- [(3f?) - leucyl] -L-leucyl-D-arginyl-L-isoleucyl-alotreonyl trifluoroacetate glycyl - [(3S) -3-hydroxy-asparaginyl] -serine (dihydrolisobactin) and Example 2A D-Leucyl-L-leucyl- [3-cyclohexyl-L-alanyl] - [(3R) -leucyl] -L trifluoroacetate -leucyl-D-arginyl-L-iso-leucyl-alotreonyl-glycyl - [(3S) -3-hydroxy-asparaginyl] -serine (octahydrolisobactin) The preparation of lysobactin bistrifluoroacetate by fermentation and its isolation is described in WO 2004/099239. Lysobactin bistrifluoroacetate (20 g, 13.29 mmol) is dissolved in two portions of isopropanol / water 9: 2 (110 ml each). Under a protective atmosphere of argon gas, palladium on carbon (10%, 5 g in each case) is added. The reaction mixture is stirred (after degassing) under a hydrogen pressure of 80-70 bar and at 40 ° C in a pressurized autoclave for 12 h. Palladium on carbon (10%, 5 g) is again added to the reaction. The reaction mixture is stirred (after degassing) again under a hydrogen pressure of 80-70 bar and at 40 ° C in a pressurized autoclave for 12 h. The reaction mixture is stirred (after degassing) again under a hydrogen pressure of 80-70 bar and at 40 ° C in a pressurized autoclave for 12 h. Now no more lysobactin detected by analytical HPLC (method 10). The reaction mixture is filtered through kieselguhr, concentrated in vacuo and dried under high vacuum. 20.10 g (99% of theory) of product are obtained (60% dihydrolisobactin, 40% octahydrolisobactin). Example 3A [(3f?) - Leucyl] -L-leucyl-D-arginyl-L-isoleucyl-alotreonyl-glycyl trifluoroacetate - [(3S) -3-hydroxy-paraparaginyl] -serine Preparative chymotrypsin cleavage of the dihydro / octahydrolisobactin mixture, substrate concentration 5 mg / ml 20 g of dihydro- (approximately 40%) and octahydrolisobactin (approximately 60%) are dissolved in 400 ml of methanol and then 3400 ml of methanol are added. Clivage buffer (0.1 M ammonium bicarbonate / 0.5 M urea pH 8). Before adding the enzyme, the solution is heated to 37 ° C in a drying oven. 800 mg of chymotrypsin (100 ml of chymotrypsin solution in water / ethylene glycol 1: 1, 4 mg / ml, 1:25, preheated to 37 ° C) are added and the reaction is carried out at 37 ° C. Aliquots of 200 μ are taken after 0.5, 1 h, and cleavage of the enzyme is stopped with 200 μ? 30% acetonitrile / 0.1% TFA. Samples are analyzed in parallel to cleavage of the enzyme by HPLC for 15 min (retention time of fragments 4-11 approximately 3.6 min, fragment 1-3 (LLF) approximately 9.6 min, fragment 1-3 ( LLA (3- cyclohexyl)) approximately 11.3 min) (solvent 0.1% TFA, solvent B 60% acetonitrile / 0.1% TFA, gradient 0 min 30% B, 10 min 80% B, 11 min 100 % B, 12 min 30% B, 15 min 30% B; flow rate: 0.7 ml / min, temperature: 40 ° C, UV detection 210 nm). The reaction of the enzyme is stopped after 60 min with 150 ml of acetonitrile and about 30 ml of TFA. The pH of the solution should be between 1 and 2. The solution can be stored at -20 ° C until the preparative separation. The activity of the chymotrypsin batch used (70U / mg) is tested by a control cleavage with the interleukin-4 double mutein protein Arg (121)? Asp (121) / Tyr (124)? Asp (124) (Bayer Healthcare AG, D-Wuppertal). Preparative purification: First, 500 ml portions of a solution of the cleavage mixture described above are filtered through a Celite layer under vacuum and then through a pressure filter funnel (450 μm with pre-filter). The filtered material is loaded in a Varian Metaflash C-18 40M cartridge. The elution is carried out with the following program: solvent A: 0.05% TFA in water, solvent B: 0.05% TFA in acetonitrile. Flow rate: 50 ml / min; 0-3 min 5% B; pending; 30 min 90% B, 33 min. 90% B. The fractions containing the product are combined and lyophilized. 11.8 g (87% of theory) of the title compound are obtained from the fractions containing the combined product. Example 4A (Z) -2 - [(fer-butoxycarbonyl) amino] -4,4-dimethylpent-2-enoate methyl Pivalaldehyde is dissolved (303.2 g, 3.41 mol, 10 eq.) And. { [(tert-butoxy) carbonyl] amino} (dimethoxyphosphoryl) methyl acetate (101.5 g, 0.341 mol, 1.0 eq.) in THF (800 ml) and cooled to -70 ° C. At -70 ° C, TMG (78.7 g, 0.683 mmol, 6.95 mL, 2.0 eq.) Is slowly added dropwise and the mixture is then stirred at -70 ° C for 4 h and then at room temperature. for 4 days. The reaction mixture is concentrated and then extracted by shaking with ethyl acetate (twice 500 ml) and water, and the combined organic phases are washed with a saturated solution of sodium chloride (100 ml) and dried over sodium sulfate. . After concentration, the crude product is subjected to chromatography (1.5 kg of silica gel, eluent: cyclohexane / ethyl acetate 5: 1). 67 g (76% of theory) of the title compound are obtained. Alternatively, the crude product after the aqueous process can be purified by crystallization from cyclohexane / ethyl acetate. (silica gel, cyclohexane / ethyl acetate 4: 1) = 0.5 LC-MS (Method 18): R, = 2.5 min; MS (ESlpos.): Mz (%) = 158 (100) [M - C4H8 - COz + H] +, 280 (5) [M + Na] \ 1 H NMR (400 MHz, d g - DMSO): d 1, 08 (s, 9H, C (CH3) 3), 1.38 (s, 9H, OC (CH3) 3), 3.61 (s, 3H, C02CH3), 6.40 (s, 1 H, H * ), 8.14 (s, 1 H, NH). 13 C NMR (126 MHz, cfe-DMSO): d 28.46 (3C), 29.53 (3C), 33.28, 52.22, 78.89, 125.62, 147.05, 154.67, 166.25. HR-TOF-MS (Method 24): C13H23N04 [M + H] + found 258.1696, calculated 258.1700. Example 5A / v - (fer-Butoxycarbonyl) -3-yer-butyl-D-alanine methyl ester Dissolve (2Z) -2 - [(fer-butoxycarbonyl) amino] -4,4-dimethylpent-2-enoate methyl (example 4A, 60 g, 233.2 mmol) in ethanol for 3: 1 dioxan (1000 my). A protective gas atmosphere is passed with a needle (-10 min). The solution is placed in an ultrasonic bath (approximately 5 min) and triflate of (+) - 1, 2-bis [(2R, 5?) - diethylphospholane] benzene (cyclooctadiene) rhodium (i) (600 mg, 1) is added. % in weigh). The mixture is hydrogenated under a pressure of 3.5 bar of hydrogen and at room temperature for 3 days. The reaction mixture is filtered through kieselguhr, and the eluate is concentrated. The crude product is subjected to chromatography (silica gel, eluent: cyclohexane / ethyl acetate 4: 1). 60 g (99% of theory) of the title compound are obtained. [] 20Na = + 5 ° (c = 0.33 in CHCI3). DCI-MS (NH3): m z (%) = 221 (100), 260 (40) [M + H] \ 277 (100) [M + NH4] +. 1 H NMR (400 MHz, CDCl 3): d 0.93 (s, 9H, C (CH 3) 3), 1.40 (m, 10H, OC (CH 3) 3), 1.68 ("d", J = 14.5 Hz, 2H, hA 3.68 (s, 3H, OCH3), 4.30 (t, J = 7.9 Hz, 1 H, H "), 4.81 (d, br, J = 7 , 7 Hz, 1 H, NH). 13 C NMR (126 MHz, CDCl 3): d 28.30 (3 C, CH 2 C (CH 3) 3), 29.52 (3 C, OC (CH 3) 3), 30.61 ( CH2C (CH3) 3), 46.27 (??). 51, 19 (? A), 52, 17 (OCH3), 79.79 (OC (CH3) 3), 155.11 (NHC02), 174, 39 (COzCH3) HR-TOF-MS (Method 24): Calculated C26H51N208 519.3640, found 519.3634 [M + H] + Example 6A A / 4-fer-Butoxycarbonyl-J-S-fer-butyl-D-alanine W-Fer-butoxycarbonyl-3-fer-butyl-D-alanine methyl ester (example 5A, 60 g, 231 mmol) is dissolved in THF p.a. (463 mi) At room temperature, a solution of lithium hydroxide monohydrate (19.4 g, 462.7 mmol) in water (463 ml) is added slowly by dropping. When the HPLC chromatogram (method 1) shows complete conversion (approximately 20 h), the reaction mixture is carefully adjusted to pH 3-4 using 1N aqueous hydrochloric acid and cooled with ice. Solid sodium chloride (150 g) is added to the reaction mixture, which is then extracted twice with ethyl acetate (500 ml). The combined organic phases are washed with a saturated solution of sodium chloride and then dried with sodium sulfate and filtered. He The filtrate is concentrated in a rotary evaporator and dried under high vacuum. 55.4 g (98% of theory) of the title compound are obtained. HPLC / UV-Vis (Method 3): R, = 4.2 min. DCI-MS (NH3): m / z (%) = 263 (100) [M + NH4] +, 280 (5) [M + N2H7] +. 1 H NMR (400 MHz, CDCl 3): d = 0.96 (s, 9H, C (CH 3) 3), 1.42 (m, 10H, OC (CH 3) 3, H "), 1.79 (" d ", J = 14.4 Hz, 2H, H ^), 4.31 (t, J = 8.0 Hz, 1 H, H"), 4.82 (d, J = 8.4 Hz, 1 H , NH). 13 C NMR (126 MHz, CDCl 3): d = 28.32 (3 C), 29.54 (3 C), 30.74, 45.92, 51, 24, 80.19, 155.41, 178 93. HR-TOF-MS (Method 24): C 24 H 47 N 2 O 8 calculated 491, 3327, found 491, 3328 [2M + H] + Example 7 A [/ ^ - (fer-Butoxycarbonyl-tert-butyl-D- methyl ester alanyl-IS-fer-butyl-L-alanine) HOBt (3 eq., 39.4 g, 292 mmol), NMM (3 eq., 32.1 ml, 291.8 mmol), N-fer-butoxycarbonyl-3-fer-butyl-D-alanine are successively added. (example 6A, 1.0 eq., 97.3 mmol), EDC (2 eq., 37.3 g, 194.6 mmol) and again NMM (2 eq., 21.4 mL, 194.5 mmol) to a solution of methyl ester hydrochloride of 3-fer-butyl-L-alanine (1.1 eq., 21 g, 107 mmol) in dichloromethane. (1, 4 I) at -20 ° C. The reaction mixture is heated slowly to room temperature (approximately 12 h) where the complete conversion of the amine component is observed by HPLC. The reaction mixture is then washed with a saturated aqueous solution of sodium bicarbonate (300 ml), 5% aqueous citric acid (500 ml), a saturated aqueous solution of sodium bicarbonate (500 ml) and a saturated solution of chloride of sodium. The reaction mixture was dried over sodium sulfate and filtered. The reaction mixture is evaporated to dryness in vacuo and then dried under high vacuum. 36 g (96% of theory) of the title compound are obtained which is reacted without subsequent purification. W20Na = + 24 ° (c = 0.10 in CH2CI2). DCI-MS (NH3): m / z (%) = 387 (40) [M + H] +, 404 (100) [M + NH4] +. LC-MS (Method 20): R, = 2.6 min; MS (ESlpos.): M / z (%) = 287 (100) [M-C502H8 + H] +, 387 (60) [M + H] +. 1 H NMR (400 MHz, dg-DMSO): d 0.95 (s, br, 18H, tBu), 1.35 (dd, 1H), 1.45 (s, 9H, OtBu), 1.50 (dd) , 1 H), 1.65 (dd, 1H), 1.95 (dd, br, 1H), 3.70 (s, 3H, OCH3), 4.15 ("t", br, 1H), 4 , 55 ("f, br, 1 H), 4.80 (d, 1H), 6.65 (d, br, 1H). 13C NMR (126 MHz, cfe-DMSO): d 28.39 (3C, C (CH3) 3), 29.49 (3C, C (CH3) 3), 29.67 (3C, C (CH3) 3), 30.40 (C (CH3) 3), 30.44 (C ( CH3) 3), 44.25, 45.12, 49.56, 52.06, 52.21, 78.17, 154.93, 173.00, 173.35 HR-TOF-MS (Method 24) : C2oH39N205 [M + H] + found 387.2860, calculated 387.2859.Example 8A [/ ^ - (tert-Butoxycarbonyl-J-S-fer-butyl-D-alanyl-S-yer-butyl-L-alanine The compound of Example 7A (36 g, 93.1 mmol) is dissolved in THF p.a. (279 mi) At about 10 ° C, a solution of lithium hydroxide monohydrate (7.82 g, 186.3 mmol, 2 eq.) In water (187 ml) is added slowly by dropping. When the HPLC chromatogram (method 1) shows complete conversion (approximately 20 h), the reaction mixture is freed from the THF under 200 mbar and then extracted with MTBE (200 ml). The organic phase is diluted with ethyl acetate (500 ml), then mixed with water and then carefully adjusted to pH 3-4 using 1N aqueous hydrochloric acid. The combined organic phases are washed with saturated brine, dried over sulfate of sodium, they are filtered, evaporated under vacuum and dried under high empty. 97.4 g (97% of theory) of the title compound are obtained. LC-MS (Method 18): R, = 2.26 min; MS (ESlpos.): M / z (%) = 373 (100) [M + H] +. 1 H NMR (400 MHz, cfe-DMSO): d 0.83 (s, br, 18H, tBu), 1.31 (s, 9H, OtBu), 1.40 (m, 2H, -CH2), 1.48 (dd, J = 14.1, 9.4 Hz, 1H, β-CH), 1.59 (dd, J = 14.1, 2.7 Hz, 1H, β-CH '), 3 , 98 (m, 1H, or-CH), 4.12 (m, 1H, -CH), 6.73 (d, J = 9.1 Hz, 1H, NH), 7.72 (d, J = 7.9 Hz, 1H, NH), 12, 42 (s, br, 1H, C02H). 13 C NMR (126 MHz, cfe-DMSO): d 28.49 (3C), 29.66 (3C), 29.78 (3C), 30.52, 30.58, 44.63. { ß- 2), 45.24 (fi-C2), 49.67 (a-CH), 52.40 (a-CH), 78.29, 155.05, 172.97, 174.61. HR-TOF-MS (Method 24): C19H37N205 calculated 373.2702, found 373.2717 [M + H] +. Example 9A (3-tert-Butyl-D-alanyl) -3-rer-butyl-L-alanine hydrochloride The compound of Example 8A (4.5 g, 12.1 mmol) is pre-dissolved in dioxane (3 mL). At room temperature, a 4 N solution of hydrochloric acid in dioxane (30.2 mmol, 120 mmol, 10 eq.) Is added dropwise. The reaction mixture is stirred for 30 min, evaporated in vacuo and dried under high vacuum. The title compound is obtained as a colorless solid (3.5 g, 99% of theory). LC-MS (Method 18): R, = 1.52 min; MS (ESlpos.): M / z (%) = 273.6 (100) [M + H] +; ESlneg: m / z = 271.5 (100) [M-Hf. 1 H NMR (500 MHz, de-DMSO): d 0.85 (s, 9H, tBu), 0.86 (s, 9H, tBu), 1.49 (dd, J = 14.3, 1.6 Hz , 1H, ß-CH), 1.50 (d, J = 13.8 Hz, 1H, ß-CH), 1.64 (dd, J = 14.3, 4.0 Hz, 1H, ß-CH ), 1.71 (dd, J = 14.3, 6.9 Hz, 1H, ß-C), 3.77 ("t", J = 6.5 Hz, 1H, a-CH), 4, 14 (m, 1H, a-CH), 8.27 (s, br, 3H), 8.94 (d, J = 8.2 Hz, 1H, NH), 12.58 (s, br, 1H, C02H) .13C NMR (126 MHz, cfe-DMSO): d 28.41 (3C), 29.50 (3C), 30.08, 30.38, 44.46, 44.80, 50.03, 50 , 30, 169.10, 173.98.

HR-TOF-MS (Method 24): C14H29 203 calculated 273.2173, found 273.2167 [M + H] +. Example 10A [/ ^ - (Benzyloxycarboni-S-fer-butyl-D-alanyl-J-S-fer-butyl-L-alanine The dipeptide (example 9A, 3.73 g, 12.1 mmol) is dissolved in THF (170 ml) under a protective atmosphere of argon gas. Addition of water (170 ml), benzyloxycarbonyloxysuccinimide ester (4.52 g, 18.1 mmol, 1.5 eq.) And NMM (4.28 g, 4.23 mmol, 3.5 eq.) At 0 ° C is continued by vigorous stirring at room temperature until all the starting material is reacted (several hours, HPLC monitoring, method 1). The mixture is stopped with glacial acetic acid. The THF is removed under vacuum. The remaining aqueous phase is covered with a layer of ethyl acetate, acidified to pH < 3 using 4N hydrochloric acid and then extracted several times with ethyl acetate. The organic phases are washed with a saturated solution of sodium chloride, dried over sodium sulfate, filtered and concentrated. The resulting foam is stirred with acetonitrile, where a colorless solid is formed which is collected by filtration and then washed with a little acetonitrile. This process can be repeated again several times with the filtrate then concentrate. The combined solids are dried under high vacuum, where the title compound is obtained as a solid. The remaining mother liquor is concentrated and purified by preparative HPLC (method 26). The title compound (combined solids and product of HPLC separation purification) is obtained as a colorless solid (3.49 g, 71% of theory). HPLC / UV-Vis (Method 1): R, = 2.6 min.

LC- S (Method 21): R, = 2.46 min; MS (ESIpos.): M / z (%) = 363 (60), 407 (100) [M + H] +. ESIneg: m / z = 297 (100), 405.5 (40) [M - H] ~. 1 H NMR (500 MHz, cfe-DMSO): d 0.81 (s, 9H, tBu), 0.83 (s, 9H, tBu), 1, 40-1, 44 (m, 2H, ß-? 2 ), 1.49 (dd, J = 14.3, 9.7 Hz, 1 H, ß-CH), 1.58 (dd, J = 13.5, 1, 4 Hz, 1 H, ß-CH ), 4.07 (m, 1 H, a-CH), 4.13 (m, 1 H, a-CH), 4.94 (d, J = 12.3 Hz, 1 H, CHHPh), 4 , 99 (d, J = 12.5 Hz, 1 H, CHHPh), 7.25-7.32 (m, 5H, ArH), 7.92 (d, J = 8.5 Hz, 1 H, NH ). 13 C NMR (126 MHz, c / e-DMSO): d 29.49 (3C), 29.75 (3C), 30.41, 30.46, 44.52, 45.11, 49.55, 52, 73, 65.49, 127.70 (2C), 127.91, 128.48 (2C), 137.31, 155.59, 172.52, 174.50. HR-TOF-MS (Method 24): C ^ H ^ Os calculated 407.2515, found 407.2531 [M + H] +. Example 11A (2R *, 3R *) - / \ / 2 - [(benzylloxy) carbonyl] -A / 2 - [(benzyloxy) carbonylamino] -3 - [(fer-butoxycarbonyl) amino] phenylalaninate of methyl Under a protective atmosphere of argon gas, a 1 N solution of lithium hexamethyldisilazide (157.5 mmol, 157.5 mL, 2.2 eq.) In THF in the THF reaction solvent (300 mL) is provided. At -78 ° C, a solution of methyl (rac) -3 - [(fer-butoxycarbonyl) amino] -3-phenylpropanoate (AV Rao Rama, AK Singh, Ch. VNS Varaprasad, Tetrahedron Lett, 1991, 32) is added. , 4393-4396) (20 g, 71.2 mmol) slowly dropwise. The mixture is stirred at -25 ° C for 10 min and then cooled again to -78 ° C. Dibenzyl azadicarboxylate (34.2 g, 114.6 mmol, 1.6 eq.) Is added in a portion to the reaction mixture. The mixture is stirred at -60 to -45 ° C for 3 h. to stop the reaction, the mixture is again cooled to -78 ° C, and acetic acid (20.5 ml, 358 mmol, 5 eq.) is added, and the mixture is then heated to 0 ° C and finally to room temperature . The reaction mixture is evaporated in vacuo and placed in ethyl acetate (1000 ml). The suspension is washed twice with a saturated aqueous solution of sodium bicarbonate, once with water, twice with 5% aqueous citric acid and once with a saturated aqueous solution of sodium chloride. All the aqueous phases are extracted again separately with ethyl acetate. All the organic phases are evaporated in vacuo and replaced in dichloromethane (2000 ml), filtered, dried over sodium sulphate, filtered again, evaporated in vacuo and dried under high vacuum. 7.2 g (18% of theory) of the title compound are obtained as a solid. The filtrate from the dichloromethane phase (see above) is concentrated and then recrystallized again from methanol, where 13.2 g (26% of theory) of the title compound are obtained. LC-MS (Method 23): R, = 6.8 min; MS (ESlpos.): M z (%) = 578 (40) [M + H] +, 1156 (100) [2M + H] +. MS (ESlneg.): M / z (%) = 576 (100) [M - H] ~. Example 12A (2S *, 3f? *) - A / 2 - [(benzyloxy) carbonyl] - / \ / 2 - [(benzyloxy) carbonylamino] -3 - [(ery-butoxycarbonyl) amino] phenylalaninate methyl Under a protective atmosphere of argon gas, TMG (50 ml, 399 mmol) is added to a solution of (2R *, 3R *) - A / 2 - [(benzyloxy) carbonyl] - / / 2 - [(benzyloxy) carbonylamino] -3 - [(fer-butoxycarbonyl) amino] phenylalaninate methyl (Example 1 A, 20.5 g, 35.5 mmol) in dry DMF (750 mi) at 0 ° C. The reaction mixture is allowed to thaw and is stirred until the HPLC chromatogram (method 1) indicates the complete conversion (approximately 60% of the product) (approximately 12 h), so as to then stop the reaction by adding acetic acid (pH 4-). 6). The reaction mixture is evaporated in vacuo at room temperature and placed in ethyl acetate. The organic phase is washed twice with water, twice with 5% citric acid, once with water, twice with a saturated aqueous solution of sodium bicarbonate, once with a saturated aqueous solution of sodium chloride, dried on sodium sulfate, filtered, evaporated in vacuo and dried under high vacuum. The crude product is purified by preparative HPLC (method 30) or flash chromatography (silica gel, cyclohexane / ethyl acetate 3: 1). 7.7 g (37% of theory) of the title compound and 5 g of the starting compound (25% of theory) are obtained. HPLC / UV-Vis (Method 1): R, = 3.0 min. LC-MS (Method 10): R, = 3.0 min; MS (ESlpos.): M / z (%) = 478 (100) [M -Boc + H] +, 578 (30) [M + H] +. LC-MS (Method 23): R, = 7.0 min; MS (ESlpos.): M / z (%) = 578 (40) [M + H] \ 1156 (100) [2M + H] +. MS (ESlneg.): M / z (%) = 576 (100) [M - Hf. Example 13A (2S *, 3 /? *) - 3 - [(Ie-butoxycarbonyl) amino] phenylalaninate methyl Under a protective atmosphere of argon gas, Raney nickel (61 mg, approximately 10 mol%) is added to a solution of (2S *, 3R *) - A / 2 - [(benzyloxy) carbonyl] - v - [(benzyloxy) carbonylamino] -3 - [(io-butoxycarbonyl) amino] phenylalaninate methyl (Example 12A, 705 mg, 1.22 mmol) in methanol / dichloromethane 1: 1 (42 mL). The reaction mixture is hydrogenated in a pressurized autoclave under a hydrogen pressure of 80 bar and at room temperature (40 h). The HPLC chromatogram shows complete conversion. The reaction mixture is filtered under a protective atmosphere of argon gas through a glass frit, and the glass frit is washed several times with methanol / water / 0.2% acetic acid. The filtrate is evaporated in vacuo and dried under high vacuum. A solid (approximately 3 g) is obtained which is then suspended in ethyl acetate in an ultrasonic bath. The suspension is mixed with a solution of EDTA (400 mg) in a 7% aqueous solution of sodium bicarbonate (400 ml). The aqueous phase was extracted with ethyl acetate (100 ml, three times). The combined organic phases are then washed once with a saturated aqueous solution of sodium bicarbonate, and twice with a saturated aqueous solution of sodium chloride. All the aqueous phases are extracted again separately with ethyl acetate. The combined organic phases are then dried over sodium sulfate, filtered and dried under high vacuum. The product obtained is a solid (1.26 g, quantitative) which is then reacted without fine purification. HPLC / UV-Vis (Method 2): R, = 1.7 min. LC-MS (Method 23): R, = 4.1 min; MS (ESlpos.): M / z (%) = 239 (100), 295 (80) [M + H] +. Example 14A (2S *, 3 /? *) - / V2 - [(benzyloxy) carbonyl] -3 - [(ery-butoxycarbonyl) amino] phenylalaninate methyl Under a protective atmosphere of argon gas, NMM (260 mg, 2.6 mmol, 2.1 eq.) Is added to a solution of (2S *, 3R *) - 3 - [(urea-butoxycarbonyl) amino] phenylalaninate from methyl (Example 13A, 360 mg, 1.2 mmol) and N-benzyloxycarbonyloxysuccinimide ester (610 mg, 2.44 mmol, 2 eq.) in THF (25 mL) at 0 ° C. The reaction mixture is heated slowly (12 h), where the complete conversion is observed by HPLC (method 2). Acetic acid (0.7 ml) is added, and the mixture is then concentrated in vacuo and purified by preparative HPLC (method 31). 396 mg (76% of theory) of the title compound are obtained. HPLC / UV-Vis (Method 2): R, = 2.7 min. LC-MS (Method 23): R, = 6.4 min; MS (ESlpos.): M / z (%) = 329 (100) [M - C4H8 - C02 + Hf, 429 (80) [M + H] +, 858 (60) [2M + H] +. Example 15A (2S *, 3? *) - A / 2 - [(Benzyloxy) carbonyl] -3 - [(fe -butoxycarbonyl) amino] phenylalanine Under a protective atmosphere of argon gas, a solution of methyl (2S *, 3R *) - / V - [(benzyloxy) carbonyl] -3 - [(fer-butoxycarbonyl) amino] phenylalaninate (example 15A, 755 mg, 1.76 mmol) in THF / water 2: 1 (30 mL). At 0 ° C, under vigorous stirring, a degassed 1% aqueous solution of lithium hydroxide monohydrate (86.5 mg, 3.6 mmol, 2 eq.) Is added slowly by dropping. The mixture is stirred at room temperature until the HPLC chromatogram (method 1) indicates complete conversion (approximately 1 h). Then acetic acid (0.5 ml) is added, and the reaction mixture is concentrated in vacuo and covered with a layer of ethyl acetate (100 ml). The aqueous phase is then acidified using 5% citric acid (pH 2-3) and then extracted three times with ethyl acetate (50 ml). The combined organic phases are washed twice with a saturated aqueous solution of sodium chloride (20 ml), dried over sodium sulfate, filtered, concentrated in vacuo and dried under high vacuum. 750 mg (quantitative) of crude product of the title compound is obtained which is finely purified by preparative HPLC (method 31). HPLC / UV-Vis (Method 1): R, = 2.4 min. LC-MS (Method 23): R, = 6.1 min; MS (ESlpos.): M / z (%) = 359 (100), 415 (60) [M + H] \ 829 (60) [2M + H] +. MS (ESlneg.): M z (%) = 413 (100) [M - H] ~. Example 16A (S ^ -Zv ^ - ^ BenzyloxyJ-Carbonyl-J-S-tifero-butoxycarbonylJaminoj-L-phenylalanine The mixture of enantiomers of (2S *, 3f? *) - A - [(benzyloxy) carbonyl] -3 - [(i.e-butoxycarbonyl) amin] phenollanine (example 15A, 750 mg, 1 , 8 mmol) is separated by preparative HPLC (method 38). 334 mg (98% ee, 45% of theory) of (2S, 3 /?) - A / - [(benzyloxy) carbonyl] -3 - [(fer-butoxycarbonyl) amino] phenylalanine (title compound) are obtained and 275 mg (98% ee, 37% of theory) (2R, 3S) -A / - [(benzyloxy) -carbonyl] -3 - [(fer-butoxycarbonyl) amino] phenylalanine (another enantiomer). Determination of enantiomer by method 14. [a] 20Na = + 22 ° (c = 0.50 in chloroform) (title compound). [a] 2 ° Na = _20 ° (c = 0.49 in chloroform) (another enantiomer). Example 17A (S ^ -AZ- ^ benzyloxyJJbonbonyl-S- ^ rer -butoxycarbonyl ^ aminol-L-phenylalaninate pentafluorophenyl The compound of example 16A (2.0 g, 4.83 mmol) is provided in dichloromethane (30 ml), and pentafluorophenol (4.4 g, 24.13 mmol, 5 eq.) And EDC (1.4 g) are added. g, 7.24 mmol, 1.5 eq.) at 0 ° C. The reaction is brought slowly to room temperature and stirred at this temperature overnight. After the preparation, the solvent is completely removed in a rotary evaporator at a maximum bath temperature of 30 ° C, and after fine purification of the residue by preparative HPLC (method 28) 2.3 g are isolated (83.3 % of the theoretical) of product. HPLC (Method 1) R, = 3.44 min. LC-MS (Method 18): R, = 3.23 min; MS (ESlpos): m / z (%) = 581 (13) [M + H] +, 525 (100) [M - C4H8 + H] +. 1 H NMR (500 MHz, cfe-DMSO): d = 1.36 (s, 9H, 3 CH3), 4.97 (d, J = 7.1 Hz, 2H, PhCH20), 5.15 (dd, J = 9.7, 4.8 Hz, 1 H), 5.49 (dd, J = 10.2, 4.6 Hz, 1 H), 7.18 (d, J = 10.4 Hz, 1 H , ArH), 7.25-7.42 (m, 8H, ArH), 7.68 (d, J = 10.4 Hz, 1 H, NH), 7.90 (d, J = 9.8 Hz , 1 H, NH). 3C NMR (126 MHz, cf <rDMSO): d = 27.97, 54.33, 58.72, 65.75, 78.65, 124.10, 126.48, 127.37 127.46, 127 , 82, 128.23 (2C), 136.40 / 138.36 (CF), 136.54, 138.49 / 140.27 (CF), 139.34 / 141, 40 (CF), 154.72 , 156.04, 167.10. HR-TOF-MS (Method 24): CzeHze zOe [M + H] + found 581, 1719, calculated 581, 1706. Example 18A (SRÍ-A ^ -IbenbenzyloxyJJbonbonyl-S-L-butoxycarbonylJaminol-L-phenylalaninate 2,5-dioxopyrrolidin-1-yl Under a protective atmosphere of argon gas, (3R) - / v - [(benzyloxy) carbonyl] -3 - [(fer- butoxycarbonyl) amine] -L-phenylalanine (example 16A, 100.0 mg, 241, 28 μm) in methylene chloride (10 ml), the solution is cooled to 0 ° C, added W-hydroxysuccinimide (33.3 mg, 289.53 pmol, 1.2 eq.) And EDC (55.5 mg, 289.53 pmol, 1.2 eq.), And the mixture is stirred at 0 ° C for the night. For the preparation, the solvent is completely removed in a rotary evaporator at a bath temperature of 30 ° C, and after fine purification by preparative HPLC (method 32) 96.0 mg (77.8% of theory) are isolated of product. HPLC (Method 1) R, = 2.53 min. LC-MS (Method 18): R, = 2.58 min; MS (ESlpos): m z (%) = 529 (28) [M + NH 4] \ 412 (100). Example 19A methyl [^ - [(benzyloxyJJbonbonyl-S-fer-butyl-D-alanyl] - ^ phenylalaninate] Under a protective atmosphere of argon gas, N-benzyloxycarbonyl-protected dipeptide (Example 10A, 58.4 mg, 0.14 mmol) in methylene chloride (5 mL) is supplied, the solution is then cooled to -10 ° C, and HOBt (77.7 mg, 0.57 mmol, 4 eq.), NMM (47 μ ?, 43.7 mg, 0.43 mmol, 3 eq.) and EDC (55.1 mg, 0) were successively added. , 29 mmol, 2 eq.), And finally compound of example 13A (94.0 mg, 0.14 mmol, 1 eq.), And NMM 32?, 29.1 mg, 0.29 mmol, 2 are added. eq.). The reaction is slowly warmed to room temperature and stirred at this temperature overnight. For the preparation, the precipitate is removed by filtration, the filtrate is concentrated in a rotary evaporator at a bath temperature of 30 ° C, and after fine purification of the residue by HPLC. preparation (method 31), 77.9 mg (79.4% of theory) of the product are obtained. HPLC (Method 1) R, = 3.12 min. LC-MS (Method 23): R, = 7.05 min; MS (ESlpos): m / z (%) = 683 (100) [M + H] +, 1366 (75) [2M + 2H] 2+. 1 H NMR (300 MHz, CDCl 3): d = 0.89 (d, J = 4.6, 9H, CH 2 C (CH 3) 3), 0.96 (d, J = 2.9, 9H, CH 2 C (CH 3) 3), 1.23-1.49 (m, 11H: including 1.39 (s, 9H, OC (CH3) 3), 1.85 (m, 2H, CH2C (CH3) 3), 3.59 / 3.68 (2s, 3H, OCH3), 4.04 (m, 1 H, aCH), 4.41 (m, 1 H, aCH), 4.88-5.42 (m, 6H), 5, 99 (m, 1 H, NH), 6.22 (m, 1H, NH), 7.13-7.42 (m, 10H, ArH). HR-TOF-MS (Method 24): C ^ Hss ^ Oe calculated 683,4015, found 683,4033 [M + H] + Example 20A [^ - (Benzyloxycarbonyl-J-S-fer-butyl-D-alanylHS- ^ phenylalanine] The ester (Example 19A, 1.0 g, 1.46 mmol) is provided in a mixture of THF (100 mL) and water (50 mL) and, at 0 ° C, a solution of lithium hydroxide is added to the 0.5% (12 mL, 59.6 mg, 2.49 mmol, 1.7 eq.) Per drop. The solution is stirred at 0 ° C for 4 h until the conversion is complete. For the preparation, the reaction is mixed with potassium dihydrogen phosphate (996.4 mg, 7.32 mmol), the solvent is completely removed in a rotary evaporator at a bath temperature of 30 ° C, and the residue is purified by Preparative HPLC (method 28). 737.0 mg (75.3% of theory) of product are obtained. HPLC (Method 1) R, = 2.86 min.

LC-MS (Method 21): R, = 2.89 min; MS (ESIpos): m / z (%) = 669 (20) [M + H] +, 569 (100) [M - C4H8 - C02 + H] +. HR-TOF-MS (Method 24): C36H53N408 [M + H] + found 669.3881, calculated 669.3858. Example 21 A [A / ^ benzyloxycarbonyl-J-S-fer-butyl-D-ala-phenylalaninate] of 2,5-dioxopyrrolidin-1-ylo Under a protective atmosphere of argon gas, exemplary Compound 20A (30.0 mg, 44.85 μ ??) is dissolved in dichloromethane (6 ml), the solution is cooled to 0 ° C., N-hydroxysuccinimide is added (6.2 mg, 53.83 mmol, 1.2 eq.), EDC (10.3 mg, 53.83 μ ???, 1.2 eq.) And 4Á molecular filters, and the mixture was Stir at 0 ° C overnight. The solvent is removed in a rotary evaporator at a maximum bath temperature of 30 ° C, the residue is taken up in ethyl acetate and washed successively twice with a solution of 5% citric acid and twice with a solution saturated with sodium chloride, the organic phase is dried over sodium sulfate and filtered, the solvent is concentrated in a rotary evaporator at a bath temperature of 30 ° C, and 34.0 mg (98.7% of theory) of product is isolated from the residue after fine purification in a RP cartridge (eluent: ethyl acetate). HPLC (Method 1) R, = 2.99 min. LC-MS (Method 20): R, = 2.88 min; MS (ESlpos): m / z (%) = 766 (57) [M + H] +, 666 (100) [M + H - C4H8 - C02] +. Example 22A A / 4-Butoxycarbonyl H-Alotreonine Dissolve L-alo-threonine (3.15 g, 26.44 mmol) in water-dioxane (1 + 2.75 mL), add di-tert-butyl dicarbonate (6.35 g, 29.09 mmol) , 1.1 equivalents) and triethylamine (4.79 ml, 34.38 mmol, 1.3 equivalents) and the mixture is stirred at room temperature overnight. The solvent is then removed in vacuo. The residue is taken up in ethyl acetate and extracted with 1 M citric acid. The aqueous phase is extracted several more times with ethyl acetate until no more product can be detected (HPLC)., method 5). The combined organic extracts are then dried over sodium sulfate, concentrated and dried under vacuum by an oil pump at a constant weight. The product is then reacted without subsequent purification. Yield: 6.5 g of crude product. HPLC (Method 5): R, = 3.23 min. LC-MS (Method 22): R, = 2.51 min, MS (ESlneg): m / z (%) = 217.8 (100) [MH] \ 1 H NMR (400 MHz, cfe-DMSO) d ( ppm) = 1.08 (d, J = 5.4 Hz, 3H), 1.38 (s, 9H), 3.72-3.84 (m, 2H), 6.77 (d, J = 7 , 4 Hz, 1 H). EXAMPLE 23A / ^ - (Benzyl-fero-butoxycarboni-L-alotreoninate) The method was carried out analogously to the following literature: SB Cohen, R. Halcomb, J. Am. Chem. Soc 2004, 124, 2534-25M 43. W. Jiang, J. Wanner, RJ Lee, P. -Y. Bounaud, D. L. Boger, J. Am. Chem. Soc 2003, 125, 1877-1887. The compound of example 22A (6.8 g of crude product, 26.44 mmol) is taken up in methanol (177 ml), cesium carbonate (5.56 g, 17.06 mmol, 0.63 equivalent) is added, and the mixture is stirred until the dissolution is complete. The solvent is then removed by distillation, DMF (42 ml) and then benzyl bromide (4.06 ml, 34.12 mmol, 1.26 equivalents) are added. The mixture is stirred for 16 h and the DMF is then removed substantially under vacuum. The residue is taken up in water and extracted with 3 portions of dichloromethane. The combined organic phases are dried over sodium sulfate, filtered and concentrated in vacuo. The crude product is purified on Biotage RP18-Flash (water-acetonitrile gradient: 0-5 min, 10% acetonitrile, 3-30 min, 10-90% acetonitrile, 30-35 min, 90% acetonitrile, flow: 20ml / min.). Yield: 5.00 g (16.16 mmol, 52% of theory). HPLC (Method 5): R, = 4.36 min. LC-MS (Method 18): R, = 2.39 min, MS (ESlpos): m / z (%) = 332.6 (25) [M + H] +. 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 1, 09 (d, J = 6.4, 3 H), 1.37 (s, 9 H), 3.82 (m, 1 H), 3 , 95 (dd, j = 6.4, J = 8.1 Hz), 4.98 (d, J = 5.4 Hz, 1 H), 5.09 (d, J = 12.7 Hz, 1 H), 5, 16 (d, J = 12.7 Hz, 1 H), 7.10 (á, J = 8.1 Hz, 1 H), 7.31-7.37 (m, 5H). Example 24A Benzyl L-Alotreoninate Trifluoroacetate 530 mg of the compound of example 23A are reacted with 8.0 ml of the TFA solution according to procedure 2. The crude product (589 mg, quantitative) is then reacted without further purification. HPLC (Method 5): R, = 3.18 min. LC-MS (Method 22): R, = 2.24 min, MS (ESlpos): m / z (%) = 210.0 (100) [M + Hf. 1 H NMR (400 MHz, de-DMSO) d (ppm) = 1.15 (d, J = 6.6 Hz, 3H), 4.09-4.10 (m, 2H), 5.26 (s, 2H), 7.36-7.44 (m, 5H), 8.34 (br.S, 2H). Example 25A [/ v ^ - (fer-butoxycarbonyl) -L-isoleucyl] -L-alotreonamide benzyl The compound of example 24A (2.30 g 7.12 mmol) and N- (tert-butoxycarbonyl) -L-isoleucine (2.14 g, 9.25 mmol, 1.3 equivalents) are dissolved in DMF (21, 0 mi). 4-Methylmorpholine (1.3 mL, 12.02 mmol, 1.7 equivalents) and HATU (3.52 g, 9.25 mmol, 1.3 equivalents) are added, and the mixture is stirred at room temperature for 16 hours. h. The complete mixture is then purified by chromatography first according to method 45 and then according to method 46. Yield: 1.75 g (4.14 mmol, 58% of theory) as a pale beige amorphous solid. HPLC (Method 5): R, = 4.59 min. LC-MS (Method 18): R, = 2.56 min, MS (ESlpos): m / z (%) = 423.8 (70) [M + H] +. 1 H NMR (400 MHz, cfrDMSO) d (ppm) = 0.74-0.78 (m, 6H), 1.01-1.07 (m, 2H), 1.10 (d, J = 6.3) Hz, 3H), 1.37 (s, 9H), 1.64-1.66 (m, 1H), 3.86-3.94 (m, 1H), 4.28 (dd, J = 7, 3, J = 7.3 Hz, 1H), 5.05 (d, J = 5.6 Hz), 5.09 (d, J = 12.7 Hz, 1H), 5.13 (d, J = 12.7 Hz 1H), 6.70 (d, J = 9.0 Hz, 1H), 7.31-7.36 (m, 5H), 8.11 (d, J = 8.1 Hz). HR-TOF-MS (Method 24): C22H35N206 calculated 423.2490, found 423.2489 [M + H] +. Example 26A Trifluoroacetate L-isoleucyl-L-benzyl alotreoninate The compound of example 25A (224 mg, 0.53 mmol) is treated with 8.0 ml of the TFA solution according to procedure 2. 253 mg of crude product from example 26A (approximately 91% pure, , 53 mmol, quantitative) and reacted without subsequent purification. HPLC (Method 5): R, = 3.51 min. LC-MS (Method 18): R, = 1.58 min, MS (ESlpos): m / z (%) = 323.6 (100) [M + H] +. 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 0.77-0.86 (m, 6H), 1.02 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H), 1.45 (m, 1H), 1.77 (m, 1H), 3.97 (m, 1H), 4.34 (m, 1H), 5.11 (d, J = 12.5 Hz, 1H), 5.16 (d, J = 12.5 Hz, 1 H), 7.37-7.39 (m, 5H), 7.47 (m, 1 H), 8.07-8 , 08 (m, 3H), 8.69 (d, J = 7.3 Hz, 1 H). Example 27A [/ ^ - (Fer-butoxycarbonyl-J-D-arginylj-L-isoleucyl-L-benzyl alotreoninate] The compound of Example 26A (253 mg 91% pure, 0.53 mmol) and A / 3-tert-butoxycarbonyl-J-D-arginine (145 mg, 0.53 mmol, 1 equivalent) are dissolved in DMF (3.0 ml) . 4-Methylmorpholine (76 μ ?, 0.70 mmol, 1.3 equivalents) and HATU (221 mg, 0.58 mmol, 1.1 equivalents) are added, and the mixture is stirred at room temperature for 16 h. The complete mixture is then placed on an HPLC column and purified by chromatography (method 34). Yield: 364 mg (0.53 mmol, 99% of theory). HPLC (Method 5): R, = 3.91 min. LC-MS (Method 18): R, = 2.04 min, MS (ESlpos): m / z (%) = 579.9 (100) [M + H] +. 1 H NMR (400 MHz, oVDMSO) d (ppm) = 0.72-1, 16 (m, 8H), 1.37 (s, 9H), 1.46 (m, 2H), 1.60 (m, 1 H), 1.69 (m, 1 H), 3.06 (m, 2H), 3.93-4.01 (m, 2H), 4.25 (m, 1 H), 4.33 ( m, 1 H), 5.07-5.14 (m, 2H), 6.96 (d, J = 7.8, 1H), 7.35 (m, 5H), 7.45 (m, 1 H), 7.66 (d, J = 8.8), 8.33 (m, 1H). Example 28A Benzyl D-arginyl-L-isoleucyl-L-alotreoninate trifluoroacetate The compound of example 27A (237 mg, 0.34 mmol) is treated with 2.0 ml of the TFA solution according to procedure 2. 255 mg of crude product of example 28A (94%) are obtained. pure, 0.34 mmol, quantitative), and reacted without subsequent purification. HPLC (Method 5): R t = 3.42 min. LC-MS (Method 22): R, = 2.42 min, MS (ESlpos): m / z (%) = 479.3 (50) [M + H] \ 1 H NMR (400 MHz, drDMSO) d ( ppm) = 0.73-0.81 (m, 5H), 1, 11-1, 19 (m, 5H), 1, 33-1, 49 (m, 3H), 1.74 (m, 3H) , 3.10 (m, 2H), 3.88-3.95 (m, 2H), 4.25 (dd, J = 6.8, J = 7.1 Hz, 1 H), 4.46 ( dd, J = 7.3, J = 8.8 Hz, 1 H), 5.09 (d, J = 12.5 Hz, 1 H), 5.15 (dd, J = 12.5 Hz), 7.36 (m, 5H), 7.61 (m, 1 H), 8.10 (m, 2H), 8.51 (d, J = 7.6 Hz, 1 H), 8.57 (d. , J = 9.0 Hz, 1 H). Example 29A Trifluoroacetate of [/ ^ - (Benzene-butoxycarbonyl-L-leucyl-D-arginyl-L-isoleucyl-L-alotreoninate benzyl) The compound of Example 28A (240 mg, 0.34 mmol) and / V- (fer-butoxycarbonyl) -L-leucine (79 mg, 0.34 mmol, 1 equivalent) are dissolved in dichloromethane-DMF ( 5 + 1, 6 mi). Diisopropylethylamine (296 μl, 1.70 mmol, 5 equivalents) and HATU (194 mg, 0.51 mmol, 1.5 equivalents) are added, and the mixture is stirred at room temperature for 24 h. The complete mixture is then placed on a column of gel chromatography and purified by chromatography (method 45, the eluent is methanol). Yield: 146 mg (0.18 mmol, 53% of theory). HPLC (Method 5): R, = 4.15 min. LC-MS (Method 18): R, = 1.92 min, MS (ESlpos): m / z (%) = 692.8 (100), [M + H] +. 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 0.72-1, 23 (m, 22H), 1.37 (s, 9H), 1, 38-1, 71 (m, 3H), 3.08 (m, 2H), 3.91-4.00 (m, 2H), 4.26 (m, 1 H), 4.33-4.42 (m, 2H), 5.07-5 , 15 (m, 2H), 6.92 (d, J = 7.8 Hz, 1 H), 7.35 (m, 5H), 7.47 (m, 1 H), 7.88 (d, J = 8.1 Hz, 1 H), 7.93 (d, J = 9.0 Hz, 1 H), 8.35 (d, J = 7.3 Hz, 1 H).

EXAMPLE 30A L-leucyl-D-arginyl-L-isoleucyl-L-allyl-benzyl bistrifluoroacetate The compound of example 29A (220 mg, 0.27 mmol) is treated with 2.0 ml of the TFA solution according to procedure 2. 223 mg of crude product of example 28A (0.27 mmol, quantitative ), and they are reacted without subsequent purification. HPLC (Method 4): R, = 3.80. LC-MS (Method 22): R, = 2.54 min, MS (ESlpos): m / z (%) = 592.4 (2) [M + H] +. 1 H NMR (400 MHz, cfe-D SO) d (ppm) = 0.73-1, 11 (m, 13H), 1, 22-1, 74 (m, 12H), 3.11 (m, 4H) , 3.60 (m, 2H), 3.87 (m, 1H), 3.95 (m, 1 H), 4.25 (m, 1 H), 4.38 (dd, J = 7.8 , J = 8.6 Hz, 1 H), 4.64 (dd, J = 7.8, J = 13.7 Hz, 1 H), 5.09 (d, J = 12.7 Hz, 1 H ), 5.13 (d, J = 12.7 Hz, 1 H), 7.35 (m, 5H), 7.58 (m, 1 H), 8.07 (m, 2H), 8.25 (d, J = 8.8 Hz, 1 H), 8.39 (d, J = 7.6 Hz, 1 H), 8.77 (d, J = 8.3 Hz, 1 H). Example 31 A Trifluoroacetate of [(SRJ-A ^ -ery-butoxycarbonyl-J-S-hydroxy-L-leucyl-L-leucyl-D-arginyl-L-isoleucyl-L-allyl-benzyl ether) The compound of Example 30A (223 mg, 0.27 mmol) and / V- (fer-butoxycarbonyl) - (3R) -3-hydroxy-L-leucine (89 mg, 0.33 mmol, 1.22 equivalents) was Dissolve in DMF (6 mi), and the solution is cooled to -20 ° C. 4-Methylmorpholine (150 μ ?, 1.36 mmol, 5 equivalents) and HATU (165 mg, 0.44 mmol, 1.6 equivalents) are added, and the mixture is stirred at room temperature for 16 h. The complete mixture is then placed on a column of gel chromatography and purified by chromatography (method 45, the eluent is methanol). Yield: 188 mg (0.20 mmol, 74% of theory). HPLC (Method 5): R, = 4.24 min. LC-MS (Method 19): R, = 1.99 min, MS (ESlpos): m / z (%) = 821, 9 (100) [M + H] +. 1 H NMR (400 Hz, cfe-DMSO) d (ppm) = 0.71-0.90 (m, 15H), 1.00 (m, 1 H), 1.10 (d, J = 6.4 Hz , 3H), 1, 24-1, 26 (m, 3H), 1, 38 (s, 9H), 1, 42-1, 71 (m, 6H), 3.06-3.17 (m, 3H) ), 3.45 (m, 1 H), 3.61 (m, 1 H), 3.93 (m, 1 H), 4.05 (m, 1 H), 4.26 (m, 1 H) ), 4.35 (m, 2H), 4.54 (d, J = 7.8 Hz, 1H), 5.07-5.15 (m, 2H), 5.45 (d, J = 9, 0 Hz, 1H), 7.35 (m, 5H), 7.46 (m, 1 H), 7.85 (d, J = 7.8 Hz, 1 H), 7.89 (d, J = 8.8 Hz, 1 H), 7.97 (d, J = 8.1 Hz, 1 H), 8.35 (d, J = 7.6 Hz, 1 H). Example 32A Trifluoroacetate of [(SR ^) fer-Butoxycarbonyl-J-S-hydroxy-L-leucyl-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonine * TFA The compound of Example 31A (100 mg, 0.11 mmol) is dissolved in glacial acetic acid (4.3 ml), palladium on 10% activated carbon (22 mg) is added, and the mixture is hydrogenated under atmospheric pressure at room temperature for 2 h. The catalyst is removed by filtration, and the filtrate is lyophilized. The crude product is purified by chromatography (method 33). 58 mg (60 μ? T, 55% of theory) of the title compound are obtained. HPLC (Method 5): R, = 3.75 min. LC-MS (Method 1 Method 19): R, = 1.80 min, MS (ESlpos): m / z (%) = 731, 8 (100) [M + H] +. EXAMPLE 33A [04] - (04-Methyl-butoxycarbonylJ-glycyl-SSS-S-hydroxy-L-aspartate (3S) -3-Hydroxyapartic acid is prepared by the method of G. Cardillo, L. Gentilucci, A. Tolomelli, C. Tomasini, Synlett 1999, 1727-1730, and is converted analogously to PG Mattingly, MJ Miller, J. Org. Chem. 1983, 48, 3556-3559, using microwave radiation in a closed reactor in (2S, 3S) -2-amino-3-hydroxy-4-methoxy-4-oxobutyric acid hydrochloride. Dissolve (2S, 3S) -2-amino-3-hydroxy-4-methoxy-4-oxobutyric acid hydrochloride (447 mg, 2.24 mmol) in DMF (9 ml). The solution is cooled to 0 ° C, Boc-glycine-A / -hydroxysuccinimide ester (763 mg, 2.91 mmol, 1.3 equivalents), DMAP (14 mg, 0.1 1 mmol, 0.05 equivalents) are added. ) and finally DIPEA (1170 μ ?, 6.72 mmol, 3 equivalents). The mixture is allowed to warm slowly to room temperature and then it is stirred for 2 h. The mixture is acidified with glacial acetic acid, mixed with acetonitrile and chromatographed on Sephadex LH 20 (method 45). The fractions containing the product are combined, concentrated and rechromatographed (method 46). The product obtained (761 mg, quantitative) is then reacted without subsequent purification. For analytical purposes, a pure sample is obtained by HPLC (method 44). HPLC (Method 5): R, = 3.15 min LC-MS (Method 1): R, = 1.17 min, MS (ESlpos) = 321, 2 [M + H] +. [] 20Na = + 39 ° (c = 0.55, MeOH). 1 H NMR (300 MHz, d 6 -DMSO) d (ppm) = 1.40 (s, 9 H), 3.49-3.60 (m, 2 H), 3.61 (s, 3 H), 4 , 29 (m, 1 H), 4.73 (d, J = 6.6 Hz, 1 H), 7.01 (m, 1 H), 7.49 (d, J = 6.99 Hz, 1 H). 13 C-NMR (d6-acetone, 126 MHz, DEPT) d (ppm) = 28.5 (CH3), 42.2 (CH2), 51.8 (CH3), 53.7 (CH), 56.0 ( CH), 79.2 (cuat), 169.6 (cuat), 169.7 (cuat), 172.8 (cuat), 173.8 (cuat). HR-TOF-MS (Method 24): C ^ H ^ NzOe [M + H] + calculated: 321, 1298, found: 321, 1299. Example 34A [/ ^ - (fer-butoxycarbonylJglicilHISSJ-S-benzyl hydroxide The compound of Example 33A (390 mg, 1.22 mmol) and benzyl 0- (fer-butyl) -L-serinate (445.14 mg, 1.22 mmol, 1 equivalent) are dissolved in DMF (9 mL) . The solution is cooled to 0 ° C and then 2.44 ml (2 equivalents) of a 1 M solution of 4-methylmorpholine in DMF is added, followed by HATU (925 mg, 2.44 mmol, 2 equivalents). The mixture is stirred at OcC for about 15 minutes, another 2.44 ml (2 equivalents) of the 4-methylmorpholine solution are added, and the mixture is stirred at room temperature for 2 h. Then water is added and the mixture is extracted with 2 portions of ethyl acetate. The combined organic extracts are washed with 1 M citric acid, concentrated sodium bicarbonate and concentrated brine. The organic phase is then dried over sodium sulfate, the solvent is distilled off and the residue is subjected to chromatography (method 46). Yield: 413 mg (61% of theory) as a solid. HPLC: R, = 4.46 min. LC-MS: R, = 2.37 min. MS (ESlpos): 554.4 [M + H] +. [a] 20Na = -1, 7 (c = 0.57, CH3CN). 1 H NMR (400 MHz, d 6 -DMSO) d (ppm) = 1, 09 (s, 9 H), 1.45 (s, 9 H), 3.17 (br s, 1 H), 3.50 - 3.56 (dd, J = 2.85 Hz, J = 8.8 Hz, 1 H), 3.59 (s, 3 H), 3.61 - 3.67 (m, 3 H), 4, 66 (s, 1 H), 4.70 - 4.72 (m, 1 H), 4.97 (dd, J = 2.7 Hz, J = 8.65 Hz, 1 H), 5.14 ( d, J = 12.3 Hz, 1 H), 5.19 (br s, 1 H), 5.23 (d, J = 12.3 Hz, 1 H), 7.11 (d, J = 7 , 45 Hz, 1 H), 7.19 (d, J = 8.5 Hz, 1 H), 7.46 (m, 5 H). 13 C-NMR-DEPT (126 MHz, d 6 -DMSO) d (ppm) = 28.5 (CH 3), 29.6 (CH 3), 45.5 (CH 2), 54.4 (CH 3), 54.5 ( CH), 55.9 (CH), 62.8 (CH2), 68.6 (CH2), 71, 7 (CH), 75.0 (cuat), 81, 8 (cuat), 129.6 (CH) ), 129.7 (CH), 129.9 (CH), 136.7 (cuat), 157.3 (cuat), 169.9 (cuat), 171, 2 (cuat), 173.4 (cuat) . HR-TOF-MS: C26H4o 3010 [M + H] + calc'd: 554.2714, found: 554.2707. Example 35A [/ ^ - (fer-butoxycarboni glycyl-tISS-S-hydroxy-L-asparaginyl-J-O] fer-butyl-J-L-serinate benzyl Compound 34A (430 mg, 0.78 mmol) is dissolved in acetonitrile (30 mL) and cooled to 0 ° C. HE add concentrated ammonia (15 mL) and stir the mixture for approximately 15 min. Upon completion of the reaction (detection by HPLC, method 5), acetic acid is added to acidify, and the mixture is diluted with water. The mixture was extracted with 2 portions of ethyl acetate. The combined organic extracts are washed with concentrated brine, dried over sodium sulfate, concentrated and purified by HPLC. Yield: 158 mg (38% of theory) as a solid. [afNa = -16 ° (c = 0.53, eOH). HPLC: R, = 4.18 min. LC-MS: R, = 2.14 min, MS (ESlpos) m / z = 539.4 [M + H] +. HR-TOF-MS: C 25 H 39 N 4 O 9 [M + H] + calc'd: 539.2717, found: 539.2709. 1 H NMR (300 MHz, d 6 DMSO) d (ppm) = 1.05 (s, 9 H), 1.38 (s, 9 H), 3.50 - 3.56 (m, 2 H), 3.61 - 3.67 (m, 2 H), 4.33 (s, 1 H), 4.48 (m, 1 H), 4.71 (m, 1 H, 5.10 (d, J = 12, 7 Hz, 1 H), 5.19 (d, J = 12.7 Hz, 1 H), 7.07 (m, 1 H), 7.17 (br s, 1 H), 7.33 - 7.46 (m, 6 H), 7.65 (d, J = 8 , 8 Hz, 1 H), 7.83 (d, J = 7.7 Hz, 1 H). 3C-NMR-DEPT (126 MHz, d6-acetone) d (ppm) = 27.54 (CH3), 28.58 (CH3), 44.73 (CH2), 54.06 (CH), 55.67 ( CH), 62.61 (CH2), 67.08 (CH2), 71, 64 (CH), 73.90 (cuat), 79.70 (cuat), 128.75 (CH), 128.82 (CH) ), 129.25 (cuat), 137.20 (cuat), 157.04 (cuat), 170.56, 170.62 (cuat), 170.72 (cuat), 174.13 (cuat). Example 36A - [(3S) -3-hydroxy-L-asparaginyl] -03- (fer-butyl) -L-serine benzyl trifluoroacetate 55 mg (100 μ ??) of compound of example 35A are reacted in 2 ml of the reagent solution according to procedure 2. The product is reacted without subsequent purification. Yield: 50 mg (quantitative). HPLC (Method 3): R, = 3.05 min. LC-MS (Method 22): R t = 2.22 min; MS (ESlpos) m / z (%) = 383.0 (100) [M + H] \ Example 37A Trifluoroacetate de. { (SR ^ A / ^ Benzyloxycarbonyl-S-ér-butoxy ^ hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-gltorine The product of the degradation of example 3A (2.8 g, 2.53 mmol) and the compound of example 17A (1.5 g, 2.53 mmol, 1 eq.) In DMF (70 ml) are provided. The solution is cooled to 0 ° C, DIEA (2.64 ml, 2.0 g, 15.14 mmol, 6 eq.) Is added, and the reaction mixture is warmed slowly to room temperature and stirred at this temperature. for 3 h. The solvent is partially removed in a rotary evaporator, the temperature of the bath must not exceed 30 ° C. After fine purification by preparative HPLC (method 28), 2.2 g (61.4% of theory) of product are isolated. HPLC (Method 9) R, = 17.03 min. LC-MS (Method 20): R, = 1.79 min; MS (ESlpos): m / z (%) = 1301 (28) [M + H] +, 601 (100) [M - C4H8 - C02 + 2H] 2+; MS (ESlneg.): M / z (%) = 1300 (100) [M - H] ~. Example 38A Trifluoroacetate of. { (3R) -N2 - [(benzyloxy) carbonyl] -3-amino-L-phenylalanyl} - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine The Boc protecting group is removed from the compound of example 37A (2.2 g, 1.55 mmol) according to procedure 1. After chromatography (method 28), 1.8 g (87.1% of theory) are obtained. ) of product. HPLC (Method 9) R, = 12.37 min. LC-MS (Method 20): R, = 1.17 min; MS (ESlpos): m / z (%) = 1201 (8) [M + H] +, 601 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1199 (100) [M - Hf. Example 39A C1 ^ - / V3 'Trifluoroacetate-lactam of. { (SRJ-A ^ -KBenzyloxy carbonill-S-amino-L-phenylalani ^ hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glidl - [(3S) -3-hydroxy -L-asparagi In a protective gas atmosphere, the compound of Example 38A (1.3 g, 0.89 mmol) in DMF (700 mL) is provided, the solution is cooled to 0 ° C and then HATU (1.0 g) is added. , 2.68 mmol, 3 eq.) And NMM (0.8 ml, 0.7 g, 7.14 mmol, 8 eq.). After stirring under a gentle stream of argon at 0 ° C for 3 h, the conversion is completed. For the preparation, the reaction is mixed with methanol (30 ml), the solvent is removed in a rotary evaporator at a bath temperature of 30 ° C, the residue is suspended in methanol (30 ml) in an ultrasonic bath, and the precipitate that has separated is removed by filtration. The filtrate is concentrated in a rotary evaporator at a maximum bath temperature of 30 ° C, and after fine purification by preparative HPLC (method 28) 905.6 mg (78.3% of theory) of the desired compound are obtained. . HPLC (Method 9) R, = 15.09 min. LC-MS (Method 18): R, = 1.75 min; MS (ESlpos): m / z (%) = 1183 (100) [M + H] +. Example 40 A. { N2 - [(benzyloxy) carbonyl] -3-tert-butyl-D-alanyl} -. { 3-tert-butyl-L-alanyl} - [(3R) -3 - [(tert-butoxycarbonyl) amino] -L-phenylalaninate] pentafluorophenyl Under a protective atmosphere of argon gas, the acid (example 20A, 170.0 mg, 0.25 mmol) is supplied in methylene chloride (5 ml) and cooled to 0 ° C, and then pentafluorophenyl diphenylphosphate is added ( 146.5 mg, 0.38 mmol, 1.5 eq.) And NMM (140 μ ?, 128.5 mg, 1.27 mmol, 5 eq.). The reaction is slowly warmed to room temperature and stirred at this temperature overnight. For the preparation, the solvent is removed in a rotary evaporator at a bath temperature of 30 ° C, the residue is purified by preparative HPLC (method 32), the concentrated product fractions are again mixed with toluene and dichloromethane, the solvents then they are completely removed again in a rotary evaporator at a bath temperature of 30 ° C, the residue is lyophilized for 2 h and the product is stored at -25 ° C. 130.8 mg (61.6% of theory) of product are obtained. HPLC (Method 1) R, = 3.30 min. LC-MS (Method 18): R, = 3.42 min; MS (ESlpos): m / z (%) = 835 (100) [M + H] +, 735 (54) [M - C4H8 - C02 + H] +, MS (Sleng.): M / z (%) = 833 (60) [M-H] ~, 183 (100). Example 41 A 03- (tert-butyl) -N2 - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-serine bound to chlorotryl resin Chlorotrityl chloride resin (4.0 g, 5.96 mmol) is supplied in dichloromethane (40 ml) and then 0- (fer-butyl) -A / - [(9-fluororen-9-ylmethoxy) carbonyl is added. ] -L-serine (8.0 g, 20.86 mmol, 3.5 eq.) And DIEA (10.3 ml, 7.7 g, 59.60 mol, 10 eq.). After stirring at room temperature for 20 h, the polymer is collected by suction filtration on a fritted disk and then washed successively three times with dichloromethane / methanol / DIEA 17/2/1, three times with dichloromethane, twice with DMF and three times with dichloromethane. Removal of a sample with acetic acid / trifluoroethanol / dichloromethane 1: 1: 3 gives the amino acid protected by corresponding Fmoc. HPLC (Method 13) R, = 1.95 min. LC-MS (Method 20): R, = 2.38 min; MS (ESlpos): m / z (%) = 384 (35) [M + H] \ 767 (10) [2M + H] +, 105 (100); MS (ESlpos): m / z (%) = 382 (25) [M-H] ", 765 (10) [2M-H]", 160 (100). Example 42A. { / ^ - [(W-fluoren-g-ilmetox carbonyl-A / - tr ^ attached to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 41 A, 2.0 g, 2.98 mmol), as described in procedure 7. The deprotected amino acid attached to the resin is then reacted with N2 - [(9H-fluoren -9-ylmethoxy) carbonyl] - / \ / - trityl-L-asparagine (3.6 g, 5.96 mmol, 2 eq.), DIEA (1.5 ml, 1.2 g, 8.94 mmol, 3 eq.) And TBTU (1.9 g, 5.96 mmol) overnight to give the dipeptide protected by Fmoc. The processing of the polymer is carried out analogously to method 7. The corresponding protected side chain dipeptide is confirmed after taking a sample. HPLC (Method 13) R, = 2.43 min. LC-MS (Method 18): R, = 3.10 min; MS (ESlpos): m / z (%) = 740 (5) [M + H] \ 243 (100); MS (ESlpos): m / z (%) = 738 (40) [M-H] ", 516 (85) [M-Fmoc- H] ~, 542 (100). HR-TOF-MS (Method 24) C45H46N3O7 [M + Hf found 740.3342, calculated 740.3331, Example 43A {W2 - [(9H-Fluoren-9-methylmethoxy) carbonyl] - () attached to resin of chlorotritil Polymer The Fmoc protecting group is removed from the polymer (example 42A, 2.0 g, 2.98 mmol), as described in procedure 7. The deprotected dipeptide attached to the resin is then reacted with N - [(9H-fluoren- 9-ylmethoxy) carbonyl] glycine (1.8 g, 5.96 mmol, 2 eq.), DIEA (1.5 ml, 1.2 g, 8.94 mmol, 3 eq.) And TBTU (1 , 9 g, 5.96 mmol, 2 eq.) Overnight to give the tripeptide protected by Fmoc. The processing of the polymer is carried out analogously to method 7. The protected tripeptide with corresponding side chain is confirmed after taking a sample. HPLC (Method 13) R, = 2.33 min. LC-MS (Method 21): R, = 2.99 min; MS (ESlpos): m / z (%) = 797 (5) [M + Hf, 243 (100); MS (ESlpos): m / z (%) = 795 (40) [M-H] ", 573 (100) [M-Fmoc-H]". HR-TOF-MS (Method 24): C 7H49N4O8 [M + H] + found 797.3556, calculated 797.3545. Example 44A { 03- (tert-butyl) -W2 - [(9H-fluoren-9-ylmethoxy) c ^^ butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 43A, 1000.0 mg, 1.49 mmol), as described in method 7. The deprotected tripeptide bound to the resin is then reacted with 0- (fer-butyl) - / \ / - [(9 / - / - fluoren-9-ylmethoxy) carbonyl] alotreonine (1184.5 mg, 2.98 mmol, 2 eq.), DIEA (772 μ ?, 577.7 mg, 3 eq.) and TBTU (956.6 mg, 2.98 mmol, 2 eq.) overnight to give the tetrapeptide protected by Fmoc. The processing of the polymer is carried out analogously to method 7. The corresponding tetrapeptide with corresponding side chain is confirmed after taking a sample. HPLC (Method 13) R, = 2.48 min. LC-MS (Method 20): R, = 3.02 min; MS (ESlpos): m / z (%) = 954 (100) [M + H] +; MS (ESlpos): m / z (%) = 752 (100) [M - H] -. HR-TOF-MS (Method 24): CsaH ^ NsO ^ [M + H] + found 954.4663, calculated 954.4648. Example 45A { W2 - [(9 «-fluoren-9-methylmethoxycarbonyl]} -L-isoleucyl K asparaginyl) - [03- (fer-butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 44A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected tetrapeptide bound to the resin is then reacted with A / - [(9H-fluoren- 9-ylmethoxy) carbonyl] -L-isoleucine (1053.2 mg, 2.98 mmol, 2 eq.), DIEA (772 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU (956 , 6 mg, 2.98 mmol, 2 eq.) Overnight to give the pentapeptide protected by Fmoc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain pentapeptide is confirmed after taking a sample. HPLC (Method 13) R, = 2.57 min. LC-MS (Method 21): R, = 3.23 min; MS (ESlpos): m / z (%) = 1067 (13) [M + H] +, 243 (100). HR-TOF-MS (Method 24): 061? 75? 6 ??? [M + H] + Found 1067.5488, calculated 1067.5489. Example 46A / V5 - [(Benzyloxy) carbonyl] -. { / v ^ - [. { [(benzyloxy) carbonyl] amino} (imino) methyl] - / \ ^ - [(9H-fluoren-ylmethoxy) carbonyl] -D-omithin} Stir / V5 - [(Benzyloxy) carbonyl] -A / 5- [. { [(benzyloxy) carbonyl] am butoxycarbonyl) -D-ornithine (4.90 g, 9.03 mmol) [M. Jetten et al., Tetrahedron Lett. 1991, 32, 6025-6028] in 4 M hydrochloric acid in dioxane (150 ml) and dichloromethane (150 ml) at room temperature overnight. The solvent is completely evaporated and the residue is dried under vacuum. The deprotected amine is then supplied in dichloromethane (180 ml), DIEA (4.5 ml, 3.5 g, 27.09 mmol, 3 eq.) And chlorotrimethylsilane (2.3 ml, 2.0 g, 18.061) are added. mmol, 2 eq.), and the mixture is stirred under reflux overnight. The solution is cooled (0 ° C), DIEA (3.0 ml, 2.3 g, 18.06 mmol, 2 eq.) And (9-fluorenylmethyl) chloroformate (2.3 g, 9.03) are added. mmol, 1 eq.), and the mixture is warmed to room temperature and stirred at this temperature overnight. For the preparation, the reaction is diluted with dichloromethane and washed with a 10% aqueous solution of citric acid, the organic phase is dried over sodium sulfate, the solvent is removed in a rotary evaporator, and the residue is dried under vacuum . After the fine purification (method 37) of the crude product, 2.0 g (32.4% of theory) of the title compound are isolated. LC- S (Method 21): R, = 2.99 min; MS (ESlpos): m / z. { %) = 665 (100) [M + H] +; MS (Sleng): m / z (%) = 663 (30) [M - H] ", 333 (100) Example 47 A [A / 5- (benzyloxycarbonyl) - / v * - ( { [benzyloxycarbonyl] amino.} - { imino.}. methyl) -A / 2- (. {9H-Fluoren-9i-ylmethoxy}. carbonyl ) -D-ornitile] -L-isoleucyl- [03- (fe ^ (rer-butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 45A, 1000.0 mg, 1.49 mmol) as described in method 7. The deprotected pentapeptide attached to the resin is then reacted with the amino acid protected with Fmoc (example 46A, 1980.9 mg, 2.98 mmol, 2 eq.), DIEA (772 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU (956.6 mg, 2.98 mmol, 2 eq. .) overnight to give the hexapeptide protected with Fmoc. The processing of the polymer is carried out analogously to process 7. The polymer-bound hexapeptide is processed immediately without analytical confirmation. Example 48A { W2 - [(9H-Fluoren-9-methylmethoxy) carbon] l -L-leucl} - [W5- ^ ( { [Benzyloxycarbonyl] amino.} { Imino.}. Methyl) -D-ornithyl] -L-isoleucyl- [03- (y-butyl) -L-alotreonyl] -glici trityl-L-asparaginyl) - [03- (tert-butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 47A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected hexapeptide bound to the resin is then reacted with W - [(9H-fluoren-9 -ylmethoxy) carbonyl] -L-leucine (1053.2 mg, 2.98 mmol, 2 eq.), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) and TBTU (956, 7 mg, 2.98 mmol, 2 eq.) Overnight to give the heptapeptide protected with F-moc. The processing of the polymer is carried out analogously to process 7. The heptapeptide protected with corresponding side chain is confirmed after taking a sample. LC-MS (Method 18): R, = 3.51 min; MS (ESlpos): m / z (%) = 1605 (100) [M + H] +. Example 49A { / v ^ - [fer-Butoxycarbonyl] - [(3R) -3-hydroxy-Ll ^^ ( { tbenzyloxycarbonyl] amino.}. {imino} methyl) -D-ornithyl] -L-isoleucyl - [03- (fer-butyl) -L-allotreonyl] -glici L-asparaginyl) - [03- (fer-butyl) -L-serine] The Fmoc protecting group is removed from the polymer (example 48A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected heptapeptide bound to the resin is then reacted with (3R) -3-hydroxy- / V- (fer-butoxycarbonyl) -L-leucine (552.7 mg, 2.24 mmol, 1.5 eq.), DIEA (597 μ ?, 442.9 mg, 3.43 mmol, 2.3 eq. ) and TBTU (717.6 mg, 2.24 mmol, 1.5 eq.) overnight to give the octapeptide protected with F-moc. The processing of the polymer is carried out analogously to process 7. The octapeptide is completely removed from the polymer in a solution of acetic acid, trifluoroethanol and dichloromethane (1: 1: 3). For the preparation, the resin is removed by filtration in a frit, the filtrate is concentrated in vacuo and finally purified by chromatography (method 32). 56 mg (16% of theory) of the title compound are obtained. LC-MS (Method 18): R, = 3.48 min; MS (ESlpos): m / z. { %) = 1613 (15) [M + Hf, 806 (60) [M + 2H] 2+, 243 (100); MS (ESlneg): m z (%) = 1611 (100) [M + H] +. Example 50A [(3R) -3-Hydroxy-L-leucyl] -L-leucyl-. { / V5- [benzyloxycarbonyl] - / vi- [. { [benzyloxycarbonyl] amino} (ornithil.}. -L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine The peptide (example 49A, 22.0 mg, 13.65 pmol) is provided in TFA (5.25 ml) and water (0.25 ml), then p-cresol (10.0 mg, 92.48) is added. μ? t ???), and the solution is stirred at room temperature for 1 h. For the preparation, the solvent is removed in a rotary evaporator at a bath temperature of 30 ° C. After the fine purification of the residue by preparative HPLC (method 26), 4.4 mg (27.9% of theory) of product are obtained. HPLC (Method 1) R, = 2.07 min LC-MS (Method 18): R, = 2.12 min; MS (ESlpos): m / z (%) = 1158 (5) [M + H] +, 579 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1156 (100) [M - H] ~. Example 51 A [^ - (Benzyloxycarboni -S-fer-butyl-D-alanylHS-fe ^ phenylalanil} -. { (3R) -3-hydroxy-L-leucl} -W [. { [benzyloxycarbonyl] amino} (imino ^ The amine (example 50A, 4.0 mg, 3.46 pmol) and the activated acid (example 40A, 3.2 mg, 3.82 pmol, 1.1 eq.) Are supplied in DMF (500 μ?), the solution is cooled to 0 ° C, then DIEA (4 μ ?, 2.7 mg, 20.74 mmol, 6 eq.) is added, and the reaction is warmed to room temperature and stirred at this temperature overnight . For the preparation, the solvent is removed in a rotary evaporator at a bath temperature of 30 ° C, the residue is prepurified by gel chromatography (method 45, eluent: methanol), and then fine purification by preparative HPLC (method 26), 3.0 mg (24.0% of theory) of the product are obtained. HPLC (Method 10) R, = 11, 37 min LC-MS (Method 18): R, = 3.37 min; MS (ESlpos): m / z (%) = 904 (100) [M + 2H] 2+. EXAMPLE 52A [/ ^ - (Benzyloxycarboni-S-ér-butyl-D-alanyl-J-t-yrt-butyl-L-alanyl-SRJ-S-amino-L-phenylalanyl) trifluoroacetate. /?) - 3-hydroxy-L-leucyl. -L-leucyl- { ^ [ { [Benzyloxycarbonyl] amino.}. (Imino) methyl] -D-ornityl.} -L -isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L The Boc protecting group is removed from the compound of example 51 A (2.5 mg, 1.38 pmol) according to the general procedure 1. After the fine purification by preparative HPLC (method 26) 2.2 mg are obtained ( 87.3% of theory) of product. HPLC (Method 9) R, = 24.14 min LC-MS (Method 18): R, = 2.63 min; MS (ESlpos): m / z (%) = 854 (100) [M + 2H] 2+; MS (ESlneg.): M / z. { %) = 1706 (100) [M - Hf. HR-TOF-MS (Method 24): C ^ H ^ N ^ C ^ [M + H] + found 1707.8989, calculated 1707.8993. Example 53A C1 1-N 3 3-lactam trifluoroacetate of [/ ^ - (Benzyloxycarbonyl-J-S-fer-butyl-D-alanyl-J-IS-yer-butyl-L-alanyl] (3R) -3-amino-L-phenylalanyl .) - { (3fi) -3-hydroxy ^ [ { [Benzyloxycarbonyl] amino} (imnino) methyl] -D-ornityl}. -L-isoleucyl-L-alotreonyl-glycyl -L-asparaginyl-L-seri Under a protective atmosphere of argon gas, the deprotected amine (example 52A, 2.0 mg, 1.01 pmol) is supplied in DMF (1 mL), the solution is cooled to 0 ° C, HATU is added (1.3 mg, 3.29 pmol, 3 eq.) and NMM (0.7 μ |, 0.7 mg, 6.58 pmol, 6 eq.), and the reaction is brought slowly to room temperature and stirred at this temperature overnight. For the preparation, the solution is purified by preparative HPLC (method 26). 1.9 mg (90.1% of theory) of the desired compound are obtained. HPLC (Method 10) R, = 10.70 min. LC-MS (Method 18): R, = 3.25 min; MS (ESlpos): m / z (%) = 1691 (53) [M + H] +, 846 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1688 (100) [M - H] _. HR-TOF-MS (Method 24): C84H121N16021 [M + H] + found 1689.8929, calculated 1689.8887. Example 54A { (3?) - A / 2- (fer-Butoxycarbonyl) -3-hydroxy-L-leucyl} -L-leucyl-D-arginyl-L-isoleucyl-. { 03- (urea-butyl alotreonyl.) -glycyl- { / VJ'-trityl-L-asparaginyl.} - [03- (fer-butyl) -L-serine] * 2 TFA The benzyl ester-protected compound (Example 49A, 62.0 mg, 38.46 pmol) is converted to the product by hydrogenolysis in methanol (20 mL) in 1 h. After preparative HPLC chromatography (method 26) the desired compound is obtained (34.3 mg, 61.2% of theory). HPLC (Method 1) R, = 2.51 min. LC-MS (Method 20): R, = 2.36 min; MS (ESlpos): m / z (%) = 1343 (38) [M + H] \ 243 (100); MS (ESlneg.): M / z (%) = 1341 (100) [M - Hf. Example 55A [(3?) - 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine bistrifluoroacetate.

Compound of example 54A (32.0 mg, 21, 95 pmol) is stirred in a solution of TFA (7.3 ml), water (250 μl) and triisopropylsilane (323 μl) at room temperature for 2 h. For the preparation, the solvent is removed in a rotary evaporator at a bath temperature of 30 ° C, and the residue is concentrated in vacuo once with toluene and once with methylene chloride at a temperature of 30 ° C bath. After drying under high vacuum, the crude product is dissolved in 0.1% aqueous TFA and extracted with MTBE and the separated aqueous phase is concentrated in vacuo and then finely purified by preparative HPLC (method 27). 22.5 mg (91.8% of theory) of the title compound are obtained. HPLC (Method 9) R, = 8.38 min. LC-MS (Method 22): R, = 2.30 min; MS (ESlpos): m / z (%) = 889 (12) [M + Hf, 445 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 887 (100) [M - H] ~. HR-TOF-MS (Method 24): [M + H] + found 889.5102, calculated 889.5102. Example 56A [/ v * - (Benzyloxycarbonyl) -3-fer-butyl-D-alanyl] -3-tert-butyl] -butoxycarbonyl) amino] -L-phenylalanyl trifluoroacetate} -. { (3R) -3-hydroxy glycyl-L-asparaginyl-L-serine Compound of example 55A (19.0 mg, 17.00 pmol) and 40A (15.6 mg, 18.70 pmol) in DMF (1 ml) are supplied, A /, / V-diisopropylamine (18 μm) is added. , 13.2 mg, 102.00 mmol, 6 eq.) At 0 ° C, and the mixture is stirred at this temperature for 2 h. The reaction is warmed to room temperature and then stirred overnight. For the preparation, the solution is concentrated in vacuo and finally finely purified by preparative HPLC (method 26). 24.4 mg (86.7% of theory) of the desired compound are obtained.

HPLC (Method 9) R, = 23.17 min. LC-MS (Method 18): R, = 2.37 min; MS (ESIpos): m / z (%) = 720 (100) [M - C4H8 - C02 + 2H] 2+; MS (ESIneg.): Mlz (%) = 1438 (100) [M - C4H8 - C02 - Hf. HR-TOF-MS (Method 24): C73H119N1602o [M + H] + found 1539.8772, calculated 1539.8782. Example 57 A [/ v ^ - (Benzyloxycarbonyl) -3-tert-butyl-D-alanylH ^^ L-phenylalanylH (3R) -3-hydroxy-L-leucyl bistrifluoroacetate} -L-leucyl-D-arginyl-L-sulfate-L-alotreonyl-glycyl-L-asparagine Exemplary Compound 56A (23.0 mg, 13.91 μ ??) is converted to the deprotected amine according to procedure 1. After fine purification (method 26) 19.9 mg (85, 8% of theory) of the title compound. HPLC (Method 9) R, = 17.05 min. LC-MS (Method 18): R, = 1.98 min; MS (ESlpos): m / z (%) = 1441 (3) [M + H] +, 720 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1438 (100) [M-H] ~ HR-TOF-MS (Method 24): CeeHmN ^ of [M + H] + found 1439.8271, calculated 1439, 8257. Example 58 A C1-N3 3-lactam trifluoroacetate of [/ ^ - (Benzyloxycarboni -S-fer-butyl-D-alanylj-tS-ier-butyl-L- alanil] -. { (3?) - 3-amino-L-phenylalanyl (3 /?) - 3-hydroxy-L-leu glycyl-L-asparaginyl-L-serine Under a protective atmosphere of argon gas, the deprotected amine (example 57A, 19.0 mg, 11.39 μm) is provided in DMF (10 ml), the solution is cooled to 0 ° C, HATU is added (13.0 mg, 34.18 μ ???, 3 eq.) And NMM (8 μ ?, 6.9 mg, 68.35 μ ????), and the reaction is allowed to stand at 4 °. C for 3 days. For the preparation, methanol is added to the mixture at 0 ° C, and the mixture is concentrated under vacuum at a maximum bath temperature of 30 ° C, and finally finely purified by preparative HPLC (method 26). 14.0 mg (80.0% of theory) of the title compound are obtained. HPLC (Method 9) R, = 22.44 min. LC-MS (Method 18): R, = 2.30 min; MS (ESlpos): m z (%) = 1422 (12) [M + H] \ 711 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1420 (28) [M-H] ", 710 (100) [M-2H] 2_. HR-TOF-MS (Method 24): [M + Hf found 1421, 8165, calculated 1421, 8152. Example 59A (3R) -3 - [(fer-Butyloxycarbonyl) amino] -L-phenylalanine According to procedure 5 the compound of Example 16A (1000.0 mg, 2.41 mmol) is converted with 10% palladium / carbon (100 mg, 93.98 pmol, 4 mol%) in methanol (100 ml) in the title compound in 1 h. After removing the catalyst by filtration through kieselguhr and concentrating, 624.0 mg (92.3%) of crude product are obtained. HPLC (Method 9) R, = 10.27 min. LC-MS (Method 18): R, = 1.52 min; MS (ESlpos.): M / z (%) = 281 (82) [M + H] +, 561 (10) [2M + H] +, 225 (100); MS (ESlneg.): M / z (%) = 279 (70) [M-Hf, 559 (5) [2M-H] ', 205 (100). 1 H NMR (500 MHz, ck-DMSO): d = 1.34 (s, 9H, OC (CH 3) 3), 3.51 (d, J = 4.8 Hz, 1 H, H "), 4, 88 (dd, J = 8.6 Hz, 4.8 Hz, 1 H, H ^), 7.21-7.35 (m, 7H, ArH, NH2), 8.04 (d, J = 8.6 Hz, NH). 13 C NMR (126 MHz, cfe-DMSO): d = 28.04 (3C), 53.81, 56.27, 78.06, 127.24, 127.42 (2C), 128.07 (2C), 138.99, 154.12, 167.93. HR-TOF-MS (Method 24): C14H21N204 [M + Hf found 281, 1506, calc'd 281, 1496. Example 60A [/ ^ - (Benzyloxycarbonyl-J-D-leucyl-J-L-methyl leucinate Dissolve / ^ - (benzyloxycarboni-D-leucine (BACHEM Cat No zl3351.) (6.37 g, 24 mmol)) and L- * methyl leucinate (3.49 g, 24 mmol, 1 eq.) In DMF (75 ml) at 0 ° C, and then NMM (5.28 ml, 48 mmol, 2 eq.) And HATU (13.69 g, 36 mmol, 1.5 eq.) Are added. The mixture is stirred at room temperature for three hours. MTBE and a saturated solution of sodium bicarbonate are added, and extraction is carried out. The aqueous phase is extracted with a second portion of MTBE, and the combined organic phases are then washed with 1 M citric acid as well as again with a saturated solution of sodium bicarbonate, dried over sodium sulfate and concentrated in vacuo. The residue is purified by chromatography in two portions (Bíotage 40M, cyclohexane / ethyl acetate 3 + 1). Yield: 7.85 g (80% of theory). HPLC (Method 5): R, = 4.82 min. LCMS (Method 18): R, = 2.65 min; MS (ESlpos.): M / z (%) = 393 (100) [M + H] +. [α] 20Na = -5.2 ° (c = 0.52, MeOH). 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 0.77-0.92 (m, 12H), 1, 31-1, 66 (m, 6H), 3.60 (s, 3H), 4, 10 (m, 1 H), 4.28 (m, 1 H), 5.02 (s, 2H), 7.25-7.38 (m, 6H), 8.23 (d, 1 H). 13 C-NMR (126 MHz, de-DMSO) d (ppm) = 21.1 (CH3), 21.5 (CH3), 22.8 (CH3), 22.9 (CH3), 24.2 (CH), 41, 0 (CH2), 50.0 (CH), 51, 8 (CH3, OCH3), 52.9 (CH), 65.3 (CH2, OCH2Ph), 127.6 (CH, ar -C), 127.7 (CH, ar-C), 128.3 (CH, ar-C), 137, 1 ((C cuat, ar-C), 155.8 (C cuat, NCOC (CH3) 3), 172 , 4 (C cuat, C = 0), 172.9 (C cuat, C = 0) Example 61 A [/ ^ - (BenzyloxycarbonylJ-D-leucylJ-L-leucine Compound 60A (7.70 g, 19.62 mmol) is taken up in 200 ml of THF / water (3 + 1), cooled to 0 ° C and Lithium hydroxide monohydrate (1.65 g, 39.24 mmol, 2 eq.) is added. The mixture is stirred at 0 ° C until, according to the HPLC monitoring, the reaction is complete (approximately 45 min). Most of the THF is removed by vacuum distillation, the pH is then adjusted to about 4 by adding citric acid, and the mixture is extracted with 2 portions of ethyl acetate. The combined organic phases are dried over sodium sulphate, they filter and concentrate. The product is obtained as an amorphous substance in a yield of 6.87 g (89% of theory). HPLC (Method 5): R, = 4.45 min. LCMS (Method 18): R, = 2.39 min, MS (ESlpos.) M / z (%) = 379 (100) [M + H] \ 757 (40) [2M + H] +. [] 20Na = +4.7 ° (c = 0.50, MeOH). 1 H NMR (300 MHz.cfe-DMSO) d (ppm) = 0.77-0.92 (m, 12H), 1.34-1.68 (m, 6H), 4.04-4.26 (m , 2H), 5.02 (s, 2H), 7.25-7.38 (m, 6H), 8.12 (d, 1 H), 12.50 (br. S, 1 H). HR-TOF-MS (Method 24): C20H31N2O5 [M + H] + calculated 379.2228, found 379.2216. Example 62A A / - [benzyloxycarbonyl] -D-leucyl-L-leucinate pentafluorophenyl According to the preparation method (example 17A), compound of Example 61 A (1000.0 mg, 2.64 mmol), pentafluorophenol (2431, 7 mg, 13.21 mmol, 5 eq.) And EDC (759) are converted. , 8 mg, 3.96 mmol, 1.5 eq.) In the title compound. After fine purification (method 28), 1.3 g (93.0% of theory) of product is obtained, which is kept at -25 ° C until its later use. HPLC (Method 1) R, = 3.08 min. LC-MS (Method 18): R, = 3.26 min; MS (ESlpos.): M / z (%) = 545 (100) [M + H] +, 1089 (43) [2M + H] +. 1 H NMR (400 MHz, c / rDMSO): d = 0.78-0.99 (m, 12H, 2 [CH (CH 3) 2]), 1, 30-1, 88 (m, 6H), 4, 16 (m, 1 H,? A), 4.38-4.55 (2m, 1?,? "), 4.95-5.11 (m, 2 ?, PhCH2), 7.21-7.38 (m, 5H, ArH), 7.41 (d, J = 7.4 Hz, 1 H, NH), 8.69 (d, J = 7.0 Hz, 1H, NH) Example 63A. (Benzyloxycarbonyl) -D-leucyl] -L-leucyl - [(3R) -3 - [(ert-butoxycarbonyl) amino] -L-phenylalanine Under a protective atmosphere of argon gas, the amino acid is provided (example 59A, 493.0 mg, 1.76 mmol and the activated dipeptide with carboxylic acid (example 62A, 1197.0 mg, 1.76 mmol) in DMF (50 mi), and then DIEA (2.4 ml, 1818.4 mg, 14.07 mmol, 8 eq.) is added to the solution at 0 ° C. After the addition of the base, the reaction is slowly brought to The mixture is stirred at this temperature until the conversion is complete (3 h) .For the preparation, potassium dihydrogen phosphate (2.4 g, 17.59 mmol, 10 eq.) is added to the reaction and the mixture is stirred for 10 min, the solid is removed by filtration, and the filtrate is concentrated in vacuo at a bath temperature of 30 ° C. 750.0 mg (66.6% of theory) of the title compound are isolated after the fine purification (method 28) HPLC (Method 1) R, = 2.72 min LC-MS (Method 18): R, = 2.86 min; MS (ESlpos.): m / z (%) = 641 (100) [M + H] \ 541 (76) [M - C4H8 - C02 + H] +, 1281 (42) [2M + H] +; MS (ESIneg.): M / z (%) = 639 (100) [M - H] ", 1280 (92) [2M - Example 64A A / - [(benzyloxy) carbonyl] -D-leucllL -leucyl - [(3f?) - 3 - [(tert-butoxycarbonyl) amino] -L-phenylalaninate] pentafluorophenyl The title compound is prepared according to the exemplary method (example 17A) of the tripeptide (example 63A, 200 mg, 0.31 mmol) and pentafluorophenol (287.3 mg, 1.56 mmol, 5 eq.) In dichloromethane ( 10 ml) using EDC (89.8 mg, 0.49 mmol, 1.5 eq.). Complete conversion is achieved by stirring the reaction at 0 ° C for 2 h and allowing to stand in a refrigerator at 4 ° C overnight. After fine purification (method 32), 211.0 mg (83.8% of theoretical) of product are obtained. HPLC (Method 1) R, = 3.23 min. LC-MS (Method 21): R, = 3.22 min; MS (ESlpos.): M / z (%) = 807 (30) [M + H] \ 707 (100) [M - C4H8 - C02 + H] +; MS (ESlneg.): M / z (%) = 805 (10) [M-H] ", 183 (100) Example 65A . { 03- [tert-butyl] - / V2 - [(9H-fluoren-9- ^ butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 43A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected tripeptide attached to the resin is then reacted with 0- (fer-butyl) -W - [(9-Fluoren-9-ylmethoxy) carbonyl] -L-threonine [Echner, Hartmut; Voelter, Wolfgang; Liebigs Ann. Chem .; GE; 1988; 1095-1098] (1184.5 mg, 2.98 mmol, 2 eq.), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU (956.6 mg, 2, 98 mmol, 2 eq.) Overnight to give the tetrapeptide protected with F-moc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain peptide is confirmed after taking a sample. LC-MS (Method 20): R, = 3.07 min; MS (ESlpos): m / z (%) = 955 (80) [M + H] +, 243 (100); MS (ESlneg): m / z (%) = 953 (100) [M - H] ". HR-TOF-MS (Method 24): [M + H] + Found 954.4636, calculated 954.4648. Example 66A. { A / 2 - [(9AV-Fluoren-9-ylmethoxy) carbonyl] -L-isoleucyl} -. { [03- (fer-butyl)] - L-threonyl} -gli asparaginyl) - [03- (rer-butyl) -L-serine] bound to chlorotrityl resin The Fmoc protecting group is removed from the polymer (example 65A, 1000.0 mg, 1, 49 mmol) as described in procedure 7. The deprotected tetrapeptide bound to the resin is then reacted with / V - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-isoleucine (1053.2 mg, 2, 98 mmol, 2 eq.) (H. Echner et al., Liebigs Ann. Chem. 1988, 1095-1098), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU ( 956.6 mg, 2.98 mmol, 2 eq.) Overnight to give the pentapeptide protected by Fmoc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain peptide is confirmed after taking a sample. HPLC (Method 13) R, = 2.61 min. LC-MS (Method 21): R, = 3.26 min; MS (ESlpos): m / z (%) = 1068 (15) [M + H] \ 243 (100); MS (Sleng): m / z (%) = 1066 (100) [M-H] ". HR-TOF-MS (Method 24): CeiHysNeOn [M + H] + found 1067.5503, calculated 1067.5489. Example 67A { N2 - [(9H-Fluoren-9-ylmethoxy) carbonyl] - [W5- (im ^ chromen-6-yl) sulfonyl] amino.} Methyl) -D-ornitol]. -L-iso asparaginyl) - [03- (rer-butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 66A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected pentapeptide attached to the resin is then reacted with / V2 - [(9H-fluoren- 9-ylmethoxy) carbonyl] - / V5- (imino. {[[(2, 2,5,7, 8-pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino} methyl. ) -L-ornithine (1283.9 mg, 1.94 mmol, 1, 3 eq.), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU (956.6 mg) , 2.98 mmol, 2 eq.) Overnight to give the hexapeptide protected with Fmoc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain peptide is confirmed after taking a sample. LC-MS (Method 20): R, = 3.24 min; MS (ESlpos): m / z (%) = 1490 (85) [M + H] +, 282 (100); MS (ESlpos): m / z (%) = 1488 (100) [M + Hf. HR-TOF-MS (Method 24): [M + H] + Found 1489.7456, calculated 1489.7477. Example 68A { N2 - [(9H-Fluoren-9-ylmethoxy) carbonyl] -L-leucyl-1-chromen-6-yl) sulfonyl] amino} methylene) -D-ornithyl] -L-α-asparaginyl) - [03 - (/ er-butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 67A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected hexapeptide bound to the resin is then reacted with W - [(9H-fluoren-9 -ylmethoxy) carbonyl] -L-leucine (1053.2 mg, 2.98 mmol, 2 eq.), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) and TBTU ( 956.6 mg, 2.98 mmol, 2 eq.) Overnight to give the heptapeptide protected with F-moc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain peptide is confirmed after taking a sample. LC-MS (Method 18): R, = 3.54 min; MS (ESlpos): m / z (%) = 1602 (100) [M + H] +; MS (ESlpos): m / z (%) = 1600 (100) [M - H] "Example 69A [(3R) -W2- (fer-Butoxycarbonyl) -3-hydroxy-L-leucyl] -L-leucyl - [/ V5- (imino { [(2,2,5,7,8-penta 2H-chromen-6-yl) sulfonyl] amino} methyl) -D-ornithi-asparaginyl) - [03- (ér-butyl) -L-serine] The Fmoc protecting group is removed from the polymer (example 68A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected heptapeptide bound to the resin is then reacted with (3R) -3-hydroxy-A - (tert-butoxycarbonyl) -L-leucine (552.7 mg, 2.24 mmol, 1.5 eq.), DIEA (597 μ ?, 442.9 mg, 3.43 mmol, 2.3 eq.) and TBTU (717.6 mg, 2.24 mmol, 1.5 eq.) overnight to give the octapeptide protected with Fmoc. The processing of the polymer is carried out analogously to process 7. The octapeptide bound to the resin is completely removed from the polymer in a solution of acetic acid, trifluoroethanol and dichloromethane (1: 1: 3). For the preparation, the resin is filtered through a fritted disk, and the filtrate is concentrated under vacuum and finally purified by chromatography (method 28). 418.0 mg (17.4% of theory) of the title compound are obtained. HPLC (Method 13) R, = 2.85 min. HPLC (Method 1) R, = 3.32 min. LC-MS (Method 18): R, = 3.39 min; MS (ESlpos.): M / z (%) = 1610 (40) [+ H] +, 806 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1608 (100) [M-H] ". HR-TOF-MS (Method 24): CesH ^ N ^ O ^ S [M + H] + found 1609, 8971, calculated 1609. 8951. Example 70 A [(3R) -3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-threonyl-glycyl-L-asparaginyl-L-serine bistrifluoroacetate Under a protective atmosphere of argon gas, compound of example 69A (200.0 mg, 0.12 mmol) is stirred in a solution of TFA (25.3 ml), water (667 μl) and triisopropylsilane (667 μl). at room temperature for 1 h. For the preparation, the solvent is removed in a rotary evaporator at a bath temperature of 30 ° C, and the residue is concentrated in vacuo once with toluene and once with methylene chloride at a bath temperature of 30 ° C. The residue is dissolved in 0.1% aqueous TFA and extracted once with MTBE, and the separated aqueous phase is concentrated in vacuo and then finely purified by preparative HPLC (method 26). 138.0 mg (99.5% of theory) of the title compound are obtained. HPLC (Method 9) R, = 8.60 min. LC-MS (Method 22): R, = 2.43 min; MS (ESlpos): m / z (%) = 889 (15) [M + H] +, 445 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 887 (100) [M - H] ~. Example 71A Trifluoroacetate of [/ V2- (Benzyloxycarbonyl) -D-leucyl] -L-leucyl - [(3R) - / 3- (fe / '-butoxycarbonyl) -3-amino-L-phenylalanylH (3R) - 3-hydroxy-L-leucyl} -L-leucyl-D-arginyl-L-isoleucyl-L-threonyl-glycyl-L-as serine The title compound is prepared from the octapeptide (example 70A, 70.0 mg, 62.66 pinol), the tripeptide activated with carboxylic acid (example 64A, 60.7 mg, 75.19 μ? T ???, 1, 2 eq.) Using N, N-diisopropylamine (65 μ ?, 48.6 mg, 375.96 pmol, 6 eq.) As indicated in the method of preparation of the compound of example 56A. The reaction is brought to an almost complete conversion at room temperature overnight. After chromatography (method 26), 73.9 mg (72.5% of theory) of the product are obtained. HPLC (Method 9) R, = 22.16 min. LC-MS (Method 20): R, = 2.07 min; MS (ESlpos): m / z (%) = 1512 (25) [M + H] +, 706 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1510 (18) [M - H] ", 700 (100). HR-TOF-MS (Method 24): [M + H] + found 1511, 8474, calculated 1511, 8469. Example 72A Bistrifluoroacetate of [/ ^ - (Benzyloxycarboni-D-leucylj-L-leucyl-KS ^ -S-amino-L-phenylalanylj-fYSRJ-S-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L -soleucil-L-threonyl-glycyl-L-asparaginyl-L-serine Compound of example 71A (70.0 mg, 43.06 pmol) is converted to the deprotected amine according to procedure 1. After fine purification (method 26), 45.0 mg (63.7% of theoretical ) of the title compound. HPLC (Method 9) R, = 16.77 min. LC-MS (Method 18): R, = 1.85 min; MS (ESlpos): m / z (%) = 1412 (10) [M + H] \ 706 (100) [M + 2H] 2+; MS (ESlneg.): M / z. { %) = 1410 (90) [M-H] ~, 650 (100). HR-TOF-MS (Method 24): C66H107 16O18 [M + H] + found 1411, 7958, calculated 1411.7944. Example 73A C1 1 -N 3 3-lactam trifluoroacetate of [/ ^ - (benzyloxycarbonyl-J-D-leucyl-L-leucyl-SR) ^ phenylalanyl] - [(3?) - 3-hydroxy-L-leucyl] -L- leucyl-D-arginyl-L-isoleucyl-L-threonyl-glycyl-L-asparag The title compound is prepared according to the method of preparation (example 58A) from the compound of Example 73A (42.0 mg, 25.61 prnol), HATU (29.2 mg, 76.83 pmol, 3 eq. .) and NMM (17 μ ?, 15.5 mg, 153.66 pmol). The complete conversion is achieved by stirring at room temperature in 3 h. 34.1 mg (88.3% of theory) of product are isolated after fine purification (method 26). HPLC (Method 9) R, = 20.29 min. LC-MS (Method 18): R, = 2.06 min; MS (ESlpos): m / z (%) = 1393 (32) [M + H] +, 797 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1391 (100) [M-H] ~, 695 (32) [M-2H] 2". HR-TOF-MS (Method 24): [M + H] + Found 1393.7848, calculated 1393.7839. Example 74A A / 5- [Benzyloxycarbonyl] - / V2 - [(9H-fluoren-9-ylmethoxy) carbonyl] -D-ornithine A 5 - [(Benzyloxy) carbonyl] -D-ornithine (3.8 g, 14.27 mmol) is provided [Ulhaq, Saraj et al .; Bioorg. Med. Chem .; IN; 7; 9; 1999; 1787-1796] in dichloromethane (190 ml), DIEA (2.4 ml, 1.8 g, 17.27 mmol, 1 eq.) And chlorotrimethylsilane (3.6 ml, 3.1 g, 28.53) are added. mmol, 2 eq.), and the mixture is stirred under reflux overnight. The reaction is cooled (0 ° C) and DIEA (4.7 ml, 3.7 g, 28.54 mmol, 2 eq.) Is added again and (9-fluorenylmethyl) chloroformate (3.7 g, 14, 27 mmol, 1 eq.), And the mixture is warmed to room temperature and stirred at this temperature overnight. For the preparation, the reaction is diluted with dichloromethane and washed with a 10% aqueous solution of citric acid, the organic phase is dried over sodium sulfate, the solvent is removed in a rotary evaporator and the mixture is dried under vacuum. 6.5 g (93.2% of theory) of the title compound are obtained. LC-MS (Method 18): R, = 2.57 min; MS (ESlpos): m / z (%) = 489 (100) [M + H] \ 977 (100) [2M + H] +; MS (ESlneg.): M / z (%) = 487 (80) [M - Hf, 975 (100) [2M - Hf. Example 75A { / v5- [benzyloxycarbonyl] - / v2 - [(9H-fluoren-9-ylmethoxy) -carbonyl] ^^ L-alotreonylj-glycyl-Ia ^ -trityl-L-asparaginyl J-IO ^ fer-butyl-J-L-serine] bound to chlorotrityl resin The Fmoc protecting group is removed from the polymer (example 45A, 1000.0 mg, 1.49 mmol), as described in procedure 7. The deprotected pentapeptide bound to the resin is then reacted with the amino acid protected with Fmoc (example 74A , 1455.9 mg, 2.98 mmol, 2 eq.), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU (956.8 mg, 2.98 mmol, 2 eq.) overnight to give the hexapeptide protected with Fmoc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain peptide is confirmed after taking a sample. HPLC (Method 13) R, = 2.73 min. LC-MS (Method 18): R, = 3.27 min; MS (ESlpos): m / z (%) = 1316 (100) [M + H] +; MS (ESlneg): m / z (%) = 1314 (100) [M + H] +. Example 76A { / v ^ (9H-fluoren-9-ylmethoxy) carbonyl] -L-leucyl-butyl) -L-alotreonyl] -glycyl- (AT'-trityl-L-asparaginyl) - [03- (ier- butyl) -L-serine] bound to chlorotrityl resin Polymer The Fmoc protecting group is removed from the polymer (example 75A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected hexapeptide bound to the resin is then reacted with / V - [(9H-fluoren- 9-ylmethoxy) carbonyl] -L-leucine (1053.2 mg, 2.98 mmol, 2 eq.), DIEA (779 μ ?, 577.7 mg, 4.47 mmol, 3 eq.) And TBTU (956 , 8 mg, 2.98 mmol, 2 eq.) Overnight to give the heptapeptide protected with F-moc. The processing of the polymer is carried out analogously to process 7. The corresponding protected side chain peptide is confirmed after taking a sample. HPLC (Method 13) R, = 2.84 min. LC-MS (Method 18): R, = 3.36 min; MS (ESlpos): m / z (%) = 1429 (95) [M + H] +, 1430 (100); MS (ESlpos): m / z (%) = 1427 (80) [M - H] ", 1428 (100). HR-TOF-MS (Method 24): [M + H] + Found 1067.5488, calculated 1067.5489. Example 77A [(3R) -A / 2- (fer-Butoxycarbonyl) -3-hydroxy-L-leuci ^ [O] -er-buty-L-alotreonyl-glycyl-IA ^ -trityl-L-asparaginyl-IO ^ Ífer-buti -L-serine] The Fmoc protecting group is removed from the polymer (example 76A, 1000.0 mg, 1.49 mmol) as described in procedure 7. The deprotected heptapeptide bound to the resin is then reacted with (3R) -3-hydroxy- W- (fe-butox-carbobon) -L-leucine [Oliyai, Reza, Siahaan, Teruna J., Stella, Valentino J .; Pharm. Beef.; IN; 12; 3; nineteen ninety five; 323-328] (552.7 mg, 2.24 mmol, 1.5 eq.), DIEA (597 μ ?, 442.9 mg, 3.43 mmol, 2.3 eq.) And TBTU (717.6 mg, 2.24 mmol, 1.5 eq.) overnight to give the octapeptide protected with Fmoc. The processing of the polymer is carried out analogously to process 7. The octapeptide bound to the resin is completely removed from the polymer in a solution of acetic acid, trifluoroethanol and dichloromethane (1: 1: 3). For the preparation, the resin is filtered through a fritted disk, and the filtrate is concentrated under vacuum and finally purified by chromatography (method 28). 604.0 mg (28.3% of theory) of the title compound are obtained. HPLC (Method 13) R, = 2.68 min. HPLC (Method 1) R, = 3.15 min. LC-MS (Method 18): R, = 3.26 min; MS (ESlpos.): M / z (%) = 1437 (100) [M + H] +; MS (ESlneg.): M / z (%) = 1435 (100) [M-H] \ Example 78A Trifluoroacetate of [(SRJ-S-Hydroxy-L-leucyl-L-leucyl-fA ^ -benzyloxycarboni-D- ornitilJ-L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine The title compound is prepared from the compound of Example 77 A (200.0 mg, 0.14 mmol), as described in the exemplifying method (example 70A). After complete conversion to room temperature (1 h), the solution is concentrated in vacuo at a bath temperature of 30 ° C, concentrated once with toluene and once with methylene chloride under vacuum at a bath temperature. 30 ° C, and finally finely purified by preparative RP-HPLC (method 26). 121.0 mg (79.3% of theory) of the product are obtained. HPLC (Method 9) R, = 13.26 min. LC-MS (Method 22): R, = 3.04 min; MS (ESlpos): m / z (%) = 981 (100) [M + H] +, 491 (10) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 979 (100) [M - H] "Example 79 A [W2- (Benzylcarbonyl) -3-fe-butyl-D-alan l] - [3-te ^ ^ amino-L-phenylalanyl.} - { (3 /?) - 3-hydroxy-L-leucyl.] -L-leucyl - [^ alotreonyl-glycyl] -L-asparaginyl-L-serine The title compound is prepared from the octapeptide (example 78A, 59.6 mg, 54.44 μ? T), the tripeptide activated with carboxylic acid (example 40A, 50.0 mg, 59.89 pmol, 1.1 eq.) And using / V, V-düsopropylamine (57 μ ?, 42.2 mg, 326.7 pmol, 6 eq.) As described in exemplary method 56A). The reaction is brought to complete conversion at room temperature overnight. After fine purification (method 26), 52.9 mg (59.5% of theoretical) of product are obtained. HPLC (Method 10) R, = 10.32 min. LC-MS (Method 18): R, = 3.07 min; MS (ESlpos): m / z (%) = 1633 (40) [M + H] +, 817 (90) [M + 2H] 2+, 767 (100); MS (ESlneg.): M / z (%) = 1631 (65) [M - Hf, 761 (100). HR-TOF-MS (Method 24): C8oH123N14022 [M + H] + found 1631, 8898, calc. 1631, 8931. EXAMPLE 80 A [/ ^ - (Benzyloxycarboni-S-ér-butyl-D-alanylj-fS-fer-butyl-L-alanyl-IS-R-S-amino-L-phenylalanyl) (3R) -3-h Trifluoroacetate Drox-L-leucl.}. -L-leucyl- [A ^^ glycyl-L-asparaginyl-L-serine The compound of Example 79A (50.0 mg, 30.64 μ? T) is converted to the deprotected amine according to procedure 1. After the fine purification (method 26) 27.5 mg are obtained ( 54.5% of theory) of the title compound. HPLC (Method 9) R, = 21, 85 min. LC-MS (Method 20): R, = 2.18 min; MS (ESlpos): m / z (%) = 1533 (20) [M + H] \ 766 (100) [M + 2H] 2+; MS (ESlneg.): NVz (%) = 1531 (58) [M - H] ~, 764 (12) [M - 2H] 2", 710 (100). HR - TOF - MS (Method 24): CTsHmN ^ Ozo [M + H] + found 1531, 8385, calculated 1531, 8407. EXAMPLE 81 A C1"- / V ^ -lactam of [/ ^ - (BenzyloxycarbonylJ-S-fer-butyl-D-alan ^^ L- phenylalanyl.} - [(3R) -3-h¡drox¡-L-leucyl] -L-leucyl - [^ glycyl-L-asparaginyl-L-serine The title compound is prepared according to the method of preparation (example 58A) from the compound of example 80A (25.0 mg, 15.19 μm), HATU (17.3 mg, 45.57 mg). μ ????, 3 eq.) and NMM (10 μ ?, 9.2 mg, 91, 14 μ ????). The complete conversion is achieved after 3 days at 4 ° C. 21.0 mg (91.3% of theory) of the product are isolated after fine purification (method 26). HPLC (Method 9) R, = 26.28 min. LC-MS (Method 18): R, = 2.98 min; MS (ESlpos): m / z (%) = 1514 (20) [M + H] \ 758 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): CTSHUSNMO ^ [M + H] + found 1513.8298, calculated 1513.8301. Example 82 A (2fT, 3R *) - / V2 - [(benzyloxy) carbonyl] - / v - [(benzyloxy) carbonylamino] -3 - [(fer-butoxycarbonyl) amino] -0 methyl methylirosinate Under a protective atmosphere of argon gas, a 1 M solution of LHMDS (213.3 mmol, 213.3 ml, 2.2 eq.) In THF is provided in the THF reaction solvent (1.35 I). At -78 ° C, a solution of methyl (rac) -3 - [(tert-butoxycarbonyl) amino] -3- (4-methoxyphenyl) propanoate (DM Kalvin, RW Woodard, J. Org. Chem. 50, 13, 1985, 2259-2263) (30 g, 96.9 mmol) slowly dropwise. The mixture is stirred at -25 ° C for 10 min and then cooled again to -78 ° C. Dibenzyl azadicarboxylate (46.3 g, 155.2 mmol, 1.6 eq.) Is added in one portion to the reaction mixture. The mixture is stirred at -60 to -45 ° C for 2 h. To stop the reaction, the mixture is again cooled to -78 ° C and acetic acid (29.1 ml, 484.9 mmol, 5 eq.) Is added, and the mixture is then heated to 0 ° C and finally to a temperature ambient. The reaction mixture is evaporated in vacuo and placed in ethyl acetate (1000 ml). The suspension is washed twice with a saturated aqueous solution of sodium bicarbonate, twice with water, twice with 5% aqueous citric acid and once with a saturated aqueous solution of sodium chloride. All the aqueous phases are extracted again separately with ethyl acetate. All the organic phases are evaporated in vacuo and replaced in dichloromethane (2000 ml), filtered, dried over magnesium sulfate, filtered again and evaporated in vacuo. The residue is stirred with cyclohexane, collected by filtration and dried under high vacuum. 25.7 g (44% of theory) of the title compound are obtained as a solid. HPLC / UV-Vis (Method 5): R, = 4.97 min. HPLC / UV-Vis (Method 3): R, = 5.00 min. LC-MS (Method 18): R, = 2.87 min, MS (ESlpos.): Miz (%) = 508 (100), 608 (20) [M + H] +; MS (ESIneg.): M / z (%) = 532 (50), 606 (100) [M - H] ~. Example 83A (2S *, 3R A / ^ benzyloxycarbonyl] - / vi - [(benzyloxycarbonyl) amino] -3 - [(fer-butoxycarbonyl) amin methylthirosirate methyl Under a protective atmosphere of argon gas, TMG (5.78 ml, 46.1 mmol, 11.2 eq.) Is added to a solution of Example 82A (2.5 g, 4.1 mmol) in dry DMF p.a. (87 mi) at 0 ° C. The reaction mixture is allowed to thaw and is stirred until the HPLC chromatogram (method 5) indicates the complete conversion (approximately 70% of product) (approximately 24 h), so as to then stop the reaction by adding acetic acid (pH 4-). 6). The reaction mixture is evaporated in vacuo at room temperature and placed in ethyl acetate. The organic phase is washed twice with water, twice with 5% citric acid, once with a saturated aqueous solution of sodium bicarbonate., once with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, filtered, evaporated in vacuo and dried under high vacuum. The crude product is purified by flash chromatography (silica gel, toluene / ethyl acetate 20: 1). 1.89 g (73% of theory) of the title compound are obtained. HPLC / UV-Vis (Method 5): R, = 5.11 min. HPLC / UV-Vis (Method 4): R, = 5.37 min. LC-MS (Method 18): R, = 3.07 min, MS (ESlpos.): M / z. { %) = 508 (100), 608 (20) [M + H] +; MS (ESlneg.): M / z (%) = 532 (100), 606 (30) [M - H] ~.

IR vmax (NaCl, cm "1): 3281, 2974, 1755, 1740, 1686, 1508, 1457, 1416, 1323, 1288, 1267, 1208, 1168, 1137, 1043, 1027. 1 H NMR (300 MHz, cfe- DMSO): d = 1.29 (s, 9H, fBu), 3.29 (s, 3H, OCH3), 3.72 (s, 3H, COOCH3), 4.80-5.20 (m, 6H) , 6.84 (d, J = 8.5 Hz, 1 H), 7.20-7.40 (m, 12H, ArH), 7.50-7.65 (m, 1 H, NH). -TOF-MS (Method 24): CazHseNsOg [M + H] + calculated 608.2603, found 608.2590.Example 84A (+) - (2 3S) - / v ^ - [benzyloxycarbonyl] - / V2 - [( benzyloxycarbonyl) amino] -3 - [(fer-butoxycarbonyl) amino] -0-methylthiroshirate methyl The enantiomer mixture of Example 83A (10.6 g, 17.44 mmol) is separated by preparative HPLC (method 39). 4.18 g (99.5% ee, 79% of theory) of the title compound and 5.2 g (99.5% ee, 98% of theory) of the (-) enantiomer are obtained (example 85A). Determination of enantiomers by method 15. HPLC / UV-Vis (Method 15): R, = 3.86 min. [] 20Na = + 54 ° (c = 0.24 in MeOH). HPLC / UV-Vis (Method 5): R, = 5.11 min. HPLC / UV-Vis (Method 4): R, = 5.23 min. LC-MS (Method 18): R, = 3.07 min, MS (ESlpos.): M / z (%) = 508 (100), 608 (20) [M + H] +; MS (ESlneg.): M / z (%) = 532 (100), 606 (30) [M - H] ~. HR-TOF-MS (Method 24): C 32 H 38 N 3 O 9 [M + H] + calculated 608.2603, found 608.2592.

Example 85A (-) - (2S, 3R) -A / 2- [benzyloxycarbonyl] - / V2 - [(benzyloxycarbonyl) to methyl methyltyrosirate The preparation is carried out analogously to Example 84A. Determination of enantiomers by method 15. HPLC / UV-Vis (Method 15): R, = 7.20 min. [] 20Na = -34 ° (c = 0.27 in MeOH). HPLC / UV-Vis (Method 5): R, = 5.11 min. HPLC / UV-Vis (Method 4): R, = 5.21 min. LC-MS (Method 23): R, = 2.87 min, MS (ESlpos.): M / z (%) = 508 (100), 608 (90) [M + H] +; MS (ESlneg.): M / z (%) = 532 (60), 606 (100) [M - H] ~. HR-TOF-MS (Method 24): CazHssNaOg [M + Hf calculated 608.2603, found 608.2594. Example 86A (2S *, 3 /? *) - 3 - [(fer-butoxycarbonyl) amino] -0-methylstyrosirate methyl Under a protective atmosphere of argon gas, Raney nickel (about 1 g) is added to a solution of Example 83A (2.81 g, 4.62 mmol) in methanol / dichloromethane 1: 1 (100 mL). The reaction mixture is hydrogenated in a pressurized autoclave under a hydrogen pressure of 80 bar and at room temperature (12 h). The HPLC chromatogram (method 8) shows the complete conversion. The reaction mixture is filtered under a protective atmosphere of argon gas through a glass frit / kieselguhr layer, and the glass frit is washed several times with methanol. The filtrate is evaporated in vacuo and dried under high vacuum. The product obtained is a solid (1.50 g, quantitative) which is then reacted without fine purification. HPLC / UV-Vis (Method 8): R, = 3.66 min. Example 87A (+) - (2R, 3S) -3 - [(fer-butoxycarbonyl) amino] -0-methylstyrosirate methyl Under a protective atmosphere of argon gas, Raney nickel (about 0.8 g) is added to a solution of example 84A (4.00 g, 6.58 mmol) in methanol / dichloromethane 1: 1 (100 ml). The reaction mixture is hydrogenated in a pressurized autoclave under a hydrogen pressure of 80 bar and at room temperature (72h). The reaction mixture is filtered under a protective atmosphere of argon gas through a glass frit / kieselguhr layer, and the glass frit is washed several times with methanol. The filtrate is evaporated in vacuo and placed in ethyl acetate. A solution of EDTA (2 g) in a 50% aqueous solution of sodium bicarbonate (700 ml) is added to the solution. The aqueous phase was extracted 5x with ethyl acetate (100 ml). The combined organic phases are then washed twice with a saturated aqueous solution of sodium bicarbonate and twice with a saturated aqueous solution of sodium chloride. All the aqueous phases are extracted again separately with ethyl acetate. The combined organic phases are then dried over magnesium sulfate. They are filtered and dried under high vacuum. The product obtained is a solid (1.04 g, 49% of theory, 96% ee). HPLC / UV-Vis (Method 16): R, = 7.8 min. [a] 20Na = + 7.7 ° (c = 0.34 in MeOH). HPLC / UV-Vis (Method 5): R, = 3.69 min. HPLC / UV-Vis (Method 4): R, = 3.87 min. LC-MS (Method 20): R, = 1.17 min; MS (ESlpos.): M / z (%) = 208 (90), 269 (100), 325 (40) [M + H] +. IR max (NaCl, cnrf1): 2933, 1737, 1709, 1611, 1511, 1365, 1243, 1164, 1030. Example 88 A (-) - (2S, 3R) -3 - [(fer-butoxycarbonyl) amino] - Methyl 0-methyltyrosilate Under a protective atmosphere of argon gas, Raney nickel (about 0.7 g) is added to a solution of Example 85A (5.20 g, 8.56 mmol) in methanol / dichloromethane 1: 1 (140 mL). The reaction mixture is hydrogenated in a pressurized autoclave under a hydrogen pressure of 80 bar and at room temperature (72 h). The reaction mixture is filtered under a protective atmosphere of argon gas through a glass frit / kieselguhr layer, and the glass frit is washed several times with methanol. The filtrate is evaporated in vacuo and placed in ethyl acetate. The mixture prepurify by chromatography on silica gel (cyclohexane / ethyl acetate 3: 1-1: 3) and separate by preparative HPLC (method 31). The title compound is obtained (324 mg, 91% ee, 8% of theory). HPLC / UV-Vis (Method 16): R, = 9.3 min. HPLC / UV-Vis (Method 5): R, = 3.69 min. HPLC / UV-Vis (Method 4): R, = 3.84 min. LC-MS (Method 20): R, = 1, 17 min; MS (ESlpos.): M / z (%) = 208 (90), 269 (100), 325 (40) [M + H] +. 1 H NMR (500 MHz, cfe-DMSO): d = 1.37 (s, 9 H, C (CH 3) 3), 3.53 (s, 3 H, OCH 3), 3.74 (s, 3 H, OCH 3), 4.26 (m, 1 H, ß-C), 5.00 (t, J = 9.0 Hz, 1 H, -CH), 6.93 (d, J = 8.0 Hz, 2H, ArH ), 7.23 (d, J = 8.0 Hz, 2H, ArH), 7.52 (d, J = 10.0 Hz, 1 H, NH), 8.45 (br. S, 2H, NH2) ). Example 89A (2S *, 3f? *) - / V2- [benzylloxycarbonyl] -3 - [(ery-butoxycarbonyl) amino] -0-methylstyrosirate methyl Under a protective atmosphere of argon gas, NaHCO3 (0.58 g, 6.94 mmol, 1.5 eq.) And tetra-N-butylammonium iodide (0.17 g, 0.47 mmol, 0.1 g) are added. eq.) to a solution of Example 86A (1.5 g, 4.62 mmol) and benzyloxycarbonyloxysuccinimide W-ester (1268 mg, 5.09 mmol, 1.1 eq.) in dichloromethane / water (1: 2, 150 mi) at 0 ° C. The reaction mixture is heated slowly (12 h), where the complete conversion is observed by HPLC (method 1). A solution of citric acid (5%) is added to the solution. The aqueous phase was extracted three times with dichloromethane (100 ml). The combined organic phases are then washed twice with a saturated aqueous solution of baking soda and twice with a saturated aqueous solution of sodium chloride. The combined organic phases are then dried over magnesium sulfate, filtered and dried under high vacuum. The product obtained is the title compound as a solid (2.1 g, 99% of theory). HPLC / UV-Vis (Method 5): R, = 4.73 min. HPLC / UV-Vis (Method 4): R, = 4.68 min. IR vmax (NaCl, cm "1): 3356, 1737, 1680, 1514, 1242, 1161, 1026, 1004. 1 H NMR (500 MHz, cfe-DMSO): d = 1.36 (s, 9H, C (CH3 ) 3), 3.61 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 4.51 (dd, J = 9.5, 4.0 Hz, 1 H, a-? ß -), 4.94 (m, 2H, PhCH20), 5.20 (dd, J = 10.0, 4.0 Hz, 1 H, a-? ß-), 6.87 (d, J = 8 , 5 Hz, 2H, ArH), 7.15-7.22 (m, 4H, ArH), 7.29-7.37 (m, 3H, ArH), 7.50 (d, J = 10.0 Hz, 1 H, NH), 7.57 (d, J = 10.0 Hz, 1 H, NH) 3C NMR (126 MHz, dg-DMSO): d = 27.9, 51, 9, 53, 8, 54.9, 58.9, 65.4, 78.3, 113.5, 126.8, 127.3, 127.5, 127.7, 128.2, 130.9, 136.6, 154.6, 155.9, 158.2, 170.6 HR-TOF-MS (Method 24): C25H3oN207 [M + H] + found 459.2140, calculated 459.2126.Example 90A (+) - ( 2f?, 3S) -A / 2- [benzyloxycarbonyl] -3 - [(fer-butoxycarbonyl) amino] -0-methylthiroshirate methyl Example 87A (1.0 g, 3.08 mmol) is reacted analogously to the preparation method of example 89A (reaction time: 12 h). The crude product is purified by preparative HPLC (method 32). 1.4 g (61% of theoretical, 96% ee) of the title compound are obtained. HPLC / UV-Vis (Method 16): R, = 7.3 min. [] 20Na = + 4.0 ° (c = 0.17 in MeOH).

HPLC / UV-Vis (Method 5): R, = 4.73 min. HPLC / UV-Vis (Method 4): R, = 4.81 min. IR vma] ((NaCl, cnrf1): 3346, 1741, 1707, 1680, 1517, 1270, 1248, 1160, 1028, 1007. LC-MS (Method 23): R, = 2.63 min; MS (ESIpos. ): mz (%) = 298 (100), 459 (30) [M + H] +, MS (ESIneg.): m / z (%) = 383 (100), 457 (10) [M - H] ~. HR-TOF-MS (Method 24): C25H3oN207 [M + H] + found 459.2128, calculated 459.2126.Example 91 A (-) - (2S, 3 /?) - W2- [benzyloxycarbon] L] -3 - [(tert-butoxycarbonyl) amino] -0-methylstyrosirate methyl Example 88A (0.32 g, 0.98 mmol) is reacted analogously to the preparation method of example 89A (reaction time: 12 h). The product obtained is the product of the title as a solid (0.38 g, 85% of theory). HPLC / UV-Vis (Method 16): R, = 6.3 min. HPLC / UV-Vis (Method 5): R, = 4.73 min. HPLC / UV-Vis (Method 4): R, = 4.81 min. LC-MS (Method 23): R, = 2.60 min; MS (ESlpos.): M z (%) = 298 (100), 459 (70) [M + H] +; MS (ESlneg.): M / z (%) = 383 (100), 457 (10) [M - Hf. Example 92 A (2S *, 3R *) - / V2- [Benzyloxycarbonyl] -3 - [(fer-butoxycarbonyl) amino] -0-methyltyrosine Under a protective atmosphere of argon gas, a solution of example 89A (759 mg, 1.69 mmol) in THF / water 2: 1 (12 ml) is provided. At 0 ° C, under vigorous stirring, an aqueous solution of lithium hydroxide monohydrate (81 mg, 3.39 mmol, 2.05 eq.) Is slowly added dropwise. The mixture is stirred at room temperature until the HPLC chromatogram (method 5) indicates complete conversion (about 3 h). Then add potassium hydrogen phosphate (225 mg), and the reaction mixture is concentrated in vacuo and covered with a layer of ethyl acetate (100 ml). The aqueous phase is then acidified with 5% citric acid (pH 2-3) and then extracted three times with ethyl acetate (50 ml). The combined organic phases are washed twice with a saturated aqueous solution of sodium chloride (20 ml), dried over sodium sulfate, filtered, concentrated in vacuo and dried under high vacuum.The title compound is obtained ( 735 mg quantitative). HPLC / UV-Vis (Method 5): R, = 4.45 min. LC-MS (Method 21): R, = 2.33 min; MS (ESlpos.): M / z (%) = 389 (100), 445 (90) [M + H] +; MS (ESlneg.): M / z (%) = 335 (60), 443 (100) [M-H] ". 1 H NMR (400 MHz, cfg-DMSO): d = 1.35 (s, 9H, C (CH3) 3), 3.72 (s, 3H, OMe), 4.35-4.40 (m, 1 H, aH), 4.94 (s, 2H, PhCH20), 5.19 (dd) , J = 10.0, 4.0 Hz, 1 H, ß-?), 6.86 (d, J = 9.0 Hz, 2H), 7.17-7.34 (m, 7H, ArH) 7.44-7.48 (m, 2H, 2 NH), 12.9 (s, br, 1H, C02H) Example 93A (+) - (3S) - V2- [Benzyloxycarbonyl] -3 - [( fer-butoxycarbonyl) amino] -0-methyl-D-tyrosine Method A: The enantiomer mixture of Example 92A (735 mg, 2.83 mmol) is separated by preparative HPLC (method 40). 319 mg (99.5% ee, 43% of theory) of the title compound and 307 mg (99.5% ee, 42% of theory) of the other enantiomer are obtained (example 94A). Determination of enantiomers by method 16. HPLC / UV-Vis (Method 16): R, = 10.9 min. [a] 20Na = + 8 ° (c = 0.04 in MeOH). HPLC / UV-Vis (Method 5): R, = 4.45 min. LC-MS (Method 21): R, = 2.33 min; MS (ESlpos.): M / z (%) = 389 (100), 445 (90) [M + Hf; MS (ESlneg.): M / z (%) = 335 (60), 443 (100) [M - H] ~. IR vmax (NaCl, cm "): 3358, 2978, 1705, 1683, 1615, 1515, 1245, 1167, 1027. HR-TOF-MS (Method 24): 0.3? 29? 2? 7 [M + H ] + found 445, 1976, calculated 445, 1970. Method B: Example 93A (1.30 g, 2.83 mmol) is reacted analogously to the preparation method of Example 92A (reaction time: 2 h) As the product, the title compound is obtained as a solid product (0.61 g, 48% of theory, 95% ee) HPLC / UV-Vis (Method 16): R, = 10.9 min [< x] 20Na = + 15o (c = 0.23 in MeOH) HPLC / UV-Vis (Method 5): R, = 4.41 min HPLC / UV-Vis (Method 4): R, = 4.54 min HR-TOF-MS (Method 24): C23H2BM207Na [M + Na] + found 467.1788, calculated 467.1794.

Example 94A (-J-ÍS ^ -A ^ -tBenzyloxycarbonylj-S- ^ fer-butoxycarbonylJaminol-O-methyl-L-tyrosine Method A: Preparation method under example 93A (method A) HPLC / UV-Vis (Method 16): R, = 13.3 min. [a] 20Na = -10 ° (c = 0.12 in MeOH). HPLC / UV-Vis (Method 5): R, = 4.45 min. LC-MS (Method 21): R, = 2.33 min; MS (ESlpos.): M / z (%) = 389 (100), 445 (90) [M + H] +; MS (ESlneg.): M / z (%) = 335 (60), 443 (100) [M-H] ". HR-TOF-MS (Method 24): C23H29N2O7 [M + H] + Found 445.1976 , calculated 445.1970. Method B: Example 90A (0.38 g, 0.84 mmol) is reacted analogously to the preparation method of example 92A (reaction time: 2 h). compound of the title as a solid (0.132 g, 35% theoretical, 94% ee) HPLC / UV-Vis (Method 16): R, = 13.3 min. [a] 20Na = -5o (c = 0, 1 in MeOH) HPLC / UV-Vis (Method 5): R, = 4.41 min HPLC / UV-Vis (Method 4): R, = 4.49 min LC-MS (Method 18): R , = 2.38 min; MS (ESlpos.): M / z (%) = 389 (100), 445 (100) [M + H] +; MS (Sleng.): M / z (%) = 335 (60), 443 (100) [M-H] ". 13 C NMR (126 MHz, cfe-DMSO): d = 28.0, 53.9, 54.9, 58.8, 65.2, 78.2, 113.4, 127.2, 127.3, 127 , 6, 128, 1, 128.2, 131, 7, 136.8, 154.7, 156.0, 158, 1, 171, 4. HR-TOF-MS (Method 24): C 23 H 29 N 2 O 7 [M + H] + Found 445.1966, calculated 445.1970. Example 95A (1S, 2R, 5R) - [(3S) - / [2- (benzyloxycarbonyl] -3 - [(fer-butoxycarbonyl) amino]] - 0-methyl-D-tyrosirate 2-lsopropyl-5 -methylcyclohexyl Under a protective atmosphere of argon gas, a solution of example 93A (34 mg, 76 pmol, 1 eq.) And (1 S, 2R, 5S) - (+) - menthol (12 mg, 76 pmol, 1 eq. .) in dichloromethane. At 0 ° C, DMAP (17.3 mg, 84 pmol, 1.1 eq.) Is added, and a solution of DCC (17.3 mg, 84 μ? T ???, 1.1 eq. ) in dichloromethane (0.5 ml) slowly dropwise. The mixture is stirred at room temperature until the HPLC chromatogram (method 5) indicates complete conversion (about 2 h). The reaction mixture is then filtered through kieselguhr and concentrated in vacuo, and ethyl acetate / petroleum ether 3: 1 is added. A white solid precipitates and is removed by filtration. The filtrate is concentrated and prepurified by chromatography on silica gel (petroleum ether / ethyl acetate 3: 1). The purification is carried out by preparative HPLC (method 43). The title compound is obtained (17 mg, 38% of theory). HPLC / UV-Vis (Method 5): R, = 5.74 min. HPLC / UV-Vis (Method 4): R, = 5.72 min. LC-MS (Method 18): R, = 3.46 min; MS (ESlpos.): M / z (%) = 483 (100), 527 (80), 583 (40) [M + H] +. 1 H NMR (500 MHz, cfe-DMSO): d = 0.71 (d, 3 H, J = 7 Hz, CH 3), 0.81 (d, 3 H, J = 7 Hz, CH 3), 0.81-0 , 84 (m, 3H), 0.87 (d, 3H, J = 7 Hz, CH3), 1, 00-1, 06 (m, 1 H), 1, 22-, 28 (m, 1 H) , 1, 35 (s, 9H, C (CH3) 3), 1, 61-1, 70 (m, 3H), 1, 89-1, 92 (m, 1 H), 3.72 (s, 3H , OMe), 4.49 (dd, 1 H, J = 4.5, 9.5 Hz, ß-), 4.59 (dt, J = 4.0, 11, 0 Hz, 1 H, O- CH), 4.91 (d, J = 12.0 Hz, 1 H, PhCH20), 4.97 (d, J = 12.0 Hz, 1 H, PhCH20), 5.17 (dd, J = 4 , 5, 9.5 Hz, 1 H, ß-?), 6.86 (d, 2H, J = 9.0 Hz, ArH), 7.16-7.24 (m, 4H, ArH), 7 , 28-7.34 (m, 3H, ArH), 7.46 (d, 1 H, J = 8.0 Hz, NH), 7.55 (d, 1 H, J = 8.0 Hz, NH ). EXAMPLE 96A (+) - (3S) -W2- [benzyloxycarbonyl] -3 - [(fer-butoxycarbonyl) amine] -0-methyl-D-t -rostarrate 2- (Trimethylsilyl) ethyl A mixture of example 93A (261 mg, 0.59 mmol), 2- (trimethylsilyl) ethanol (694 mg, 5.87 mmol, 10 eq.) And molecular filters of 4 A (approximately 20 mg) in dry dichloromethane p.a. (10 ml) is stirred under a protective atmosphere of argon gas at room temperature for 10 min. Then, at -30 ° C, DCC (244 mg, 1.17 mmol, 2 eq.) And DMAP (71 mg, 0.59 mmol, 1 eq.) Are added. The reaction mixture is allowed to thaw (approximately 12 h) and is stirred at room temperature until the HPLC chromatogram (method 5) indicates complete conversion (12 h). The reaction mixture is evaporated in vacuo at room temperature and purified by chromatography on silica gel (petroleum ether / ethyl acetate 3: 1). 244 mg (76% of theory, 99% ee) of the title compound are obtained. HPLC / UV-Vis (Method 16): R, [a]? 3 = + 10 ° (c = 0.1 in MeOH).

HPLC / UV-Vis (Method 5): R, = 5.34 min. HPLC / UV-Vis (Method 4): R, = 5.42 min. IR vmax (NaCl, cm "1): 3361, 2931, 2118, 1735, 1706, 1681, 1515, 1247, 1165, 1019. LC-MS (Method 21): R, = 3.16 min; MS (ESIpos. ): m / z {%) = 166 (100), 545 (15) [M + H] +. HR-TOF-MS (Method 24): C28H4iN207Si [M + H] + found 545.2678, calculated 545, 2678. EXAMPLE 97 A (-HS ^ -A ^ -benzenoxycarbonyl-S-urea-butoxycarbonyl-Jaminol-O-methyl-L-tyrosarylate 2- (Trimethylol) ethyl) Example 94A (130 mg, 0.29 mmol) is reacted analogously to the preparation method of Example 96A (reaction time: 12 h). As the product, the title compound is obtained as a solid (149 mg, 94% of theory,> 99.5% ee). HPLC / UV-Vis (Method 16): R, = 7.2 min. [] 20Na = -9 ° (c = 0.1 in MeOH). HPLC / UV-Vis (Method 5): R, = 5.34 min. HPLC / UV-Vis (Method 4): R, = 5.32 min. LC-MS (Method 18): R, = 3.24 min; MS (ESlpos.): M / z (%) = 545 (100) [M + H] +. Example 98A (+) - (3S) -3-amino-A / 2- [benzyloxycarbonyl] -0-methyl-D-tyrosinate trifluoroacetate of 2- (trimethylsilyl) ethyl Example 96A (222 mg, 0.41 mmol, 1 eq.) In dichloromethane (3 mL) is suspended and then, under a protective atmosphere of argon gas, trifluoroacetic acid (9 mL) is added and the mixture is stirred at room temperature. environment for 15 min until the HPLC chromatogram shows complete conversion (method 5). The solvent is then removed by vacuum distillation, the temperature of the bath not exceeding 30 ° C. The crude product is purified by preparative HPLC (method 43). 179 mg (79% of theory,> 99.5% ee) of the title compound are obtained. HPLC / UV-Vis (Method 16): R t = 8.66 min. [a] 20Na = + 20 ° (c = 0.22 in MeOH). HPLC / UV-Vis (Method 5): R, = 4.33 min. HPLC / UV-Vis (Method 4): R, = 4.55 min. IR vma) ((NaCl, crrf1): 2956, 1672, 1613, 1518, 1251, 1181, 1138, 1029. LC-MS (Method 18): R, = 2.18 min; MS (ESlpos.): M / z (%) = 225 (100), 549 (100) [M + H] +. 1 H NMR (500 MHz, cfe-DMSO): d = -0.07 (s, 9H, Si (CH3) 3), 0.43-0.52 (m, 2H, CH2Si), 3.75 (s, 3H, OMe), 3.74-3.78 (m, 1 H, CH2CH2Si), 3.82-3.88 (m, 1 H, CH2CH2Si), 4.38-4.42 (m, 1 H, ß- ), 4,58 (tapp, J = approx, 9.0 Hz, 1H, -), 5.08 (s, 2H, PhCH20), 6.98 (d, 2H, J = 8.5 Hz, ArH), 7.34- 7.40 (m, 8H, ArH), 8.07 (d, 1 H, J = 8.0 Hz, NH), 8.49 (s, br, 2H, 2 NH). 3 C NMR (125 MHz, cfe-DMSO): d = -1, 8 (3 C, (S 1 (CH 3) 3)), 16.3 (CH 2 Si), 54.5 (C 4), 55.1 (C ), 57.7 (OMe), 62.9 (CH2CH2S1), 66.0 (PhCH20), 113.9 (2C), 125.3, 127.8 (2C), 127.9, 128.3 ( 2C), 129.4 (2C), 136.4, 155.8 (C02Bn), 159.9, 168.9 (C02TMSE). HR-TOF-MS (Method 24): C23H33N205Si [M + H] + found 445.2168, calculated 445.2154. Example 99A (-) - (3f?) - 3-amino- / V - [benzyloxycarbonyl] -0-methyl-L-t -rosinate trifluoroacetate of 2- (trimethylsilyl) ethyl Example 96A (120 mg, 0.22 mmol) is reacted analogously to the preparation method of example 98A (reaction time: 50 min). As the product, the title compound is obtained as a solid (71 mg, 56% of theory,> 99.5% ee). HPLC / UV-Vis (Method 16): R, = 7.49 min. HPLC / UV-Vis (Method 5): R, = 4.33 min. HPLC / UV-Vis (Method 4): R, = 4.50 min. IR vmax (NaCl, cm ~ 1): 2956, 1672, 1613, 1518, 1251, 1181, 1138, 1029. HR-TOF-MS (Method 24): C23H33N2O5S1 [M + H] + found 445.2151, calculated 445 , 2154. EXAMPLE 100 A [(aRJ-A ^ -ifor-Butoxycarbonyl-J-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl [(3S) -3-hydroxy] trifluoroacetate -L-asparaginyl] -L-serine Method A: Under a protective atmosphere of argon gas, di-fer-butyl dicarbonate (369 mg, 1.69 mmol, 2.5 eq.) And / V-methylmorpholine (68 mg, 680 pmol, 1 eq. ) to a solution of the degradation product of example 3A (690 mg, 680 pmol) in water-dioxane 1: 2 (30 ml). The reaction mixture is stirred until the HPLC chromatogram (method 1) shows complete conversion (approximately 48 h). Diasporate potassium phosphate (5 eq.) Is added to the reaction mixture and the mixture is concentrated in vacuo and purified by preparative HPLC (method 43 or method 30 followed by a subsequent salt metathesis of the chromatography product by adding TFA ( 2000 μ? T ???, as a 0.05% solution in acetonitrile-water 1: 1)). 531 mg (70% of theory) of the title compound are obtained. Method B: First of gel chromatography the trifluoroacetate of the Edman30 precursor (100 mg, 0.1 mmol, 1 eq.) (Method 45, MeOH, 0.2% TFA). Di-tert-butyl dicarbonate (43 mg, 0.2 mmol, 2 eq.) Is added to a solution of this material in water (1 mL) and dioxane (2 mL) at room temperature, and NMM is added. , 6 μ ?, 0.2 mmol, 2 eq.) Per drop. The reaction mixture is stirred at room temperature until analytical HPLC monitoring (approximately 12 h) (method 8) indicates sufficient conversion (> 99%). Diasporate potassium phosphate (67 mg, 0.49 mmol, 5 eq.) Is added, the reaction mixture is concentrated on a rotary evaporator and then finely purified by preparative HPLC (method 26). 83 mg (76% of theory) of the title compound are obtained. W20Na = -18.0 ° (c = 0.19 in methanol). HPLC / UV-Vis (Method 2): R, = 1.7 min. HPLC / UV-Vis (Method 5): R, = 3.57 min. HPLC / UV-Vis (Method 4): R, = 3.79 min. LC-MS (Method 18): R, = 1, 70 min; MS (ESlpos.): M / z (%) = 453 (100), 1005 (80) [M + H] +; MS (ESlneg.): M / z (%) = 1003 (100) [M - H] _. LC-MS (Method 23): R, = 4.6 min; MS (ESlpos.): M / z (%) = 453.5 (60) [M - C4H8 - C02 + 2H] 2+, 1006 (100) [M + H] +; MS (ESlneg.): M / z (%) = 1004 (100) [M - H] ~. IR vmax (NaCl, cm ~ 1): 3288, 2966, 2359, 2341, 1645, 1520, 1368, 1 160, 1 137, 1054. 1 H NMR (500 MHz, (/ j-pyridine) d = 9.72 ( br.s, 1 H, NH-Glu6), 9.31 (br d, J = about 7.0 Hz, 1 H, NH- Arg3), 9.23 (d, J = 6.0 Hz, 1 H, NH-Leu2), 9.19 (br. S, 1 H, e ?? - Arg3), 9.00 (d, J = 9.0 Hz, 1 H, NH-β - Asn7), 8.88 (d, J = 7.0 Hz, 1 H, NH-Thr5), 8.78 (d, J = 7.0 Hz , 1 H, NH-lle4), 8.64 (d, J = 7.5 Hz, 1 H, NH-Ser8), 8.40 (br. S, 1 H, NH2-pOH-Asn7), 8, 34 (br.s, 1 H, NH2-pOH-Asn7), 5.96 (d, J = 8.0 Hz, 1 H, aCH-pOH-Asn7), 5.51 (s, 1 H, pCH- pOH-Asn7), 5, 11-5.09 (m, 1 H, aCH-Ser8), 5.04 (t, J = 7.5 Hz, 1 H, aCH-Thr5), 4.95-4, 91 (m, 3H, aCH-Arg3 and aCH-pOH-Leu1 and aCH-Leu2), 4.82 (t, J = 7.0 Hz, 1 H, aCH-lle4), 4.71-4.66 ( m, 1 H, pCH-Thr5), 4.44 (dd, J = 4.5 and 10.5 Hz, 1 H, pCH-Ser8), 4.31-4.26 (m, 3H, pCH-Ser8 and pCH-pOH-Leu1 and aCH-Gly6), 4.20 (dd, J = 6.0 and 16.5 Hz, 1 H, aCH-Gly6), 3.43 (br d, J = approximately 6, 0 Hz, 2H, 5CH-Arg3), 2.39-2.36 (m, 2H, pCH-Arg3 and pCH-lle4), 2.27-2.20 (m, 1H, pCH-Arg3), 2 , 10-2.05 (m, 2H, and CH-pOH-Leu1 and yCH-Arg3), 1, 93-1, 79 (m, 4H, pCH-Leu2, and CH-Leu2, and CH-Arg3 and yCH-lle4) , 1.55 (d, J = 6.0 Hz, 3H, and CH3-Thr5), 1.45 (s, 9H, O-ZBu), ca. 1, 47 (hidden, 1 H, and CH-lle4), 1, 17-1, 15 (m, 4H, 6CH3-pOH-Leu1 and yCH-lle4), 1.05 (d, J = 6.0 Hz, 3H, 5CH3-pOH-Leu1), 1.05 (t, J = 7.0 Hz, 3H, 5CH3-lle4), 0.80 (d, J = 6.0 Hz, 3H, 6CH3-Leu2), 0 , 78 (d, J = 6.0 Hz, 3H, 6CH3-Leu2). 13 C NMR (125 MHz, ds-pyridine) d = 175.58 (yCO-pOH-Asn7), 174.23 (CO-pOH-Leu1), 173.97 (CO-Arg3), 173.89 (CO-Ser8 or CO-Leu2), 173.69 (CO-Thr5), 173.55 (CO-Ser8 or CO-Leu2), 172.48 (CO-lle4), 170.90 (CO-pOH-Asn7), 170, 50 (CO-Gly6), 158.67 (??-Arg3), 157.06 (CO-Boc), 79.13 (C-Boc), 77.09 (PCH-pOH-Leu1), 72.29 ( pCH-pOH-Asn7), 68.32 (pCH-Thr5), 63.24 (pCH-Ser8), 59.79 (aCH-lle4), 59.60 (aCH-Thr5), 58.35 (aCH-pOH) -Leu1), 57.11 (aCH-pOH-Asn7), 56.94 (aCH-Ser8), 54.06 (aCH-Arg3), 53.60 (aCH-Leu2), 44.32 (aCH2-Gly6) , 41, 75 (5CH2-Arg3), 40.41 (pCH2-Leu2), 36.70 (pCH-lle4), 31, 56 (and CH-pOH-Leu1), 29.47 (pCH2-Arg3), 28, 48 (Me3-Boc), 26.11 (and CH-Arg3), 25.74 (and CH2-lle4), 24.93 (and CH-Leu2), 22.94 (5CH3-Leu2), 21, 71 (8CH3-Leu2) ), 21, 20 (and CH-Thr5), 19.48 (6CH3-pOH-Leu1), 19.43 (5CH3-pOH-Leu1), 16.02 (and CH-lle4), 11, 20 (5CH3-lle4) . HR-TOF-S (Method 24): C42H77N12016 [M + H] + found 1005.5560, calculated 1005.5576. Example 101A (2- (Trimethylsilyl) ethyl) ester trifluoroacetate of / V2- (Benzyloxycarbonyl) - / / 3-. { / \ / 2 '-fer-butoxycarbonyl [(3R) -3-hydroxy-L-leucyl] -L-leucylD-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S -3-hydroxy-L-asparaginyl] -L-seryl} - (3S) -3-amino-0-methyl-D-trosine Under a protective atmosphere of argon gas, first HATU (2.5 eq., 71 mg, 186 mole) is added to a solution of Example 98A (1.2 eq., 50 mg, 89 μ ????), of the octapeptide acid (example 100A, 1.0 eq., 83 mg, 75 μg ??) and A / -methylmorpholine (3.5 eq., 29 μ? t ???) in dry dimethylformamide (0, 5 mi) at 0 ° C. The reaction mixture is stirred at 0 ° C (about 3 h). The reaction mixture then shows complete conversion of the amine component (HPLC Monitoring, method 5). Solid potassium diacid phosphate (101 mg, 746 μ? T, 10 eq.) Is added to the reaction mixture and the mixture is filtered and then evaporated under high vacuum and purified by chromatography (method 43). 96.5 mg (84% of theory) of product are obtained. [a] 20Na = -6o (c = 0.04 in methanol). HPLC / UV-Vis (Method 5): R, = 4.47 min. HPLC / UV-Vis (Method 4): R, = 4.88 min. LC-MS (Method 18): R, = 2.26 min; MS (ESlpos.): M / z (%) = 652 (100), 1432 (50) [M + H] +; MS (ESlneg.): M / z (%) = 1430 (100) [M - H] ~. HR-TOF-MS (Method 24): [M + H] + found 1431, 7570, calculated 1431, 7550. Example 102 A (2- (Trimethylsilyl) ethyl) ester trifluoroacetate of A / 2- (Benzyloxycarbonyl) - / V3-. { / V2 1-tert-butoxycarbonyl [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L- asparaginyl] -L-seril} - (3R) -3-amino-0-methyl-L-tyrosine Example 99A (65 mg, 0.116 mmol) is reacted analogously to the preparation method of example 101 A (reaction time: 150 min). As the product, the title compound is obtained as a solid (111 mg, 74% of theory). [] 20Na = -17 ° (c = 0.09 in methanol). HPLC / UV-Vis (Method 5): R, = 4.47 min. HPLC / UV-Vis (Method 4): R, = 4.87 min. LC-MS (Method 18): R, = 2.16 min; MS (ESlpos.): M / z (%) = 652 (100), 1432 (60) [M + H] +; MS (ESlneg.): M / z (%) = 1430 (100) [M - H] _. HR-TOF-MS (Method 24): CesH ^ N ^ CboSi [M + H] + found 1431, 7509, calculated 1431, 7550. Example 103 A / ^ - (Benzyloxycarbonyl-J-A / 3- ^ 2 '-fer- ^ leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- [(3S methyl-D-tyrosine) trifluoroacetate Example 101A (96 mg, 62 μ? T ???) in dry THF (4 mL) is provided under a protective atmosphere of argon gas. Under vigorous stirring at room temperature, a 1 N solution of TBAF-THF (310 μ ?, 5 eq.) Is added dropwise. More portions of TBAF (each 5 eq.) Are added at regular intervals of 30 min. After approximately 45 eq., The HPLC chromatogram (method 5) shows the complete conversion. The reaction mixture is then neutralized with potassium dihydrogen phosphate (253 mg, approximately 30 eq.). The reaction mixture is filtered, evaporated in vacuo and purified by preparative HPLC (method 43). 83 mg (93% of theory) of the title compound are obtained. HPLC / UV-Vis (Method 5): R, = 3.93 min. HPLC / UV-Vis (Method 4): R, = 4.27 min. LC-MS (Method 18): R, = 2.00 min; MS (ESlpos.): M / z (%) = 616 (100), 1332 (20) [M + H] +; MS (ESlneg.): M / z (%) = 1330 (100) [M-H] ". HR-TOF-MS (Method 24): C60H95 14O20 [M + H] + found 1331, 6844, calculated 1331, 6842. EXAMPLE 104 A / ^ - (Benzyloxycarbonyl-9-A / 2-butoxycarbonyl ^ SRJ-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl- trifluoroacetate glycyl - [(3S) -3-methyl-L-tyrosine Example 102A (105 mg, 0.068 mmol) is reacted analogously to the preparation method of Example 103A (total 45 eq of TBAF). As the product, the title compound is obtained as a solid (90 mg, 99% of theory).

Na = -9 ° (c = 0.135 in methanol). HPLC / UV-Vis (Method 5): R, = 3.93 min. HPLC / UV-Vis (Method 4): R, = 4.15 min. LC-MS (Method 20): R, = 1.80 min; MS (ESlpos.): M / z (%) = 616 (100), 1332 (40) [M + H] +; MS (ESlneg.): M / z (%) = 664 (60), 1330 (100) [M - H] ~. HR-TOF-MS (Method 24): C60H95N14O20 [M + H] + found 1331, 6840, calculated 1331, 6842. Example 105A A 2- (benzyloxycarbonyl) -A / 3 - ([(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl trifluoroacetate - [(3S) -3-hydroxy-L-asparaginyl] -L-seryl.} - - (3S) -3-amino-0-methyl-D-tyrosine According to method 1, Example 103A (10 mg, 7 pmol) is reacted under a protective atmosphere of argon gas. 9.3 mg (99.9% of theory) of the title compound are obtained after freeze-drying. HPLC / UV-Vis (Method 5): R, = 3.47 min. LC-MS (Method 18): R, = 1.50 min; MS (ESlpos.): M / z (%) = 616 (100), 1232 (5) [M + H] +; MS (ESlneg.): M / z (%) = 1230 (100) [M - H] ~. HR-TOF-MS (Method 24): C55H87N14018 [M + H] + found 1231, 6300, calculated 1231, 6318. EXAMPLE 106 A ^ - (Benzyloxycarboni -A / 3- ^ 2 '-fer-butoxycarbonyl [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-allotreonyl- glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-seryl.} - - (3f?) - 3-amino-0-methyl-L-tyrosine According to procedure 1, Example 104A (240 mg, 166 μ? T) is reacted under a protective atmosphere of argon gas. 116 mg (57% of theory) of the title compound are obtained after freeze-drying. M20Na = -24 ° (c = 0.07 in methanol). HPLC / UV-Vis (Method 5): R, = 3.47 min. HPLC / UV-Vis (Method 4): R, = 3.83 min. LC-MS (Method 18): R, = 1.51 min; MS (ESlpos.): M / z (%) = 616 (100), 1232 (5) [M + H] +; MS (ESlneg.): M / z (%) = 1230 (100) [M - Hf. HR-TOF-MS (Method 24): C55H87N14018 [M + H] + found 1231, 6361, calculated 1231, 6318. EXAMPLE 107 A C1- N3 'Trifluoroacetate-N2 * - (benzyloxycarbonyl) - [(3S) -3-amino-0-methyl-D-tyrosyl)] - [(3 /?) - 3-hydroxy- L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-aspara L-serine First, HATU (1.5 mg, 8 μ ??, 5 eq.) Is added to a solution of example 105A (1.9 mg, 2 μ? T ???, 1 eq.) And NMM (1, 7 L, 15 pmol, 10 eq.) In dry DMF (200 μ?) At 0 ° C under a protective atmosphere of argon gas. The reaction mixture is stirred at 0 ° C (approximately 90 min). The reaction mixture then shows complete conversion of the amine component (HPLC Monitoring, method 5). Solid potassium diacid phosphate (20 eq., 4.2 mg, 31 μ? T) is added, and the reaction mixture is filtered and then evaporated under high vacuum and purified by chromatography (method 45). 1.8 mg (96% of theory) of product are obtained. HPLC / UV-Vis (Method 5): Rt = 3.65 min. HPLC / UV-Vis (Method 4): Rt = 3.91 min. LC-MS (Method 18): R, = 1, 67 min; MS (ESlpos.): M / z (%) = 1214 (100) [M + H] +. HR-TOF-MS (Method 24): C55H85N14017 [M + H] + found 1213.6232, calculated 1213.6312. EXAMPLE 108 A C1- N3 'Trifluoroacetate-N2 J- (benzyloxycarbonyl) - [(3f?) - 3-amino-0-methyl-L-tyrosyl]] - [(3R) -3-hydroxylactam) -L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-aspara L-serine Example 106A (120 mg, 0.097 mmol) is reacted analogously to the preparation method of Example 107A (reaction time 1 h). The title compound is obtained as a solid (39 mg, 33% of theory). W20Na = -58 ° (c = 0.07 in methanol). HPLC / UV-Vis (Method 5): R, = 3.71 min. HPLC / UV-Vis (Method 4): R, = 3.98 min. LC-MS (Method 18): R, = 1.74 min; MS (ESlpos.): M / z (%) = 1214 (100) [M + H] +; MS (ESlneg.): M / z (%) = 1212 (100) [M - H] -. HR-TOF-MS (Method 24): Csar ^ N ^ O ^ [M + Hf found 1213.6227, calculated 1213.6312. Example 109 A C1"- / V3 'Bistrifluoroacetate-[(3S) -3-amino-0-methyl-D-tyrosyl)] - [(3f?) - 3-hydroxy-L-leucyl] -L- lactama leucyl-D-arginyl-L-iso-leucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine Example 107A (65 mg, 49 μ? T) is dissolved in methanol (5 ml) and, under a protective atmosphere of argon gas, 10% palladium on carbon (10 mg) as well as hydrochloric acid are added. aqueous 1 N (250 μ?). The hydrogenation is carried out at room temperature and under atmospheric pressure until the analytical HPLC (approximately 90 min) (method 5) indicates complete conversion. The reaction mixture is filtered (through kieselguhr, Celite® or a syringe filter, Biotage, PTFE), concentrated in vacuo and purified by chromatography (method 43). 40.6 mg (63% of theory) of the title compound are obtained. [a] 20Na = -21 ° (c = 0.06 in methanol). HPLC / UV-Vis (Method 5): R, = 3.28 min. HPLC / UV-Vis (Method 4): R, = 3.55 min. LC-MS (Method 18): R, = 1, 20 min; MS (ESlpos.): M / z (%) = 540 (100), 1079 (20) [M + H] +; MS (ESlneg.): M / z (%) = 1077 (100) [M - H] ~. HR-TOF-MS (Method 24): C47H78NÍ40Í5 [M + H] + found 1079.5835, calculated 1079.5844. Example 110A C '"-? / 3' Bistrifluoroacetate-[(3f?) - 3-amino-0-methyl-L-tyrosyl)] - [(3f?) - 3-hydroxy-L-leucyl] -lactam] - L- leucyl-D-arginyl-L-iso-leucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-senna Example 108A (12 mg, 9 μ? T) is reacted analogously to the preparation method of example 109A (reaction time 90 min). As the product, the title compound is obtained as a solid (10.3 mg, 87% of theory). 20 Na = -52 ° (c = 0.03 in methanol). HPLC / UV-Vis (Method 5): R, = 3.18 min. HPLC / UV-Vis (Method 4): Rt = 3.52 min. LC-MS (Method 18): R, = 1.25 min; MS (ESlpos.): M z (%) = 540 (100), 1079 (5) [M + H] +; MS (ESlneg.): M / z (%) = 1077 (100) [M-H] "Example 111 A [C1-7] N3 3-lactam trifluoroacetate of [/ ^ - (Benzyloxycarboni-S-fer-butyl- D-alanylj-fS-yer-butyl-L-alanyl] - [(3S) -3-amino-0-methyl-D-tyrosyl) H (3?) - 3-hydroxy-L-leucyl] -L- leucyl-D-arginyl-L-isoleuci alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine First, HATU (2.2 mg, 6 mol, 2.5 eq.) Is added to a solution of Example 109A (3.0 mg, 2 pmol, 1.0 eq.), The acid dipeptide (Example 10A, 2, 3 mg, 6 pmol, 2.5 eq.) And NMM (11 pmol, 5 eq.) In dry DMF (1 ml) at -30 ° C under a protective atmosphere of argon gas. The reaction mixture is stirred and heated slowly (approximately 1 h) at 0 ° C. NMM (6 prnol, 2.5 eq. Each time) and HATU (6 pmol, 2.5 eq. Each time) are added to the reaction mixture at regular intervals (30 min.) Until HPLC monitoring (method 5) indicates the complete conversion of the amine component. In total, approximately 20 eq. of NMM and HATU for this. Solid potassium diacid phosphate (9.4 mg, 69 pmol, 30 eq.) Is added, and the reaction mixture is filtered and then evaporated under high vacuum and purified by chromatography (method 43). 2 mg (55% of theoretical) of product are obtained. HPLC / UV-Vis (Method 5): R, = 4.2 min. HPLC / UV-Vis (Method 4): R, = 4.49 min. LC-MS (Method 18): R, = 2.07 min; MS (ESlpos.): M / z (%) = 734 (100) [M + 2H] 2 \ 1468 (20) [M + H] +; MS (ESlneg.): M / z (%) = 678 (100), 732 (5) [M-2H] 2, 1466 (10) [M-H] _.

HR-TOF-MS (Method 24): [M + H] + Found 1467.8228, calculated 1467.8206. Example 112A C1-N3 3-lactam trifluoroacetate of [/ ^ - (Benzyloxycarboni -S-fer-butyl-D-alanylj-fS-tert-butyl-L-alanyl] - [(3R) -3-amino -0-metN-L-tyrosl]] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleu alotreonyl-glycyl - [(3S) - 3-hydroxy-L-asparaginyl] -L-serine Analogous preparation to Example 111A from the compound of Example 109A (30 mg, 23 μ? T) and compound of Example 10A (23.3 mg, 57 mol, 2.5 eq.). The crude product is purified by chromatography (method 43), where after drying by freezing, 25 mg (69% of theory) of product is obtained as a solid. [α] 20Na = -62 ° (c = 0.06 in methanol). HPLC / UV-Vis (Method 5): R, = 4.4 min. LC-MS (Method 18): R, = 2.31 min. MS (ESlpos.): M / z (%) = 734 (100) [M + 2H] 2+, 1468 (20) [M + H] +; MS (ESlneg.): M / z (%) = 678 (70), 733 (100) [M-2H] 2 ~, 1466 (10) [M-H] ~. HR-TOF-MS (Method 24): C69H111N16019 [M + H] + found 1467.8206, calculated 1467.8206.

Example 113A 3-amino-3- (4-bromophenyl) propionic acid 4-Bromobenzaldehyde (50.0 g, 270 mmol), malonic acid (28.1 g, 270 mmol) and ammonium acetate (27.7 g, 359 mmol, 1.3 eq.) Are dissolved in ethanol ( 400 mi). The mixture is refluxed for 16 h. The resulting solid is collected in a glass filter funnel, collected by suction filtration and washed with ethanol. The residue is then crystallized from methanol (80 ml). It is then triturated with ethyl acetate and collected by filtration with suction. 41.0 g (0.16 mmol, 62% of theory) of the title compound are obtained as a colorless crystalline solid. HPLC (Method 5): R, = 3.13 min. LC-MS (Method 20): R, = 0.97 min, MS (Sleng.): M / z (%) = 242.0 (100) and 244.0 (80) [M-H] \ 1H NMR (300 MHz, oVDMSO) d = 2.36-2.38 (m, 2H, 2-H), 4.25 (T, J = 6.8, 7.6 Hz, 2H, 3-H), 6 , 56 (d, J = 16.1 Hz, 1 H, NH), 7.38 (d, J = 8.5 Hz, 1 H, NH), 7.52-7.71 (m, 4H, arom. H). 13 C-NMR (126 MHz, DCOOD) d = 36.5 (CH 2, C-2), 51, 9 (CH, C-3), 123.7 (C cuat), 129.2 (CH), 132, 4 (CH), 133.5 (C cuat), 174.0 (C cuat, C-1). HR-TOF-MS (Method 24): C9H11N02Br [M + H] + calculated 243.9968, found 243.9980. Example 114A Methyl 3-amino-3- (4-bromophenyl) propionate hydrochloride 41.0 g (157 mmol) of compound 113A are suspended in methanol (1000 ml) under a protective atmosphere of argon gas. 102 ml (410 mmol, 2.6 eq.) Of 4 M hydrochloric acid in 1,4-dioxane are added. The starting material dissolves spontaneously with the addition of hydrochloric acid, and The mixture is stirred at room temperature overnight. The mixture is then concentrated to dryness under vacuum. The product (51.8 g, purity approximately 69%, yield 77% of theory) is obtained as a solid and is used without subsequent purification in the next step. HPLC (Method 5): R, = 3.35 min. LC-MS (Method 20): R, = 1.24 min, MS (ESlpos.): M / z (%) = 240.9 (20) and 242.8 (20) [M-NH2 + H] + . 1 H NMR (300 MHz, dg-DMSO) d = 2.99 (dd, J2.3 = 8.7 Hz, J2 2 = 16.4 Hz, 1 H, 2-HA), 3.16 (dd, J2 3 = 4.0 Hz, J2.2 = 16.4 Hz, 1 H, 2-HB), 3.56 (s, 3H, OCH3), 4.62 (br. S, 1 H, 3-H) , 7.49 (d, J = 8.5 Hz, 2H, 2'-H), 7.65 (d, J = 8.5 Hz, 2H, 2'-H), 8.64 (br. , 2 H, NH 2). 13 C-NMR (126 MHz, CDCl 3) d = 43.8 (CH 2, C-2), 51, 8 (CH 3, OCH 3), 52.1 (CH, C-3), 121, 2 (C cuat, C -4 '), 128.0 (CH, C-arom.), 131, 7 (CH, C-arom.), 143.6 (C cuat, C-1'), 172.2 (C cuat, C -1). HR-TOF-MS (Method 24): C10H13NO2Br [M + H] + calculated 258.0125, found 258.0119. Example 115A / Methyl V-butoxycarbonyl-3-amino-3- (4-bromophenyl) propionate Compound 114A (51.8 g, 121 mmol, 69% purity) is dissolved in 1,4-dioxane / water (2: 1, 540 mL). Di-tert-butyl dicarbonate (29.1 g, 133 mmol, 1.1 eq.) And triethylamine (38.8 ml, 28.22 g, 2.3 eq.) Are added, and the mixture is stirred at room temperature for 150 min. The dioxane is distilled off in vacuo, and 150 ml of ethyl acetate and 200 ml of a saturated aqueous solution of sodium bicarbonate are added. Part of the product 115A precipitates spontaneously and is isolated by filtration. The phases of the filtrate are separated, and the organic phase is washed with 0.5 M citric acid, dried over sodium sulfate and concentrated. Another 115A fraction is obtained from the residue by trituration with methanol. Total yield: 32.9 g (92 mmol, 76% of the theoretical) of the title compound as a solid. HPLC (Method 5): R, = 4.80 min. LC-MS (Method 20): Rt = 2.37 min, MS (ESlpos.): M / z (%) = 358.0 (15) and 360.0 (15) [M + H] +. 1 H NMR (300 MHz, cfe-DMSO) d = 1.34 (s, 9H, COC (CH 3) 3), 2.62-2.79 (m, 2H, 2-H), 3.55 (s, 3H, OCH3), 4.87 (dd, J1 = 7.9 Hz, J2 = 15.1 Hz, 1H, 3-H), 7.26 (d, J2.3 = 8.3 Hz, 2H , 2'-H), 7.51 (d, J2, 3. = 8.3 Hz, 2H, 3'-H). 13 C-NMR (126 MHz, CDCl 3) d = 28.3 (CH 3, COC (CH 3) 3), 40.4 (CH 2, C-2), 50.6 (CH, C-3), 51, 9 ( CH3, OCH3), 79.9 (C cuat, COC (CH3) 3), 121, 4 (C cuat, C-4 '), 127.9 (CH, C-arom.), 131, 7 (CH, C-arom.), 140.3 (C cuat, C-1 '), 155.0 (C cuat, COC (CH3) 3, 171, 2 (C cuat, C-1) HR-TOF-MS ( Method 24): C15H2iN04Br [M + H] + calculated 358.0649, found 358.0659.Example 116 A (S) -A / -butoxycarbonyl-3-amino-3- (4-bromophenyl) propionate methyl The racemic compound 115A is separated into the title compound (96% ee) and the other enantiomer (> 99% ee) by chiral HPLC (method 42). 750 mg of 115A are loaded per run. The (S) -enantiomer (example 116A) and the (R) -enantiomer are quantitatively isolated in 50% of the theoretical in each case. Determination of enantiomers by method 17. HPLC / UV-VIS (Method 17): R, = 4.31 min (title compound) [a] 20Na = -38.6 (c = 1.0, MeOH). (title compound) HPLC / UV-VIS (Method 17): R, = 3.82 min. (another enantiomer) [< x] 0 Na = + 36.8 (c = 1.0, MeOH). (another enantiomer) Example 117A (S) -N-butoxycarbonyl-3-amino-3- (4-dimethylaminophenyl) propionate methyl When carrying out this reaction, care must be taken that oxygen and moisture are strictly excluded and that the reagents are kept under a protective atmosphere of argon gas, because otherwise only inadequate conversion is achieved. Because the size of the microwave limits the size of the batch, the larger quantities are divided into portions of about 7 mmol of Example 116A and processed sequentially. Example 116A (2.5 g, 6.98 mmol), dimethylamine (1 M in THF, 16 mL, 32 mmol, 4.6 eq.), XPHOS (0.4 g, 0.84 mmol, 0, 12 eq.), Cesium carbonate (3.2 g, 9.75 mmol, 1.4 eq.) And bis (dibenzylideneacetone) palladium (0) (0.20 g, 0.35 mmol, 0.05 eq. ) under a protective atmosphere of argon gas in a 20 ml microwave container and screwed. The mixture is heated in a microwave reactor (single-mode Emrys Optimizer laboratory microwave reactor) at 170 ° C for 1 h. After cooling, extraction is carried out with water and ethyl acetate, and the organic phase is dried over sodium sulfate. The solvent is removed, the residue is dissolved in methanol, the solution is filtered and the filtrate is concentrated. 117A is obtained in a yield of 2.0 g (6.19 mmol, 89% of theory) and in a sufficient purity for the next reaction. For analytical purposes, a sample of example 117A is finely purified by preparative HPLC (method 33). HPLC (Method 5): R, = 3.60 min. LC-MS (Method 20): R, = 1.84 min, MS (ESlpos.): M / z (%) = 323.3 (100) [M + H] +. [a] 20Na = -31.0 (c = 1, 0, MeOH). 1 H NMR (400 MHz, cfe-DMSO) d = 1.35 (s, 9H, COC (CH3) 3), 2.63 (dd, J2.3 = 6.6 Hz, Jgem = 15.5 Hz, 1 H, 2-HA), 2.72 (dd, J2¡3 = 8.8 Hz, Jgem = 15.5 Hz, 1 H, 2-HB), 2.93 (s, 6H, N (CH3) 2), 3.54 (s, 3H, OCH3), 4.84 (m, 1 H, 3-H), 6.88 (br. S, 2H, 2'-H), 7.20 (d, J y = 8.3 Hz, 2H, 3'-H), 7.36 (d, J = 8.8 Hz, 1 H, NH). 13 C-NMR (126 MHz, CDCl 3) d = 28.3 (CH 3, COC (CH 3) 3), 40.3 (CH 2, C-2), 44.9 (CH 3, N (CH 3) 2), 50, 3 (CH, C-3), 52.0 (CH3, OCH3), 80.1 (COC (CH3) 3), 119, 1 (CH, C-3 '), 128.0 (CH, C-2) '), 140.3 (C cuat, C-1'), 144.1 (C cuat, C-4 '), 155.1 (C cuat, COC (CH3) 3), 171, 2 (C cuat, C-1). HR-TOF-MS (Method 24): C17H27N204 [M + H] + calculated 322.1893, found 322, 1890. Example 118A (3R) -A / 2 - [(benzyloxy) carbonyl] -W2 - [(benzyl) loxy) carbonylamino] -3 - [(fer-butoxycarbonyl) amino] -3- (4-dimethylamophenyl) -D-alaninate methyl mixed with (SR ^ W ^ benzyloxycarbonyl-W2- [(benzyloxy) carbonylamino] -3 - [(fer-butoxycarbonyl) amino] -3- (4-dimethylaminophenyl) -L-alaninate methyl A 1 M solution of LHMDS in THF (21.3 mL, 21.29 mmol, 2.2 eq.) Is added to 70 mL of absolute THF under a protective atmosphere of argon gas and cooled to -78 ° C. A solution of compound 1 17A (3.1 g, 9.68 mmol) in THF (35 mL) is added and the solution is warmed to -25 ° C, at which time it is stirred for another 10 min. The mixture is then cooled again to -78 ° C, dibenzyl azadicarboxylate (3.2 g, 10.65 mmol, 1.1 eq.) Is added all at once, and the mixture is stirred for 3 h. At the end the reaction is stopped with acetic acid (2.8 ml, 48.39 mmol, 5 eq.) At -78 ° C and stirred for another 15 min. at this temperature. After heating to temperature At room temperature, a concentrated aqueous solution of sodium bicarbonate is added and the extraction is carried out with several portions of ethyl acetate. The combined organic extracts are washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated. The amorphous orange-brown residue is covered with a layer of diethyl ether and allowed to stand for a few hours. Part of the product of Example 1 18A is separated in the form of crystals during this time. The remaining product of example 1 18A can be isolated from the filtrate by flash chromatography (Biotage 40M silica gel, cyclohexane / ethyl acetate 3: 1) and renewed crystallization in the presence of diethyl ether, by mixing the product with the diastereomer of example 1 19A. Total yield of all stereoisomers and mixtures: 1.5 g (2.48 mmol, 18% of theory). For analytical purposes, a sample of the pure diastereoisomer of Example 118A is finely purified by preparative HPLC (method 33). HPLC (Method 5): R, = 4.52 min. LC-MS (Method 20): R, = 2.87 min, MS (ESlpos.): M / z (%) = 621, 5 (50) [M + H] +. [a] 20Na = -22.8 (c = 1.0, MeOH). 1 H NMR (400 MHz, cfe-DMSO) d = 1.30 (s, 9 H, COC (CH 3) 3), 2.86 (s, 6 H, N (CH 3) 2), 3.30 (s, 3 H, OCH3), 4.74-5, 11 (m, 6H), 6.62 (d, J = 8.8 Hz, 2H), 7.15-7.51 (m, 12H, arom.H). Example 119A ^^ -? / ^ ß ????? ? ßG ?????? -? / ^? ß ?? ^^ dimethylaminophenyl) -L-alaninate methyl The compound of Example 118A (1.6 g, 1.90 mmol) is dissolved in dichloromethane (60 mL). At 0 ° C, TMG (2.6 mL, 20.93 mmol, 11 eq.) Is added and the reaction is stirred at room temperature overnight. To stop the reaction, the mixture is first cooled to 0 ° C and then acetic acid (1.3 ml, 22.83 mmol, 12 eq.) Is added. The mixture is diluted with water and extracted with 3 portions of dichloromethane, and the combined organic extracts are concentrated. The residue is triturated with a mixture of ethyl acetate / diethyl ether. The compound of Example 119A crystallizes, and the compound of Example 118A remains predominantly in the supernatant. The latter is concentrated and subjected again to isomerization with 2 ml of TMG and dichloromethane (40 ml). In this way a second portion of the title compound of example 119A is obtained. The supernatant of the crystallization is subjected to chromatography (method 33) and reisomerized, and a third portion of example 119A is obtained. Total yield: 1.1 g (1.72 mmol, 90% of theory) of example 119A in the form of crystals. HPLC (Method 5): R, = 4.76 min. LC-MS (Method 20): R, = 3.12 min, MS (ESlpos.): M / z (%) = 621.5 (90) [M + H] +; MS (Sleng): m / z (%) = 619.5 (60) [M - H] \ [] 20Na = -118 ° (c = 1.0, CHCl3). 1 H NMR (400 MHz, cfe-DMSO) d = 1.30 (s, 9 H, COC (CH 3) 3), 2.86 (s, 6 H, N (CH 3) 2), 3.30 (s, 3 H, OCH3), 4.75-5.23 (m, 4H), 6.62 (d, J = 8.8 Hz, 2H), 7.15-7.61 (m, 12H), 8.29 (br s, 1H, NH), 8.72 (br. s, 1H, NW). 13C-NMR (126 ??), d = 27.94 and 28.07 (CH3, C (CH3) 3), 51, 31 (CH3), 51, 62 (CH3), 51.98 (CH, C -7), 61, 81 (CH, C-6), 66.18 and 66.32 and 66.50 (CH2 > OCH2Ph), 67.49 and 67.65 (CH2, OCH2Ph), 78.68 and 78.90 (C quat, C-11), 111.74 (CH, C-3 '), 123.54 (CH), 124.06 (CH), 126.76 (CH), 127.18 (CH) ), 127.30 (CH), 127.55 (CH), 127.76 (CH), 127.83 (CH), 127.98 (CH), 128.24 (CH), 128.30 (CH) , 128.79 (CH), 135.59 (C cuat), 135.77 (C cuat), 135.99 (C cuat), 136.11 (C cuat), 149.74 (C cuat), 154, 21 (C cuat), 154.68 (C cuat), 154.92 (C cuat), 155.03 (C cuat), 155.14 (C cuat), 156.09 (C cuat), 156.24 (C cuat), C cuat), 166.97 (C cuat, C = 0). HR-TOF-MS (Method 24): C33H41N408 [M + H] + calculated 621, 2919, found 621, 2922. Example 120 A (3R) -3 - [(fer-butoxycarbonyl) amino] -4- (dimethylaminophenyl) -L-alaninate methyl The compound of Example 119A (938 mg, 1.51 mmol) is dissolved in dichloromethane-methanol 1: 1 (30 mL). Raney nickel (approximately 200 mg) is added under a protective atmosphere of argon gas, and the mixture is hydrogenated under 80 bar for 4 d. When no more starting material can be detected by HPLC (method 5), the catalyst is removed by filtration. The filtrate is concentrated. 0.6 g of crude product are obtained (purity approximately 70%) and used without subsequent purification in the next step. For analytical purposes, a sample of the pure compound of Example 120A is finely purified by preparative HPLC (method 27). HPLC (Method 5): R, = 3.25 min. LC-MS (Method 20): R, = 1.34 min, MS (ESlpos.): M / z (%) = 338.2 (30) [M + H] +. [afVia = -11, 5o (c = 1, 0, MeOH). 1 H NMR (500 MHz, cfe-DMSO) d = 1.37 (s, 9 H, COC (CH 3) 3), 2.90 (s, 6 H, N (CH 3) 2), 3.54 (s, 3 H, OCH3), 4.24 (d, J = 5.4 Hz, 1 H, ß-?), 4.96 (dd, J = 8.4 Hz, J = 8.0 Hz, 1 H, aH), 6.73 (d, Jz y = 8.0 Hz, 2H, 3'-H), 7.13 (d, J2.r = 8.0 Hz, 2H, 2'-H), 7.46 (d , J = 9.6 Hz, 1 H, NH), 8.470 (br.s, 2H, NH2). 13 C-NMR (126 MHz, cfe-DMSO) d = 28.07 (CH 3, COC (CH 3) 3), 40, 19 (CH 3, N (CH 3) 2), 52.68 (CH 3, OCH 3), 54, 11 (CH, CD), 56.79 (CH, CD), 78.87 (C cuat, COC (CH3) 3), 112.53 (CH, C-3 '), 127.65 (CH, C- 2 '), 149.87 (C cuat), 154.61 (C cuat, COC (CH3) 3), 167.96 (C cuat, C02CH3). HR-TOF-MS (Method 24): C17H28N304 [M + H] + calculated 338.2075, found 338.2064. Example 121 A (3 /?) - A / 2- (benzyloxy) carbonyl) -3 - [(ery-butoxycarbonyl) amino] -4- (dimethylaminophenyl) -L-alaninate methyl 550 mg (1.14 mmol, 70% purity) of the compound of Example 120A are dissolved in dioxane / water 8: 2.8. Sodium bicarbonate (479 mg, 5.71 mmol, 5 eq.) And benzyl chloroformate (212 μ ?, 1.48 mmol, 1.3 eq.) Are added and the mixture is stirred at room temperature for 2.5 hours. h. The mixture is then extracted with water and ethyl acetate, and the organic phase is dried over sodium sulfate and concentrated. The title compound of example 121A can be obtained as crystals from the resiby trituration with diethyl ether. Yield: 490 mg (1.04 mmol, 91% of theory). HPLC (Method 5): R, = 4.14 min. LC-MS (Method 20): R, = 2.52 min, MS (ESlpos.): M / z (%) = 472.3 (100) [M + H] +. H20Na = -13.4 ° (c = 1.0, MeOH). 1 H NMR (400 MHz, cfe-DMSO) d = 1.36 (s, 9 H, COC (CH 3) 3), 2.86 (s, 6 H, N (CH 3) 2), 3.30 (s, 3 H, OCAY3), 4.45 (dd, Jatfip = 4.2 Hz, J = 9.3 Hz, 1 H, ß-?), 4.94 (d, Jgem = 12.5 Hz, 1 H, OCH2Ph), 4.99 (d, Jgem = 12.5 Hz, 1 H, OCH2Ph), 5.15 (dd, = 4.2 Hz, J = 10.3 Hz, 1 H, aH), 6.65 (d, J2.3. = 8 , 8 Hz, 2H, 3'-H), 7.10 (d, J2.3 = 8.8 Hz, 2H, 2'-H), 7.23-7.37 (m, 5H), 7.54 (d, J = 9.3 Hz, 1 H, NH). 13 C-NMR- (126 MHz, d 6 -DMSO) d = 28.0 (CH 3, COC (CH 3) 3), 41, 1 (CH 3, N (CH 3) 2), 52.0 (CH 3, OCH 3), 53 , 8 (CH, C-ß), 59.0 (CH, Ca), 65.4 (CH2, OCH2Ph), 78.3 (C cuat, COC (CH3) 3), 113.7 (CH), 126.9 (C cuat), 127.3 (CH), 127.5 (CH), 127.8 (CH), 128.2 (C cuat), 128.3 (CH), 136, 6 (C cuat), 154.6 (C cuat, NC02), 156.0 (NC02), 170.7 (C02CH3). HR-TOF-MS: C25H34N306 [M + H] + calculated 472.2443, found 472.2460.

Example 122 A (SRJ-A ^ - Benzyloxycarbon-S-fer-buto ^ Compound 121 A (444 mg, 0.94 mmol) is dissolved in a mixture of 5 ml of THF and 830 μ? of water. At 0 ° C, 99 mg (2.35 mmol, 2.5 eq.) Of lithium hydroxide monohydrate are added. The reaction is carried out at 0 ° C for about 2 h until no further starting material 121A can be detected (HPLC, method 5). The reaction is then stopped with acetic acid (620 μ ?, 2.83 mmol, 3 eq.). The mixture is diluted with water and extracted with ethyl acetate. The organic phase is dried over sodium sulfate and the solvent is distilled off. Yield: 430 mg (quantitative). HPLC (Method 5): R, = 3.80 min. LC-MS (Method 20): R, = 2.21 min, MS (ESlpos.): M / z (%) = 458.2 (100) [M + Hf; MS (ESlneg): m / z (%) = 456, 3 (100) [M-H] \ [a] 20Na = -16.5 (c = 1.0, MeOH). 1 H NMR (500 MHz, cfe-DMSO) d = 4.39 (dd, Ja = 3.5 Hz, J = 9.6 Hz, 1 H, ß-?), 4.92 (d, Jgem = 12, 8 Hz, 1 H, OCH2Ph), 4.97 (d, Jgem = 12.8 Hz, 1 H, OCH2Ph), 5.19 (dd, Ja = 3.5 Hz, J = 10.0 Hz, 1 H , aH), 6.86 (br.s, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.24 (d, J = 7.0 Hz, 2H), 7.23 -7.29 (m, 2H), 7.41 (d, J = 10.1 Hz, 1 H, NH), 7.48 (d, J = 1 Hz, 1 H, NH), 13.0 ( br.s, 1 H, COOH). 13 C-NMR (126 MHz, cfe-DMSO) d = 28.0 (CH 3, COC (CH 3) 3), 41, 2 (CH 3, N (CH 3) 2), 53.9 (CH, C-β), 58.8 (CH, Ca), 65.3 (CH2, OCH2Ph), 78.1 (C cuat, COC (CH3) 3), 113.7 (CH), 126.7 (C cuat), 127.1 (CH), 127.3 (CH), 127.6 (CH), 128.1 (C cuat), 128.2 (CH), 136.9 (C cuat), 154.7 (C cuat, NC02) , 156.1 (NC02), 171, 4 (C02H). HR-TOF-MS (Method 24): C 24 H 32 N 306 [M + H] + calculated 458.2286, found 458.2277. Example 123A (3 /?) - / V - [(benzylloxy) carbonyl] -3 - [(ery-butoxycarbonyl) amino] -4- (dimethylamino phenyl) -L-alaninate pentafluorophenyl Compound 122A (408 mg, 0.89 mmol) is dissolved in dry THF (11 mL) at 0 ° C under a protective atmosphere of argon gas. Pentafluorophenyl diphenylphosphate (514 mg, 1.34 mmol, 1.5 eq.) And NMM (360 mg, 3.57 mmol, 4 eq.) Are added, and the reaction mixture is stirred at room temperature for 16 h. The solvent is then removed and the residue purified by chromatography (method 33: modified gradient: 0-10 min 10% B, slope, 30 min 65% B, 36-38 min 10% B). In addition to 123A (250 mg, 0.40 mmol, 45% of theory), unreacted starting material is isolated (example 122A, 41 mg, 9 pmol, 10% of theory). HPLC (Method 5): R, = 3.66 min. LC-MS (Method 20): R, = 3.23 min, MS (ESlpos.): M / z (%) = 624.4 (100) [M + H] +. [] 20Na = -19.8 ° (c = 0.5, CH2Cl2). 1 H NMR (400 MHz, c / 6-DMSO) d = 1.36 (s, 9H, COC (CH3) 3, 2.90 (s, 6H, N (CH3) 2), 4.96-5.04 (m, 3H, ß-? and OCH2Ph), 5.39 (dd, Ja, p = 4.4 Hz, J = 10.2 Hz, 1 H, aH), 6.75 (br. s, 2H) , 7.21-7.33 (m, 7H), 7.57 (d, J = 10.3 Hz, 1 H, NH), 7.89 (d, J = 9.3 Hz, 1 H, NH 13C-NMR (126 MHz, de-DMSO) d = 28.2 (CH3, COC (CH3) 3), 43.8 (CH3, N (CH3) 2), 55.6 (CH, C-) H.H), 59.1 (CH, Ca), 67.5 (CH2, OCH2Ph), 80.9 (C cuat, COC (CH3) 3), 117.8 (CH), 124.4 (C cuat, m), 128 , 1 (CH), 128.4 (CH), 128.6 (CH), 128.7 (CH), 132.9 (C cuat, m), 136.8 (C cuat, m), 138.9 (C cuat, m), 139.9 (C cuat, m), 141, 9 (C cuat, m), 155.7 (C cuat, NC02), 156.2 (NC02), 166.2 (C02H) . Example 124A Bistrifluoroacetate of. { (3?) - / V - [(Benzyloxy) carbonyl] -3 - [(fer-butoxycarbonyl) amino] -4- (dimethylaminophenyl) -L-alanyl} - [(3R) -3-hydroxyl-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-gli [(3S) -3-hydroxy-L- asparaginyl] -L-serine * 2 TFA Compound 123A (237 mg, 0.38 mmol) and compound Edman30 (compound of Example 3, 465 mg, 0.46 mmol, 1.2 eq.) Are dissolved in DMF (40 ml) at 0 °. C, and DIEA (0.40 ml, 2.28 mmol, 6 eq.) Is added. The reaction mixture is then stirred overnight, during which it is slowly heated to room temperature. The DMF is then removed in a rotary evaporator, and the residue is purified by chromatography (method 44). Yield: 550 mg (92% of theory). HPLC (Method 5): R, = 3.62 min. LC-MS (Method 20): R, = 2.01 min, MS (ESlpos.): M / z (%) = 673.3 (100) [M + 2H] 2+, MS (ESlneg) mz (% ) = 1343 [M - H] \ HR-TOF-MS (Method 24): [M + H] + calculated 1344.7158, found 1344.7155. Example 125A Bistrifluoroacetate Tristrifluoroacetate of. { (3R) -3-amino- / V - [(benzyloxy) carbonyl] -4- (dimethylaminophenyl) -L-alanyl} - [(3R) -3-hydroxy-L-leuc ^ [(3S) -3-hydroxy-L-asparaginyl] -L-serine 550 mg (0.35 mmol) of the compound of Example 124A are dissolved in dichloromethane (2 mL) and then 14 mL of 30% TFA in dichloromethane are added. The mixture is stirred at room temperature for 15 min and then concentrated and dried under vacuum by oil pump. The crude product (644 mg, approximately 70% pure, 0.28 mmol, 80% of theory) is then reacted without purification. HPLC (Method 7): R, = 3.46 min. LC-MS (Method 20): Rt = 1.56 min, MS (ESLs.): M / z (%) = 622.9 (100), [M + 2H] 2+, MS (Sleng.): M / z (%) = 1242.6 [M-H] \ Example 126A C1- N3 'Bistrifluoroacetate-N2 J- (benzyloxycarbonyl) - [(3 /?) - 3-amino-4- (dimethylamino) lactam -L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycol - [(3S) -3-h asparaginyl] -L-serine The crude product of Example 125A (644 mg, 0.28 mmol) is dissolved in DMF (30 mL) and cooled to 0 ° C. HATU (349 mg, 0.92 mmol, 3 eq.) Is added, followed by NMM (200 μ ?, 1.84 mmol, 6 eq.). After 5 min, the ice bath is removed and the mixture is stirred at room temperature for 3 h. The reaction is stopped by adding methanol and the mixture is prepurified initially by gel chromatography (method 45, eluent: methanol). The fractions containing the product are combined and finely purified by preparative HPLC (method 33). Yield: 211 mg (52% of theory). HPLC (Method 5): R, = 3.64 min. LC-MS (Method 20): R, = 1.70 min, MS (ESlpos.): M / z (%) = 614 (100) [M + 2H] 2+, 1226.8 (20) [M + H] +; MS (ESlneg.): M / z (%) = 1224.9 (100) [M-H] \ HR-TOF-MS (Method 24): CseHeeN ^ O ^ [M + H] + calculated 1226.6528, found 1226.6534. EXAMPLE 127 A C1""? / 3 'Tris-hydrochloride-[(3R) -3-Amino-4- (dimethylaminophenyl) -L-alanyl] - [(3R) -3-hydroxy-L-leucyl] -L lactama -leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-aspar ^ The compound of Example 126A (209 mg, 0.14 mmol) is dissolved in methanol (50 mL), and 1 M aqueous hydrochloric acid (860 μ ?, 6 eq.) As well as 10% palladium-carbon are added. The hydrogenation is carried out under ambient pressure and at room temperature for 90 min. The mixture is tfiltered to remove the catalyst and concentrated. The residue is collected in water and lyophilized. 170 mg (98% of theory) of the title compound are obtained. HPLC (Method 7): R, = 3.19 min. LC-MS (Method 20): R, = 1.26 min, MS (ESlpos.): M / z (%) = 547.1 (100) [M + 2H] 2+, 1092.8 (5) [M + H] +. HR-TOF-MS (Method 24): C ^ H ^ N ^ O ^ [M + H] + calculated 1092.6161, found 1092.6133. EXAMPLE 128A-11-N3-N-3-lactam bis-hydrochloride of N2 ^ (rt-butoxycarbonyl-HS-fer-butyl-D-alanyl-2-y-butyl-L-alanyl] - [(3R) -3-amino-4- ( dimethylaminopl) -L-alanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L -asparaginyl] -L-serine The compound of example 127A (85 mg, 71 μ? T) and the dipeptide (example 9A, 40 mg, 106 pmol, 1.5 eq.) Are dissolved in DMF (4 ml) and cooled to 0 °. C. TNMM (31 μ ?, 281 μ? P ??, 4 eq.) And HATU (43 mg, 113 μ? T ???, 1.6 eq.) Are added and the ice bath is tremoved. The mixture is heated slowly to room temperature. After 1 h, the reaction is stopped by adding methanol, and chromatography is carried out using methanol as mobile phase (method 45). The eluate is verified by HPLC (method 7), and the fractions containing the product are combined and concentrated. 105 mg of the title compound is obtained approximately 66% pure (65% of theory). This material is used in the next step without subsequent purification. HPLC (Method 7): R, = 4.47 min. LC-MS (Method 20): R, = 2.24 min, MS (ESlpos.): M / z. { %) = 724.3 (100) [M + 2H] 2+, 1448.3 (5) [M + H] +. Example 129A (2S) -W- (1-Butoxycarbonyl) -3- (trimethylsilyl) alanine and Example 130 A (2 /?) - N- (tert-Butoxycarbonyl) -3- (trimethylsilyl) alanine The desired compound is prepared according to M. Merget, K. Günther,. Bernd, E. Günther, R. Tacke, J. Organomet. Chem. 2001 628, 183-194. The separation of the enantiomers is achieved by preparative HPLC (method 41) in a chiral phase and the isomers are assigned by HPLC comparison with an autic sample of / V- (tert-butoxycarbonyl) -L-3-trimethylsilylalanine (2R isomer, Mercachem AMR 39,260). Example 129 A A / - (Ier-Butoxycarbonyl) -3- (trimethylsilyl) -D-alanine Chiral HPLC (Method 41): R, = 4.16 min, e.e. > 99% [a] D20 = +1.1 (c = 0.83, methanol) Example 130 A / V- (Ier-Butoxycarbonyl) -3- (trimethylsilyl) -L-alanine Chiral HPLC (Method 41): R, = 9.27 min, e.e > 99% [a] D20 = - 1, 6 (c = 0.66, methanol) Example 131A [/ - (fer-butoxycarboniO-S -trimethylsilyl -D-alanylJ ^ -fer-butyl-L-alaninate methyl] Methyl 2-ér-butyl-L-alaninate trifluoroacetate (215 mg, 0.82 mmol) is dissolved [S.D. Bull, S.G. Davies, AC Garner, MD O'Shea, J. Chem. Soc. Perkin Trans, 1, 2001, 3281-3287] and example 129A (225 mg, 0.82 mmol, 1 eq.) In DMF (5 ml) a 0 ° C. TNMM (360 μ ?, 3.29 mmol, 4 eq.) And HATU (470 mg, 1.24 mmol, 1.5 eq.) Are added, and the mixture is stirred at room temperature for 2 h. The extraction is carried out twice with MTBE and a saturated aqueous solution of sodium bicarbonate, and the combined organic phases are washed with 1 M citric acid and again with a saturated aqueous solution of sodium bicarbonate, dried over sodium sulfate. and they concentrate. After purification by chromatography (method 33), 290 mg (0.72 mmol, 88% of theory) of the title compound are obtained. HPLC (Method 7): R, = 5.37 min. LC-MS (Method 18): R, = 3.02 min, MS (ESlpos.): M / z (%) = 403.5 (100) [M + H] +. 1 H NMR (400 MHz, drDMSO) d = 0.01 (s, 9 H, Si (CH 3) 3), 0.89 (m, 11 H), 1.37 (s, 9 H, COC (CH 3) 3), 1.55 (dd, J = 8.8 Hz, 14.2 Hz, 1 H), 1.63 (dd, J = 3.4 Hz, 14.2 Hz, 1 H), 3.62 (s, 3H, OCH3), 4.04 (m, 1 H), 4.27 (m, 1 H), 6.70 (d, J = 9.0 Hz, 1 H, NH), 7.96 (d, J = 8.1 Hz, 1 H, NH). Example 132A [/ * - (fer-Butoxycarbonyl) -3- (trimethylsilyl) -D-alanyl] -2-yer-butyl-L-alanine Place Example 131 A (274 mg, 0.68 mmol) in THF / water (3: 1, 21 mL) and cool to 0 ° C. HE add lithium hydroxide monohydrate (57 mg, 1.36 mmol, 2 eq.) and the mixture is stirred at 0 ° C for 1 h. Most of the THF is removed in vacuo, the pH is adjusted to 4 by adding 1 M citric acid, and the mixture is extracted twice with ethyl acetate. The combined organic phases are dried over sodium sulfate and concentrated. After purification by chromatography (method 33 with modified gradient: 0-2 min 30% B, slope, 30-35 min-90% B), 237 mg (0.61 mmol, 90% of theory) of the title as a colorless solid. HPLC (Method 7): R, = 4.93 min. LC-MS (Method 18): R, = 2.76 min, MS (ESlpos.): M / z (%) = 389.4 (100) [M + H] +. H NMR (400 MHz, cfe-DMSO) d = 0.00 (s, 9H, Si (CH3) 3), 0.88 (m, 11 H), 1.36 (s, 9H, COC (CH3) 3 ), 1.51 (dd, J = 9.3 Hz, 14.2 Hz, 1 H), 1.64 (dd, J = 3.0 Hz, 14.2 Hz, 1 H), 4.02 ( m, 1 H), 4.20 (m, 1 H), 6.71 (d, J = 9.3 Hz, 1 H, NH), 7.80 (d, J = 8, 1, 1 H, NH), 12.49 (br s, 1 H, COOH). EXAMPLE 133A N2 '- (3-trimethylsilyl-D-alanyl] - [3-rer-butyl-L-alanyl] - [(3R) -3 C1"-? / 33-lactam bischlorohydrate - (fer-Butoxycarbonyl) - -amino-4- (dimethylaminophenyl) -L-alanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-argini isoleucyl-L-alotreonyl-glycyl - [(3S) -3- hydroxy-L-asparaginyl] -L-serine The compound of example 127A (102 mg, 85 μ ??) and the dipeptide (example 132A, 50 mg, 127 μ ?t ???, 1.5 eq.) Are dissolved in DMF (4 ml) and cool to 0 ° C. Then NMM (37 μ ?, 340 μ? T ??, 4 eq.) And HATU (65 mg, 170 μ ??, 2.0 eq.) Are added and the ice bath is then removed. The mixture is heated slowly to room temperature. After 1 h, the reaction is stopped by adding methanol, and chromatography is carried out on Sephadex LH20 using methanol as the mobile phase (method 45). The eluate is verified by HPLC (method 7), and the fractions containing the product are combined and concentrated. 126 mg (82 μ ??, 96% of theory) of the title compound are obtained. HPLC (Method 7): R t = 4.55 min. Example 134A / ^ - (Benzoyl benzene-fero-butoxycarbonyl-J-D-phenylalanyl-L-phenylalaninate HOBt (2.0 g, 15.08 mmol, 4 eq.), NMM (1.2 mL, 1.1 g, 11.31 mmol, 3 eq.), N- (tert-butoxycarbonyl) -D are added. phenylalanine (1.0 g, 3.77 mmol, 1 eq.) [Anderson, McGregor; J. Am. Chem. Soc; 79; 1957; 6180.6181], EDC (1.4 g, 7.54 mmol, 2 eq.) And again NMM (0.8 ml, 0.8 g, 7.54 mmol, 2 eq.) In succession to a solution of benzyl L-phenylalaninate hydrochloride (1.1 g, 4.15 mmol, 1.1 eq.) in dichloromethane (365 mi) at -10 ° C. The reaction mixture is slowly warmed to room temperature and stirred at this temperature overnight. The solvent is completely removed, and the residue is mixed with ethyl acetate and the mixture is then washed with a saturated aqueous solution of sodium bicarbonate, 5% aqueous citric acid, a saturated aqueous solution of sodium bicarbonate (500 ml). and a saturated aqueous solution of sodium chloride. The mixture is dried over sodium sulfate and filtered. The mixture is evaporated to dryness in vacuo and then dried under high vacuum. 1.8 g (96% of theory) of the title compound are obtained and they are reacted without subsequent purification. HPLC (Method 12): R, = 9.16 min. HPLC (Method 4): R, = 5.16 min. 1 H NMR (400 MHz, cfe-DMSO): d = 1, 18/1, 27 (2s, 9H, OtBu), 2.47-2.57 (m below the H-DMSO signal, 1 H, ß -?), 2.66 (dd, J = 13.8, 3.7 Hz, 1 H, ß-CH), 2.91 (dd, J = 13.8, 9.4 Hz, 1 H, ß -CH), 3.09 (dd, J = 13.8, 3.1 Hz, 1 H, ß-CH), 4.19 (td, J = 9.3, 4.2 Hz, 1 H, a -CH), 4.57 (td, J = 8.8, 5.9 Hz, 1 H, a-CH), 5.12 (s, 2H, OCH2Ph), 6.76 (d, J = 9, 2 Hz, 1 H, NH), 7.08-7.43 (m, 15H, Aril-H), 8.48 (d, J = 8.1 Hz, 1 H, NH). HR-TOF-MS (Method 24): C 30 H 36 2 O 5 [M + H] + Found 503.2566, calculated 503.2546. Example 135A / ^ - (fer-Butoxycarbonyl-J-D-phenylalanyl-L-phenylalanine The title compound is prepared from the compound of Example 134A (563, 0 mg, 1.12 mmol) according to procedure 5. After stirring under an atmosphere of hydrogen under atmospheric pressure and at room temperature for 3 h, complete conversion is achieved according to the monitoring of the reaction (method 12). ). 452.2 mg (97.9% of theory) of product are obtained. M2 ° Na = + 33.2 ° (c = 0.57 in CH2CI2). HPLC (Method 12): R, = 7.64 min. HPLC (Method 4): R, = 4.45 min. 1 H NMR (400 MHz, ck-DMSO): d = 1.19 / 1, 26 (2s, 9H, OtBu), 2.44-2.56 (m below the H-DMSO signal, 1 H, ß -?), 2.69 (dd, J = 14.0, 3.8 Hz, 1 H, ß-CH), 2.86 (dd, J = 14.0, 9.5 Hz, 1 H, ß -CH), 3.08 (dd, J = 14.0, 4.6 Hz, 1 H, ß-CH), 4.18 (td, J = 9.7, 3.57 Hz, 1 H, a -CH), 4.48 (td, J = 9.3, 4.5 Hz, 1 H, a-CH), 6.71 (d, J = 8.7 Hz, 1 H, NH), 7, 08-7.32 (m, 10H, Aril-H), 8.27 (d, J = 8.0 Hz, 1 H, NH), 12.77 (s br., 1 H, COOH). HR-TOF-MS (Method 24): C23H30N2O5 [M + H] + found 413.2082, calculated 413.2076. Example 136A ^ - [(benzyloxycarbonyl-S-urea-butoxycarboni-amino-L-alaninate 2- (trimethylsilyl) ethyl) Dissolve / V - [(benzyloxy) carbonyl] -3 - [(fer-butoxycarbonyl) amino] -L-alanine (1000.0 mg, 2.96 mmol) [Rane, F.Dinanath et al .; Tetrahedron Lett .; IN; 3. 4; twenty; 1993; 3201-3204] in dichloromethane (20 ml), and trimethylsilylethanol (4.2 ml, 3.5 g, 29.55 mmol, 10 eq.), DCC (1.22 g, 5.91 mmol, 2 eq.) and DMAP (361, 1 mg, 2.96 mmol, 1 eq.) are added successively to the solution at -20 ° C. The reaction is warmed to room temperature and stirred at this temperature overnight and brought to full conversion. For the preparation, the ure is concentrated, and the residue is taken up in diethyl ether and then extracted twice with water and once with a saturated aqueous solution of sodium chloride. The ether phase is dried over sodium sulfate, the desiccant is removed by filtration through silica gel, and most of the solvent is removed from the filtrate in a rotary evaporator. If a precipitate separates during the concentration, it can be removed again where appropriate through silica gel. The residue obtained is then finely purified by chromatography (method 31) and 1.1 g (86.4% of theory) of the title compound are obtained. HPLC (Method 12): R, = 9.31 min. LC-MS (Method 18): R, = 2.97 min, MS (ESlpos.): M / z (%) = 439 (100) [M + H] +.

Example 137A S-amino-A / 2-benzyloxycarbonyl-L-alaninate trifluoroacetate of 2- (trimethylsilyl) etiol The title compound is prepared from the compound of Example 136A (100.0 mg, 0.23 mmol) as described in procedure 1. 41 mg (39.7% of theory) of the product are isolated from the crude product after the fine purification (method 35). HPLC (Method 12): R, = 6.33 min. LC-MS (Method 23): R, = 4.83 min, MS (ESlpos.): M / z (%) = 339 (15) [M + H] \ 311 (100). EXAMPLE 138A 2- (Trimethylsilyl) ethyl ester trifluoroacetate / ^ - (BenzyloxycarbonylJ-A ^ -fA / 2 1-tert-butoxycarbonyl [(3 /?) - 3-hydroxy-L-leucyl] -L- leuciL The octapeptide (example 100A, 9.0 mg, 8.04 pmol) and compound of example 137A (17.0 mg, 39.95 pmol, 5 equivalents) are supplied in DMF (900 μm) under a protective gas atmosphere. Argon at 0 ° C. Next, base (9 μ ?, 0.8 mg, 8.04 pmol, 1 eq.) Is added from a stock solution of NMM (0.91 mmol / ml in DMF), HATU (6.1 mg, 16.08 pmol, 2 eq.) and again NMM solution (9 μ ?, 0.8 mg, 8.04 pmol, 1 eq.) successively to the ure. After stirring for 15 min, NMM stock solution (22 μ ?, 2 mg, 20.10 μ? T ??, 2.5 eq.) Is finally added, and the ure is heated slowly to room temperature and It is stirred at this temperature overnight. The solution is prepurified by preparative HPLC (method 36) and finely purified by gel chromatography (method 45, eluent: methanol with 0.25% glacial acetic acid). 8.0 mg (69.1% of theory) of the title compound are obtained. HPLC (Method 12): R, = 7.21 min. LC-MS (Method 23): R, = 5.30 min, MS (ESlpos.): M / z (%) = 1325 (75) [M + H] +; MS (ESlneg.): M / z (%) = 1323 (100) [M - Hf. Example 139A A- (Benzyloxycarbonyl) -A / 3- Trifluoroacetate. { Ay2 '-ier-butoxycarbonyl (3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparagin l] -L-seril} - (3R) -3-ami alanine The compound of example 138A (7.5 mg, 5.21 μ ???) is provided in 900 μ? of THF, and 4 portions of a 1 M solution of TBAF are added in THF (26 μ ?, 6.8 mg, 26.05 μ? t ??, 5 eq.) and then 15 eq. of base, molecular filters (4 Á). The reaction is stirred at room temperature for 1 h, and complete conversion is established by HPLC Monitoring (method 12). For the preparation, the ure is neutralized with glacial acetic acid and then concentrated in vacuo and chromatographed by preparative HPLC (method 29). 6.2 mg (88.9% of theory) of the title compound are obtained. HPLC (Method 12): R, = 6.24 min. LC-MS (Method 23): R, = 4.88 min, MS (ESlpos.): M / z (%) = 1224 (80) [M + H] +, 242 (100); MS (ESlneg.): M / z (%) = 1223 (100) [M - Hf. Example 140 A pentafluorophenyl ester trifluoroacetate of / ^ -. { benzyloxycarboni -A ^ A 2 1-tert-butoxycarbonyl [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L -soleucyl-L-alotreonyl-glycyl - [(3S) -3 -hydro ^ L-asparaginyl] -L-seryl} - (3R) -3-amino-L-alanine Under a protective atmosphere of argon gas, the compound of Example 139A (3.1 mg, 2.31 pmol) is provided in dichloromethane (1 mL), and pentafluorophenol (4.3 mg, 23.14 μ? T? ??, 10 eq.). The reaction is cooled to -20 ° C and finally EDC (1.0 mg, 5.32 pmol, 2.3 eq.) Is added, and the mixture is warmed to room temperature and stirred at this temperature overnight. For the process, the solvent is completely removed and the residue is dried by freezing. The title compound is then reacted as a crude product, and a quantitative yield is assumed. HPLC (Method 12): R, = 7.18 min. LC-MS (Method 23): R, = 5.56 min, MS (ESlpos.): M / z (%) = 1392 (80) [M + H] +. Example 141 A W2- (benzyloxycarbonyl) pentafluorophenyl ester-hydrochloride / / 3-. { [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-N-alanine] The title compound is prepared from the compound of Example 140A (3.0 mg, 1.99 μm) according to procedure 3. After the addition of hydrochloric acid at 0 ° C, the conversion is complete is established by HPLC Monitoring (method 12) after 30 min. The title compound is obtained as a crude product, assuming a quantitative yield. LC-MS (Method 23): R, = 4.47 min, MS (ESlpos.): M / z (%) = 1292 (3) [M + H] +, 646 (100) [M + 2H] 2 +, MS (ESlneg.): M / z (%) = 1290 (40) [M - Hf, 1 106 (100). EXAMPLE 142A Cl-1-N3 'Hydrochloride - /' - (Benzyloxycarbonyl-thiSRJ-S-amino-L-alanyl-L-thio RJ-S-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L- isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine Under a protective atmosphere of argon gas, the compound of example 141A (3.0 mg, 2.20 pmol) is provided in chloroform (20 ml). Triethylamine (22 pl, 15.8 mg, 131, 94 pmol) is dissolved in chloroform (25 ml) and added dropwise to the solution for 1 h. After the addition is complete, the reaction is stirred at room temperature overnight. For the preparation, the mixture is neutralized with TFA, then concentrated in vacuo and prepurified by gel chromatography (method 45, eluent: methanol with 0.25% glacial acetic acid), 0.4 mg (0.4 mg) is isolated. , 9% of theory) of the product after fine purification by preparative HPLC (phase separation: Xterra 10 mm, eluent: 0.1% TFA, gradient of acetonitrile-water). HPLC (Method 12): R, = 5.96 min. LC-MS (Method 18): R, = 1.72 min, MS (ESlpos.): M / z (%) = 1108 (48) [M + H] +, 132 (100); MS (ESlneg.): M / z (%) = 1106 (100) [M-H] \ Example 143A C1-N3 '- Hydrochloride - [(3R) -3-Amino-L-alanyl)] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine The title compound (0.4 mg, 0.35 pmol) is prepared from the compound of example 142A as described in procedure 4. The complete conversion is achieved after hydrogenation under atmospheric pressure and at room temperature for 6 h. 0.3 mg (81.9% of theory) of the title compound is obtained as a crude product which is then reacted. Example 144A Nitric acid 11-N3 3-lactam trifluoroacetate of N2 ^ fer-butoxycarbonyl) - [D-phenollanyl] - [L-phenollanyl] - [(3R) -3-amino-L- alanyl)] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl ^ 3-hydroxy-L-asparaginyl] -L-serine The deprotected amine (Example 143A, 0.3 mg, 0.29 μ? T) and the dipeptide (1.2 mg, 2.86 pmol, 10 eq.) Are supplied under a protective atmosphere of argon gas in DMF (100 μ?), And the solution is cooled to 0 ° C. Base (16 μ ?, 147 μg, 1, 43 μ ??, 5 eq.) Is added from the NMM stock solution (90.9 μ ?? / ml in DMF), HATU (1, 1 mg, 2.95 μ? T ??, 10.3 eq.) And more NMM stock solution (16 μ ?, 147 μg, 1, 43 μ? T ??, 5 eq. .), and the reaction is stirred for 15 min. Finally, base (40 μ ?, 367 μg, 3.62 μ ??, 12.5 eq.) Is added again to the mixture, which is brought to room temperature by stirring. Stirring is continued at this temperature overnight. For the preparation, the mixture is concentrated in vacuo and finely purified by gel chromatography (method 45, eluent: methanol). 0.3 mg (70.6% of theory) of the title compound are obtained. HPLC (Method 12) R, = 7.80 min. LC-MS (Method 18): R, = 2.17 min; MS (ESlpos): m / z (%) = 1368 (5) [M + H] \ 634 (100); MS (ESlneg.): M / z (%) = 1367 (30) [M-Hf, 683 (100) [M-2H] 2".Example 145A [A / 2-fluorenylmethoxycarbonyl-L-isoleucyl] - 03- (fer-butyl) -L-serine polymer bound The Fmoc protecting group is removed from the polymer (example 41 A, 500 mg, 0.75 mmol) as described in procedure 7. The deprotected amino acid attached to the resin is then reacted with / V - [(9 / - / - fluoren-9-ylmethoxy) carbonyl] -L-isoleucine (1.05 g, 2.98 mmol, 4 eq.), DIEA (0.78 ml, 577 mg, 4.47 mmol, 6 eq.) and TBTU ( 957 mg, 2.98 mmol, 4 equivalents) overnight to give the dipeptide protected by Fmoc. The processing of the polymer is carried out analogously to method 7. The corresponding protected side chain dipeptide is confirmed after taking a sample. LC-MS (Method 21): R, = 2.68 min; MS (ESlpos): m / z (%) = 497.5 (60) [M + H] +, 441, 4 (100); MS (Sleng): m / z (%) = 495.5 (5) [M-H] ~, 273.4 (100). EXAMPLE 146 A [(/ ^ - (9H-Fluoren-9-ylmethoxy) carbonyl) - / V5- (imino { [(2,2,5,7,8 ^ entamethyl-3,4-dihydro-2H- chrome il) sulfonyl] amino] methyl) -D-ornytyl] -L-isoleucyl-03- (fer-butyl) -L-serine polymer bound Polymer The Fmoc protecting group is removed from the polymer (example 145A, 500 mg, 0.75 mmol) as described in method 7. The deprotected amino acid attached to the resin is then reacted with (A 2- (9-fluororen-9) -lmetoxy) carbonyl) - / V5- (imino { [(2,2,5J, 8-pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino.}. Methyl) - D-ornithine (740 mg, 1.12 mmol, 1.5 eq.), DIEA (0.39 ml, 289 mg, 2.24 mmol, 3 eq.) And TBTU (318 mg, 0.99 mmol, 2 equivalents) overnight to give the tripeptide protected by Fmoc. The processing of the polymer is carried out analogously to method 7. The corresponding protected side chain dipeptide is confirmed after taking a sample. LC-MS (Method 21): R, = 2.89 min; MS (ESlpos): m / z (%) = 919.5 (100) [M + Hf; MS (ESlneg): m / z (%) = 917.7 (100) [M-H] \ Example 147 A [(/ V - (9H-fluoren-9-ylmethoxy) carbonyl) -L-leucyl] - [ / V5- (imino- { [(2,2,5,7,8-pentamethyl-3,4-dihydro-2 / - -chromen-6-yl) sulfonyl] amino.} Methyl) -D- ornitil] -L-isoleucyl-03- (fer-butyl) -L-serine polymer bound Polymer H3C CH3 The Fmoc protecting group is removed from the polymer (example 146A, 500 mg, 0.75 mmol) as described in method 7. The deprotected amino acid attached to the resin is then reacted with / ^ - [(gZ-Z-fluoren- g-ylmethoxyJcarbonylJ-L-leucine (1.05 g, 2.98 mmol, 4 eq.), DIEA (0.78 ml, 577 mg, 4.47 mmol, 6 eq.) and TBTU (956 mg, 2, 98 mmol, 4 equivalents) overnight to give the tetrapeptide protected by Fmoc The processing of the polymer is carried out analogously to procedure 7. The corresponding protected side chain dipeptide is confirmed after taking a sample. -MS (Method 21): R, = 3.27 min; MS (ESlpos): m / z (%) = 1033.3 (100) [M + H] +; MS (ESlneg): m / z (% ) = 1032.2 (100) [M-H] "Example 148A [(3R) -A / 2- (Ier-Butoxycarbonyl) -3-hydroxy-L-leucyl] -L-leucyl- [A / s- (imino { [(2,2,5,7,8 ^ en ^ dihydro-2 / - / - chromen-6-yl) sulfonyl] amino.} methyl) -D-ornithyl].}. -isoleucyl-03- (ér-butyl) -L-serine The Fmoc protecting group is removed from the polymer (example 147A, 500 mg, 0.75 mmol) as described in method 7. The deprotected amino acid attached to the resin is then reacted with (SR ^ / v ^ / er-butoxycarboni - S-hydroxy-L-leucine (276 mg, 1.12 mmol, 1.5 eq.), DIEA (0.26 mL, 193 mg, 1.49 mmol, 2 eq.) And TBTU (359 mg, 1, 12 mmol, 1.5 equivalents) overnight to give the pentapeptide protected by Boc, then washed with DMF, THF and finally dichloromethane and removed from the resin with a mixture of glacial acetic acid, trifluoroethanol and dichloromethane (1 + 1). +3) The product of the crude reaction is purified by chromatography The title compound is isolated in a yield of 145 mg (19% of theory) LC-MS (Method 21): R, = 3.17 min; MS (ESlpos): m / z (%) = 1040.0 (100) [M + H] +; MS (ESlneg): m / z (%) = 1038.0 (100) [M-H] \ Example 149 A Trifluoroacetate L-serinate benzyl * TFA 500 mg (1.69 mmol) of benzyl A / -fero-butoxycarbonyl-L-serinate are reacted according to procedure 2 in 5.50 ml of the reagent solution. The product is reacted without subsequent purification. Yield: 505 mg (1.63 mmol, 96% of theory). HPLC (Method 3): R, = 3.10 min. LC-MS (Method 22): R, = 1.94 min; MS (ESlpos) m / z (%) = 196.0 (100) [M + H] +. Example 150 A [/ ^ - (Fer-butoxycarbonyl-J-L-seryl-J-L-serinate benzyl The compound of Example 149A (500 mg, 1.62 mmol) and W-Ier-butoxycarbonyl-L-serine (332 mg, 1.62 mmol, 1 equivalent) are dissolved in dichloromethane (8.2 ml) and cooled to 0 ° C. HATU (922 mg, 2.43 mmol, 1.5 equivalents) is added and then, for 15 min, a solution of N, N-diisopropylethylamine (1.41 mL, 8.08 mmol, 5 equivalents) in dichloromethane is added. (5 mi) drip. The mixture is then stirred at room temperature for 72 h and then washed with sodium bicarbonate, and the organic phase is dried and concentrated. The crude product is purified by chromatography (method 34). The fractions containing the product are combined and lyophilized. Yield: 308 mg (0.81 mmol, 50% of theory) as a colorless solid. HPLC (Method 4): R, = 3.81 min. LC-MS (Method 18): R, = 1.98 min; MS (ESlpos): m / z (%) = 283.5 (100) [M-Boc + H] +; 383.6 (30) [M + H] +. Example 151A [/ ^ - (fer-butoxycarbonyl-J-S-IS-pyridyl-J-L-alanyl-J-L-benzyl serinate] According to the method of preparation of the compound of example 150A the title compound is obtained in a yield of 780 mg (69% of theory) from the compound of example 149A (780 mg, 2.52 mmol) and A ^ - fer-butoxycarbonyl-S-IS-pyridyl-L-alanine (707 mg, 2.52 mmol). HPLC (Method 5): R, = 3.61 min. LC-MS (Method 22): R, = 2.82 min, MS (ESlpos): m / z (%) = 444.2 (100), [M + H] +. Example 152A [/ ^ - (Fer-butoxycarbonyl-J-L-phenylalanyl-benzyl L-serinate According to the method of preparation of the compound of example 150A the title compound is obtained in a yield of 275 mg (55% of theory) from the compound of example 149A (350 mg, 1.13 mmol) and A ^ - fer-butoxycarbonyl-L-phenylalanine (300 mg, 1.13 mmol). HPLC (Method 6): R, = 4.50 min. LC-MS (Method 20): R, = 2.23 min, MS (ESlpos): m / z (%) = 443.2 (100) [M + H] +; MS (ESlneg): m / z (< ¼) = 441 (50) [MH] \ HR-TOF-MS (Method 24): C24H31N206 calculated 443.2177, found 443.2180 [M + H] \ Example 153A [/ ^ - (fer-butoxycarbonyl-J-L-threonyl-O-fer-butyl-L-serinate benzyl According to the method of preparation of the compound of example 150A, the title compound is obtained in a yield of 196 mg (49% of theory) from benzene 03- (e-butyl) -L-serinate (320 mg, 0.88 mmol) and / v ^ -fer-butoxycarbonyltreonine (192 mg, 0.88 mmol). HPLC (Method 5): R, = 4.73 min. LC-MS (Method 19): R, = 2.56 min, MS (ESlpos): m / z (%) = 453.0 (100) [M + H] +. EXAMPLE 154A [/ - (Benzoylcarbonyloxy-J-L-alotreonyl-J-L-serinate] Benzyl L-serinate (314 mg, 1.02 mmol) and NMM (335 μ ?, 3.05 mmol, 3 equivalents) are provided in DMF at 0 ° C. Then add (v ^ -fer-butoxycarboni alotreonine (223 mg, 1.02 mmol, 1 equivalent), followed by TCTU (506 mg, 1.42 mmol, 1.4 equivalents) .The mixture is stirred overnight and it is then processed by chromatography according to method 45. The title compound is obtained in a yield of 298 mg (73% of theory) HPLC (Method 5): R, = 3.89 min LC-MS (Method 19): R, = 1, 91 min, MS (ESlpos): m / z (%) = 397.0 (100) [M + H] +. HR-TOF-MS (Method 24): C19H29N207 calculated 397, 1970, found 397.1971 [M + H] \ Example 155A [/ v ^ - (fer-butoxycarbonyl) -L-alanyl] -L-benzyl ester According to the method of preparation of the compound of example 150A the title compound is obtained in a yield of 277 mg (78% of theory) from benzyl L-serinate (300 mg, 0.97 mmol) and A ^ -fer-butoxycarbonylalanine (220 mg, 1.16 mmol). HPLC (Method 5): R, = 4.05 min. LC-MS (Method 20): R, = 1.81 min, MS (ESlpos): m / z (%) = 367.2 (50) [M + H] +. Example 156A [/ ^ - (tert-butoxycarbonyl-J-L-asparaginylj-L-benzyl serinate] According to the method of preparation of the compound of Example 150A the title compound is obtained in a yield of 313 mg (39% of theory) from benzyl L-serinate (610 mg, 1.97 mmol) and A ^ -fer-butoxycarbonylaseparagin (458 mg, 1.97 mmol, 1 equivalent). HPLC (Method 5): R, = 3.70 min. LC-MS (Method 20): R, = 1.78 min, MS (ESlpos): m / z (%) = 410.1 (100) [M + H] +. HR-TOF-MS (Method 24): C ^ 27N307 calculated 410.1922, found 410.1914 [M + H] +. Example 157 A Benzyl L-seryl-L-serinate trifluoroacetate The compound of example 150A (290 mg, 0.76 mmol) is reacted according to procedure 2. 451 mg (quantitative) of the crude title compound are obtained and reacted without further purification. LC-MS (Method 22): R, = 2.16 min; MS (ESlpos) m / z (%) = 283.0 (100) [M + H] +. Example 158A Benzyl [3- (3-pyridyl) -L-alanyl] -L-serinate bistrifluoroacetate The compound of Example 151 A (460 mg, 0.99 mmol) is reacted according to procedure 2. 565 mg (quantitative) of the crude title compound are obtained and reacted without further purification. HPLC (Method 5): R, = 3.03 min. LC-MS (Method 22): R, = 2.23 min, MS (ESlpos): m / z (%) = 344.2 (30) [M + H] +. Example 159 A L-phenylalanyl-L-serinate benzyl trifluoroacetate The compound of example 152A (275 mg, 0.62 mmol) is reacted according to procedure 2. 285 mg (93% of theory) of the crude title compound are obtained and reacted without further purification.

HPLC (Method 6): R, = 3.33 min. LC-MS (Method 20): R, = 1, 14 min, MS (ESIpos): m / z (%) = 343.3 (100) [M + H] +; MS (ESIneg): m / z (%) = 341, 3 (100) [M-H] "Example 160 A ^ Trifluoroacetate of L-threonyl-L-serinate benzyl The compound of example 153A (195 mg, 0.43 mmol) is reacted according to procedure 2. 235 mg (quantitative) of the crude title compound are obtained and reacted without further purification. HPLC (Method 5): R, = 3.20 min. LC-MS (Method 22): R, = 2.32 min, MS (ESlpos): m / z (%) = 297 (100) [M + Hf. Example 161 A L-Alotreonyl-L-serinate Benzyl Trifluoroacetate The compound of example 154A (286 mg, 0.72 mmol) is reacted according to procedure 2. 326 mg (quantitative) of the crude title compound are obtained and reacted without further purification. HPLC (Method 5): R, = 3.16 min. LC-MS (Method 19): R, = 1.38 min, MS (ESlpos): m / z (%) = 297 (15) [M + H] +. HR-TOF-MS (Method 24): C14H2iN205 calculated 297.1445, found 297.1436 [M + H] +.

Example 162A L-alanyl-L-serinate benzyl trifluoroacetate * TFA The compound of example 155A (277 mg, 0.76 mmol) is reacted according to procedure 2. 285 mg (quantitative) of the crude title compound are obtained and reacted without further purification. HPLC (Method 5): R, = 3.20 min. LC-MS (Method 22): Rt = 2.35 min, MS (ESlpos): m / z (%) = 267 (100) [M + H] +. Example 163A L-Asparaginyl-L-serinate Benzyl Trifluoroacetate The compound of example 156A (313 mg, 0.76 mmol) is reacted according to procedure 2. 428 mg (quantitative) of the crude title compound are obtained and reacted without further purification. HPLC (Method 6): R, = 2.96 min. LC-MS (Method 22): R, = 2.07 min, MS (ESlpos): m / z (%) = 310 (100) [M + H] +. Example 164A [/ v ^ - (fer-butoxycarbonyl) glycyl] -L-seryl-L-serinate benzyl The compound of example 157A (360 mg, 0.85 mmol) and / v-fer-butoxycarbonylglycine (149 mg, 0.85 mmol, 1 equivalent) are dissolved in dichloromethane (4.4 ml) and cooled to 0 ° C. . HATU (485 mg, 1.28 mmol, 1.5 equivalents) is added and then, for 15 min, a solution of N, N-diisopropylethylamine (0.74 ml, 4.26 mmol, 5 equivalents) in dichloromethane is added. (3 mi) drip. The mixture is then stirred at room temperature for 24 h and then washed with sodium bicarbonate, and the organic phase is dried (sodium sulfate) and concentrated. The crude product is purified by chromatography (method 34). The fractions containing the product are combined and lyophilized. Yield: 220 mg (0.50 mmol, 59% of theory) as a colorless solid. HPLC (Method 3) R, = 3.70 min. LC-MS (Method 1): R, = 1.93 min, MS (ESlpos): m / z (%) = 440.7 (100). Example 165A [/ ^ - (Yer-butoxycarboni glycyl-lS-SS-pyridyl-L-alanyl-L-serinate benzyl According to the method of preparing the compound of example 164A with DMF (1.8 ml) in place of dichloromethane as the solvent, the title compound is obtained in a yield of 405 mg (85% of theory) from the compound of the example 158A (565 mg, 0.95 mmol) and N-tert-butoxycarbonylglycine (166 mg, 0.95 mmol, 1 equivalent). HPLC (Method 5): R, = 3.52 min.

LC-MS (Method 20): R, = 1.49 min, MS (ESIpos): m / z (%) = 501, 4 (100) [M + H] +. Example 166A [/ ^ - (Fer-butoxycarbonylJglicilj-L-phenylalanyl-L-serinate benzyl According to the method of preparing the compound of example 164A with DMF (2.0 ml) instead of dichloromethane as the solvent, the title compound is obtained in a yield of 237 mg (82% of theory) from the compound of the example 159A (285 mg, 0.58 mmol) and N-tert-butoxycarbonylglycine (122 mg, 0.70 mmol, 1 equivalent). HPLC (Method 6): R, = 4.28 min. LC-MS (Method 19): R, = 2.29 min, MS (ESlpos): m / z (%) = 500.2 (100) [M + H] +. HR-TOF-MS (Method 24): calculated CzeH ^ C 500.2392, found 500.2399 [M + H] \ Example 167A [Benzene] -er-butoxycarbonyl-glycyl-L-threonyl-L-serinate According to the method of preparing the compound of example 164A with DMF (1.8 ml) in place of dichloromethane as the solvent, the title compound is obtained in a yield of 84 mg (34% of theory) from the compound of the example 160A (173 mg, 0.49 mmol) and f-tert-butoxycarbonylglycine (103 mg, 0.59 mmol, 1.2 equivalent). HPLC (Method 5): R, = 4.45 min.

LC-MS (Method 19): R, = 2.38 min, MS (ESIpos): m / z (%) = 510.2 (100) [M + Hf. Example 168 A [/ v ^ -fer-butoxycarbonyl-glycyl-L-alotreonyl-benzyl L-serinate The compound of Example 161A (295 mg, 0.72 mmol) and A ^ -fero-butoxycarbonylglycine (126 mg, 0.72 mmol, 1.0 equivalent) are provided in DMF at 0 ° C. Then TCTU (329 mg, 0.87 mmol, 1.2 equivalents) and NMM (238 μ ?, 2.16 mmol, 3 equivalents) are added. The mixture is stirred at room temperature overnight and then processed by chromatography according to method 45. The fractions containing the product are combined and purified by chromatography according to a modified method 32 (gradient: 0-5 min. 10% B, 5.01-35 min 85% B slope, 35.01-40 min 85% B). The title compound is obtained in a yield of 170 mg (52% of theory). HPLC (Method 5): R, = 3.73 min. LC-MS (Method 19): R, = 1.82 min, MS (ESlpos): m / z (%) = 454.1 (80) [M + Hf. HR-TOF-MS (Method 24): C2iH32N308 calculated 454.2184, found 454.2177 [M + Hf. Example 169A [Benzyl] -Bethoxycarbonyl-glycyl-L-alanyl-L-serinate According to the method of preparing the compound of example 164A with DMF (1.8 ml) instead of dichloromethane as the solvent, the title compound is obtained in a yield of 172 mg (43% of theory) from the compound of the example 162A (285 mg, 0.75 mmol) and N -ter- butoxycarbonylglycine (157 mg, 0.90 mmol, 1.2 equivalents). HPLC (Method 5): R, = 3.83 min. LC-MS (Method 21): R t = 1.85 min, MS (ESIpos): m / z (%) = 424.4 (100) [M + H] +. Example 170A [/ ^ - (Fer-butoxycarbonyl-J-glycyl-L-asparaginyl-L-serinate benzyl According to the method of preparing the compound of example 164A with DMF (2.0 ml) instead of dichloromethane as the solvent, the title compound is obtained in a yield of 208 mg (56% of theory) from the compound of the example 163A (428 mg, 0.80 mmol) and f-tert-butoxycarbonylglycine (167 mg, 0.96 mmol, 1.2 equivalents). HPLC (Method 6): R, = 3.60 min. LC-MS (Method 21): R, = 1.75 min, MS (ESlpos): m / z (%) = 467.0 (100) [M + H] +. HR-TOF-MS (Method 24): C2iH3i 408 calculated 467.2137, found 467.2142 [M + H] +. Example 171A Benzyl glycyl-L-seryl-L-serinate trifluoroacetate The compound of example 164A (88 mg, 0.20 mmol) is reacted according to procedure 2 in 1.5 ml of the reagent solution. The crude product is then reacted without subsequent purification. Yield: 118 mg (quantitative) HPLC (Method 3): R, = 3.08 min. LC-MS (Method 22): R, = 2.56 min, MS (ESIpos): m / z (%) = 340.0 (100) [M + H] +. EXAMPLE 172 A [Glycyl] - [3- (3-pyridyl) -L-alanyl] -L-benzyl serinate bistrifluoroacetate The compound of example 165A (60 mg, 0.12 mmol) is reacted according to procedure 2 in 1.5 ml of the reagent solution. The crude product is then reacted without subsequent purification. Yield: 81 mg (quantitative) HPLC (Method 5): R, = 3.05 min. LC-MS (Method 22): R, = 2.36 min, MS (ESlpos): m / z (%) = 401, 0 (40) [M + H] +. Example 173A Benzyl glycyl-L-phenylalanyl-L-serinate trifluoroacetate The compound of example 166A (63 mg, 0.13 mmol) is reacted according to procedure 2 in 1.0 ml of the reagent solution. The crude product is then reacted without subsequent purification. Yield: 65 mg (96% of theory). HPLC (Method 6): R, = 3.35 min. LC-MS (Method 22): R, = 1.26 min, MS (ESlpos): m / z (%) = 400.1 (90) [M + H] +; MS (ESlneg): m / z (%) = 398.1 (100) [MH] \ HR-TOF-MS (Method 24): C21H26N3O5 calculated 400.1867, found 400.1869 [M + H] + Example 174A Glycyl-L-threonyltrifluoroacetate Benzyl L-serinate The compound of example 167A (82 mg, 0.16 mmol) is reacted according to procedure 2 in 1.5 ml of the reagent solution. The crude product is purified by chromatography (method 44). Yield: 43 mg (76% of theory). HPLC (Method 5): R, = 3.16 min. LC-MS (Method 22): R, = 2.35 min, MS (ESlpos): m / z (%) = 354 (50) [M + H] +. Example 175A Glycyl-L-alotreonyl-L-serinate benzyl trifluoroacetate The compound of example 168A (169 mg, 0.37 mmol) is reacted according to procedure 2 in 1.5 ml of the reagent solution. The crude product (194 mg, approximately quantitative) is then reacted without subsequent purification. HPLC (Method 5): R, = 3.16 min. LC-MS (Method 21): R, = 0.78 min, MS (ESlpos): m / z (%) = 354.3 (100) [M + H] +. HR-TOF-MS (Method 24): C16H24N406 calculated 354.1660, found 354.1648 [M + H] +. Example 176A Glycyl-L-alanyl-L-serinate benzyl trifluoroacetate The compound of example 169A (172 mg, 0.32 mmol) is reacted according to procedure 2 in 3.0 ml of the reagent solution. The crude product is then reacted without purification. Delivery: 175 mg (99% of theory). HPLC (Method 5): R, = 3.20 min. LC-MS (Method 22): R, = 2.41 min, MS (ESlpos): m / z (%) = 324 (40) [M + H] +. Example 177A Glycyl-L-asparaginyl-L-serinate benzyl trifluoroacetate The compound of example 170A (60 mg, 0.13 mmol) is reacted according to procedure 2 in 1.0 ml of the reagent solution. The crude product is then reacted without purification. Yield: 62 mg (quantitative). HPLC (Method 6): R, = 2.89 min. LC-MS (Method 22): R, = 2.14 min, MS (ESlpos): m / z (%) = 367 (100) [M + H] +. HR-TOF-MS (Method 24): C16H23N406 calculated 367.1613, found 367.1609 [M + H] +. Example 178 A [(S ^ -A ^ -butoxycarboni S-hydroxy-L-leucyl-J-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-seryl-L-serinate trifluoroacetate benzyl The compounds of example 32A (75 mg, 38 pmol) and 171A (26 mg, 45 pmol, 1.2 equivalents) are dissolved in DMF (950 pl), and the solution is cooled to -20 ° C. 4-Methylmorpholine (29 pl, 263 pmol, 7 equivalents) and HATU (23 mg, 60 pmol, 1.6 equivalents) are added, and the mixture is stirred at room temperature for 16 h. The complete mixture is then placed on an HPLC column and purified by chromatography according to method 33. The fractions containing the product are combined and lyophilized. 15 mg (34% of theory) of the title compound are obtained as a colorless solid. HPLC (Method 5): R, = 3.89 min. LC-MS (Method 19): R, = 1.81 min, MS (ESlpos): m / z (%) = 1053 (90) [M + H] +. Example 179A Trifluoroacetate of [(SRJ-A ^ -ifor-butoxycarboni-S-hydroxy-L-leucyl-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- [3- (3-pyridyl) - L-alanyl] -L-benzyl serinate According to the method of preparing the compound of Example 178A, the title compound is obtained in a yield of 34 mg (33% of theoretical yield) from the compound of Example 32A (80 mg, 83 μ? T). and the compound of Example 172A (79 mg, 125 prnol, 1.5 equivalents). HPLC (Method 5): R, = 3.75 min. LC-MS (Method 18): R, = 1.52 min, MS (ESlpos): m / z (%) = 557.6 (100) [M + 2H] 2+; 1113.8 (10) [M + H] +. Example 180A Trifluoroacetate of [(SRJ-A ^^ fer-butoxycarboni-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-phenylalanyl-L-serinate benzyl i According to the method of preparation of the compound of Example 178A, the title compound is obtained in a yield of 39 mg (33% of theoretical yield) from the compound of Example 32A (82 mg, 97 μ ??) and the compound of Example 173A (65 mg, 126 μ? t ??, 1.3 equivalents). HPLC (Method 6): R, = 3.96 min. LC-MS (Method 19): R, = 1.87 min, MS (ESlpos): m / z (%) = 506.8 (90) [M + 2H] 2+; 1112.5 (100) [M + H] +; MS (ESlneg): m / z (%) = 1110.5 (100) [MH] \ HR-TOF-MS (Method 24): C ^ HeeNnO ^ calculated 1112.6351, found 1112.6343 [M + H] +. Example 181 A [(S ^ JA ^ -ifor-Butoxycarbonyl-J-S-hydroxy-L-leucyl-J-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-threonyl-L-serinate benzyl The title compound is obtained in a yield of 21 mg (20% of theoretical yield) according to the method of preparing the compound of Example 178A from the compound of Example 32A (67 mg, 80 μ ??) and the compound of example 174A (31 mg, 88 μ? t ??, 1.1 equivalents). HPLC (Method 5): R, = 3.89 min. LC-MS (Method 19): R, = 1.71 min, MS (ESlpos): m / z (%) = 1066.7 (100) [M + H] +. HR-TOF-MS (Method 24): calculated 1066.6143, found 1066.6130 [M + H] +. Example 182A Trifluoroacetate of [(SR ^ v ^ -ifer-butoxycarbonyl-J-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alotreonyl-L-serinate benzyl The compound of Example 32A (57 mg, 59 pmol) and the compound of Example 175A (48 mg, 71 pmol, 1.2 equivalents) are reacted according to the method of preparation of the compound of Example 178A. The subsequent treatment is carried out in Sephadex LH20 (method 45) and then subjected to chromatography according to a modified method 44 (gradient: 0-5 min 5% B, slope, 30-35 min 75% B, 35, 01 -40 min 75% B). The title compound is obtained with a yield of 65 mg (93% of theory). HPLC (Method 6): R, = 3.70 min. LC-MS (Method 19): R, = 1.70 min, MS (ESlpos): m / z (%) = 483.9 (100) [M-Boc + 2H] 2+, 1066.6 (70) [M + H] +. HR-TOF-MS (Method 24): C49H84 1i015 calculated 1066.6143, found 1066.6134 [M + H] +. Example 183A Trifluoroacetate of [(SRJ-A ^ -ifor-butoxycarbonyl-J-S-hydroxy-L-leucyl-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alanyl-L-serinate benzyl) According to the method of preparing the compound of example 178A and after further purification by chromatography (Kromasil RP-18 5 μm, 100 μA, 250 × 20 mm; eluent A: water + 0.05% TFA, eluent B: acetonitrile + 0.05% TFA: flow rate: 10 ml / min; 60% A, 40% B Socratic), the title compound is obtained in a yield of 48 mg (50% of theoretical yield) from compound of example 32A (80 mg, 84 μm) and the compound of example 176A (60 mg, 109 pmol, 1.3 equivalents). HPLC (Method 5): R, = 3.99 min. LC-MS (Method 19): R, = 1.70 min, MS (ESlpos): m / z (%) = 1036.6 (100) [M + H] +. HR-TOF-MS (Method 24): C48H81NHOH calculated 1036.6038, found 1036.6027 [M + H] +. Example 184A [(3f?) - A 2- (rer -butoxycarbonyl) -3-hydroxy-L-leucyl] -L-leucyl- [W5- (imino-. {[[(2,2,5,7 , 8-pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino.} Methyl) -D-orn¡W [(3S) -3-hydroxy-L-asparaginyl] - Benzyl L-serinate According to the method of preparation of the compound of example 178A and after further purification by chromatography (Kromasil RP-18 5, 100 A, 250 x 20 mm, eluent A: water + 0.05% TFA, eluent B: acetonitrile + 0.05% TFA: flow rate: 10 ml / min; 60% A, 40% B issocratic), the title compound is obtained in a yield of 62 mg (49% of theory) from the compound of example 148A (87 mg, 84 pmol) and the compound of example 36A (50 mg, 101 μ? T ???, 1, 2 equivalents). HPLC (Method 5): R, = 4.40 min. LC-MS (Method 19): R, = 2.97 min, MS (ESlpos): m / z (%) = 1403.7 (100) [M + H] +. HR-TOF-MS (Method 24): Cee N ^ O ^ S calculated 1403,7491, found 1403.7517 [M + H] +.

Example 185A Trifluoroacetate of [(SRJ-A ^ -ifor-butoxycarbonyl-J-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serinate benzyl According to the method of preparation of the compound of Example 178A, the title compound is obtained in a yield of 48 mg (31% of theoretical yield) from the compound of Example 32A (100 mg, 118 μ ??) and the compound of example 177A (62 mg, 130 mol, 1.1 equivalents). HPLC (Method 6): R, = 3.66 min. LC-MS (Method 22): R, = 1, 66 min, MS (ESlpos): m / z (%) = 490.3 (100) [M-Boc + 2H] 2+, 1079.6 (80) [M + Hf. HR-TOF-MS (Method 24): C49H83 12015 calculated 1079.6096, found 1079.6090 [M + H] +. EXAMPLE 186A [(3R) -A 2- (Ier-butoxycarbonyl) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-seryl trifluoroacetate -L-serine OH The compound of example 178A (21 mg, 18 pmol) is hydrogenated in 750 μ? of acetic acid in the presence of 5 mg palladium-carbon 10% at room temperature under atmospheric pressure for 2 h. The mixture is filtered to remove the catalyst and dried to constant weight under vacuum by oil pump. The title compound is obtained in quantitative yield (20 mg) and reacted without purification. HPLC (Method 5): R, = 3.56 min. LC-MS (Method 19): Rt = 1.72 min, MS (ESlpos): m / z (%) = 963.0 (90) [M + H] +. HR-TOF-MS (Method 24): C ^ HreNnO ^ calculated 962.5517, found 962.5537 [M + H] +. Example 187A Bistrifluoroacetate of [(SR ^ / v ^ -i / er-butoxycarbonylJ-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- [3- (3- pyridyl) -L-alanyl] -L-serine The compound of Example 179A (55 mg, 45 pmol) is hydrogenated according to the method of preparation of the compound of Example 186A. After concentration of the crude product, it is directly subjected to Boc elimination according to procedure 2 and again concentrated. 41 mg (88% of theory) of the title compound are obtained and reacted without further purification. HPLC (Method 5): R, = 3.56 min. LC-MS (Method 22): R, = 2.19 min, MS (ESlpos): m / z (%) = 462 (40) [M + H] +; (ESlneg): m / z (%) = [MH] \ HR-TOF-MS (Method 24): C ^ H ^ N ^ O ^ calculated 923.5309, found 923.5321 [M + H] \ Example 188A Trifluoroacetate of [(SRJ-A ^ -yer-Butoxycarbonyl-J-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-phenylalanyl-L-serine The compound of Example 180A (39 mg, 32 μ? T) is hydrogenated according to the preparation method to prepare the compound of Example 186A. 36 mg (quant.) Of the title compound are obtained and reacted without further purification. HPLC (Method 6): R, = 3.55 min. LC-MS (Method 18): R, = 1.75 min, MS (ESlpos): m / z (%) = 462 (100) [M-Boc + 2 H] 2 \ 1022.1 (10) [M + H] +; (Sleng): m / z (%) = 1020.8 [M-H] '. HR-TOF-MS (Method 24): C47H80N11O14 calculated 1022.5881, found 1022.5876 [M + H] +.

Example 189A Bistrifluoroacetate of [(S ^ -A ^ -ifer-Butoxycarboni-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-threonyl-L-serine The compound of Example 181A (21 mg, 18 μ? T) is hydrogenated according to the method of preparation of the compound of Example 186A. 18 mg (98% of theory) of the title compound are obtained as a colorless solid. HPLC (Method 5): R, = 3.58 min. LC-MS (Method 19): R, = 1.58 min, MS (ESlpos): m / z (%) = 976.6 (80) [M + H] +. Example 190 A [(3R) -3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alotreonyl-L-serine bistrifluoroacetate The compound of example 197A (44 mg, 37 μ? T) is dissolved in methanol (5.0 ml), 10% Pd / C (20 mg) is added, and the mixture is hydrogenated at room temperature under pressure atmospheric for 2 h. The mixture is filtered to remove the catalyst and the filtrate is concentrated. 42 mg (quant.) Of the crude title compound are obtained and reacted without purification. HPLC (Method 5): R, = 3.00 min. LC-MS (Method 22): R, = 2.32 min, MS (ESlpos): m / z (%) = 439 (100) [M + 2H] 2+; MS (ESlneg): m / z (%) = 875 (100) [M-H] \ HR-TOF-MS (Method 24): calculated 876.5150, found 876.5146 [M + H] +. EXAMPLE 191A [(SRJ-A ^ -ifor-Butoxycarbonyl-J-S-hydroxy-L-leucyl-J-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alanyl-L-serine Trifluoroacetate The compound of Example 183A (47 mg, 41 pmol) is hydrogenated according to the method of preparation of the compound of Example 186A. 43 mg (99% of theory) of the title compound are obtained as a solid. HPLC (Method 5): R, = 3.62 min. LC-MS (Method 19): R, = 1.58 min, MS (ESlpos): m / z (%) = 946.5 (100) [M + H] +. HR-TOF-MS (Method 24): calculated 946.5568, found 946.5569 [M + H] +. Example 192 A [(3R) - / V2- (rer-Butoxycarbonyl) -3-hydroxy-L-leucyl] -L-leucyl- [A / 5- (imino. {[[(2,2,5J, 8-pentamethyl-3,4- ^ 2H-chromen-6-yl) sulfonyl] amino} methyl) - ^ L-asparaginyl] -L-serine The compound of Example 184A (62 mg, 41 pmol) is hydrogenated according to the method of preparation of the compound of Example 186A. 56 mg (96% of theory) of the title compound are obtained as a solid. HPLC (Method 5): R, = 4.57 min. LC-MS (Method 19): R, = 3.06 min, MS (ESlpos): m / z (%) = 1313.7 (100) [M + H] +. HR-TOF-MS (Method 24): calculated 1313.7022, found 1313.7020 [M + H] +. Example 193A Trifluoroacetate of [(SR ^ Z-ether-Butoxycarbonyl-J-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine The compound of Example 185A (48 mg, 40 μ? T) is hydrogenated according to the method of preparation of the compound of Example 186A. 42 mg (99% of theory) of the title compound are obtained as a colorless solid. HPLC (Method 5): R, = 3.40 min. LC-MS (Method 19): R, = 1.57 min, MS (ESlpos): m / z (%) = 445.3 (100) [M + 2H] 2+, 9989.6 (70) [M + H] +. HR-TOF-MS (Method 24): C42H77N12015 calculated 989.5626, found 989.5619 [M + H] +. Example 194A [(3R) -3-Hydroxy-L-leucyl] -L-leucyl-r-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-serybistrifluoroacetate The compound of Example 186A (20 mg, 18 μ ??) is reacted according to the Method 2. 20 mg (99% of theory) of the title compound is obtained as a solid. HPLC (Method 5): R, = 2.96 min. LC-MS (Method 22): Rt = 2.25 min, MS (ESlpos): m / z (%) = 432 (100) [M + 2H] 2+, 862.6 (1) [M + H] +. HR-TOF-MS (Method 24): Cae ^ NnO ^ calculated 862.4993, found 862.5027 [M + H] +. Example 195A [(3R) 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-phenyl-alanyl-L-serine bistrifluoroacetate The compound of Example 188 A (36 mg, 32 pmol) is reacted according to procedure 2. 36 mg (99% of theory) of the title compound is obtained as a solid. HPLC (Method 6): R, = 2.98 min. LC-MS (Method 19): R, = 1, 11 min, MS (ESlpos): m / z (%) = 461, 8 (100) [M + 2H] 2+, 922.5 (10) [M + H] +; MS (ESlpos): m / z (%) = 920.5 (100) [MH] ". HR-TOF-MS (Method 24): C42H72N11012 calculated 922.5357, found 922.5357 [M + H] +. Example 196A [(3-R) -3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-threonyl-L-serine bistrifluoroacetate The compound of Example 189A (18 mg, 17 μ? T ??) is reacted according to procedure 2. 18 mg (94% of theory) of the title compound is obtained as a solid. HPLC (Method 5): R, = 2.99 min. LC-MS (Method 22): R, = 2.47 min, MS (ESlpos): m / z (%) = 439 (100) [M + 2H] 2t. HR-TOF-MS (Method 24): Ca / HyoN Ou calculated 876.5150, found 876.5161 [M + H] +. Example 197A [(3 /?) - 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycol-L-bistrifluoroacetate The compound of Example 182A (57 mg, 48 pmol) is reacted according to procedure 2. After purification by chromatography according to a modified method 44 (gradient: 0-5 min 5% B, slope, 30- 35 min 60% B, 35.01-40 min 60% B) 45 mg (78% of theory) of the title compound are obtained. HPLC (Method 5): R, = 3.40 min. LC-MS (Method 19): R, = 1.12 min, MS (ESlpos): m / z (%) = 483.9 (100) [M + 2H] 2+, 966.6 (10) [M + H] +. HR-TOF-MS (Method 24): C ^^ NnO ^ calculated 966.5619, found 966.5643 [M + H] +. Example 198A [(3 /?) - 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alanyl-L-serine bistrifluoroacetate The compound of example 191A (43 mg, 38 μ? T ??) is reacted according to procedure 2 in 2 ml of the reagent solution. 45 mg of the crude title compound are obtained as a solid. HPLC (Method 5): R, = 2.99 min. LC-MS (Method 22): R, = 2.32 min, MS (ESlpos): m / z (%) = 424 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): Cse ^ N ^ O ^ calculated 846.5044, found 846.5029 [M + H] +. EXAMPLE 199A [(3f?) - 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-seryl-glycyl [(3S) -3-hydroxy] L-serinate bistrifluoroacetate L-asparaginyl] The compound of Example 192A (56 mg, 39 μ ???), 11 μ? of water and 1 1 μ? of triisopropylsilane are taken up in 4.0 ml of TFA. After 2 h, the mixture is concentrated and purified by chromatography (method 45). 40 mg of the title compound (90% of theoretical yield) are obtained as a solid. HPLC (Method 5): R, = 2.96 min. LC-MS (Method 22): R, = 2.30 min, MS (ESlpos): m / z (%) = 446 (100) [M + 2H] 2+. Example 200A [(3f?) - 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine bistrifluoroacetate The compound of Example 193A (42 mg, 38 μ? T ??) is reacted according to procedure 2 in 2 ml of the reagent solution. 42 mg (99% of theory) of the crude title compound is obtained as a solid.

HPLC (Method 5): R, = 2.77 min. LC-MS (Method 22): R, = 2.16 min, MS (ESIpos): m / z (%) = 446 (100) [M + 2H] 2+, 890 (20) [M + H] +; MS (ESIneg): m / z (%) = 888 (100) [MH] \ HR-TOF-MS (Method 24): Ca ^ N ^ O ^ calculated 889.5102, found 889.5095 [M + H] +. Example 201 A [(SRJ-A ^ -BenzyloxycarbonylJ-S- ^ fer-butoxycarbonylJaminol-L-phenylalanyl- ^ SRJ-S-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-trifluoroacetate -alotreonyl-glycyl-L-seryl-L-serine The compound of Example 194A (19 mg, 17 μ? T ??) and the compound of Example 17A (12 mg, 19 μ? T ??, 1.1 equivalents) are dissolved in DMF (530 μ?) A 0 ° C, and DIEA (15 μ ?, 87 μ? P ??, 5 eq.) Is added. The reaction mixture is further stirred overnight, warming slowly to room temperature. The mixture is taken up in acetonitrile and purified by chromatography (method 44). Yield: 14 mg, (10 μ? T, 59% of theoretical yield) of the title compound as a solid. HPLC (Method 5): R, = 3.94 min. LC-MS (Method 19): R, = 1.93 min, MS (ESlpos): m / z (%) = 1259.1 (50) [M + H] +. HR-TOF-MS (Method 24): C58H92N13018 calculated 1258.6678, found 1258.6675 [M + H] +. Example 202A Trifluoroacetate of [(SRJ-A ^ -Benzyloxycarbonyl-J-S- ^ -er-butoxycarbonylJaminoJ-L-phenylalanyl-KS-S- hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-iso The compound of example 187A (41 mg, 36 μ? T ??) is reacted with the compound of example 17A (23 mg, 39 μ? T ??, 1.1 equivalents) according to the preparation method of the compound of example 201A. 37 mg (73% of theory) of the title compound are obtained. HPLC (Method 5): R, = 3.87 min. LC-MS (Method 19): R, = 1.72 min, MS (ESlpos): m / z (%) = 660.5 (100) [M + 2H] 2+, 1319.7 (5) [M + H] +; (Sleng): m / z (%) = 1317.5 (100) [M-H] \ HR-TOF-MS (Method 24): CfahfesNuOu calculated 1319.6995, found 1319.6978 [M + H] +. Example 203A Bistrifluoroacetate of [(SRJ-W ^ Benzyloxycarboni-S-fer-butoxycarbonyl) ^ hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-phenylalanyl- L-seri The compound of example 195A (36 mg, 31 μ? T ??) is reacted with the compound of example 17A (22 mg, 39 pmol, 1.2 equivalents) according to the method of preparation of the compound of example 201A . 34 mg (70% of theory) of the title compound are obtained. HPLC (Method 6): R, = 3.93 min. LC-MS (Method 19): R, = 2.01 min, MS (ESlpos): m / z (%) = 610.1 (100) [M-Boc + 2H] 2+, 1318.8 (20) [M + H] +; (Sleng): m / z (%) = 1316.7 (100) [M-H] '. HR-TOF-MS (Method 24): C ^ HgeN ^ O ^ calculated 1318.7042, found 1318.7036 [M + H] +. EXAMPLE 204A [(SRJ-A ^ -Benzyloxycarbonyl-J-S-ether-butoxycarboniaminoH-phenylalanyl-KS /?) ^ - hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-allotreonyl trifluoroacetate -glile-L-threonyl-L-serine The compound of Example 196A (18 mg, 17 μ ??) is reacted with the compound of Example 17A (12 mg, 21 μ ?t ??,, 1.1 equivalents) according to the method of preparing the compound of example 201 A. After purification according to method 45, 17 mg (76% of theory) of the title compound are isolated. HPLC (Method 5): R, = 3.96 min. LC-MS (Method 19): Rt = 1.97 min, MS (ESlpos): m / z (%) = 1272.8 (40) [M + H] + HR-TOF-MS (Method 24): C59H94N13018 calculated 1272.6835, found 1272.6853 [M + H] +. EXAMPLE 205A L-Serinate Trifluoroacetate of [(SRJ-A ^ -Benzyloxycarboni-S- ^ rer -butoxycarboni aminol-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D- arginyl-L-isoleucyl-L-alotreonyl-glycyl ^ The compound of Example 190A (44 mg, 40 μ? T ??) is reacted with the compound of Example 17A (25 mg, 44 μp, 1.1 equivalents) according to the compound preparation method from example 201A. After purification according to method 45, 50 mg (90% of theory) of the title compound are isolated. HPLC (Method 5): R, = 3.80 min. LC-MS (Method 19): R, = 1.98 min, MS (ESlpos): m / z (%) = 1272.7 (20) [M + H] + HR-TOF-MS (Method 24): C s ^ N ^ O ^ calculated 1272.6835, found 1272.6846 [M + H] +. Example 206A Trifluoroacetate of [(SR ^ A ^ -Benzyloxycarboni-S- ^ fer-butoxycarboni aminoJ-L-phenylalanyl] - ^^ /?) ^ - hydroxy-L-leucyl] -L-leucl-D-arg¡n¡ l -soleucyl-L-alotreonyl-glycyl-L-alanyl-L-serine The compound of example 198A (45 mg, 42 pmol) is reacted with the compound of example 17A (32 mg, 54 pmol, 1.3 equivalents) according to the method of preparation of the compound of example 201A. After purification according to method 45, 38 mg (67% of theory) of the title compound are isolated. HPLC (Method 5): R, = 3.99 min. LC-MS (Method 19): R, = 2.12 min, MS (ESlpos): m / z (%) = 571, 9 (90) [M-Boc + 2H] 2+; 1242.7 (100) [M + H] +. HR-TOF-MS (Method 24): calculated 1242.6729, found 1242.6691 [M + H] +. EXAMPLE 207 A [(S ^ -A / ^ Benzyloxycarbonyl ^ S-ftfer-butoxycarboni am phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl- L-serinate trifluoroacetate L-Isoleucyl-L-seryl-glycyl - [(asparaginyl)] The compound of example 199A (39 mg, 35 pmol) is reacted with the compound of example 17A (24 mg, 42 pmol, 1.2 equivalents) according to the method of preparation of the compound of example 201A. After purification according to method 45, 42 mg (80% of theory) of the title compound are isolated. HPLC (Method 5): R, = 3.93 min. LC-MS (Method 19): R, = 1.93 min, MS (ESlpos): m / z (%) = 594.4 (100) [M-Boc + 2H] 2+; 1287.7 (30) [M + H] +. Example 208A Trifluoroacetate of [(SRJ-A ^ -BenzyloxycarbonylJ-S- ^ fer-butoxycarbonylJaminoJ-L-phenylalanyl-K ^^-S-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L -isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine The compound of example 200A (42 mg, 38 μ ??) is reacted with the compound of example 17A (26 mg, 45 μ ?t ??, 1.2 equivalents) according to the method of preparing the compound of example 201 A. After purification according to method 45, 46 mg (81% of theory) of the title compound are isolated. HPLC (Method 5): R, = 3.78 min. LC-MS (Method 19): R, = 1.91 min, MS (ESlpos): m / z (%) = 1285.7 (40) [M + H] +. HR-TOF-MS (Method 24): CsgHgsNwO ^ calculated 285.6787, found 1285.6777 [M + H] +. Example 209A [(3?) - A / 2- (Benzyloxycarbonyl) -3-amino bistrifluoroacetate} -L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-seryl-L-serine The compound of example 201A (14 mg, 10 pmol) is reacted according to procedure 2 with 0.5 ml of the reagent solution. Without further purification, 13 mg (9.3 pmol, 95% of theory) of the title compound is obtained as a solid. HPLC (Method 5): R, = 3.44 min. LC-MS (Method 20): R, = 1.19 min, MS (ESlpos): m / z (%) = 580 (100) [M + 2H] 2+, 1158.6 (5) [M + H ] +. HR-TOF-MS (Method 24): CsaH ^ N ^ O ^ calculated 1158.6154, found 1158.6183 [M + H] +. Example 210A [(3R) - / V2- (Benzyloxycarbonyl) -3-amino bistrifluoroacetate} -L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- [3- (3-pyridyl) -L-alanil ] -L-serine The compound of example 202A (37 mg, 26 μm) is reacted according to procedure 2 with 0.5 ml of the reagent solution. Without further purification, 46 mg of the crude title compound are obtained. HPLC (Method 5): R, = 3.39 min. LC-MS (Method 22): R, = 2.67 min, MS (ESlpos): m / z (%) = 610 (20) [M + 2H] 2+; (ESlneg m / z (%) = 1218 (100) [MH] '. HR-TOF-MS (Method 24): C ^ H ^ N ^ Cs calculated 1219.6470, found 1219.6472 [M + H] + Example 211 A [(3f?) - / V2- (Benzyloxycarbonyl) -3-amino] -L-phenylalanyl] - [(3f?) - 3-hydroxy-L-leucyl] -L-leucyl- bistrifluoroacetate. D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-phenylalanyl-L-serine The compound of Example 203A (34 mg, 22 μ? T ???) is reacted according to procedure 2 with 2.0 ml of the reagent solution. Without further purification, 34 mg (quant.) Of the crude title compound is obtained. HPLC (Method 5): R, = 3.34 min. LC-MS (Method 20): R, = 1.37 min, MS (ESlpos): m / z (%) = 610, 1 (100) [M + 2H] 2 \ 1218.8 (5) [M + H] +; (ESlneg m / z (%) = 1216.8 (100) [M-H] \ HR-TOF-MS (Method 24): calculated 1218.6518, found 1218.6539 [M + H] +. Example 212 A [(SRJ-A ^ -Benzyloxycarbonyl-J-S-aminoH-phenylalanyl-SRJ-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-bistrifluoroacetate -treonyl-L-serine The compound of Example 204A (17 mg, 12 μ? T ??) is reacted according to procedure 2 with 1.0 ml of the reagent solution. Without further purification, 17 mg (quant.) Of the crude title compound are obtained. HPLC (Method 5): R, = 3.48 min. LC-MS (Method 21): R, = 1, 49. min, MS (ESlpos): m / z (%) = 587.2 (100) [M + 2H] 2+, 1 172.7 (5) [M + H] +. HR-TOF-MS (Method 24): C54H86N13016 calculated 1172.6310, found 1172.6328 [M + H] +. Example 213A L-serinate bistrifluoroacetate of [(3R) - / V2- (Benzyloxycarbonyl) -3-amino} -L-phenylalanyl] - [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alotreonyl The compound of Example 205A (50 mg, 36 μ? T ??) is reacted according to procedure 2 with 4.8 ml of the reagent solution. Without further purification, 56 mg (quant.) Of the crude title compound is obtained and reacted without purification. HPLC (Method 6): R, = 3.22 min. LC-MS (Method 19): R, = 1.32 min, MS (ESlpos): m / z (%) = 586.9 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): C54H86N13016 calculated 1 172.6310, found 1172.6323 [M + H] +. Example 214A Bistrifluoroacetate of [(SRJ-A ^ -Benzyloxycarbonyl-J-S-amine-L-phenylalanyl-t-SR-S-hydroxy-L-leucylj-L- leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-alanyl-L-serine The compound of Example 206A (49 mg, 36 μm) was reacted according to procedure 2 with 1.0 ml of the reagent solution for 1 h. Without further purification, 49 mg (quant.) Of the crude title compound is obtained. HPLC (Method 5): R, = 3.46 min. LC-MS (Method 19): R, = 1.49 min, MS (ESlpos): m / z (%) = 572.0 (100) [M + 2H] 2+, 1142.6 (5) [M + H] +. HR-TOF-MS (Method 24): CssH ^ N ^ O ^ calculated 1142.6205, found 1142.6221 [M + H] +. EXAMPLE 215A L-Serinate Bistrifluoroacetate of [(3?) - W2- (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl -L-isoleucyl-L-seryl-glycyl - [(3S) -3-hydroxy-L-asparagini The compound of Example 207A (42 mg, 28 pmol) is reacted according to procedure 2 with 1.0 ml of the reagent solution for 1 h. Without further purification, 43 mg (quant.) Of the crude title compound are obtained. HPLC (Method 5): R, = 3.43 min. LC-MS (Method 19): R, = 1.34 min, MS (ESlpos): m / z (%) = 594.5 (100) [M + 2H] 2+, 1187.6 (5) [M + H] +. HR-TOF-MS (Method 24): CsaHeaN ^ O ^ calculated 1187.6056, found 1187.6074 [M + H] +. Example 216A Bistrifluoroacetate of [(SRJ-A ^ -Benzyloxycarboni-S-amino-L-phenylalanyl- ^ SRJ-S-hydroxy-L-leucine-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- L-asparaginyl-L-serine The compound of example 208A (46 mg, 30 μ? T ???) is reacted according to procedure 2 with 1.0 ml of the reagent solution for 30 min. Without further purification, 46 mg (quant.) Of the crude title compound is obtained. HPLC (Method 5): R, = 3.21 min. LC-MS (Method 19): R, = 1.31 min, MS (ESlpos): m / z (%) = 593.5 (100) [M + 2H] 2+, 1185.5 (5) [M + H] +. HR-TOF-MS (Method 24): C54H85N14016 calculated 1185.6263, found 1185.6241 [M + H] +. Example 217 A [1- (3R) -A 2- (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3 /?) - 3-hydroxy-L-leucyl] - trifluoroacetate of C1 9-N3 1-lactam L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-seryl-L-serine The compound of Example 209A (13 mg, 9.3 μ? - ???) is dissolved in DMF (480 μ?), And the solution is cooled to 0 ° C. 4-Methylmorpholine (6 μ ?, 56 μ? T ??, 6 equivalents) and HATU (11 mg, 28 pmol, 3 equivalents) are added, and the mixture is stirred at 0 ° C for 2 h. The complete mixture is then placed on an HPLC column and purified by chromatography according to method 44. The fractions containing product are combined and lyophilized. 5 mg (4.0 μ ??, 43% of theoretical yield) of the title compound are obtained as a solid. HPLC (Method 5): R, = 3.70 min. LC-MS (Method 20): R, = 1.49 min, MS (ESlpos): m / z (%) = 570.9 (80) [M + 2H] 2+, 1140.6 (90) [M + H] +. HR-TOF-MS (Method 24): CsaHezN ^ O ^ calculated 1140.6048, found 1140.6066 [M + H] +. EXAMPLE 218A C1-9-N3 1-lactam trifluoroacetate of [(3R) -A- (benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3 /?) - 3-hydroxy- L-leucl] -L-leucyl D-arginyl-L-isoleucyl-L-ato According to the method of preparing the compound of Example 217A, the title compound is obtained in a yield of 17 mg (51% of theoretical yield) from the compound of Example 210A (37 mg, 26 μ? T) . HPLC (Method 5): R, = 3.60 min. LC-MS (Method 19): R, = 1.45 min, MS (ESlpos): m / z (%) = 601, 5 (100) [M + 2H] 2+, 1201, 6 (20) [M + H] \ HR-TOF-MS (Method 24): CsaHes ^ O ^ calculated 1204.6365, found 1201.6338 [M + H] +. Example 219A C 9 -N Trifluoroacetate-lactam of [(SRJ-A ^ -Benzyloxycarbonyl-J-S-amino-L-phenylalanyl-lSf?) ^ -hydroxy-L-leucyl] -L-leucyl-D-arginyl -L-isoleucyl-L-alotreonyl-glycol-phenylalanyl] -L-serine According to the method of preparing the compound of Example 217A, the title compound is obtained in a yield of 28 mg (96% of theoretical yield) from the compound of Example 211 A (34 mg, 22 μ? T ??? ). HPLC (Method 6): R, = 3.78 min. LC-MS (Method 20): R, = 1.75 min, MS (ESlpos): m / z (%) = 601, 0 (50) [M + 2H] 2+, 1200.8 (100) [M + H] +; MS (ESlneg): m / z (%) = 1198.8 (100) [MH] \ Example 220 A C 9 -N 3 Trifluoroacetate-[(3 /?) - W 2 - (Benzyloxycarbonyl) -3-lactam -amino-L-phenylalanyl] - [(3 /?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-threonyl-L-serine According to the method of preparing the compound of Example 217A, the title compound is obtained in a yield of 10 mg (65% of theory), from the compound of Example 212A (17 mg, 12 pmol). HPLC (Method 5): R, = 3.75 min. LC-MS (Method 19): R, = 1.59 min, MS (ESlpos): m / z (%) = 1154.7 (100) [M + H] +. HR-TOF-MS (Method 24): C ^ H ^ N ^ OIS calculated 1154.6205, found 1154.6194 [M + Hf. EXAMPLE 221 A C1-N3 Trifluoroacetate-lactam of [(SRJ-A / ^ Benzyloxycarboni-S-amino-L-phenylalanyl H ^ RJ-S-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L- isoleucyl-L-alotreonyl-glycyl-L-alotreonyl-L-serinate The compound of Example 213A (50 mg, 36 μm) is cyclized according to the method of preparation of the compound of Example 217A. Then method 45 is used for chromatography. The title compound is obtained with a crude yield of 52 mg (75% pure, 86% of theoretical yield) and is not further purified. HPLC (Method 6): R, = 3.55 min. LC-MS (Method 19): R, = 1, 60 min, MS (ESlpos): m / z (%) = 1154.7 (100) [M + H] +. HR-TOF-MS (Method 24): CMH ^ ^ O ^ calculated 1154.6205, found 1154.6171 [M + H] +. EXAMPLE 222A C1-9-IM3 1-lactam trifluoroacetate of [(S ^ -A ^ -BBenzyloxycarbonyl-J-S-amino-L-phenylalanyl-thia) ^ -hydroxy-L-leucyl] -L-leucyl-D-arginyl -L-valeucyl-L-alotreonyl-glycyl-L-alanyl-L-serine According to the method of preparing the compound of example 217A, where the purification is carried out according to method 45, the title compound is obtained in a yield of 34 mg (77% of theoretical yield) from the compound of Example 214A (49 mg, 36 prnol). HPLC (Method 5): R, = 3.78 min. LC-MS (Method 19): R, = 1.61 min, MS (ESlpos): m / z (%) = 1124.6 (100) [M + H] +. HR-TOF-MS (Method 24): C53H82N13Oi4 calculated 1154.6099, found 1124.6073 [M + H] +. EXAMPLE 223A C1-9-N3 1-lactam trifluoroacetate of [(3f?) - A 2- (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L- leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-aspa According to the method of preparation of the compound of example 217A, where the purification is carried out according to method 45, the title compound is obtained in a yield of 28 mg (73% of theoretical yield) from the compound of Example 215A (42 mg, 27 μ? t ???). HPLC (Method 5): R, = 3.68 min. LC-MS (Method 19): R, = 1.57 min, MS (ESlpos): m / z (%) = 1169.6 (100) [M + H] +. HR-TOF-MS (Method 24): C53H81N14016 calculated 1169.5950, found 1169.5939 [M + H] +. EXAMPLE 224 A C1-N3 1-lactam trifluoroacetate of [(SR ^ / v ^ Benzyloxycarboni-S-amino-L-phenylalan N ^ hydroxy-L-leucyl] -L-leucyl- [argin ¡L -soleu According to the method of preparing the compound of example 217A, where the purification is carried out according to method 45, the title compound is obtained in a yield of 29 mg (75% of theoretical yield) from the compound of Example 216A (45 mg, 30 μ ????). HPLC (Method 5): R, = 3.52 min. LC-MS (Method 19): R, = 1.56 min, MS (ESlpos): m / z (%) = 1167.5 (100) [M + H] +. HR-TOF-MS (Method 24): C54H83N14O15 calculated 1167.6157, found 1167.6152 [M + H] +. EXAMPLE 225A [(3R) -3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-1-lactam bis-hydrochloride isoleucyl-L-alotreonyl-glycyl-L-seryl-L-serine The compound of Example 217A is dissolved in methanol (750 pL) in the presence of 1 M hydrochloric acid (24 μ ?, 6 equivalents) and hydrogenated in the presence of 3 mg palladium-carbon 10% under atmospheric pressure at room temperature for 1 hour. 5 h. The solution is filtered to remove the catalyst and concentrated. The title compound is obtained in a yield of 4.3 mg (quant.) As a solid. HPLC (Method 5): R, = 3.21 min. LC-MS (Method 20): R, = 0.90 min, MS (ESlpos): m / z (%) = 503.9 (100) [M + 2H] 2 \ 1006.6 (3) [M + H] +. HR-TOF-MS (Method 24): calculated 1006.5681, found 1006.5670 [M + H] +. Example 226A [(3R) -3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-1-lactam bis-hydrochloride isoleucyl-L-alotreonyl-glycyl- [3- (3-pyridyl) -L-alanyl] -L-serine According to the method of preparation of the compound of example 225A, the title compound is obtained in a yield of 17 mg (quant.) From the compound of example 218A (17 mg, 13 pmol). HPLC (Method 5): R, = 3, 17 min. LC-MS (Method 22): R, = 2.34 min, MS (ESlpos): m / z (%) = 534 (20) [M + 2H] 2+; (ESlneg): m / z (%) = 1065 (100) [M-H] \ HR-TOF-MS (Method 24): calculated 1067.5997, found 1067.6006 [M + H] +. Example 227A [(3R) -3-Amino-L-phenylalanyl] - [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-1-lactam bis-hydrochloride -isoleucyl-L-alotreonyl-glycyl-L-phenylalanyl-L-serine According to the method of preparation of the compound of Example 225A, the title compound is obtained in a yield of 24 mg (99% of theory) from the compound of Example 219A (28 mg, 21 pmol). HPLC (Method 5): R, = 3.17 min. LC-MS (Method 21): R, = 1, 15 min, MS (ESlpos): m / z (%) = 534 (100) [M + 2H] 2+; (Sleng): m / z (%) = 1064.8 (50) [M-H] \ HR-TOF-MS (Method 24): C5iH8oN13012 calculated 1066.6044, found 1066.6013 [M + H] +. Example 228A [(3R) -3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-1-lactam bis-hydrochloride isoleucyl-L-alotreonyl-glycyl-L-threonyl-L-serine According to the method of preparation of the compound of Example 225A, the title compound is obtained in a yield of 8.5 mg (99% of theory) from the compound of Example 220A (10 mg, 8 μ? T? ??). HPLC (Method 5): R, = 3.25 min. LC-MS (Method 22): R, = 2.49 min, MS (ESlpos): m / z (%) = 511 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): C46H78N13013 calculated 1020.5837, found 1020.5831 [M + H] +. EXAMPLE 229A [(3)) - 3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L C1-N-3-lactam bis-hydrochloride -isoleucyl-L-alotreonyl-glycyl-L-alotreonyl-L-serinate According to the method of preparation of the compound of Example 225A, the title compound is obtained in a yield of 40 mg (86% of theoretical yield) from the compound of Example 221A (52 mg, 41 μ? T ??? ). HPLC (Method 6): R, = 2.93 min. EXAMPLE 230A [(3R) -3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-1-lactam hydrochloride isoleucyl-L-alotreonyl-glycyl-L-alanyl-L-serine According to the method of preparation of the compound of example 225A, the title compound is obtained in a yield of 29 mg (99% of theoretical yield) from the compound of example 222A (34 mg, 27 μ? T ??? ). HPLC (Method 5): R, = 3.24 min. LC-MS (Method 22): R, = 2.48 min, MS (ESlpos): m / z (%) = 496 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): EXAMPLE 231A [(3R) -3-Amino-L-phenylalanyl] - [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L Bis-C1-N3-lactam hydrochloride -isoleucyl-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine According to the method of preparing the compound of Example 225A, the title compound is obtained in a yield of 21 mg (95% of theory) from the compound of Example 223A (28 mg, 20 pmol). HPLC (Method 5): R, = 3.16 min. LC-MS (Method 22): R, = 2.43 min, MS (ESlpos): m / z (%) = 519 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): C45H75N14O14 calculated 1035.5582, found 1035.5585 [M + H] +. EXAMPLE 232 A [1- (3 /?) - 3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl C1-N-3-lactam bis-hydrochloride -L-isoleucyl-L-alotreonyl-glycyl-L-asparaginyl-L-serine According to the method of preparing the compound of Example 225A, the title compound is obtained in a yield of 24 mg (96% of theory) from the compound of Example 224A (29 mg, 23 μ). . HPLC (Method 5): R, = 2.90 min. LC-MS (Method 22): R, = 2.32 min, MS (ESlpos): m / z (%) = 517 (100) [M + 2H] 2+, 1033 (5) [M + H] + . HR-TOF-MS (Method 24): calculated 1033.5790, found 1033.5773 [M + H] +. EXAMPLE 233 A C1-N33-lactam hydrochloride of [/ ^ - (Benzyloxycarboni -S-fer-butyl-D-alanylj-fS-fer-butyl-L-alanyl] - [(3R) -3-amino-L phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-g seryl-L-serine The compound of Example 225A (4.3 mg, 4 pmol) and the compound of Example 10A (2.5 mg, 6 pmol, 1.5 equivalents) are dissolved in DMF (300 μm) and the solution is cooled to 0 ° C. 4-Methylmorpholine (20 μ ?, 16 μ ??, 4 equivalents) and HATU (2.4 mg, 6 μ? T ??,, 1.6 equivalents) are added and the mixture is stirred at room temperature for 2 h. The reaction is then quenched with 3 ml of methanol and purified by chromatography according to method 45. The fractions containing product are combined and concentrated. 4 mg (2.8 μ? T, 70% of theoretical yield) of the title compound are obtained as a solid. HPLC (Method 5): R, = 4.45 min. LC-MS (Method 19): R, = 2.08 min, MS (ESlpos): m / z (%) = 698.6 (100) [M + 2H] 2+, 1395.4 (30) [M + H] +. HR-TOF-MS (Method 24): C ^ H ^ N ^ O ^ calculated 1394.8043, found 1394.8070 [M + H] +. Example 234A C1-N3 3-lactam hydrochloride of [/ v - (Benzyloxycarbonyl) -3-fer-butyl-D-alanyl] - [3-fer-bu ^ [(3 /?) - 3 -amino-L-phenylalanyl] - [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-allotreonil ^ (3-pyridyl) -L-alanyl] -L-serine According to the preparation method for preparing compound of example 233A, the title compound is obtained in a yield of 12 mg (54% of theoretical yield) from the compound of example 226A (17 mg, 13 μ ???? ). HPLC (Method 5): R, = 4.25 min. LC-MS (Method 22): R, = 3.61 min, MS (ESlpos): m / z (%) = 729 (100) [M + 2H] 2+; (Sleng): m / z (%) = 1454 (100) [MH] ". HR-TOF-MS (Method 24): C72H111N16016 calculated 1455.8359, found 1455.8347 [M + H] \ Example 235A Hydrochloride C1 11-N33-lactam of [/ ^ - (fer-Butoxycarboni-S-fer-butyl-D-alanyl HS-ér-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] - [ (3R) -3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-sulphonyl-alotreonyl-glycyl-L-phenylalanyl-L-serine According to the method of preparation of the compound of example 233A, the title compound is obtained in a yield of 19 mg (62% of theoretical yield) from the compound of example 227A (24 mg, 21 pmol) and the dipeptide of the Example 8A (10 mg, 27 pmol, 1.3 equivalents). HPLC (Method 6): R, = 4.57 min. LC-MS (Method 20): R, = 2.291 min, MS (ESlpos): m / z (%) = 661, 2 (100) [M-Boc + 2H] 2+, 1421, 0 (30) [M + H] +; (Sleng): m / z (%) = 1419.1 (20) [M-H] \ HR-TOF-MS (Method 24): C / oHusNisOie calculated 1420.8563, found 1420.8558 [M + H] +. EXAMPLE 236A C1-N3 3-lactam hydrochloride of [/ v ^ - (fer.-Butoxycarbonyl) -3-fer-butyl-D-ata [(3f?) - 3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leu-threonyl] -L-serine According to the method of preparing the compound of Example 233A, the title compound is obtained in a yield of 10 mg (91% of theory) from the compound of Example 228A (8.5 mg, 8 μ). ) and the dipeptide of example 8A (4 mg, 10 μ ??, 1.3 equivalents). HPLC (Method 5): R, = 4.65 min. LC-MS (Method 19): R, = 2.09 min, MS (ESlpos): m / z (%) = 1374.8 (30) [M + H] + HR-TOF-MS (Method 24): ^ H ^ N ^ O ^ calculated 1374.8356, found 1374.8376 [M + H] \ Example 237 A C1-N3: 3-lactam hydrochloride of [/ ^ - (fer.-ButoxycarbonylJ-S-fer- butyl-D-alan-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-argyl According to the method of preparation of the compound of Example 233A, the title compound is obtained in a yield of 47 mg (purity 77%, 69% of theoretical yield) from the compound of example 229A (40 mg, 35 pmol) and the dipeptide of Example 8A (17 mg, 46 μ? t ??, 1.5 equivalents). HPLC (Method 6): R, = 4.31 min. LC-MS (Method 19): R, = 2.08 min, MS (ESlpos): m / z (%) = 1374.8 (50) [M + Hf HR-TOF-MS (Method 24): C65H112N15017 calculated 1374.8356, found 1374.8362 [M + H] \ Example 238 A C1-N3 3-lactam hydrochloride of [/ ^ - (fer-Butoxycarboni-S-fer-butyl ^ [(3R) -3-amino] -L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-allotreon alanyl-L-serine According to the method of preparing the compound of Example 233A, the title compound is obtained in a yield of 37 mg (98% of theory) from the compound of Example 230A (29 mg, 27 μ? T). and the dipeptide of Example 8A (13 mg, 35 pmol, 1.3 equivalents). HPLC (Method 5): R, = 4.60 min. LC-MS (Method 19): R, = 2.10 min, MS (ESlpos): m / z (%) = 623.0 (100) [M-Boc + 2H] 2+; 1344.9 (90) [M + H] + HR-TOF-MS (Method 24): C ^ H ^ N ^ O ^ calculated 1344.8250, found 1344.8241 [M + H] \ Example 239A C1 Hydrochloride 11-N33-lactam of [/ - (erer.-Butoxycarboni -S-fer-butyl-D-alanylj-lS-ér-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] - [(3?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreoni [(3S) -3-hydroxy-L-asparaginyl] -L-serine CH, NH According to the method of preparation of the compound of Example 233A, the title compound is obtained in a yield of 24 mg (89% of theory) from the compound of Example 231A (21 mg, 19 μ) and the dipeptide of Example 8A (9 mg, 25 μm, 1.3 equivalents). HPLC (Method 5): R, = 4.42 min. LC-MS (Method 19): R, = 2.03 min, MS (ESlpos): m / z (%) = 645.5 (100) [M-Boc + 2H] 2+; 1389.9 (40) [M + Hf HR-TOF-MS (Method 24): calculated 1389.8101, found 1389.8105 [M + H] +. EXAMPLE 240 A C1- N3'-Hydrochloride - [A / 4-fer.-Butoxycarboni-S-fer-butyl-D-ala ^ [(3 /?) - 3-amino-L-phenylalanyl] -lactam ] - [(3R) -3-hydroxy-L-te ^ asparaginyl-L-serine According to the method of preparing the compound of Example 233A, the title compound is obtained in a yield of 30 mg (97% of theory) from the compound of Example 232A (24 mg, 22 μ? T). and the dipeptide of example 8A (11 mg, 28 μm, 1.3 equivalents). HPLC (Method 5): R, = 4.26 min. LC-MS (Method 21): R, = 2.19 min, MS (ESlpos): m / z (%) = 644.7 (100) [M-Boc + 2H] 2+. HR-TOF-MS (Method 24): ??? ^? ^? ^ Calculated 1387.8308, found 1387.8304 [M + H] +. Example 241A / ^ - (benzyl fer-butoxycarbonyl-J-L-alaninate Dissolve / ^ - (fer-Butoxycarbonyl H-alanine (1.13 g, 5.83 mmol) in dry DCM (6 mL), add 3 A molecular sieves, and the mixture is then cooled to 0 ° C. add benzyl alcohol (1.81 ml, 17.48 mmol, 3 equivalents), EDCI (2.23 g, 11.65 mmol, 2 equivalents), and DMAP (71 mg, 0.58 mmol, 0.1 equivalent) The mixture is stirred for 150 min, allowed to slowly warm to room temperature, the mixture is then concentrated to dryness and the residue is subjected to further treatment by chromatography (Biotage, cyclohexane-ethyl acetate 9: 1). The product is combined and concentrated The title compound is obtained in a yield of 1.03 g (63% of theory) HPLC (Method 5): R = 4.70 min LC-MS (Method 21) : R, = 2.44 min, MS (ESlpos): m / z (%) = 280.3 (30) [M + H] \ Example 242A L-alaninate benzyl trifluoroacetate The compound of example 241A (200 mg, 716 pmol) is reacted according to procedure 2 with 2.0 ml of the reagent solution for 60 min. Without further purification, they obtain 200 mg (95% of theory) of the crude title compound. LC-MS (Method 22): R, = 2.30 min, MS (ESlpos): m / z (%) = 180 (100) [M + H] +. Example 243A [/ - (Fer-butoxycarbonylJ-glycine-KSSJ-S-hydroxy-O ^ -methyl-L-aspartylj-L-benzyl alaninate The compound of example 33A (441 mg, 895 μ ??) and the compound of Example 242A (315 mg, 1.07 mmol, 1.2 equivalents) are dissolved in DMF (4.8 ml) and cooled to -20 ° C. Then 4-methylmorpholine (492 μ ?, 4.48 mmol, 5 equivalents) and HATU (510 mg, 1.34 mmol, 1.5 equivalents) are added, and the mixture is warmed slowly to room temperature and stirred for about 16 h. The mixture is then purified by two step chromatography (method 45, then method 34). The title compound is obtained in a yield of 277 mg (64% of theory). HPLC (Method 5): R, = 4.06 min. LC-MS (Method 19): R, = 2.13 min, MS (ESlpos): m / z (%) = 482.1 (100) [M + H] +. HR-TOF-MS (Method 24): C22H32N309 calculated 482.2134, found 482.2120 [M + H] +. Example 244A [/ ^ - (Benzoyl-benzoyl-benzoyl-2-butoxycarbonyl-glycyl-3-S-S-hydroxy-L-asparaginylj-L-alaninate] The compound of Example 243A (139 mg, 288 μm) is provided in 5.1 mL of acetonitrile and cooled to 0 ° C; 3.1 ml of an aqueous solution of concentrated ammonia are added, and stirring is continued at 0 ° C. After 20 min, the reaction is stopped with glacial acetic acid (2.6 ml), diluted with water and extracted with ethyl acetate. The organic extract is washed with concentrated brine, dried over sodium sulfate and concentrated. Yield: 122 mg (75% of theory) of the crude title compound which is reacted without purification. HPLC (Method 6): R, = 3.78 min. LC-MS (Method 20): R, = 1.69 min, MS (ESlpos): m / z (%) = 467.1 (100) [M + H] +; MS (ESlneg): m / z (%) = 465.2 (100) [M-H] \ HR-TOF-MS (Method 24): C2iH31N408 calculated 467.2137, found 467.2137 [M + H] +. Example 245A glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-alaninate benzyl trifluoroacetate The compound of example 241A (122 mg, 217 μ? T ??) is reacted according to procedure 2 with 2.0 ml of the reagent solution for 60 min. Without further purification, 100 mg (96% of theory) of the crude title compound are obtained. HPLC (Method 6): R, = 3.05 min. LC-MS (Method 22): R, = 2.23 min, MS (ESlpos): m / z (%) = 367 (100) [M + H] +. HR-TOF-MS (Method 24): C16H23N406 calculated 367.1613, found 367.1622 [M + H] +. Example 246A [(SRJ-A ^ -ifor-butoxycarboni-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreon hydroxy-L-asparaginyl] -L-alaninate benzyl trifluoroacetate The compound of Example 32A (133 mg, 139 μ? T) and the compound of Example 245A (100 mg, 208 μ? T ??, 1.5 equivalents) are dissolved in DMF (950 μ?), and the solution is cooled to -20 ° C. 4-Methylmorpholine (46 μ?, 416 [mu], 3 equivalents) and HATU (84 mg, 222 [mu] p, 1.6 equivalents), and the mixture is stirred at room temperature for 16 h. The complete mixture is then purified by chromatography according to method 45. Fractions containing product are combined and lyophilized. 157 mg (95% of theory) of the title compound are obtained as a solid. HPLC (Method 6): R, = 3.66 min. LC-MS (Method 19): R, = 1.71 min, MS (ESlpos): m / z (%) = 1079.1 (80) [M + H] +. HR-TOF-MS (Method 24): C49H83N12015 calculated 1079.6096, found 1079.6094 [M + H] +. Example 247A [(3R) -A / - (Ier-Butoxycarbonyl) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl [(3S)] trifluoroacetate 3-hydroxy-L-asparaginyl] -L-alanine The compound of Example 246A (190 mg, 159 μp) is hydrogenated according to the method for preparing the compound of Example 186A. 172 mg (98% of theory) of the title compound are obtained as a solid. HPLC (Method 6): R, = 3.39 min. LC-MS (Method 19): R, = 1.55 min, MS (ESlpos): m / z (%) = 445.3 (100) [M + 2H] 2+, 989.5 (60) [M + H] +; MS (ESIneg): m / z (%) = 987.5 (100) [M-H] ~. HR-TOF-MS (Method 24): C42H77N12015 calculated 989.5626, found 989.5651 [M + H] +. Example 248 A [(3f?) - 3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginirj bistrifluoroacetate] -L-alanine The compound of example 247A (172 mg, 156 μm) was reacted according to procedure 2 with 2.0 ml of the reagent solution for 30 min. Without further purification, 174 mg (quant.) Of the crude title compound is obtained. HPLC (Method 6): R, = 2.78 min. LC-MS (Method 22): R, = 2.17 min, MS (ESlpos): m / z (%) = 889 (80) [M + H] +; MS (ESlneg): m / z (%) = 887 (100), [M-H] \ HR-TOF-MS (Method 24): CsT ^ N ^ 0 calculated 889.5102, found 889.5096 [M + Hf. Example 249A [(SRJ-A ^ -Benzyloxycarboni-S- ^ fer-butoxycarbonylJaminoH-phenylalanyl-thiS-S-hydroxy-L-leucyl] -L-leucyl- [arginyl-L-isoleucyl-L-alotreonyl-glyc] trifluoroacetate L - [(3S) -3-hydroxy-L-asparagi According to the method for preparing the compound of example 201A the compound of example 248A (174 mg, 156 mol) is reacted with the compound of example 17A (99 mg, 171 μl, 1.1 equivalents). After purification by chromatography (variant of method 36, instead of gradient, the separation is carried out in a sodium form with eluent A: eluent B = 3: 2), 81 mg (34% of the theoretical yield) are isolated. composed of the title. HPLC (Method 6): R, = 3.76 min. LC-MS (Method 19): R t = 1.89 min, MS (ESlpos): m / z (%) = 593.4 (100) [M-Boc + 2H] 2+, 1285.7 (30) [ M + H] +; (Sleng): m / z (%) = 1283.5 (100) [M-H] \ HR-TOF-MS (Method 24): C59H93N14018 calculated 1285.6787, found 1285.6781 [M + H] +. Example 250A Bistrifluoroacetate of [(SRJ-A ^ -Benzyloxycarbonyl-J-S-amino-L-phenylalanyl HISRJ-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S -3-hydroxy-L-asparaginyl] -L-alanine The compound of example 249A (81 mg, 54 pmol) is reacted according to procedure 2 with 2.0 ml of the reagent solution for 60 min. Without further purification, 81 mg (99% of theory) of the crude title compound are obtained. HPLC (Method 6): R, = 3.20 min. LC-MS (Method 19): R, = 1.29 min, MS (ESlpos): m / z (%) = 593.7 (100) [M + 2H] 2+, 1185.6 (5) [M + H] +; MS (ESlneg): m / z (%) = 1183.7 (100), [MH] \ HR-TOF-MS (Method 24): CMHSSN ^ O ^ calculated 1 185.6263, found 1185.6249 [M + H] +. EXAMPLE 251A C 1 9-N 3 1-lactam trifluoroacetate of [(SRJ-A ^ -Benzyloxycarbonyl-J-S-amino-L-phenylalanyl-J- ^ S ^ -S-hydroxy-L-leucyl] -L-leucyl-D-arginyl- L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparagi According to the method for preparing the compound of example 217A, where the purification is carried out according to method 45, the title compound is obtained in a yield of 69 mg (93% of theoretical yield) from the compound of Example 250A (81 mg, 53 pmol). HPLC (Method 6): R, = 3.56 min. LC-MS (Method 19): R, = 1.67 min, MS (ESlpos): m / z (%) = 1167.6 (100) [M + H] +; MS (ESlneg): m / z (%) = 1165.6 (100), [MH] \ HR-TOF-MS (Method 24): C ^ H ^ NMO ^ calculated 1167.6157, found 1167.6154 [M + H] +. Example 252A [(3R) -3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-1-lactam bis-hydrochloride isoleucyl-L-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-alanine According to the method for preparing the compound of Example 225A, the title compound is obtained in a yield of 53 mg (97% of theory) from the compound of Example 251A (69 mg, 49 pmol). HPLC (Method 6): R, = 2.98 min. LC-MS (Method 20): R, = 0.96 min, MS (ESlpos): m / z (%) = 517.5 (100) [M + 2H] 2+, 1033.7 (10) [M + H] +; MS (ESlneg): m / z (%) = 1031, 7 (60) [M-H] ", 1077.7 (100) [M + HCOOH-H]". HR-TOF-MS (Method 24): C 6H77NuOi3 calculated 1033.5790, found 1033.5782 [M + H] +. Example 253A C1-N3 3-lactam hydrochloride of [/ 1 - (fer.-Butoxycarboni-S-fer-butyl-D-alan ^ [(3R) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-La [(3S) -3-hydroxy-L-asparaginyl] -L-alanine According to the method for preparing the compound of Example 233A, the title compound is obtained in a yield of 58 mg (85% of theory) from the compound of Example 252A (53 mg, 48 μ? T). and the dipeptide of Example 8A (23 mg, 62 μm, 1.3 equivalents). HPLC (Method 6): R, = 4.35 min. LC-MS (Method 19): R, = 2.08 min, MS (ESlpos): m / z (%) = 1387.9 (100) [M + H] +. HR-TOF-MS (Method 24): CesHmN ^ O ^ calculated 1387.8308, found 1387.8314 [M + H] \ Example 254A Trifluoroacetate of [(SRJ-A ^ -i / er-butoxycarbonyl-J-S-hydroxy) L-leucilj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreoninate pentafluorophenyl * TFA The compound of Example 32A (60 mg, 71 μ? T ??), pentafluorophenol (65 mg, 355 μ? T ???, d equivalents) and EDCI (20 mg, 107 μ ???, 1.5 equivalents) are dissolved in dichloromethane (0.9 ml) at 0 ° C under argon and stirring at room temperature overnight. The solvent is removed and the residue is subjected to chromatography (method 34). The title compound is isolated in a yield of 32 mg (45% of theoretical yield). HPLC (Method 6): R, = 4.12 min. LC-MS (Method 19): R, = 1.93 min, MS (ESlpos): m / z (%) = 897.4 (100) [M + H] +. Example 255A / ^ - (Pentafluorophenyl ferbatoxycarbonyl-J-D-alanine The title compound is isolated in a yield of 471 mg (64% of theoretical yield) in a manner analogous to the preparation of the compound of Example 254A from / ^ - (Ier-butoxycarbonyl) -D-alanine (390 mg, 2%). , 06 mmol). HPLC (Method 5): R, = 5.00 min. LC-MS (Method 21): R, = 2.74 min, MS (ESlpos): m / z (%) = 356 (5) [M + H] +. Example 256 A [A / 2- (fer-Butoxycarbonyl) -D-alanyl] - (3S) -04-methyl-3-hydroxy-L-aspartic acid The compound of example 255A (470 mg, 1.32 mmol) and (2S, 3S) -2-amino-3-hydroxy-4-methoxy-4-oxobutyric acid hydrochloride (see example 33A for the preparation, 407 mg, 2.04 mmol, 1.6 equivalents) are dissolved in DMF (20 mL) at 0 ° C, and DIPEA (1.78 mL, 10.20 mmol, 7.7 equivalents) is added. The mixture is stirred at room temperature for approximately 16 h and then subjected to chromatography according to method 45 and finely purified by method 32. Yield: 200 mg (29% of theory). HPLC (Method 5): R, = 3.26 min. LC-MS (Method 19): R, = 1.48 min, MS (ESlpos): m / z (%) = 335.2 (90) [M + H] \ Example 257A [^ - (fer-butoxycarbonyl-) D-alanyl-IiSSJ-O ^ methyl-S-hydroxy-L-aspartyl-J-L-serinate benzyl The compound of example 256A (195 mg, 0.58 mmol) and the compound of example 149A (190 mg, 0.61 mmol, 1.1 equivalents) are dissolved in DMF (5.0 ml), and the solution is cooled at 0 ° C. 4-Methylmorpholine (203 μ ?, 1.84 mmol, 3 equivalents) and TCTU (326 mg, 0.92 mmol, 1.5 equivalents) are added, and the mixture is stirred at room temperature for 2.5 h. The complete mixture is then subjected to chromatography (method 45) and finely purified by method 32. The Fractions containing product are combined and lyophilized. 146 mg (47% of theory) of the title compound are obtained as a solid. HPLC (Method 5): R, = 3.89 min. LC-MS (Method 19): R, = 1.94 min, MS (ESlpos): m / z (%) = 511, 1 (100) [M + H] +. [a] 20Na = +15.9 (c = 0.5, MeOH). Example 258A [^ - (tert-Butoxycarbonyl-J-D-alanyl- ^ SSJ-O ^ -methyl-S-hydroxy-L-aspartyl-L-serine The compound of example 257A (135 mg, 264 μ? T ??) is hydrogenated in the presence of 30 mg palladium-carbon 10% in methanol (8.0 ml) at room temperature for 2 h. The mixture is filtered to remove the catalyst and concentrated, and the crude product is subjected to chromatography (method 32). Yield: 117 mg (quant.). HPLC (Method 5): R, = 3.11 min. LC-MS (Method 19): R, = 1.40 min, MS (ESlpos): m / z (%) = 422.1 (100) [M + H] +. HR-TOF-MS (Method 24): C16H28 3O10 calculated 422.1770, found 422.1776 [M + H] +. Example 259A [/ ^ - (Ier-Butoxycarbonyl-J-D-alanyl- ^ SSJ-S-hydroxy-L-asparaginyl-J-L-serine The compound of example 258A (116 mg, 275 μm) is supplied in 5.0 ml of acetonitrile and cooled to 0 ° C.; 3.0 ml of an aqueous solution of concentrated ammonia are added and stirring is continued at 0 ° C. After 5 min, the reaction is stopped with glacial acetic acid (1.2 ml), concentrated and chromatographed (method 32). Yield: 64 mg (57% of theory). HPLC (Method 6): R, = 2.82 min. LC-MS (Method 19): R, = 1.12 min, MS (ESlpos): m / z (%) = 407.0 (90) [M + H] +; MS (ESlneg): m / z (%) = 405.0 (100) [M-H] \ HR-TOF-MS (Method 24): C15H27 4O9 calculated 407.1773, found 407.1781 [M + H] +. Example 260 A [D-Alanyl] - [(3S) -3-hydroxy-L-aspartyl-L-serine trifluoroacetate The compound of example 259A (63 mg, 155 μ? T ?? G) is reacted according to procedure 2 with 2.0 ml of the reagent solution for 30 min. Without further purification, 67 mg (quant.) Of the crude title compound are obtained. HPLC (Method 6): R, = 0.72 min. LC-MS (Method 19): R, = 0.52 min, MS (ESlpos): m / z (%) = 307 (100) [M + H] +. HR-TOF-MS (Method 24): C10H19N4O7 calculated 307.1259, found 307.125 [M + H] +. EXAMPLE 261 A L-Serinate Trifluoroacetate of [(SR ^ / v ^ -ioer-Butoxycarbonyl-J-S-hydroxy-L-leucylj-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-D-alanyl- [ (3S) -3-hydroxy-L-asparaginyl] The compound of Example 254A (32 mg, 32 μ ??) and the compound of Example 260A, 13 mg, 32 μ ?t ???, 1 equivalent) are dissolved in DMF (1.5 ml) at 0 °. C, and DIPEA (28 μ ?, 158 μ ??, 5 equivalents) is added. The mixture is stirred at room temperature for approximately 16 h and then subjected to chromatography according to method 45. Yield: 30 mg (84% of theory). HPLC (Method 6): R, = 3.40 min. LC-MS (Method 19): R, = 1.60 min, MS (ESlpos): m / z (%) = 460.3 (100) [M-Boc + 2H] 2+, 1019.6 (60) [M + H] +. HR-TOF-MS (Method 24): C43H79N12016 calculated 1019.5732, found 1019.5716 [M + H] +. Example 262A L-serinate bistrifluoroacetate of [(3R) -3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-D-alanyl - [(3S) -3-hydroxy -L-asparaginyl] The compound of Example 261 A (59 mg, 52 μm) is reacted according to procedure 2 with 2.0 ml of the reagent solution for 30 min. Without purification, 64 mg (quant.) Of the crude title compound is obtained. HPLC (Method 6): R, = 2.91 min. LC-MS (Method 22): R, = 2.20 min, MS (ESlpos): m / z (%) = 461 (100) [M + 2H] 2+; MS (ESlneg): m / z (%) = 918 (100) [M-H] \ HR-TOF-MS (Method 24): C ^ ^ N O calculated 919.5208, found 919.5212 [M + H] +. Example 263A [(3R) - / / 2- (Benzyloxycarbonyl) -3- trifluoroacetate. { (tert-butoxycarbonyl) amino} -L-phenylalanyl] - [(3f?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-D-alanyl - [(3S) -3-hydroxy- L-asparagi According to the method for preparing the compound of Example 201A the compound of Example 262A (92 mg, 80 pmol) is reacted with the compound of Example 17A (51 mg, 88 pmol, 1.1 equivalents). After purification by chromatography (method 44), 35 mg (31% of theory) of the title compound are isolated. HPLC (Method 6): R, = 3.76 min. LC-MS (Method 19): R, = 1.94 min, MS (ESlpos): m / z (%) = 608.4 (100) [M-Boc + 2H] 2+, 1315.6 (30) [M + Hf; MS (ESlneg): m / z (%) = 1313.7 (100) [M-H] \ HR-TOF-MS (Method 24): CeoHgsN Oig calculated 1315.6893, found 1315.6873 [M + H] +. Example 264A Bistrifluoroacetate of [(SR ^ / v ^ -I-Benzyloxycarboni-S-amino-L-phenylalanyl-JS ^ -S-hydroxy-L-leucyl-J-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl- D-alanyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine The compound of Example 262A (35 mg, 24 pmol) is reacted according to procedure 2 with 2.0 ml of the reagent solution for 30 min. Without further purification, 37 mg (quant.) Of the crude title compound are obtained. HPLC (Method 6): R, = 3.20 min. LC-MS (Method 19): R, = 1.36 min, MS (ESlpos): m / z (%) = 608.3 (100) [M + 2H] 2 \ 1215.7 (5) [M + H] +; MS (ESlneg): m / z (%) = 1213.7 (100) [MH] \ HR-TOF-MS (Method 24): CSS ^ NMOU calculated 1215.6369, found 1215.6340 [M + H] + . EXAMPLE 265A [(3R) - / v ^ - (Benzyloxycarbonyl) -3-amino-L-phenylalanyl-hydroxy-L-leucyl] -L-leucyl-D- trifluoroacetate C1-N-3-lactam trifluoroacetate arginyl ^ L-isoleucyl-L-alotreonyl-D-alanyl - [(3S) -3-hydroxy-L-asparagini According to the method for preparing the compound of example 217A, where the purification is carried out according to method 45, the title compound is obtained in a yield of 46 mg (48% of the theoretical yield (approximately 34% of purity)) from the compound of example 264A (36 mg, 25 prnol). HPLC (Method 6): R, = 3.55 min. LC-MS (Method 19): R, = 1.61 min, MS (ESlpos): m / z (%) = 599.3 (100) [M + 2H] 2+; 1197.6 (30) [M + H] +; MS (ESlneg): m / z (%) = 1195.6 (100), [MH] ". HR-TOF-MS (Method 24): C55H85 14016 calculated 1197.6263, found 1197.6290 [M + H] EXAMPLE 266A C1-9-N3 1-lactam trifluoroacetate of [(3R) -3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D- arginyl-L-isoleucyl-L-alotreonyl-D-alanyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine The compound of example 265A (46 mg, approximately 34% purity, approximately 12 μm) is hydrogenated in the presence of a 10% palladium on charcoal spatula tip in methanol under atmospheric pressure at room temperature for 1 h. The mixture is filtered to remove the catalyst and concentrated. The crude product (42 g) is subjected to reaction without purification. HPLC (Method 6): R, = 2.98 min. LC-MS (Method 22): R, = 2.33 min, MS (ESlpos): m / z (%) = 533 (100) [M + 2H] 2+, 1064 (10) [M + H] +; MS (Sleng) m / z (%) = 1062 (100) [M] ". HR-TOF-MS (Method 24): C47H79N14014 calculated 1063.5895, found 1063.5869 [M + H] + Example 267A Trifluoroacetate of C1 11-N3 3-lactam of [/^- (fer.-ButoxycarboniO-S-fer- butyl-D-alani ^^^ alanyl] - [(3R) -3-amino-L-phenylalanyl] - [( 3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-The alanyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine According to the method for preparing the compound of Example 233A, the title compound is obtained with a crude yield of 28 mg from the compound of Example 266A (34 mg of crude product, approximately 12 pmol) and the dipeptide of Example 8A ( 13 mg, 35 μ? T ??, approximately 2.4 equivalents). The product is used in the next synthesis step without further purification. HPLC (Method 6): R, = 4.27 min. LC-MS (Method 19): R, = 2.12 min, MS (ESlpos): m / z (%) = 659.6 (100) [M-Boc + 2H] 2 + 1417.8 (50) [ M + Hf. Example 268A rae / V- (fer-Butoxycarbonyl) -3- (trimethylsilyl) alanine The synthesis is carried out according to Merget, K. Gunther, M. Bernd, E. Gunther, R. Tacke, J. Organomet. Chem. 2001 628, 183-194. The enantiomers are separated by preparative HPLC in chiral phase: Gilson Abimed HPLC, UV detector 212 nm, column: Daicel Chiralpak AD-H 5 μ? T ?; 250 x 20 mm; flow rate: 15 ml / min; eluent A: / sohexane, eluent B: 0.2% acetic acid / 1% water / 2-propanol; Socratic Example 269A (Compound 2S or A / - (fer-butoxycarbonyl) -D-3-trimethylsilylalanine): Preparative HPLC: R, = 4.16 min No20 = +1.1 (c = 0.83, Methanol) Example 270A (2R or A / - (eer-butoxycarbonyl) -L-3-trimethylsilylalanine): Preparative HPLC: R, = 9.27 min HD2 ° = -1.6 (c = 0.66, Methanol) Example 271A / V- (fer-butoxycarbonyl) -3-pyridin-3-yl-L-alaninate methyl) Analogous to B. Neisses, W. Steglich, Org. Synth 1985, 63, 183-187. Dissolve (2S) -A / - (eer-Butoxycarbonyl) -3- (3-pyridyl) alanine (25.00 g, 93.88 mmol) in 300 ml of dichloromethane under argon. Methanol (11.4 mL, 9.02 g, 281 mmol, 3 equivalents) and a grain of DMAP are added. The mixture is then cooled to 0 ° C. EDC (19.80 g, 103 mmol, 1.1 equivalents) is added. After 5 min, the ice bath is removed and the mixture is stirred at room temperature for 1 h. The mixture is then concentrated in vacuo, and the residue is mixed with ethyl acetate and extracted with concentrated sodium bicarbonate. The aqueous phase is extracted once more with ethyl acetate, and the combined organic phrases are then washed with 0.5 M citric acid and then once again with concentrated sodium bicarbonate. The organic phase is dried over sodium sulfate, filtered and concentrated in vacuo. A transparent oil is obtained which crystallizes when dried under vacuum by an oil pump. Yield: 23.60 g (84.2 mmol, 90% of theory). HPLC / UV-Vis (Method 5): R, = 3.28 min. 1 H NMR (400 MHz, cfe-DIvISO) d 1.30 (s, 9 H), 2.86 (m, 1 H), 3.04 (m, 1 H), 3.63 (s, 3 H) , 4.22 (m, 1 H), 7.28-7.39 (m, 2 H), 7.69 (d, 1 H), 8.43 (m, 2 H). LC-MS (Method 18): R, 1, 21 min, MS (ESlpos.): M / z (%) = 281 (100) [M + H] +. Example 272 A bis (trifluoroacetate) of 3 - [(2S) -2-ammonium-3-methoxy-3-oxopropyl] pyridinium Compound 271A (11.8 g, 42.09 mmol) is dissolved in 30% TFA in dichloromethane (160 ml) and stirred at room temperature for 30 min. The mixture is then concentrated in vacuo. The residue is collected in a small amount of water and lyophilized. The lyophilisate is then mixed with toluene and concentrated in vacuo. Finally, the product is dried to constant weight under vacuum by oil pump. Yield: 17.15 g (quant.). HPLC / UV-Vis (Method 5): R, = 0.88 min. 1 H NMR (400 MHz, cfe-DMSO) d 2.79 (dd, 1 H), 2.92 (dd, 1 H), 3.60 (s, 3 H), 3.63 (m, 1 H) , 7.30 (m, 1 H), 7.62 (d, 1 H), 8.41 (m, 2 H). LC-MS (Method 18): Rt 0.46 min, MS (ESlpos.): M z (%) = 181 (100) [M + H] +. Example 273A / / - (Methyl-butoxycarbonyl) -3- (trimethylsilyl) -D-alanyl-3-pyridin-3-yl-L-alaninate methyl ester Compound 269A (10.31 g, 39.4 mmol) and compound 272A (16.10 g, 39.4 mmol, 1 equivalent) are dissolved in DMF (186 mL) at 0 ° C. Then NMM is added (17.34 ml, 16.00 g, 4 equivalents) and HATU (22.49 g, 59.16 mmol, 1.5 equivalents). The mixture is stirred at room temperature for two hours. Ite-Butylmethylether is added, and the mixture is washed with concentrated sodium carbonate. The aqueous phase is extracted once more with tert-butyl methyl ether, and the combined organic phrases are then washed with 1 M aqueous citric acid and again with concentrated sodium carbonate, dried over Na 2 SO 4, filtered and concentrated in vacuo. Filtration through silica gel is carried out (cyclohexane / ethyl acetate 2 + 1). Yield: 14.1 g (84% of theoretical yield). HPLC / UV-Vis (Method 5): R, = 3.91 min. 1 H NMR (400 MHz, cfe-DMSO) d -0.09 (s, 9 H), 0.56 - 0.75 (m, 2 H), 1.47 (s, 9 H), 2.90 ( dd, 1 H), 3.09 (dd, 1 H), 3.62 (s, 3 H), 3.98 (m, 1 H), 4.49 (m, 1 H), 3.68 ( d, 1 H), 7.26 (dd, 1 H), 7.61 (m, 1 H), 8.20 (d, 1 H), 8.40 (m, 2 H). LC-MS (Method 18): R, 1, 90 min, MS (ESlpos.): M / z (%) = 424 (50) [M + H] +. Example 274A A / - (fer-Butoxycarbonyl) -3- (trimethylsilyl) -D-alanyl-3-pyridin-3-yl-L-alanine Compound 273A (7.4 g, 17.56 mmol) is taken up in THF / water (6 + 4), cooled to 0 ° C, and lithium hydroxide monohydrate (1.47 g, 35.13 mmol) is added. , 2 equivalents). The mixture is stirred at 0 ° C. After one hour, an additional equivalent (0.74 g) of lithium hydroxide monohydrate is added, and stirring is continued for one hour. Most of the THF is removed under vacuum, and the pH is then adjusted to 4 by adding citric acid. A solid precipitates. The mixture is extracted with three portions of ethyl acetate, the solid dissolving. The combined organic phrases are dry over sodium sulfate, filter and concentrate. The crude product is purified by chromatography on Sephadex LH 20 (Method 45). Yield: 6.67 g (93% of theory). HPLC / UV-Vis (Method 5): R, = 3.73 min. 1 H NMR (300 MHz, tVDMSO) d -0.09 (s, 9 H), 0.56 - 0.75 (m, 2 H), 1.35 (s, 9 H), 2.90 (dd, 1 H), 3.09 (dd, 1 H), 3.98 (m, 1 H), 4.41 (m, 1 H), 6.70 (d, 1 H), 7.26 (dd, 1 H), 7.60 (m, 1 H), 8.00 (d, 1 H), 8.37 (m, 2 H). LC-MS (Method 18): R, 1.71 min, MS (ESlpos.): M / z (%) = 410 (100) [M + H] +. Example 275A (3 /?) - 3 - [(ert-Butoxycarbonyl) amino] -L-phenylalanine The compound of Example 16A (3.00 g, 7.24 mmol) is dissolved in methanol (60 mL), palladium on activated charcoal 10% (50 mg) is added, and the mixture is stirred under a hydrogen atmosphere at room temperature. environment and under atmospheric pressure for 6 h. The mixture is then filtered to remove the catalyst and concentrated. The crude reaction product (2.20 g, recuant.) Is used in the next step without purification. HPLC (Method 6): R, = 3.21 min. LC-MS (Method 51): R, = 1.55 min, MS (ESlpos): m / z (%) = 281, 3 (30) [M + H] +, MS (ESlneg): m / z ( %) = 279.1 (100) [MH] \ [a] 20Na = -23.4 (c = 1.0, MeOH). 1 H-NMR (400 MHz, dg-DMSO) d (ppm) = 1.34 (s, 9H), 3.52 (d, J = 4.6 Hz, 1 H), 4.88 (dd, J = 4.6, J = 8.4 Hz, 1 H), 7.29 (m, 5H), 8.02 (d, J = 8.6 Hz, 1 H). HR-TOF-MS: C 14 H 21 N 2 O 4 calculated 281, 1496, found 281, 1503 [M + H] +.

Example 276A (P ^ - -Kfer-ButoxycarbonylJaminol-A / 2 ^ The compound of example 275A (2.2 g of crude product, 7.24 mmol) and (9H-fluoren-9-methoxy) carbonylsuccinyl amide (2.90 g, 8.58 mmol, 1, 2 equivalents), as well as sodium carbonate (1.18 g, 11.70 mmol, 1.5 equivalents) are dissolved in 1,4-dioxane-water (7 + 3) and stirred at room temperature overnight. The reaction is then stopped by adding 5% aqueous citric acid and extracted with two portions of ethyl acetate. The combined organic extracts are dried over sodium sulfate and concentrated, and the residue is triturated with water and acetonitrile. The crude crystalline product is then purified by chromatography according to method 34. Yield: 2.58 g (66% of theory) as a colorless solid. HPLC (Method 6): R= 4.86 min. LC-MS (Method 20): R, = 2.51 min, MS (ESlpos): m / z (%) = 503.2 (70) [M + H] \ MS (ESlneg): m / z (% ) = 501, 3 (100) [MH] ". 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 1.38 (s, 9H), 4.75 (dd, J = 3.9, J = 9.8 Hz, 1 H), 5.29 (dd, J = 3.9, J = 10.0 Hz 1 H), 7.21-7.60 (m, 13H), 7.87 (d , J = 7.4 Hz, 1 H) HR-TOF-MS: C29H31N206 calculated 503.2177, found 503.2158 [M + H] + Example 277A (SRJ-S-Kfer-butoxycarbonylJaminol-A ^ -tigH -fluoren-g-ilmetoxyJcarbonill-L-phenylalaninate pentafluorophenyl The compound of example 276A (2.58 g, 5.14 mmol) and pentafluorophenol (4.72 g, 25.68 mmol, 5 equivalents) are dissolved in dichloromethane (350 ml), and cooled to 0 ° C. EDCI (1.48 g, 7.70 mmol, 1.5 equivalents) is added, and the mixture is stirred for 6 h while heating slowly to room temperature. The solvent is then distilled off and the residue is purified in several portions by chromatography according to method 34. Yield: 2.80 g (81% of theory) of the title compound as a colorless solid. HPLC (Method 54) R, = 5.09 min. LC-MS (Method 19): R, = 3.34 min, MS (ESlpos): m z (%) = 6693.0 (20) [M + H] +. 1 H NMR (400 MHz, oVDMSO) d (ppm) = 1.39 (s, 9H), 4.11-4.26 (m, 3H), 5.16 (dd, J = 4.4, J = 9 , 5 Hz, 1 H), 5.52 (dd, J = 4.4, J = 10.0 Hz, 1 H), 7.27-7.57 (m, 9H), 7.56 (t, J = 6.6 Hz, 2H), 7.73 (d, J = 10.3 Hz, 1 H), 7.87 (d, J = 7.4 Hz, 2H), 7.93 (d, J = 9.6 Hz, 1 H). HR-TOF-MS: C35H3o 206 calculated 669.2019, found 669.1996 [M + H] +. Example 278A (3R) -3 - [(fer-butoxycarbonyl) amino] -A / ethyl 2- (diphenylmethylene) -L-leucinate The Mannich reaction is based on a method for the addition of copper enolates to sulfonylimines: L. Bernardi, A. Gothelf, R. G. Hazell, K.A. Jorgensen, J. Org. Chem. 2003, 68, 2583-2591. [(1 E) -phenylmethylene] carbamate fer-butyl can be prepared according to the literature: A. Klepacz, A. Zwierzak, Tetrahedron Lett. 2002 43; 1079-180. Freshly activated 3A molecular sieves, tetrakis (acetonitrile) copper (l) hexafluorophosphate (293 mg, 0.79 mmol, 0.035 equivalents) and (R) - (+) - 2- (2- ( diphenylphosphino) phenyl) -4-isopropyl-2-oxazoline (335 mg, 0.90 mmol, 0.04 equivalents) under argon and abs. THF is added. (228 mi). Triethylamine (109 μ ?, 80 mg, 0.79 mmol, 0.035 equivalent) is introduced via a pipette. The mixture is cooled to -20 ° C and, once this temperature is reached, A / - (diphenylmethylene) glycinate (6.00 g, 22.44 mmol) and ferric [(1 E) phenylmethylene] carbamate are added. butyl (6.92 g, 40.4 mmol, 1.8 equivalents). The mixture is stirred for 16 h, allowing it to slowly reach room temperature. Then silica gel (approximately 15 g) is added and the solvent is distilled off under vacuum. The residue is loaded onto a glass column filled with silica gel and eluted with cyclohexane-ethyl acetate 9 + 1. The title compound (Rf = 0.22, CyHex-EtOAc 9 + 1) contains the enantiomer with the D-threo configuration and a minor amount (approximately 36%) of the two enantiomers with erythro configurations, which is eliminated in one step later. The product is very sensitive to acids, and studies by HPLC (method 6) and LC-MS (method 19) always show a proportion of benzophenone illuminated under the conditions of chromatography. Yield: 2.66 g (27% of theory).

LC-MS (Method 19): R, = 3.23 min (21%, erythro), MS (ESIpos): m / z (%) = 439.4 (100) [M + H] + and 3.23 min (48%, threo), MS (ESIpos): m / z (%) = 439.3 (100) [M + H] +. 1 H NMR (400 MHz, drDMSO) d (ppm) = 0.62 (d, J = 6.6 Hz, 3 H), 0.83 (d, J = 6.6 Hz, 3 H), 1, 13 (t J = 7.1 Hz, 3H), 1.38 (s, 9H), 1.61 (m, 1 H), 3.74 (ddd,, = 2.7, J2 = J3 = 9.6 Hz , 1 H), 3.96 (d, J = 2.7 Hz, 1 H), 3.99-4.06 (m, 2H), 6.51 (á, J = 10.0 Hz, 1 H ), 7.07 (m, 2H), 7.38-7.52 (m, 6H), 7.67-7.77 (m, 2H). HR-TOF-MS: C26H35 204 calculated 439.2592, found 439.2606 [M + H] +. Example 279A Ethyl (3R) -3 - [(fer-butoxycarbonyl) amino] -L-leucinate trifluoroacetate The title compound of example 278A (4.44 g, 10, 12 mmol) is dissolved in dichloromethane (87 ml), 857 μ? of TFA (11.13 mmol, 1.1 equivalents) and water (273 [mu], 15.18 [mu], 1.5 equivalents), and the mixture is stirred at room temperature for 1 h. All the volatile components of the reaction mixture are distilled off under vacuum, and the residue (5.97 g) is used in the next step without purification. HPLC (Method 6): R, = 3.41 min. LC-MS (Method 19): R, = 1.31 min, MS (ESlpos): m / z (%) = 275.2 (50) [M + H] +. Example 280A (SR ^ / N ^ -benzyloxycarbonyl-S-tyrol-butoxycarbonylJaminoj-L-ethyl leucinate The compound of Example 279A (5.97 g of crude product, approximately 10.1 1 mmol) and benzyloxycarbonylsuccinimide (3.02 g, 12.13 mmol, 1.2 equivalents) are dissolved in dichloromethane-water (4 + 1). , and the mixture is cooled to 0 ° C. Under vigorous stirring, sodium bicarbonate (2.55 g, 30.33 mmol, 3 equivalents) and tetrabutylammonium iodide (373 mg, 1.01 mmol, 0.1 equivalent) are added, and the mixture is stirred vigorously at room temperature. environment for 16 h. The organic phase is separated, washed with conc. NaCl, dried over sodium sulfate and concentrated. The crude product is isolated in several portions according to method 34, eliminating the benzophenone and part of the erythro diastereomer. In total, 1.65 g (4.03 mmol, 40% of theory) of the title compound are obtained. R, = 0.076 (CyHex-EtOAc 9 + 1). HPLC (Method 54): R t = 4.33 min (erythro diastereomer) and 4.52 min (threo diastereomer). LC-MS (Method 19): R, = 2.71 min, MS (ESlpos): m / z (%) = 409.3 (30) [M + H] \ erythro isomer and R, = 2.75 min , MS (ESlpos): m / z (%) = 409.0 (70) [M + H] + threo isomer. 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 0.71-0.86 (m, 6H), 1.16 (t, J = 7.1 Hz, 3H), 1.34 (s, 9H), 1.59 (m, 1 H), 3.70 (ddd, J = 3.4, J1 = f = 10.3 Hz, 1 H), 3.99-4.08 (m, 2H), 4, 32 (dd, J = 3.4, J = 9.5 Hz, 1 H), 5.03 (d, J = 12.4 Hz, 1 H), 5.10 (d, J = 12.4 Hz, 1 H), 6.62 (d, J = 10, 5 Hz, 1 H), 7.31-7.40 (m, 5H), 7.44 (d, J = 9.3 Hz, 1 H). HR-TOF-MS: C2iH33N206 calculated 409.2334, found 409.2329 [M + H] +. Example 281A (3f?) - 3 - [(eer-Butoxycarbonyl) amino] - / / - (benzyloxy) carbonyl-L-leucine The title compound of example 280A (2.78 g, 6.82 mmol) is dissolved in a mixture of THF-water (1 +1, 40 ml) at 0 ° C, lithium hydroxide monohydrate (629 mg, 15.0 mmol, 2.2 equivalents), and the mixture is stirred at 0 ° C for 3 h. The THF is then separated by filtration, and the aqueous residue is acidified with 1 M citric acid and extracted with two portions of ethyl acetate. The combined organic extracts are dried over sodium sulfate and concentrated. The crude residue (2.42 g, 93% of theory) is separated by chromatography on a chiral phase according to method 55. In this case, the enantiomers of the threo diastereomer and those of the erythro minority diastereomer are obtained separately. The e.e. of the major isomer (title compound) after chiral chromatography is determined according to method 56 and is 100%. The yield of the title compound is 780 mg (30% of the theoretical yield based on the starting compound 280A). HPLC (Method 6): R, = 4.51 min. LC-MS (Method 19): R, = 2.44 min, MS (ESlpos): m / z (%) = 381, 1 (30) [M + H] \ MS (ESlneg): m / z (% ) = 379.2 (100) [MH] \ 1 H NMR (400 MHz, oV-DMSO) d (ppm) = 0.82 (d, J = 9.3 Hz, 3H), 0.85 (d, J) = 6.6 Hz, 3H), 1, 35 (s, 9H), 3.72 (ddd, J1 = 3.2, f = = 10.0 Hz, 1 H), 4.26 (dd, J = 3.2, J = 9.6 Hz, 1 H), 5.03 (d, J = 12.7 Hz, 1 H), 5.08 (d, J = 12.4 Hz, 1 H), 6 , 63 (d, J = 10.5 Hz, 1 H), 7.31-7.40 (m, 6H), 12.62 (br s, 1 H). HR-TOF-MS: C19H28N206Na calculated 403, 1845, found 403, 1832 [M + Na] +. Chiral HPLC (Method 56): R, = 8.97 min. EXAMPLE 282A (SRÍ-S-Kérer-butoxicarboni aminol-Zv ^ -benzenoxy-J-carbonylamino-L-leucinate pentafluorophenyl The compound of example 281A (100 mg, 263 pmol) and pentafluorophenol (242 mg, 1.31 mmol, 5 equivalents) are dissolved in dichloromethane (20 ml) at room temperature, then EDCI (76 mg, 394 pmol, 1 g) is added. , 5 equivalents), and the mixture is left to stand in a refrigerator for about 12 h. The solvent is then removed by distillation in vacuo, and the residue is purified by chromatography (method 32). The title compound is obtained in a yield of 132 mg (92% of theory) as a colorless solid. HPLC (Method 54): R, = 4.89 min. LC-MS (Method 19): R, = 3.19 min, MS (ESlpos): m / z (%) = 547.2 (40) [M + H] +. EXAMPLE 283A / ^ - (Benzene-butoxycarbonyl-J-S- ^ gH-fluoren-g-ylmethoxyJcarbonyljaminol-L-alanyl-L-serinate benzyl) The compound of example 149A (2.08 g, 6.73 mmol) and A / - (urea-butoxycarbonyl) -3-. { [(9H-fluoren-9-ylmethoxy) carbonyl] amino} -L-alanine (22.73 g, 6.39 mmol, 0.95 equivalents) are dissolved in DMF (32 mL) and cooled to 0 ° C. HATU (3.84 g, 10.09 mmol, 1.5 equivalents) and 4-methylmorpholine are added. (2.22 mL, 20.18 mmol, 3 equivalents). The mixture is then stirred at room temperature for 2.5 h. The complete mixture is then loaded onto a Sephadex LH20 column and subjected to chromatography according to method 45. The fractions containing product are combined and purified according to method 34. Yield: 2.41 g (59%) of theoretical yield) as a colorless solid. HPLC (Method 6): R, = 4.81 min. LC-MS (Method 51): R, = 3.94 min, MS (ESlpos): m / z (%) = 504.4 (100) [M-BOC + H +] \ 604.4 (40) [M + H] +. [] 20Na = +1.5 (c = 0.5, MeOH). H NMR (400 MHz, c / erDMSO) d (ppm) = 1.36 (s, 9H), 3.18 (m, 1 H), 3.66 (m, 1 H), 3.75 (m, 1 H), 4.15-4.28 (m, 4H), 4.42 (m, 1H), 5.90 (t, J = 5.6 Hz, 1 H), 5.20 (s, 2H ), 6.82 (d, J = 8.04 Hz, 1 H), 7.21 (m, 1 H), 7.31-7.43 (m, 10H), 7.67 (d, J = 7.8 Hz, 1 H), 7.89 (d, J = 7.6 Hz, 1 H), 8.14 (d, J = 7.6 Hz, 1 H). HR-TOF-MS: C33H38N308 calculated 604.2654, found 604.2646 [M + H] +. Example 284A 3-. { [(9H-fluoren-9-ylmethoxy) carbonyl] amino} -L-alanyl-L-serinate benzyl trifluoroacetate The compound of example 283A (2.39 g, 3.96 mmol) is reacted according to procedure 2. 2.96 g (quant.) Of the crude title compound are obtained and reacted without further purification. HPLC (Method 6): R, = 3.84 min.

LC-MS (Method 22): R, = 3, 14 min; MS (ESIpos) m / z (%) = 504.0 (100) [M + H] +. [a] 20Na = -0.5 (c = 1, 0, MeOH). HR-TOF-MS: C28H3oN306 calculated 504.2130, found 504.2140 [M + H] +. Example 285A [/ V- (io-butoxycarbonyl) glycyl] - [3-. { [(9H-fluoren-9-ylmethoxy) carbonl] amino} -L-Alanyl] -L-benzyl serinate The compound of example 284A (2.90 g, -83% purity, 3.89 mmol) and / V-fer-butoxycarbonylglycine (751 mg, 4.29 mmol, 1 equivalent) are dissolved in DMF (20 ml) and it is cooled to 0 ° C. HATU (2.22 g, 5.85 mmol, 1.5 equivalents) and 4-methylmorpholine (2.14 mL, 19.49 mmol, 5 equivalents) are added. The reaction mixture is stirred at 0 ° C for 2.5 h and the reaction is then stopped by adding an aqueous 5% citric acid solution and extracted with 5 portions of MTBE. The combined organic extracts are dried (sodium sulfate) and concentrated. The crude product is purified by chromatography (method 34). The fractions containing product are combined and lyophilized. Yield: 1.54 g (60% of theory) as a colorless solid. HPLC (Method 3) R, = 4.64 min. LC-MS (Method 19): R, = 2.65 min, MS (ESlpos): m / z (%) = 661, 2 (100) [M + H] +. [< x] 20Na = -8.7 (c = 0.5, MeOH). HR-TOF-MS: CagH ^ Og calculated 661, 2869, found 661, 2864 [M + H] +. Example 286A Glycyl Trifluoroacetate [3-. { [(9H-fluoren-9-ylmethoxy) carbonyl] amino} -L-alanyl] -L-benzyl serinate The title compound of example 285A (88 mg, 0.20 mmol) is reacted according to procedure 2. The crude product is reacted without further purification. Yield: 1.84 g (quant.) HPLC (Method 3): R, = 3.78 min. LC-MS (Method 19): R, = 1.74 min, MS (ESlpos): m / z (%) = 561, 2 (100) [M + H] +. H20Na = 0.0 (c = 1.0, MeOH). HR-TOF-MS: C30H33N4O7 calculated 561, 2344, found 561, 2343 [M + H] +. Example 287 Trifluoroacetate of [(SR ^ A ^ -ioer-butoxycarboni-S-hydroxy-L-leucyl-J-L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- [3- { [( 9H-Fluoren-9-ylmethoxy) carbonyl] amino.}. -L-alanyl] -L-benzyl serinate The compound of Example 32A (701 mg, 830 μ? T) and 286A (700 mg, 830 pmol, 1 equivalent) are dissolved in DMF (11.2 ml), and the solution is cooled to 0 ° C. Add 4-methylmorpholine (274 μ ?, 2.49 mmol, 3 equivalents) and HATU (473 mg, 1.25 mmol, 1.5 equivalents), and the mixture is stirred at 0 ° C for 3 h. The complete mixture is then placed on a Sephadex LH-20 column and subjected to chromatography according to method 45. Fractions containing product are combined, it is concentrated and purified according to method 34. Fractions containing product are combined and lyophilized. 643 mg (56% of theory) of the title compound are obtained as a colorless solid. HPLC (Method 6): R, = 4.27 min. LC-MS (Method 19): R, = 2.13 min, MS (ESlpos): m / z (%) = 1273.9 (30) [M + H] +, MS (ESlneg) m / z (% ) = 1317.9 (100) [M + HCOOT. HR-TOF-MS: calculated 1273.6826, found 1273.6851 [M + H] +. EXAMPLE 288A [(3R) -3-Hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-3-bistrifluoroacetate. { [(9H-fluoren-9-ylmethoxy) carbonyl] amino} -L-Alanyl] -L-benzyl serinate Compound 287A (643 mg, 463 pmol) is reacted according to procedure 2. The crude title compound is obtained in approximately quantitative yield (783 mg) and is subjected to reaction without purification. HPLC (Method 5): R, = 3.61 min. LC-MS (Method 51): R, = 2.53 min, MS (ESlpos): miz (%) = 588.1 (100) [M + 2H] 2+. HR-TOF-MS: C 58 H 85 N 12 O 4 calculated 1173.6306, found 1 173.6304 [M + H] +. Peptides bound to polymer EXAMPLE 289A A / - (fer.-butoxycarbonyl) -0-tert-butyl-L-threonyl-L-leucyl-N 5 - (imn { [(2,2,5,7,8-pentamethyl-3 , 4-d, 2H-chromen-6-yl) sulfonyl] amino} .methyl) -D-ornithyl-L-isoleucyl-0-yer-butyl-L-alotreonyl-glycine l-0-fer-buti seryl-O-ér-butyl-L-serine bound to polymer 34.00 g (50.66 mmol) of 2-chlorotrityl resin (Iris Biotech, No. CAS 42074-68-0, loading 1.49 mmol / g) are provided in 400 ml of dichloromethane, and 67.999 g are added ( 177.31 mmol) of O-fer.-butyl-W - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-serine and 65.476 g (506.60 mmol) of A / -ethyl-A-isopropylpropan- 2-amine (DIEA). The mixture is stirred at room temperature overnight. 5 ml of methanol are added, and the mixture is stirred at room temperature for 30 min. The solid is collected by suction filtration, washed three times with 400 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 400 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 400 ml of dimethylformamide, and 48.564 g (126.65 mmol) of 0-fer.-butyl-N - [(9H-fluoren-9-ylmethoxy) carbonyl] -L- are added. serine, 40.665 g (126.65 mmol) of A / - [(1 H-benzotriazol-1-yloxy) (dimethylamino) -methylene] - / V-methylmethanaminium (TBTU) tetrafluoroborate and 24.553 g (189.975 mmol) of A / -ethyl- / V-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 400 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 400 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 400 ml of dimethylformamide, and 37.665 g (126.65 mmol) of / V - [(9H-fluoren-9-ylmethoxy) carbonyl] -glycine, 40.665 g ( 126.65 mmol) of A / - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] - / methylmetanaminium (TBTU) tetrafluoroborate and 24.553 g (189.975 mmol) of W-ethyl-A / - Sopropypropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 400 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 400 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 400 ml of dimethylformamide, and 50.340 g (126.65 mmol) of O-ter are added. -butyl-A - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-allotreonine, 40.665 g (126.65 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene tetrafluoroborate ] -N-methylmetanaminium (TBTU) and 24.553 g (189.975 mmol) of A / -ethyl-A / -isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 400 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 400 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. 32 g (47.68 mmol) are provided; Assume: 1.49 mmol / g charge) of the resin obtained in this way in 400 ml of dimethylformamide, and 42.128 g (119.20 mmol) of / V - [(9H-fluoren-9-ylmethoxy) carbonyl are added. ] -L-isoleucine, 38.273 g (119.20 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmethanamnine (TBTU) tetrafluoroborate and 23.109 g (178.80 mmol) ) of Ne \\ - N-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. He The solid is collected by suction filtration, washed three times with 400 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. Since the coupling was incomplete (according to HPLC), 400 ml of dimethylformamide, 25.277 g (71.52 mmol) of A / - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-isoleucine, were added again, 22,964 g (71.52 mmol) of N - [(1 H-benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmethanamine (TBTU) tetrafluoroborate and 13.865 g (107.28 mmol) of W-ethyl- / V-isopropylpropan-2-amine (DIEA), and the mixture was stirred overnight. The solid is collected by suction filtration, washed three times with 400 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 400 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min, collected by suction filtration and dried under vacuum . 14 g (20.86 mmol, assumed: 1.49 mmol / g charge) of the resin obtained in this manner are supplied in 200 ml of dimethylformamide, and 34.566 g (52.15 mmol) of ^ - [( QH-fluoren-Q-ylmethoxy) carbonyl] - / vi- (imino { [(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino .) .meth ^ D-ornithine, 16.745 g (52.15 mmol) N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmetanaminium (TBTU) tetrafluoroborate and 13.48 g ( 104.30 mmol) of W-ethyl-W-isopropylpropan-2-amine (DIEA) The mixture is stirred at room temperature overnight The solid is collected by suction filtration, washed three times with 200 ml of dimethylformamide , methanol and dichloromethane and collected by suction filtration The solid is then treated twice consecutively with piperidine as follows: the resin is mixed with 200 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min. , it is collected by suction filtration and dried under vacuum. Na obtained in this way is supplied in 200 ml of dimethylformamide, and 18,431 g (52.15 mmol) of A / - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-leucine, 16.745 g (52, 15 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmetanaminium (TBTU) tetrafluoroborate and 13,480 g (104.30 mmol) of A-ethyl-A / -isopropylpropan- 2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 200 ml of dimethylformamide, methanol and dichloromethane and collected by filtration with suction. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 200 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min, collected by suction filtration and dried under vacuum . 2.0 g (2.98 mmol, assumed: 1.49 mmol / g charge) of the resin obtained in this manner are supplied in 20 ml of dimethylformamide, and 2.462 g (8.94 mmol) of A / are added. - (fer-butoxycarbonyl) -O-ter. -butyl-L-threonine, 2,870 g (8.94 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methyl-metanaminium (TBTU) tetrafluoroborate (2,34 g) (17,88 g) mmol) of N-ethyl-N-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 20 ml of dimethylformamide, methanol and dichloromethane and collected by filtration with suction. Example 290 A W - [(9H-Fluoren-9-ylmethoxy) carbonyl] glycyl-L-serine Treat 1 g (0.62 mmol) of a Wang resin (Merck Biosciences, loading: 0.62 mmol / g) previously loaded with 0-fer.-butyl-N - [(9H-fluoren-9-ylmethoxy) carbonyl. ] -L-serine two consecutive times with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this manner is supplied in 10 ml of dimethylformamide, and 369 mg (1 mg) is added., 24 mmol) of A / - [(9H-fluoren-9-ylmethoxy) carbonyl] glycine, 398 mg (1.24 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene tetrafluoroborate ] -N-methylmetanaminium (TBTU) and 240 mg (1.86 mmol) of N-ethyl-N-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. Add 20 ml of a solution of trifluoroacetic acid in dichloromethane 50% and let it act for 60 min.

The resin is removed by filtration on a fritted disk and the resin is washed three times with 10 ml of dichloromethane. The filtrate is concentrated and the desired compound is obtained as the crude product. LC-MS (Method: LC-MS (Method 19): R, = 2, 10 min, MS (ESlpos): m / z (%) =): 385.0 [M + H] +. Example 291 A [A / -er-butoxycarbonyl- (3R) -3-hydroxy-L-leucyl] - [3-fer-butyl-L-alanyl] - [N 5 - (imino { [(2, 2, 5,7, 8-pentame-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino] -methyl] -03-fer-butyl-L-serine bound to polymer Treat 1 g (0.62 mmol) of a Wang resin (Merck Biosciences, loading: 0.62 mmol / g) previously loaded with O-ter. -butyl-N - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-serine twice consecutively with piperidine as follows: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 477 mg (1.24 mmol) of the compound of example 290A, 398 mg (1.24 mmol) of N - [(1 H-benzotriazole tetrafluoroborate) are added. -1-yloxy) (dimethylamino) methylene] -N-methylmethanaminium (TBTU) and 320 mg (2.48 mmol) of N-ethyl-N-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 423 mg (1.24 mmol) of A / - [(9H-fluoren-9-ylmethoxy) carbonyl] -D-alotreonine, 399 mg (1 , 24 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylen] -N-methylmetanaminium (TBTU) tetrafluoroborate and 320 mg (2.48 mmol) of A-ethyl-v- isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 438 mg (1.24 mmol) of A / - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-isoleucine, 399 mg (1 mg) are added. , 24 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmethanamine (TBTU) tetrafluoroborate and 240 mg (1.86 mmol) of W-ethyl- / v-; sopropilpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 821 mg (1.24 mmol) of / V2 - [(9H-fluoren-9-ylmethoxy) carbonyl] -W5- (min. [(2,2,5J, 8-pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino] methyl) -D-ornithine, 399 mg (1.24 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmetanaminium (TBTU) tetrafluoroborate and 240 mg (1.86 mmol) of / v-ethyl-A / -isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide., it is stirred for 30 min and collected by suction filtration. 812 mg (0.503 mmol) of the resin thus obtained are supplied in 10 ml of dimethylformamide, and 370 mg (1.01 mmol) of A / - [(9H-fluoren-9-ylmethoxy) -carbonyl] - are added. 4-methyl-L-leucine, 323 mg (1.01 mmol) of A / - [(1 H-benzotriazol-1-yloxy) - (dimethylamino) methylene] - / V-methylmethanamine tetrafluoroborate (TBTU) ) and 195 mg (1.51 mmol) of A / -ethyl- / V-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 157 mg (0.633 mmol) of W- (fer-butoxycarbonyl) - (3 /?) - 3-hydroxy-L-leucine, 203 mg (0.633) are added. mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmetanaminium (TBTU) tetrafluoroborate and 196 mg (1.52 mmol) of / N / -ethyl- / V-isopropylpropan -2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. Example 292 A [/ V-Ier-butoxycarbonyl- (3R) -3-hydroxy-L-leucyl] - [3-trimethylsilyl-L-alanyl] - [N 5 - (i pentamethyl-3,4-dihydro-2 H -chromen -6-yl) sulfonyl] amino} methyl) -D-ornithyl] -L-isoleucyl- [0-ér-butyl-L-alotreonyl] -glycyl- [03-fer-butyl-L-seryl] -03-fer-butyl-L-serine bound to polymer 1 g of Wang resin (Rapp Polymer, loading: 1.28 mmol / g) in 10 ml of dimethylformamide is introduced. 982 mg (2.56 mmol) of 0-fer.-butyl-A / - [(9H-fluoren-9-ylmethoxy) carbo-nyl] -L-serine, 910 mg (2.56 mmol) of tetrafluoroborate are added. of N-. { [(6-chloro-1 H-benzotriazol-1-yl) oxy] (dimethylamino) methylene} - / v "-methylmetanaminium (TCTU) and 496 mg (3.84 mmol) of N-ethyl-A / -propylpropan-2-amine (DIEA) .The mixture is stirred at room temperature overnight. Collect by suction filtration, wash three times with 10 ml of dimethylformamide, methanol and dichloromethane and collect by filtration with suction.The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml. of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration.An additional coupling with 0-ene-butyl-N - [(9H-fluoren-9-ylmethoxy) carbonyl] -L -serine is carried out using the same quantity ratios and under the conditions described (see directly above paragraph.) The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 761 mg (2.56 mmol) are added. of N - [(9H-fluoren-9-ylmethoxy) carbonyl] glycine, 910 mg (2.56 mmol) of tetrafluoroborate from A / -. [(6-chloro-1 H-benzotriazol-1-yl) oxy] (dimethylamino) methylene} -A / -methylmetanaminium (TCTU) and 496 mg (3.84 mmol) of A / -ethyl- / V-isopropylpropan-2-amine (DIEA). The mixture is stirred at temperature environment for 5 hours. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 1.017 g (2.56 mmol) of 0-ér-butyl-N - [(9H-fluoren-9-ylmethoxy) carbonyl] -D are added. -alotreonine, 910 mg (2.56 mmol) of tetrafluoroborate of / V-. { [(6-chloro-1 H-benzotriazol-1-yl) oxy] (dimethylamino) methylene} -A / -methylmetanaminium (TCTU) and 496 mg (3.84 mmol) of -eti-l- / V-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 904 mg (2.56 mmol) of N - [(9H-fluoren-9-ylmethoxy) carbonyl] -L-isoleucine, 822 mg (2, 56 mmol) of? Tetrafluoroborate? -. { [(1 H-benzotriazol-1-yl) oxy] (dimethylamino) methylene} -A / -methylmetanaminium (TBTU) and 496 mg (3.84 mmol) of W-etl- / V-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 1, 697 g (2.56 mmol) of A / 2 - [(9H-fluoren-9-ylmethoxy) carbonyl] -A / 5- ( imino { [(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-chromen-6-yl) sulfonyl] amino.} methyl) -D-ornithine, 822 mg (2, 56 mmol) of N - [(1 H -benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmetanaminium (TBTU) tetrafluoroborate and 662 mg (5.12 mmol) of W-ethyl- / V-isopropylpropan- 2-amine (DIEA). The mixture is stirred at room temperature during night. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by suction filtration. The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 982 mg (2.56 mmol) of N - [(9H-fluoren-9-ylmethoxy) carbonyl] -3- (trimethylsilyl) -L-alanine are added. , 822 mg (2.56 mmol) of? / - [(1 H-benzotriazol-1-yloxy (dimethylamino) -methylene] -methylmetanaminium (TBTU) tetrafluoroborate and 662 mg (5.12 mmol) of W- ethyl- / V-isopropylpropan-2-amino (DIEA) The mixture is stirred at room temperature overnight The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and it is collected by suction filtration The solid is then treated twice consecutively with piperidine in the following manner: the resin is mixed with 10 ml of a solution of piperidine in 20% dimethylformamide, stirred for 30 min and collected by filtration with suction The resin obtained in this way is supplied in 10 ml of dimethylformamide, and 261 mg (0.705 mmol) of threo V- (fer-butoxycarbonyl) - (3R) -3-hydroxy-L- are added. leucine, 339 mg (1.057 mmol) of N - [(1 H-benzotriazol-1-yloxy) (dimethylamino) methylene] -N-methylmetanaminium (TBTU) tetrafluoroborate and 273 mg (2,114 mmol) of W-ethyl- N-isopropylpropan-2-amine (DIEA). The mixture is stirred at room temperature overnight. The solid is collected by suction filtration, washed three times with 10 ml of dimethylformamide, methanol and dichloromethane and collected by suction filtration. Compounds 293A-458A listed in the following tables were prepared according to the indicated procedures from the indicated starting materials.

Prepared according to the procedure [A / -fe -butoxycarbonyl- (3?) - 3-hydroxy-L-leucyl] -L-step 8 from 1.75 g of isoleucyl- [A / 5- (im. no. {[[(2,2,5J, 8-pentamethyl-3,4- 2-chlorotrityl chloride loaded with dihydro-2H-chromen-6-yl) sulfonyl] amino.} methyl ) -D- 0.85 mmol of 03-fer-butyl- / V - [(9H-ornithyl) -L-isoleucyl-L-alotreonyl-glycyl- [03-fer-butyl-L-fluoren-9-ylmethoxy] carbonyl] -L-serine by seryl] -03-fer-butyl-L-serine bound to gram polymer 305A Prepared according to the procedure [W-fer-butoxycarbonyl- (3R) -3-hydroxy-L-leucyl] -L-step 8 from 1.75 g of leucyl-f / ^ -benzyloxycarbonyl-D-ornithi-L-isoleucyl- resin L- 2-chlorotrityl chloride loaded with alotreonyl-glycyl- [03-fer-butyl-L-seryl] -03-fer-butyl-L- 0.85 mmol of 03-fer-butyl-W - [(9H- polymer-bound serine fl uoren-9-ylmethoxy) ca rboni l] -L-seri na per gram Prepared according to the procedure [A / -er-butoxycarbonyl- (3R) -3-hydroxy-L-leucyl] -L-step 8 from 1.75 g of leucyl resin - [(2R) -2-amino-4- 2-chlorotrityl chloride loaded with benzyloxycarbonylaminobutyryl] -L-isoleucyl-L- 0.85 mmol of 03-ér-butyl-W - [(9H-alotreonyl-glycyl- [03-fer-butyl-L- seryl] -03-tert-butyl-fluoren-9-ylmethoxy) carbonyl] -L-serine by serine bound to gram polymer 308A Prepared in accordance with the procedure [A -fero-butoxycarbonyl- (3R) -3-hydroxy-L-leucyl] -L-step 8 from 1.75 g of leucyl-fA ^ -benzyloxycarbonyl-L-lysyl-L-isoleucyl-L resin - 2-chlorotrityl chloride loaded with alotreonyl-glycyl- [03-fer-butyl-L-seyyl] -03-fer-butyl-L- 0.85 mmol of 03-fer-butyl-N - [(9H-serine polymer bound fluoren-9-ylmethoxy) carbonyl] -L-serine per gram unprotected ctapeptides [(3R) -3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 2.70 min; LC-leucyl-D-arginyl-L-valyl-L-alotreonyl-glycyl-L-seryl-L-MS (Method 22): R, = 2.05 min, MS serine (ESlpos): m / z (%) = 425 (100) [M + 2H] 2+, MS (ESlneg) m / z (%) = 846 1.01 g from the compound of Example 294A (100) [M-H] "; HR-TOF-MS: according to procedure 9 CasHee O ^ calculated 848.4837, found 848.4810 [M + Hf. [(3R) -3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 2.84 min; LC-leucyl-D-arginyl-L-leucyl-L-alotreonyl-glycyl-L-seryl-L-MS (Method 22): R, = 2.20 min, MS serine (ESlpos): m / z (%) = 432 (100) [M + 2H] 2+, MS (Sleng): m / z (%) = 861 1.11 g (40% purity) from compound (5) [M-H] '; HR-TOF-MS: CaeHeeNnO ^ of Example 295A according to calculated 862.4993, found procedure 9 862.4977 [M + Hf. [(3?) - 3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 3.13 min; LC-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(2S) -MS (Method 19): R, = 1.26 min, MS 2-amino-4-benzyloxycarbonylamino] butyryl] -L-serine (ESlpos): m / z (%) = 505 (100) 980 mg (67% purity) from the compound [M + 2H] 2+, MS (ESlneg): m / z (%) = from example 299A according to 1007.8 (100) [MH] "; HR-TOF-MS: procedure 9, purification according to calculated C45H77N12014 1009.5677, method 45 found 1009.5704 [M + H] +. [(3?) - 3-Hydroxy-L-leucyl] -L-norvalyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-HPLC bistrifluoroacetate (Method 6): R, = 2.69 min; LC- seryl-L-serine MS (Method 22): R, = 2.03 min, MS 1320 mg (35% purity) from the compound (ESlpos): m / z (%) = 848.5 (60) [M + H] \ of Example 300A according to MS (ESlneg): m / z (%) = 846.5 (100) [M-procedure 9, purification according to H] \ method 45 A [(3f?) - 3-Hydroxy-L-leucyl] -L-valyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-seryl-L-HPLC bistrifluoroacetate (Method 6): R, = 2.74 min; LC-serine MS (Method 22): R, = 2.01 min, MS 843 mg (50% purity) from the compound (ESlpos): m / z (%) = 424.8 (100) of Example 301 A according to [M + 2H] 2+, MS (ESlneg): m / z (%) = procedure 9, purification according to 846.4 (100) [MH] "method 45 A [(3R) -3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 2.81 min; LC-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-D-seryl-L-MS (Method 22): R, = 2.19 min, MS seryl-L-serine (ESlpos): m / z ( %) = 447 (100) 900 mg (33% purity) from the compound [M + 2H] 2+, 892 (50) [M + H] +, MS of Example 302A according to (ESlneg): m / z (%) = 890 (100) [MH] -; procedure 9, purification according to the HR-TOF-MS: calculated method 45 892.5099, found 892.5120 [M + H] +. [(3R) -3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 3.03 min; LC-leucyl-D-arginyl-L-isoleucyl-L-leucyl-glycyl-L-seryl-L-MS (Method 19): R, = 1.17 min, MS serine (ESlpos): m / z (%) = 438.0 (100) 680 mg (36% purity) from the compound [M + 2H] 2+, MS (ESlneg): m / z (%) = of example 306A according to 954.5 (100) [MH] "; HR-TOF-MS: procedure 9, purification according to calculated C38H72Nii012 874.5357, method 45 found 874.5373 [M + H] +. [(3 /?) - 3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 3.43 min; LC-leucyl - [(2R) -2-amino-4-MS (Method 19): R, = 1.64 min, MS benzyloxycarbonylaminobutyryl] -L-isoleucyl-L- (ESlpos): m / z (% ) = 940.5 (100) alotreonyl-glycyl-L-seryl-L-serine [M + H] +, MS (ESlneg): m / z (%) = 938.6 1120 mg (64% purity) from compound (100) [MH] "; HR-TOF-MS: C42H70N9O15 from example 307A according to calculated 940.4986, found procedure 9, purification according to 940, 4999 [M + H] \ method 45 [(3R) -3-Hydroxy-L-leucyl] -L-HPLC bistrifluoroacetate (Method 6): R, = 2.73 min; LC- norvall-D-arginyl-lsoyl-L-alotreonyl-glycol-MS (Method 22): R, = 2.04 min, MS alanyl-L-serine (ESlpos): mz (%) = 417 (100) 1, 21 g (41% purity) from compound [M + 2H] 2+, MS (ESlneg): m / z (%) = from Example 311 A according to 830.4 ( 100) [MH] "; HR-TOF-MS: procedure 9, purification according to calculated C35H66Nii012 832.4887, method 45 found 832.4899 [M + H] +. Protected nonapeptides Yield: 1008 mg (83% purity, calculated 1125.5899, found -quantitative) as a colorless solid from 1125.5891 [M + H] +. 647 mg of the compound of example 312A and compound of example 17A according to procedure 10, purification according to method 45 and method 44 * TFA 336A [(SR ^ / V ^ Benzyloxycarbonyl) -L- (tert-butoxycarbonyl) amino] -L-phenylalanyl] -L-threonyl-L-leucyl-D-arginyl-l-isoleucyl- L-Alotreonyl-glycyl-L-HPLC (Method 6): R, = 3.71 min; LC-seryl-L-serine MS (Method 19): R, = 1.89 min, MS Yield: 21 mg (64% yield (ESlpos): m / z (%) = 1230 (30) [M + H] +, theoretical) from the compound of Example 313A MS (ESlneg): m / z (% ) = 1228.7 (100) (26 mg, 24 pmol) and 17A according to the [M-H] procedure 10, purification according to method 45.

Yield: 49 mg (43% yield (90) [? -? G; HR-TOF-MS: theoretical C58H92N13018) from the compound of Example 318A calculated 1258.6678, found (90 mg, 83 μ ??) and 17A according to 1258.6677 [M + H] +. procedure 10, purification according to method 44 [(SRJ-A ^ -Benzyloxycarbonyl-J-S-. {((fer-butoxycarbonyl) amino]} -L-phenylalanyl] - [(3R) -3-HPLC trifluoroacetate (Method 6): R, = 3.89 min; LC-hydroxy-L-leucyl] -L-leucyl-D-arginyl- [3-trimethylsilyl-L-MS (Method 19): R, = 2.06 min, MS alanyl] -L-alotreonyl-glycyl- L-seryl-L-serine (ESlpos): m / z (%) = 1288.7 (40) Yield: 42 mg (33% yield [M + H] +, MS (ESlneg): m / z (%) = 1286.7 theory) from the compound of example 319A (100) [MH] "; TOF-MS: (90 mg, 80 μ? T ???) and 17A according to the C58H94N13018 Si calculated 1288.6604, procedure 10, purification according to the found 1288.6587 [M + H] +. Method 44 3 [(SRJ-A ^ Benzyloxycarbonyl-S-. {((fer-butoxycarbonyl) amino]} -L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D trifluoroacetate -arginyl-L-phenylalanyl-HPLC (Method 6): R, = 3.80 min; LC-allotreonyl-glycyl-L-seryl-L-serine MS (Method 19): Rt = 1.97 min, MS Yield: 55 mg (49% yield (ESlpos): m / z {%) = 1292.7 (30) theory) from the compound of Example 321 A [M + H] \ MS (ESlneg): m / z (%) = 1290.7 (90 mg, 80 pmol) and 17A according to the (80) [M-H] procedure 10, purification according to method 44 trifluoroacetate ylmethoxy) carbonyl] -3 - [(fer-butoxycarbonyl) amino] -L-HPLC (Method 6): R, = 4.20 min; LC-phenylalanil} - [(3 /?) - 3-hydroxy-L-leucyl] -L-leucyl-D-MS (Method 19): R, = 2.28 min, MS arginyl-L-isoleucyl-L-alotreonyl-glycyl- [(2S) -2-amino- (ESlpos): m / z (%) = 1494.7 (20) 4-benzyloxycarbonylaminobutyryl] -L-serine [M + H] +, MS (ESlneg): nVz (%) = 1493.1 Yield: 57 mg (27% yield (50) [M-H] "; HR-TOF-MS: theoretical C74H105N14O19) from the compound of Example 322A calculated 1493.7675, found (100 mg, 81 pmol) and 277A according to 1493,7666 [M + H] +. procedure 10, purification according to method 44 Yield: 44 mg (24% yield (100) [MH] te) from the compound of example 326A (200 mg, 132 μ ??) and 17A according to procedure 10, purification according to method 44.

[(SRJ-A ^ -Benzyloxycarbonyl-J-S-. {((fer-butoxycarbonyl) amino]} -L-phenylalanyl] - [(3R) -3-HPLC trifluoroacetate (Method 6): R, = 3.79 min; LC-hydroxy-L-leucyl] -L-isoleucyl-D-arginyl-L-isoleucyl-L-MS (Method 51): R, = 2.98 min, MS alotreonyl-glycyl-L-seryl-L- serine (ESlpos): m / z (%) = 1258.9 (10) Yield: 39 mg (18% yield [M + Hf, MS (ESlneg): m / z (%) = 1257.3 theory) from the compound of Example 327A (5) [MH] "; HR-TOF- MS: ??, ??? ^? ^ (175 mg, 161 μ ??) and 17A according to the calculated 1258.6678, found procedure 10, purification according to 1258.6698 [M + H] +. method 32.

[(SRJ-W ^ -Benzyloxycarbonyl-S-. {((fer-butoxycarbonyl) amino]} -L-phenylalanyl] - [(3R) -3-HPLC trifluoroacetate (Method 6): R, = 3.89 min; LC- hydroxy-L-leucyl] -L-leucylD-arginyl-L-isoleucyl-L-MS (Method 19): Rt = 2.08 min, MS leucyl-glycyl-L-seryl-L- serine (ESlpos): m / z (%) = 1270.8 (100) Yield: 14 mg (14% yield [M + H] +, MS (ESlneg): m / z (%) = 1268.8 theory) from the compound of example 329A (100) [MH] "; TOF-MS: (130 mg, 71 pmol) and 17A according to the calculated 1270.7042, method 10, purification according to the found 1270.7047 [M + H] +. method 32. trifluoroacetate. { (SRJ-A ^ -IÍQH-Fluoren-Q-ylmethoxy) carbonyl] -3 - [(fer-butoxycarbonyl) amino] -L-HPLC (Method 6): R, = 4.71 min; LC-phenylalanil} - [(3R) -3-hydroxy-L-leucyl] -L-leucyl - [(2f?) - MS (Method 19): R, = 3.23 min, MS 2-amino-4-benzyloxycarbonylaminobutyryl] -L - (ESlpos): m / z (%) = 1425.5 (100) isoleucyl-L-alotreonyl-glycyl-L-seryl-L-serine [M + H] \ MS (ESlneg): m / z (%) = 1422.8 Yield: 106 mg (60% purity, 31% of (100) [MH] '; HR-TOF-MS: theoretical yield) from the C71 compound H98NHO20 calculated 1424.6985, example 330A (150 mg, 142 pmol ) and 277A of found 1424.6980 [M + H] +. according to procedure 10, purification according to method 34. 7 Nonapeptides partially deprotected [(3R) -N2- (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucylD-arginyl-L-isoleucyl bistrifluoroacetate l-HPLC (Method 6): R, = 3.60 min; LC-alotreonyl-glycil - [(2S) -2-amino-3- (9H-fluoren-9-MS (Method 51): R, = 2.72 min, MS ilmethoxycarbonyl) aminobutyryl ] -L-serine (ESlpos): mfr (%) = 691, 2 (100) Yield: 1110 mg (-quantitative) as a [M + 2H] 2+; HR-TOF-MS: colorless solid from 1070 mg of calculated 1379.6995, found composed of example 335A according to 1379.6998 [M + H] +. procedure 2, crude product subjected to reaction without purification. * 2 TFA bistrifluoroacetate of [(3R) -N2-HPLC (Method 6): R, = 3.11 min; LC- (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] -L-threonyl-MS (Method 20): R, = 1.13 min, MS L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl- glycyl-L- (ESlpos): m / z (%) = 566.0 (100) seryl-L-serine [M + 2H] 2+; MS (ESlneg) m / z (%) = 5 [(3R) - - (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-HPLC bistrifluoroacetate (Method 6): R, = 3.22 min; LC-hydroxyl-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-seryl-MS (Method 19): R, = 1.35 min, MS glycyl-L -seril-L-serine (ESlpos): m / z (%) = 573.0 (100) Yield: 48 mg (94% purity, -quant.) [M + 2H] 2+, MS (ESlneg): m / z (%) = as a colorless solid from 42 mg of 1142.8 (100) [MH] "; HR-TOF-MS: compound of example 339A according to C52H82Ni3016 calculated 1 144.5997, procedure 2, crude product subjected to found 1144.5963 [M + H] + reaction without purification. [(3R) -N2-HPLC bistrifluoroacetate (Method 6): R, = 3.17 min; LC- (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D MS (Method 19): R, = 1.30 min, MS - arginyl-L-valyl-L- (ESlpos): m / z (%) = 573, 1 (100) alotreonyl-glycyl-L-seryl-L-serine [M + 2H] 2+, 1 144.6 (10) ) [M + H] \ MS Yield: 54 mg (70% purity, -quantity) (ESlneg): m / z (%) = 1142.8 (100) [MH] as a colorless solid from 48 mg of the "; HR-TOF- MS: C52H82N13016 calculated as compound of Example 340A according to 1 144.5997, found 1 144.5988 procedure 2, crude product subjected to [M + H] + reaction without purification. bistrifluoroacetate. { (3R) -A / * - [(9H-Fluoren-9-ylmethoxy) carbonyl] -3-amino-L-phenylalanyl} - [(3R) -3- HPLC (Method 6): R, = 3.63 min; LC-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-tert-L-MS (Method 19): R, = 1.76 min, MS alotreonyl-glycyl - [(2S) -2 -am-no-4- (ESlpos): m / z (%) = 679.5 (100) benzyloxycarbonylaminobutyryl] -L-serine [M + 2H] 2+, MS (ESlneg): m / z (% ) = Yield: 87 mg (-quant.) As a solid 1391, 7 (100) [M-H] '; HR-TOF-MS: colorless from 72 mg of the compound of C69H calculated 1393.7, Example 345A according to the procedure 97N14017 151, found 1393.7189 [M + H] +. 2, crude product subjected to reaction without purification. [(3 /?) - / ^ - (Benzyloxycarbonyl) -3-amino-L-leucyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl bistrifluoroacetate -L-: R, = 3.18 min; LC- alotreonyl-glycyl - [(3f?) - 3-hydroxy-L HPLC (Method 6) -asparaginyl] -L-MS (Method 19): R, = 1.30 min, MS serine (ESlpos): m / z (%) = 584.6 (100) Yield: 399 mg (96% purity, -quantum) [M + 2H] 2+, MS (Sleng): m / z (%) = as a colorless solid from 311 mg of 1165.7 (100) [MH] ". Compound of Example 346A according to procedure 2, crude product subjected to reaction without purification.

Yield: 67 mg (-quantum) as a solid (ESlneg): mz (%) = 1142.8 (100) [MH] colorless from 61 mg of the compound of the "HR-TOF-MS: C52H82N13016 calculated example 348A according to procedure 1144.5997, found 1144.5995 2, crude product subjected to reaction without [M + H] + purification. bistrifluoroacetate of [(3 /?) - / ^ - A (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L- isoleucyl-L-alotreonyl-D-seryl-L-seryl-L-serine Yield: 89 mg (-quantum) as a solid HPLC (Method 6): R, = 3.64 min. colorless from 73 mg of the compound of Example 349A according to procedure 2, crude product subjected to reaction without purification.

Yield: 39 mg (96% yield 1156.7 (100) [MH] ~; HR-TOF-MS: theoretical) as a colorless solid from 391 C53H84Ni3016 calculated 1158.6154, mg of the compound of Example 351 A of agreement found 1158.6184 [M + Hf. with procedure 2, crude product subjected to reaction without purification. bistrifluoroacetate. { (SRJ-A ^ - H-Fluoren-g-ylmethoxy) carbonyl] -3-amino-L-phenylalanyl} - [(3R) -3- HPLC (Method 6): R, = 3.95 min; LC-hydroxy-L-leucyl] -L-leucyl- (A 5-benzyloxycarbonyl-D-MS (Method 19): Rt = 2.15 min, MS ornithyl) -L-isoleucyl-L-alotreonyl-glycyl-L- seryl-L-serine (ESlpos): mz (%) = 1338.7 (100) Yield: 123 mg (~ quant.) As a solid [M + Hf, MS (ESlneg): m / z (%) = 1336.7 colorless from 103 mg of the compound of (100) [M-H] '; HR-TOF-MS: Example 352A according to the procedure C67H92N110 calculated 1338.6617.2, crude product subjected to reaction without finding 1338.6619 [M + Hf. purification. bistrifluoroacetate. { (3 /?) - W2 - [(9H-Fluoren-9-ylmethoxy) carbonyl] -3-amino-L-phenylalanyl} - [(3?) - 3-hydroxy-L-leucyl] -L-leucyl - [(2f?) - 2-amino-4-HPLC (Method 6): R, = 3.92 min; LC-benzyloxycarbonylaminobutyryl] -L-isoleucyl-L-MS (Method 19): R, = 2.14 min, MS alotreonyl-glycyl-L-seryl-L-serine (ESlpos): m / z (%) = 1324, 6 (100) Yield: 131 mg (58% purity, 70% of [M + H] +, MS (ESlneg): m / z (%) = 1322.7 theoretical yield) as a colorless solid a (100) [MH] " HR-TOF-MS: from 106 mg of the compound of the example CeeHgoN O ^ calculated 1324.6460, 354A according to procedure 2, found 1324.6471 [M + H] + crude product subjected to reaction without purification. bistrifluoroacetate ilmethoxy) carbonyl] -3-amino-L-phenylalanyl} - [(3?) - 3- HPLC (Method 6): R, = 3.97 min; LC- hydroxy-L-leucylJ-L-leuci A ^ -benzyloxycarbonyl-D-MS (Method 19): R, = 2.18 min, MS lysyl) -L-isoleucyl-L-alotreonyl-glycyl-L-seryl- L-serine (ESlpos): m / z (%) = 1352.7 (100) Yield: 48 mg (90% yield [M + H] \ MS (ESlneg): mz (%) = 1351, 7 theory) as a colorless solid from 49 mg (100) [MH] "; HR-TOF -MS: of the compound of example 355A according to C68H94 11018 calculated 1352.6773, procedure 2, crude product subjected to found 1352.6771 [M + H] + reaction without purification.

Cycling Structure No. Name Analysis Performance, Method of synthesis 'TFA 383A C1 g N 'trifluoroacetate-[(3 /?) - / ^ - (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3f?) - 3-hydroxy-L-leucyl] -L-leucyl lactam -D-arginyl-L-isoleucyl-L-HPLC (Method 6): R, = 4.07 min; LC- alotreonyl-glycyl - [(2S) -2-amino-3- (9H-fluoren-9-MS (Method 19): R, = 2.02 min, MS -methoxycarbonyl) aminobutyryl] -L-serine (ESlpos) : m / z (%) = 681, 6 (100) Yield: 590 mg (67% yield [M + 2H] 2 *; HR-TOF-MS: theoretical C68H93N14016) from the compound of example 359A calculated 1361, 6889, found (1110 mg, 700 μ ??) in accordance with 1361, 6866 [M + H] +. procedure 11, purification according to method 45 and then method 34.

C1"-? / 3 'trifluoroacetate-lactam of. {(Sf?) - / ^ 2- [(9H-Fluoren-9-methylmethoxy) carbonyl] -3-amino-L-HPLC (Method 6) : Rt = 4.44 min; LC-phenylalanyl KSRVS-hydroxy-L-leucyl-L-leucyl-IW6-MS (Method 19): R, = 2.64 min, MS benzylcarbonyl-D-lysyl) -L-isoleucyl-L-allotreonyl- (ESlpos): m / z (%) = 1335.6 (100) glycyl-L-seryl-L-serine [M + H] +, MS (ESlneg): m / z (%) = 1333.6 Yield: 46 mg (64% purity, 78% of (80) [MH] "; HR-TOF-MS: ??? ^? ^ Theoretical yield) from the compound of calculated 1334.6668, found example 379A ( 48 mg, 26 μp) according to 1334.6653 [M + H] +, procedure 11, purification according to method 45.

C1- N3 'trifluoroacetate-[(3R) -l ^ - (Benzyloxycarbonyl) -3-amino-L-phenylalanyl] - [(3R) -3-HPLC) (Method 6): R, = 3.61 min; LC-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-MS (Method 19): R, = 1.62 min, MS alotreonyl-glycyl-glycyl-L-serine (ESlpos) : miz (%) = 11 0.8 (60) Yield: 160 mg (25% purity, 38% of [M + H] \ MS (ESlneg): m / z (%) = 1 108.8 theoretical yield) from the compound of (100) [MH] '; HR-TOF-MS: Example 380A (167 mg, 86 μ? T ??) according to calculated 11 10.5943, procedure 11, purification according to found 1110.5898 [M + H] +. Method 45 Yield: 107 mg (quant.) From (100) [MH] "; HR-TOF-MS: compound of Example 382A (103 mg, 76 pmol) CsaHeoN ^ Ou calculated 1 1 10.5943, in accordance with procedure 1 1, purification found 1 1 10.5936 [M + H] +, according to method 45.

H, C * 2 TFA CH, 414A C1 9-N3 bistrifluoroacetate 1-lactam of [(3R)-HPLC (Method 6): R, = 3.10 min; LC-3-Amino-L-phenylalanyl] - [(3 /?) - 3-hydroxy-L-leucyl] -L-MS (Method 19): R, = 1.13 min, MS leucyl-D-arginyl- [3-trimethylsilyl-L-alanyl] -L-allotreonyl- (ESlpos): m / z (%) = 519.1 (100) glycyl-L-seryl-L-serine [M + 2H] 2+, 1036, 7 (10) [M + H] +, MS Yield: 74 mg of crude product from (Sleng): m / z (%) = 1034.6 (100) [MH] of the compound of Example 390A (55 mg, 60% "; HR-TOF-MS: C45H78N13013Si purity, 26 pmol) according to the calculated 1036.5606, found procedure 4 as an amorphous powder 1036.5604 [M + Hf yellowish.

H3C * TFA CH, HN ^ NH NH, 415A C1 9-N3 1-lactam bischlorohydrate. { (3R) -3- HPLC (Method 6): R, = 3.32 min, LC-Amino-L-phenylalanyl} - [(3?) - 3-hydroxy-L-leucyl] -L-MS (Method 19): R, = 1.36 min, MS leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-W5 - (ESlpos): m / z (%) = 584.5 (100) benzyloxycarbonyl-L-ornithyl-L-serine [M + 2H] 2+, 1 167.7 (10) [M + H] +, MS Yield: 39 mg (70% purity, 76% of the (ESlneg): m / z (%) = 1165.7 (100) [MH] theoretical yield) from the compound of "; HR-TOF-MS: calculated example 391 A (42 mg, 28 μ ????) according to 1 167.6521, found 1 167.6541 procedure 12, purification according to [M + H] *. Method 45 C1-N3 bistrifluoroacetate-[(3 /?) - HPLC lactam (Method 6): R, = 3.00 min; LC-3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-MS (Method 22): Rt = 2.29 min, MS leucyl-D-arginyl-L-isoleucyl -L-Alotreonyl-glycyl-glycyl-L- (ESlpos): m / z (%) = 489 (100) serine [M + 2H] 2+, MS (ESlneg): m / z (%) = 975 Yield: 160 mg (97% yield (100) [MH] "; HR-TOF-MS: theoretical) from the compound of Example 404A C44H74N13012 calculated 976.5575, (167 mg, 136 pmol) according to the found 976.5537 [M + H] +, procedure 4 as an amorphous solid.

C1-9-N3 bistrifluoroacetate 1-lactam of [(3R) -3-Amino-L-phenylalanyl] - [(3f?) - 3-hydroxy-L-leucyl] -L-HPLC (Method 6): R, = 3.02 min; LC-norleucyl-D-arginyl) -L-isoleucyl-L-alotreonyl-glycil-L-MS (Method 19): R, = 1.04 min, MS alanyl-L-serine (ESlpos): m / z (%) = 990.6 (100) Yield: 77 mg (55% purity, 56% of [M + H] +, MS (ESlneg): m / z (%) = 988.6 theoretical yield) from the compound of (100) [MH] *; HR-TOF-MS: Example 405A (74 mg, 60 pmol) according to C45H76N13012 calculated 990.5731, procedure 4, purification according to found 990.5715 [M + H] +. Method 45 * 2 TFA 430A [(3R) -CHLC-C-9-N3-lactam bistrifluoroacetate (Method 6): Rt = 2.96 min; LC-3-Amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-MS (Method 22): R, = 2.21 min, MS nonalil-D-arginyl-L -isoleucyl-L-alotreonyl-glycyl-L- (ESlpos): nVz (%) = 976.5 (80) [M + H] +, alanyl-L-serine MS (ESlneg): m / z (%) = 975.5 (100) [M- Yield: 111 mg (quant.) From H] "; HR-TOF-MS: C ^ H ^ N ^ O ^ compound of Example 406A (107 mg, 87 μ? ??) calculated 976.5575, found in accordance with procedure 4, purification 976.5552 [M + H] +. according to method 45. N-terminal dipeptide fragment binding Example Structure Name or No. Performance Analysis, Synthesis method CH, * TFA HNL ^ NH 431A C1-N3 3-lactam trifluoroacetate of [/ 2- (eer.-Butoxycarbonyl) -3-fer-butyl-D-alanyl] - [3-ert-butyl-L-alanyl] - [(3R) - 3-amino-L-phenylalanyl] - [(3 R) -HPLC (Method 6): R, = 4.89 min; LC-3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-MS (Method 19): R, = 2.46 min, MS alotreonyl-glycyl - [(2S) -2 -amino-3- (9H-fluoren-9- (ESlpos): m / z (%) = 1582.8 (100) ylmethoxycarbonyl) aminobutyryl] -L-serine [M + H] +; HR-TOF-MS: C79H121 16018 Yield: 310 mg (78% of calculated yield 1581, 9040, found theoretically) from the compound of example 1581, 9067 [M + H] +. 407A (343 mg, 236 μm) and compound of Example 8A according to procedure 13. 4 Yield: 33 mg (75% purity, 89% of CesH zN ^ O ^ calculated 1358.8406, theoretical yield) from the compound of found 358.8383 [M + H] +. Example 422A (22 mg, 20 pmol) and compound of Example 8A according to procedure 13. 450A C1-N3 3-lactam hydrochloride of [/ ^ - (fer.-butoxycarbonyl) -3-fer-butyl-D-alanyl] - [3-fer-butyl-L-HPLC (Method 6): R, = 4.30 min; LC-alanyl] - [(3f?) - 3-amino-L-phenylalanyl] - [(3R) -3-MS (Method 19): R, = 2.14 min, MS hydroxy-L-leucyl] -L -isoleucyl-D-arginyl-L-isoleucyl-L- (ESlpos): m / z (%) = 1360.8 (50), MS alotreonyl-glycyl-L-seryl-L-serine (ESlneg): m / z (%) = 1358.8 (100) [MH] Yield: 15 mg (78% purity, 50% of the "; HR-TOF-MS: calculated theoretical yield) from compound 1360.8199, found 1360.8223 example 423A (19 mg, 16 pmol) and compound [M + H] +. of Example 8A according to procedure 13.

H3C. CH, 451 A C1"-A-lactam of [/ ^ - (Benzyloxycarbonyl-J-S-yer-butyl-D-alanyl] - [3-yer-butyl-alanyl] - [(3R) -3-HPLC ( Method 6): R, = 4.97 min; LC-amino-L-phenylalanyl] - [(3R) -3-hydroxyl-L-leucyl] -L-MS (Method 19): R, = 3.04 min, MS leucyl ^ ^ -benzyloxycarbonyl-D-ornithi-L-isoleucyl- (ESlpos): m / z (%) = 744.2 (100) L-Alotreonyl-glycyl-L-seryl-L- serine [M + 2H] 2+, 1487.8 (90) [M + Hf, MS Yield: 53 mg (74% purity, 59% of ESLneg): m / z (%) = 1485.9 (100 ) [MH] theoretical yield) from the compound of "HR-TOF-MS: C74H112 13019 calculated example 424A (49 mg, 45 pmol) and compound 1486.8192, found 1486.8167 of example 10A according to [ M + H] + procedure 13.

Yield: 45 mg (60% purity, 36% of theoretical yield) from the compound of example 230A (49 mg, 46 pinol) and compound of example 274A according to procedure 13, purification according to method 45.

Example 459A: tert-butyl [(phenylsulfonyl) (pyridin-3-yl) methyl] carbamate Pyridine-3-carbaldehyde (5.36 g, 50 mmol), tert-butyl carbamate (11.7 g, 100 mmol, 2 equivalents), sodium phenylsulfinate (20.36 g, 124 mmol, 2.48 g. equivalents), formic acid (1.89 ml, 2.30 g, 1 equivalent), methanol (55 ml) and water (11 ml) and stirred vigorously at room temperature for 3 d. The product precipitates in the form of colorless crystals which are collected by filtration, washed with water and a small amount of MTBE and dried under vacuum. Yield: 4.10 g (24% of theoretical yield). LC-MS (Method 51): R, = 2.51 min, MS (ESlpos): m / z (%) = 349.3 (100) [M + H] +. Example 460A: [(pyridin-3-yl) methylene] carbamate / er-butyl Potassium carbonate (4.78 g, 34 mmol, 6 equivalents) is dried under vacuum and covered with a THF layer (70 mL). The mixture is refluxed for 16 h, then allowed to cool and filtered through a pad of celite. The filtrate is concentrated and the oily residue (1.33 g of crude product, quant.) Is subjected to reaction without purification. EXAMPLE 461 A: rac-freo-S-Kérer-butoxicarboni aminol-A ^ -idifenilmetilenJ-S-pyridin-S-il-alaninate ethyl The reaction is carried out based on a method for the addition of copper enolates to sulfonylimines: L. Bernardi, A. Gothelf, R. G. Hazell, K. A. Jensen, J. Org. Chem. 2003, 68, 2583-2591. The tert-butyl [(1 E) -phenylmethylene] carbamate can be prepared according to the literature: A. Klepacz, A. Zwierzak, Tetrahedron Lett. 2002 43; 1079-1080. Freshly activated 3 A molecular sieves, tetrakis (acetonitrile) copper (I) hexafluorophosphate (179 mg, 0.48 mmol, 0.1 equivalent) and (R) - (+) - 2- (2- (diphenylphosphino)) are provided. phenyl) -4-phenyl-2-oxazoline (329 mg, 0.53 mmol, 0.11 equivalents) under argon, and abs. THF is added. (41 mi). Then (67 μ ?, 49 mg, 0.48 mmol, 0.1 equivalent) is introduced through a pipette. The The mixture is cooled to -20 ° C and, once this temperature is reached, ethyl N- (diphenylmethylene) glycinate (1.29 g, 4.81 mmol) and the compound of example 459A (1.19 g) are added. , 77 mmol, 1.2 equivalents). The mixture is stirred for 16 h, allowing it to slowly reach room temperature. Then silica gel (approximately 15 g) is added, and the solvent is distilled off in vacuo. The residue is chromatographed with cyclohexane-ethyl acetate 9 + 1 (Biotage 40M with ZIF-SIM 35). The title compound is obtained in a yield of 1.85 g (95% pure, 77% of theoretical yield). LC-MS (Method 51): R, = 3.55 min MS (ESlpos): m / z (%) = 474.3 (100) [M + H] +. Example 462 A: rac-freo-3 - [(etr-butoxycarbonyl) amino] -3-pyridin-3-yl-alaninate ethyl trifluoroacetate The title compound of Example 461A (350 mg, 0.74 mmol) is dissolved in acetonitrile (9.33 mL) and 187 μ? of TFA (2.42 mmol, 3.3 equivalents) and water (187 pl, 10.4 μ ??, 14 equivalents) and the mixture is allowed to stand at 4 ° C for 16 h. All volatile components of the reaction mixture are distilled off in vacuo, and the residue is purified by chromatography (method 34). Yield: 366 mg (92% of theory). HPLC (Method 6): R, = 3.03 min. LC-MS (Method 22): Rt = 2.32 min, MS (ESlpos): m / z (%) = 310.0 (80) [M + H] +. HR-TOF-MS: C15H24N304 calculated 310, 1762, found 310, 1767 [M + H] \ Example 463A: rac-rreo-3 - [(rer-butoxycarbonyl) amino] - / V2- (benzyloxy) carbonylamino- 3-pyridin-3-yl-alaninate ethyl The compound of example 462A (366 mg, 0.68 mmol) and benzyloxycarbonylsuccinimide (209 mg, 0.82 mmol, 1.2 equivalents) are dissolved in 5 ml of dichloromethane-water (4 + 1), and the mixture is cooled at 0 ° C. Under vigorous stirring, sodium bicarbonate (86 mg, 1.03 mmol, 1.5 equivalents) and tetrabutylammonium bromide (11 mg, 34 pmol, 0.05 equivalents) are added, and the mixture is stirred vigorously at room temperature during 16 h. The organic phase is separated, washed with conc. NaCl, dried over sodium sulfate and concentrated. The crude product is chromatographed (method 34). Yield: 314 mg (84% purity, 0.60 mmol, 88% of theory) of the title compound. Rf = 0.076 (CyHex-EtOAc 9 + 1). HPLC (Method 54): R, = 4.33 min (erythro diastereomer) and 4.52 min (threo diastereomer). LC-MS (Method 19): R, = 2.71 min, MS (ESlpos): m / z (%) = 409.3 (30) [M + H] \ erythro isomer and R, = 2.75 min , MS (ESlpos): m / z (%) = 409.0 (70) [M + H] + threo isomer). 1 H NMR (400 MHz, cfe-DMSO) d (ppm) = 0.71-0.86 (m, 6H), 1.16 (t, J = 7.1 Hz, 3H), 1.34 (s, 9H), 1, 59 (m, 1 H), 3.70 (ddd, J = 3.4, J1 = f = 10.3 Hz, 1 H), 3.99-4.08 (m, 2H) , 4.32 (dd, J = 3.4, J = 9.5 Hz, 1 H), 5.03 (d, J = 12.4 Hz, 1 H), 5.10 (d, J = 12 , 4 Hz, 1 H), 6.62 (d, J = 10.5 Hz, 1 H), 7.31-7.40 (m, 5H), 7.44 (d, J = 9.3 Hz , 1 HOUR). HR-TOF-MS: C2iH33N206 calculated 409.2334, found 409.2329 [M + H] +. Example 464A: (S ^ -S- ^ Ier-ButoxycarbonylJaminoj- ^ -benzyloxyj -carbonylamino-S-pyridin-S-il-L-alanine The title compound of example 463A (314 mg, 0.56 mmol) is dissolved in a mixture of THF-water (2 + 1, 17 ml) at 0 ° C, lithium hydroxide monohydrate (25 mg, 0, 59 mmol, 1.1 equivalents), and the mixture is stirred at 0 ° C for 3 h. The THF is then separated by filtration, and the aqueous residue is lyophilized and then purified by chromatography (method 44). The product is separated by chromatography on a chiral phase according to method 58. The enantiomers of the threo diastereomer and those of the erythro minority diastereomer are obtained separately. The e.e. of the major isomer (title compound) after chiral chromatography is determined by method 59, and is 100%. The yield of the title compound is 113 mg (38% of the theoretical yield based on the starting compound 463A). HPLC (Method 6): R, = 3.53 min. Chiral HPLC (Method 59): R t = 4.71 min. LC-MS (Method 19): R, = 1.85 min, MS (ESlpos): m / z (%) = 416.2 (100) [M + H] +, MS (ESlneg): m / z ( %) = 414, 1.2 (100) [MH] \ HR-TOF-MS: C21H26N306 calculated 416.1817, found 416.1808 [M + H] +. Example 465A: (3R) -3 - [(fer-butoxycarbonyl) amino] -N2- (benzyloxy) carbonylamino-3-pyridin-3-yl-L-alaninate pentafluorophenyl The compound of example 464A (63 mg, 19 pmol) and pentafluorophenol (24 mg, 131 pmol, 1.1 equivalents) are dissolved in dichloromethane (0.8 ml) at room temperature, then EDCI (25 mg, 131 mg) is added. μl, 1.1 equivalents), and the mixture is allowed to stand in a refrigerator for about 12 h. The solvent is then distilled off in vacuo, and the residue is purified by chromatography (method 44). The title compound is obtained in a yield of 47 mg (51% of theory) as a colorless solid. HPLC (Method 54): R, = 4.49 min. LC-MS (Method 19): R, = 2.74 min, MS (ESlpos): m / z (%) = 582.2 (40) [M + H] +. HR-TOF-MS: Cz HzsNaOeFs calculated 582.1659, found 582.1647 [M + H] \ The compounds 466A-470A listed in the following table were prepared by the indicated procedures from the indicated starting materials. [(3 /?) - / ^ - (Benzyloxycarbonyl) -3- bistrifluoroacetate. { (Ie-butoxycarbonyl) amino} HPLC (Method 6): R, = 3.42 min; LC-MS 3- (pyridin-3-yl) -L-alanyl] - [(3R) -3-hydroxy-L-leucyl] -L- (Method 19): R, = 1.75 min, MS leuci LD-arginyl-isoleucyl-L-alotreonyl-glycol - [(3f?) - (ESlpos): m / z (%) = 652.1 (100) 3-hydroxy-L-asparaginyl] - L-serine [M + 2H] 2+, 1302.7 (5) [M + H] +; MS Yield: 51 mg (49% yield (ESlneg) m / z (%) = 1300.7 (100) [M-H] "; theoretical) from the compound of Example 3A HR-TOF-MS: calculated (76 mg, 68 μm) and 465A according to 1302.6689, found 1302.6661 procedure 10, purification according to the [M + H] method. bistrifluoroacetate of [(3) -? * - (Benzyloxycarbonyl) -3-amino-3- (pyridin-3-yl) -L-HPLC (Method 6): R, = 3.12 min; LC-MS alanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L- (Method 52): R, = 0.91 min, MS isoleucyl-L-alotreonyl- glycyl - [(3R) -3-hydroxy-L- (ESlpos): m / z (%) = 602.0 (100) asparaginyl] -L-serine [M + 2H] 2+, 1202.7 (5) [M + H] +, MS Yield: 52 mg (quant.) As a solid (Sleng): m / z (%) = 1200.8 (100) [MH] "; colorless from 51 mg of HR-TOF-MS compound: calculated C53H84N15017 Example 466A according to the procedure 1202.6165, found 1202.6160 2, crude product subjected to reaction without [M + H] +.

Exemplary Embodiments Example 1 Bistrifluoroacetate of C1"-A / ^ - lactam of [3-fer-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-L- phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-asparaine The protecting group is removed from the benzyloxycarbonyl-protected peptide (example 53A, 1.5 mg, 0.89 μm) in dioxane and in aq TFA. 0.1% (1 ml, 10 equivalents) by hydrogenolysis according to procedure 4 after 1 h. 1.3 mg (96.6% of theory) of product are obtained after fine purification by preparative HPLC (method 26). As an alternative, the amine (example 1) is separated from the compound of example 58A (13.0 mg, 8.47 pmol) after the breakdown by hydrogenolysis of the ester (method 4) in methanol (5 ml) using 0.1 N hydrochloric acid (508 μ ?, 1.9 mg, 50.79 pmol, 6 eq.). After chromatography (method 26), 12.0 mg (93.5% of theory) of the title compound are isolated. HPLC (Method 9) R t = 14.73 min. LC-MS (Method 18): R, = 1, 71 min; MS (ESlpos): miz (%) = 1288 (3) [M + H] \ 644 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1286 (50) [M-Hf, 642 (38) [M-2H] 2 ~, 1332 (100). HR-TOF-MS (Method 24): C60H103Ni6O15 [M + H] + found 1287.7810, calculated 1287.7784.

EXAMPLE 2 Bistrifluoroacetate of C '^' - W ^ -lactam of D-Leucyl-L-leucyl - [(3f?) - 3-amino-L-phenylalanyl] - [(3f?) - 3-hydroxy -L-leucl] - The title compound is prepared from the benzyloxycarbonyl protected peptide (example 73A, 33.0 mg, 21, 89 prnol) after ester hydrogenolysis (method 4) in methanol (10 ml) and aqueous hydrochloric acid 0.1 N (219 μ ?, 0.8 mg, 21, 89 μ ??, 1 eq.). Fine purification is carried out by preparative HPLC (method 26) and 18.1 mg (56.1% of theory) of product is isolated. HPLC (Method 9) R, = 14.15 min. LC-MS (Method 18): R, = 1.52 min; MS (ESlpos): m / z (%) = 1259 (5) [M + H] +, 630 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1257 (100) [M-H] ~, 628 (28) [M-2H] 2 \ HR-TOF-MS (Method 24): [M + H] + found 1259.7454, calculated 1259.7471. Example 3 Bistrifluoroacetate of C1"- / v ^ -lactam of [3-fe-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-ornityl-L-isoleucyl-L-alotreonyl-glycyl-L-asparagi serine The title compound is prepared from the benzyloxycarbonyl protected peptide (example 81 A, 20.0 mg, 13.21 μ) after the ester hydrogenolysis (method 4) in methanol (10 ml) and acid aqueous hydrochloric acid 0.1 N (198 μ ?, 0.7 mg, 19.8 μ? t ??, 1.5 eq.). Fine purification is carried out by preparative HPLC (method 26), and 17.9 mg (91.9% of theory) of product is isolated. HPLC (Method 9) R, = 15.51 min. LC-MS (Method 18): R, = 1.57 min; MS (ESlpos): m / z (%) = 1245 (13) [M + H] +, 623 (100) [M + 2H] 2+; MS (ESlneg.): M / z (%) = 1243 (100) [M - H] ~. HR-TOF-MS (Method 24): [M + H] + found 1245.7560, calculated 1245.7566. EXAMPLE 4 C1-Bistrifluoroacetate-s-lactam of [3-ér-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3 /?) - 3-amino-0-methyl -L-tyrosyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [^ hydroxy-L-asparaginyl] -L -serine The compound of example 112A (23 mg, 14.5 pmol) is reacted according to procedure 5. After purification by chromatography by means of preparative HPLC (method 43), 17 mg (75% of theoretical yield) are obtained. of product by freeze drying. HPLC / UV-Vis (Method 5): R, = 3.69 min. HPLC / UV-Vis (Method 4): R, = 3.95 min. LC-MS (Method 18): R, = 1.71 min; MS (ESlpos.): M / z. { %) = 667 (100) [M + 2H] 2 \ 1333 (2) [M + H] +; MS (ESlneg.): M / z (%) = 1331 (100) [M - H] _. EXAMPLE 5 C '^ -A ^^ - lactam of [3-fer-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-4- ( dimethylaminophenyl) -L-alanyl] - [(3 /?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L -soleucyl-L-alotreonyl-glycyl - [(3S) -3- hydroxy-L-asparaginyl] -L-serine The compound of Example 128A (105 mg, 66% pure, 41 μ? T) is dissolved in 30% TFA in dichloromethane (4 mL) and stirred at room temperature for 20 min. The mixture is then concentrated in vacuo and the residue purified by chromatography (method 44 with modified gradient: 0-2 min 10% B, slope, 38 min 60% B). 49 mg (29 μp, 70% of theoretical yield) of the title compound are obtained. HPLC (Method 7): R, = 3.62 min. LC-MS (Method 20): R, = 1.72 min, MS (ESlpos.): M / z (%) = 450.0 (100) [M + 3H] 3+, 674.4 (40) [ M + 2H] 2+. HR-TOF-MS (Method 24): C62H108 i7O16 [M + H] + calculated 1346.8155, found 1346.8130. EXAMPLE 6 C1-Tristrifluoroacetate - / V ^ - [3-Trimethylsilyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-4- (dimethylol) lactam N-phenyl) -L-alanyl] - [(3R) -3-hydroxy-alotreonyl-glycyl - [(3S) -3-hydroxy-L-asparaginyl] -L-serine The compound of Example 133A (126 mg, 82 pmol) is dissolved in 30% TFA in dichloromethane (4 mL) and stirred at room temperature for 20 min. The mixture is then concentrated in vacuo and the residue purified by chromatography (method 44 with modified gradient: 0-2 min 10% B, slope, 38 min 60% B). 78 mg (46 pmol, 56% of theory) of the title compound are obtained. HPLC (Method 7): R, = 3.69 min. LC-MS (Method 20): R, = 1, 66 min, MS (ESlpos.): M / z (%) = 682.3 (100) [M + 2H] 2 \ 1364, 1 (2) [M + Hf. HR-TOF-MS (Method 24): C61H108N17O16Si [M + H] + calculated 1362.7924, found 1362.7949. EXAMPLE 7 D, Phenylalanyl-L-phenylalanyl - [(3R) -3-amino-L-alanyl] - [(3R) -3-hydroxy-L-leucyl, C, - / V3-3-lactam bistrifluoroacetate l] -L-leucyl-D-arg¡n¡lL -soleucil-L-alotreon The desired compound is prepared from the compound of example 144A (0.3 mg, 0.20 μ? T) as described in procedure 1. After fine purification by gel chromatography (method 45, eluent : methanol), 0.1 mg (23.3% of theory) of the product is isolated. HPLC (Method 12): R, = 5.74 min. LC-MS (Method 18): R, = 1.57 min, MS (ESlpos.): M / z (%) = 1268 (2) [M + H] +, 634 (100) [M + 2H] 2 +; MS (ESlpos.): M / z (%) = 1266 (50) [M - H] ", 632 (22) [M - 2H] 2", 1312 (100) [M - H + HC02H] \ MALDI- MS (Method 25): C 58 H 92 16016 [M + H] + calculated 1267.68, found 1267.65. EXAMPLE 8 Bistrifluoroacetate of C1"- / V ^ -lactam of [3-fer-Butyl-D-alanIH3-fer-Butyl-L-alanylH (3R) -3-amino-L-phenylalanyl] - [( 3R) -3-hydroxy-L-! Eucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-gly The compound of example 233A (4 mg, 3 pmol) is dissolved in methanol (1 ml). 17 μ? of 1 M hydrochloric acid and 10% palladium-carbon (2 mg) and the mixture is hydrogenated under atmospheric pressure at room temperature for 2 h. The solution is filtered to remove the catalyst and concentrated. After purification by chromatography (method 44), 2.2 mg (1.5 mol 53% of theoretical yield) of the title compound are obtained. HPLC (Method 5): R, = 4.45 min. LC-MS (Method 20): R, = 1.45 min, MS (ESlpos): m / z (%) = 631, 1 (100) [M + 2H] 2+, 1260.9 (3) [M + H] +. HR-TOF-MS (Method 24): calculated 1260.7675, found 1260.7670 [M + H] +. EXAMPLE 9 Tristrifluoroacetate of [3"-3-aminyl-3-aminyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl ] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycol- [3- (3-pyridyl) -L-alanyl] - L-serine According to the method for preparing the compound of Example 233A, the title compound is obtained in a yield of 4 mg (32% of theoretical yield) from the compound of Example 226A (12 mg, 13 μ? T). . HPLC (Method 5): R, = 3.60 min. LC-MS (Method 19): R, = 1, 43 min, MS (ESlpos): m / z (%) = 661, 5 (100) [M + 2H] 2+, 1321, 8 (10) [M + H] +. HR-TOF-MS (Method 24): C64H1o5N16014 calculated 1321, 7991, found 1321, 7955 [M + Hf. EXAMPLE 10 C1"- Bistrifluoroacetate / V ^ - [3-Ier-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] -lactam] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-phenylalkyl The compound of example 235A is reacted according to general procedure 2 with 1 ml of the reagent solution for 1 h, and the product is purified according to a modified method 44 (gradient: 0 min 25% B, gradient, 35-38 min 35% B). The title compound is obtained in a yield of 10 mg (50% of theoretical yield). HPLC (Method 5): R, = 3.41 min. LC-MS (Method 19): R, = 1.57 min, MS (ESlpos): m / z (%) = 661, 1 (100) [M + 2H] 2 \ 1320.8 (5) [M + Hf; MS (ESlneg): m / z (%) = 1318.6 (90) [MH] \ HR-TOF-MS (Method 24): C ^ H ^ eN ^ O ^ calculated 1320.8039, found 1320.8042 [ M + H] +. Example 11 Bistrifluoroacetate of C1"-A-lactam of [3-fer-Butyl-D-alanyl] - [3-ér-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] - [ (3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl- [L-treoni] The compound of example 236A is reacted according to general procedure 2 with 1 ml of the reagent solution for 30 min, and the product is purified according to method 44. The title compound is obtained in a yield of 3. mg (27% of theoretical yield). HPLC (Method 5): R, = 3.73 min. LC-MS (Method 19): R, = 1.53 min, MS (ESlpos): m / z (%) = 638.0 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): C6oHi03Ni5Oi5 calculated 1274.7831, found 1274.7827 [M + H]. EXAMPLE 12 Bistrifluoroacetate of C1-N3 3-lactam of [3-fer-Butyl-D-alanyl] - [ (3f?) - 3-amino-L-phenylalanyl] - [(3 /?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L- alotreonyl-L-serine The compound of example 237A (47 mg, 24 μ? T ??) is reacted according to general procedure 2 with 1 ml of the reagent solution for 30 min, and the product is purified according to method 44 The title compound is obtained in a yield of 21 mg (57% of theory). HPLC (Method 6): R, = 3.43 min. LC-MS (Method 19): R, = 1.52 min, MS (ESlpos): m / z (%) = 638.1 (100) [M + 2H] 2+: MS (ESlneg): m / z (%) = 1273.6 [M] \ HR-TOF-MS (Method 24): CeoH ^ N ^ O ^ calculated 1274.7831, found 1274.7800 [M + H] +. Example 13 [3-Fer-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] - [(3R) - lactam bistrifluoroacetate 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-gly The compound of Example 238A is reacted according to general procedure 2 with 1 ml of the reagent solution for 30 min, and the product is purified according to method 44. An additional fine purification is then carried out: column: Waters Symmetry-Prep ™ C-18, 7 μ? T ?, 300 mm x 19 mm; eluent A: water + 0.05% TFA, eluent B: acetonitrile + 0.05% TFA: flow rate: 10 ml / min; A: B 65/35 Socratic The title compound is obtained in a yield of 8 mg (20% of theoretical yield). HPLC (Method 5): R, = 3.71 min. LC-MS (Method 19): R, = 1.49 min, MS (ESlpos): m / z (%) = 623.2 (100) [M + 2H] 2+. HR-TOF-MS (Method 24): C59H101N15O14 calculated 1244.7726, found 1244.7748 [M + H] \ EXAMPLE 14 Bistrifluoroacetate of C1"-A / ^ - lactam of [3-fer-Butyl-D-alan] l] - [3-fer-butyl-L-alanyl] - [(3f?) - 3-amino-L-phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D- arginyl-L-isoleucyl-seryl-glycol - [(3S) -3-hi asparaginyl] -L-serine The compound of example 239A is reacted according to general procedure 2 with 1 ml of the reagent solution for 1 h, and the product is purified according to method 44. Further fine purification is then carried out: column : Waters Symmetry-Prep ™ C-18, 7 μ, 300 mm x 19 mm; eluent A: water + 0.05% TFA, eluent B: acetonitrile + 0.05% TFA: flow rate: 10 ml / min; A: B 65/35 isocratic. The title compound is obtained in a yield of 9 mg (6 pmol, 35% of theoretical yield). HPLC (Method 5): R, = 3.63 min. LC-MS (Method 19): R, = 1.43 min, MS (ESlpos): m / z (%) = 643.7 (100) [M + 2H] 2+, 1289.8 (10) [M + H] +. HR-TOF-MS (Method 24): C59H10iN16O16 calculated 1289.7576, found 1289.7578 [M + H] +. Example 15-C1-trifluoroacetate of C1"-A / ^ - lactam of [3-fer-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3f?) - 3-amino-L phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl-L-asparagi The compound of example 240A is reacted according to general procedure 2 with 1 ml of the reagent solution for 1 h, and the product is purified several times according to method 44. The title compound is obtained in a yield of 1.1 mg (6 μ ???, 3.5% theoretical yield). HPLC (Method 5): R, = 3.41 min. LC-MS (Method 22): R, = 2.90 min, MS (ESlpos): m / z (%) = 645 (100) [M + 2H] 2+, 1288 (10) [M + H] + . HR-TOF-MS (Method 24): CeoH ^ aN ^ ds calculated 1287.7784, found 1287.7786 [M + H] +. Example 16 Bistrifluoroacetate of C1"-A / ^ - lactam of [3-fer-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3f?) - 3-amino-L-phenylalanyl ] (3 /?) - 3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-glycyl - [(3S) -3-h asparaginyl] -L-alanine The compound of example 253A is reacted according to general procedure 2 with 2 ml of the reagent solution for 1 h, and the product is purified according to method 44. The product is subjected to fine purification in accordance with a variant of method 34 (use of eluent A: eluent B 3: 2; Socratic instead of gradient). The title compound is obtained in a yield of 22 mg (36% of theoretical yield). HPLC (Method 6): R, = 3.43 min. LC-MS (Method 22): R, = 2.90 min, MS (ESlpos): m / z (%) = 645 (100) [M + 2H] 2+, 1288 (60) [M + Hf; MS (ESlneg): m / z (%) = 1286 (100) [MH] \ HR-TOF-MS (Method 24): CeoH ^ N ^ O ^ calculated 1287,7784, found 1287.7800 [M + H] +. EXAMPLE 17 C1- "Bistrifluoroacetate - / v ^ - [3-Ier-Butyl-D-alanyl] - [3-yer-butyl-alanyl] - [(3R) -3-amino-L- lactam] phenylalanyl] - [(3R) -3-hydroxy-L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L-alotreonyl-D-alanyl - [(3S) -3-hydroxy- L ^ asparaginyl] -L-serine The compound of Example 267A (34 mg of crude product, approximately 6 μm) is reacted according to general procedure 2 with 1 ml of the reagent solution for 30 min. The product is obtained pure by chromatography twice according to method 33. The title compound is obtained in a yield of 6 mg (65% of theoretical yield). HPLC (Method 6): R, = 3.42 min. LC-MS (Method 22): R, = 2.90 min, MS (ESlpos): m / z (%) = 660 (100) [M + 2H] 2 \ 1317.8 (10) [M + H] +; MS (ESlneg): m / z (%) = 1315.8 (100) [M-H] \ HR-TOF-MS (Method 24): C61H105N16O16 calculated 1317.7889, found 1317.7892 [M + H] +. The compounds 19-44 shown in the following table were prepared according to the indicated procedures from the indicated starting materials.

H3C 2 TFA CH, C '"-A ^ bistrifluoroacetate-[3-yer-Butyl-D-alanyl] - [3-yer-butyl-L-alanyl]-HPLC (Method 6): R, = 3.44 min; LC - [(3R) -3-amino-L-phenylalanyl] - [(3?) - 3-hydroxy-MS (Method 19): R, = 1.67 min, MS L- leucyl] -L-leucyl-D-arginyl-lsoleucyl-L-seryl- (ESlpos): mz (%) = 624.0 (100) glycyl-L-seryl-L-serine [M + 2H] 2 \ 1246.8 (5) [M + H] +, MS Yield: 13 mg (54% yield (ESlneg): m / z {%) = 1244.8 (80) [MH] ", theoretical) from the compound of Example 1290.8 (100) [M + HCOOJ; HR-TOF-436A (23 mg, 16 pmol) according to the MS: calculated procedure 2, purification according to 1246.7518, found 1246.7500 with a variation of method 44 [M + H] +. (pending only up to 60% acetonitrile). tristrifluoroacetate of C1"- / V ^ -lactam of [3-fer-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] -HPLC (Method 6): R, = 3.23 min; - [(3R) -3-amino-L-phenylalanyl] - [(3 /?) - 3-hydroxy-MS (Method 19): R, = 1.45 min, MS L-leucyl] -L-leucyl-D-arginyl-L-isoleucyl-L- (ESlpos): m / z (%) = 425.4 (100) alotreonyl-glycyl - [(2S) -2,4-diaminobutyryl ] -L- [M + 3H] 3+, 637.6 (50) [M + 2H] 2+, 1273.9 serine (5) [M + H] +, MS (ESlneg): m / z (% ) = Yield: 7 mg (10% yield 1273, 1 (70) [M-H] 1318, 1 (100) theory) from the compound of example [M + HCOOT; HR-TOF-MS: 444A (75 mg, 46 μ ???) according to the C6oHio5 i601 calculated 1273.7991, procedure 4, multiple purification of found 1273.8020 [M + H] +. according to a variation of method 44 (pending only up to 55% acetonitrile).

C * "- bistrifluoroacetate - / V ^ - [3-yl-Butyl-D-alanyl] - [3-fer-butyl-L-alanyl] - [(3R) -3-amino-L-phenylalanyl] -lactam] - [(3R) -3-hydroxy-HPLC (Method 6): R, = 3.42 min; LC-L-leucyl] -L-norvalyl-D-arginyl-L-isoleucyl-L-MS (Method 51): R, = 2, 15 min, MS alotreonyl-glycyl-L-seryl-L-serine (ESlpos) : m / z (%) = 624.6 (100) Yield: 54 mg (27% yield [M + 2H] 2+, 1246.9 (1) [M + H] +; HR-TOF-theoretical) from the compound of Example MS: C58H 100N15O15 calculated 446A (54 mg, 37 μ? T ??) according to 1246.7518, found 1246.7549 procedure 2, purification according [M + H] +. with a variation of method 44 (pending only up to 60% acetonitrile).

B. Evaluation of physiological activity The in vitro effect of the compounds of the invention can be demonstrated in the following tests: Determination of the minimum inhibitory concentration (MIC) The MIC is determined in the liquid dilution test according to the NCCLS guidelines. The overnight cultures of Staphilococcus aureus 133, Enterococcus faecalis 27159, E. faecium 4147 and Streptococcus pneumoniae G9a are incubated with the test substances described in a 1: 2 dilution series. The determination of MIC is conducted with a cell count of 105 microbes per ml in Isosensitest medium (Difco, Irvine / USA), with the exception of S. pneumoniae, which is evaluated in BHI broth (Difco, Irvine / EE. UU.) With 10% bovine serum with a cell count of 106 microbes per ml. Cultures are incubated at 37 ° C for 18-24 hours, S. pneumoniae in the presence of 10% C02. MIC is defined as the lowest concentration of each substance at which no visible bacterial growth is observed. The MIC values are reported in g / ml. The representative data of the in vitro activity of the compounds of the invention are presented in Table A: Table A The suitability of the compounds of the invention for the treatment of bacterial infections can be demonstrated in the following model in animals: Systemic infection with Staphilococcus aureus 133: S. aureus 133 cells are grown overnight in BHI broth (Oxoid, New York / USA). The overnight culture is diluted 1: 100 in fresh BHI broth and incubated for 3 hours. The cells that are then in the logarithmic growth phase are separated by centrifugation and washed twice with physiological saline buffer. A suspension of saline cells is then photometrically adjusted to an extinction of 50 units. After a dilution step (1:15), this suspension is mixed 1: 1 with a 10% mucin solution. 0.25 ml of this infection solution is administered intraperitoneally by 20 g of mouse (equivalent to 1 106 microbes / mouse). Therapy takes place intraperitoneally or intravenously 30 minutes after infection. CFW1 female mice are used for the infection experiment. The survival of the animals is recorded for 6 days. The properties of the compounds of the invention in relation to renal tolerability can be demonstrated in the following model of animals: Mouse model for determining nephrotoxic effects: Nephrotoxic side effects of nonadepsipeptides are analyzed by histopathological examinations of the kidneys in mice after multiple administration of a particular dosage. For this purpose, 5-6 animals received daily treatment either intravenously (i.v.) or intraperitoneally (i.p.) with substances that dissolve in aqueous solution or with the addition of Solutol. The nephrotoxic effects are determined by optical microscopy evaluation of paraffin sections stained with hematoxylin and eosin (H & E) of the kidneys. Optionally a periodic acid Schiff (PAS) reaction is conducted to better visualize the glycoproteins. The nephrotoxic effects are specified semiquantitatively for each animal, such as the severities of tubular basophilia and the presence of degeneration / regeneration (severities: 0 = no effect, 1 = minimal effect, 2 = slight effect, 3 = moderate effect, 4 = severe injuries ). The average severity of tubular degeneration / regeneration is calculated as well as the incidence (number of affected animals) for each group or animal derivative. Also, beyond that, renal changes are enumerated, such as tubular dilatation as well as necrosis and the accumulation of necrotic material.

Rat model to determine nephrotoxic effects: The nephrotoxic side effects of nonadepsipeptides are analyzed by histopathological examination of the kidneys in rats after multiple administration of a particular dosage. For this purpose, 5 animals are treated every day intravenously (i.v.) with substances that dissolve in saline or Ringer's lactate solution. Nephrotoxic effects are determined by optical microscopy evaluation of paraffin sections stained with hematoxylin and eosin (H &E) of the kidneys. Optionally a periodic acid Schiff (PAS) reaction is conducted to better visualize the glycoproteins. The nephrotoxic effects are specified semiquantitatively for each animal, such as the severities of tubular basophilia and the presence of degeneration / regeneration (severities: 0 = no effect, 1 = minimal effect, 2 = slight effect, 3 = moderate effect, 4 = severe injuries ). The average severity of tubular degeneration / regeneration is calculated as well as the incidence (number of affected animals) for each group or animal derivative. Also, beyond that, renal changes are enumerated, such as tubular dilatation as well as necrosis and the accumulation of necrotic material. Principle of the determination of the free fraction by means of Transil: The method described here to determine the free fraction (fu) of a test substance is divided into 2 parts: a) Determination of the distribution ratio of Transil® / buffer solution (buffering enzyme) by incubation of the test substance in a dispersion of Transid buffer (pH 7), 4) and subsequent determination of the concentration in the dispersion and in the supernatant of buffer solution. b) Determination of the distribution ratio of Transil® / plasma (MApiasma) by incubation of the test substance in a Transil®-plasma dispersion and subsequent determination of the concentration in the dispersion and in the plasma. The quotient of the two distribution relationships allows to obtain fu. In the case of substances with high protein binding, the plasma is usually diluted with isotonic phosphate buffer (pH 7.4) and then suspended with Transil®. the determination of fu '(free fraction in diluted plasma) in this diluted solution of proteins takes place analogously to the determination of fu. The free fraction in undiluted plasma is calculated from fu 'and the dilution factor. Regarding this method, compare also: Schuhmacher, Joachim; Kohlsdorfer, Christian; Buehner, Klaus; Brandenburger, Tim; Kruk, Renate, "High-throughput determination of the free fraction of drugs strongly bound to plasma proteins." Journal of Pharmaceutical Sciences 2004, 93, 816-830. Determination of the membrane affinity of a test substance after distribution between Transil® and buffer (Aso, buffer): All incubations are conducted in suitable glass containers, eg glass vials, frosted stopper test tubes . The total volume is usually 0.5-5 ml and the volume of Transil® is 10-100 μ ?. If membrane affinities are expected to be high, the Transil® dispersion can be diluted up to 20 times with phosphate buffer at pH 7.4, for example Dulbecco's PBS. The phosphate buffer solution at pH 7.4 is provided in the incubation vessels, and the Transil® is introduced by pipetting after thorough mixing. The test substance is pipetted at a concentration of, for example, 200 ng / ml, n = 6. The proportion of organic solvent should be < 2%. The mixtures are incubated at room temperature for 30 min, for example on a mini-agitator at an angle of approximately 45 °, at approximately 400 rpm. In order to determine the value of 100%, at least one aliquot of, for example, 100 μ ?, is removed and the remaining mixture is centrifuged approximately 1800 g for about 10 min. At least 2 aliquots (for example, 100 μl) of the supernatant of each sample are removed for determination of the concentration. Determination of MAplasma in undiluted or diluted plasma: The total volume of incubation and the aggregate volume of Transil® depend on the expected free fraction. The total volume is usually 0.5-1 ml and the volume of Transil® is 10-100 pl. If the free fractions are very low, the plasma of the species to be investigated is diluted with isotonic buffer, pH 7.4, for example 10-400 times, and then Transil® is added. The subsequent procedure takes place as previously described for the determination of the values of MAS0 | Buffer Damp * Principle of the determination of the free fraction by means of ultrafiltration: The plasma of the species to be investigated is filtered through a semipermeable membrane. The concentration of the substance in the filtrate is measured and the free fraction fu is calculated therefrom. The Millipore / Amicon Centrifree micropartition system is used. The ultrafiltration membranes have a cut-off value of 30,000 Da. 1 ml of plasma is added with the substance at a concentration of approximately 1 g / ml. The solvent ratio should be < 2%. After incubation at room temperature for 30 minutes, the plasma is pipetted into the ultrafiltration system and centrifuged at 1800 g for 10 minutes. The concentration of substance in the ultrafiltrate (Cu, concentration of unbound substance) and in the plasma before centrifugation (C, total substance concentration) are measured. The free fraction is calculated according to the formula: fu (%) = CJC * 100. Determination of chemical stability in slightly alkaline aqueous solution: 0.3 mg of the test substance is dissolved in a mixture of 0.25 ml of acetonitrile, 0.25 ml of DMSO and 0.5 ml of buffer solution of pH 7 , 8 (consisting of 111 mg (1 mmol) of calcium chloride, 7.91 g (100 mmol) of ammonium bicarbonate, 100 ml of acetonitrile at 1000 ml) and left to stand at room temperature. An aliquot of 5 μ? of the solution once per hour and analyzed by HPLC (method 57). The concentration of the test compound in time 0 h, indicated by UV absorption (IE), is defined as 100%, and the decrease in time is observed. At the same time, the increase in the degradation product of the open ring is observed. This trial provided the results shown in figures 1-5. From the curves it is evident that the compounds of the invention are distinctly more stable in alkaline aqueous solution than lisobactin. C. Examples of embodiments of pharmaceutical compositions The compounds of the invention can be converted into pharmaceutical preparations in the following ways: Tablet: Composition: 100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of corn starch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate . Weight of the tablet: 212 mg. Diameter: 8 mm, radius of curvature: 12 mm. Production: The mixture of active ingredient, lactose and starch is granulated with a PVP solution in 5% water (m / m). The granules are dried and then mixed with the magnesium stearate for 5 min. This mixture is compressed using a conventional tablet press (see above for the tablet format). A compression force of 15 kN is used as a guideline for compression. Suspension that can be administered orally: Composition: 1000 mg of the compound of example 1, 1000 mg of ethanol (96%), 400 mg of Rhodigel (xanthan gum, FC, Pennsylvania, USA) and 99 g of water . 10 ml of oral suspension are equivalent to a single dose of 100 mg of the compound of the invention. Production: Rhodigel is suspended in ethanol and the active ingredient is added to the suspension. The water is added under agitation. The mixture is stirred for approximately 6 hours until the dilatation of Rhodigel is complete. Solution that can be administered intravenously: Composition: 100-200 mg of the compound of Example 1, 15 g of polyethylene glycol 400 and 250 g of water for injections. Production: The compound of Example 1 is dissolved together with polyethylene glycol 400 in the water with stirring. The solution is sterilized by filtration (pore diameter: 0.22 pm) and placed under low asepsis in sterilized infusion bottles with heat. The latter are closed with infusion caps and pressure caps.

Claims

CLAIMS A compound of formula where it represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-d-methylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl , 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1,3-thiazol-4-ylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1 , 3-thiazol-4-ylmethyl can be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, represents hydrogen, C C4-alkyl, C 3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl or 5- or 6-membered heteroarylmethyl, wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of in halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, C ^ C ^ alkoxy, CVd-alkylamino, hydroxycarbonyl, d-C4-alkoxycarbonyl, aminocarbonyl, VC-alkylaminocarbonyl and 5- or 6-membered heterocyclyl which is attached through nitrogen, it represents CpCe-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylethyl or 2-amino-2-oxoethyl, where alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [ami] no (imino) methyl] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C C4-alkyl, Ci-C4-alkoxy, CrGy-alkylamino, hydroxycarbonyl, d-C4-alkoxycarbonyl, aminocarbonyl and C Gr alkylaminocarbonyl, represents CrC6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylethyl or 2-amino-2-oxoethyl, wherein alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of in halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl they may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C1-C4-alkyl, Ci-C4-alkoxy, CrC4-alkylamino, hydroxycarbonyl , CC ^ alkoxycarbonyl, aminocarbonyl and CC -alkylaminocarbonyl, represents CrCValkyl, where alkyl is substituted with a substituent selected from the group consisting of amino, 1, 4,5,6-tetrahydropyrimidin-2-ylamino, [amino- (imino) methyl] amino, 2-pyridyl, 3-pyridyl and 4-pyridyl, represents d-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, heteroarylmethyl of 5 or 6 members or trimethylsilylmethyl, wherein alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C ^^ -alkyl, Ci-C4-alkoxy, Ci-C4-alkylamino, hydroxycarbonyl, CrC-alkoxycarbonyl, aminocarbonyl and C4-alkylaminocarbonyl, represents CrC6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl , 5 or 6 membered heteroaryl, 5 or 6 membered heteroarylmethyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, where alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1, 4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl can be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, CVC ^ alkyl, C1-C4-alkoxy, (-VCt-alkylamino, hydroxycarbonyl, C C4-alkoxycarbonyl, aminocarbonyl and C4-alkylaminocarbonyl, represents hydrogen, Ci-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl , benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, where alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxy, amino, mercapto, 1, 4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl can be substituted between 1 and 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C | -C4-alkyl, Ci-C4-alkoxy, CVGi-alkylamino, hydroxycarbonyl, CrC4 -alkoxycarbonyl, aminocarbonyl and C 1 -C 4 alkylaminocarbonyl, represents hydrogen, CrCe-alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (C1-C4-alkylamino) -2-oxoethyl or 2- (C1-C4-alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1, 4,5,6-te-trahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, where cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl , Ci-C4-alkoxy, CVCt-alkylamino, hydroxycarbonyl, dC ^ alkoxycarbonyl, aminocarbonyl and C1-C4-alkylaminocarbonyl, R1 represents C Ce-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (CC -alkylamino) -2-oxoethyl or 2- (C-C4-alkylamino) -1-hydroxy-2-oxoethyl, wherein alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto , 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkyl, cyclo alkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, C4-alkoxy, CrC4-alkylamino, hydroxycarbonyl, CrC4-alkoxycarbonyl, aminocarbonyl and 'C1-C4-alkylaminocarbonyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof, except one compound of formula wherein R 1 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-d-methylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1,3-thiazol-4-ylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy, R2 represents 2-methylprop-1-yl, 2,2-d-methylprop-1-yl, 2,2-dimethylbut-1- ilo, trimethylsilylmethyl, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl or 1,3-thiazol-4-ylmethyl, where benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 2-thienylmethyl, 3-thienylmethyl and 1, 3-thiazol-4-ylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl, methyl and methoxy; and R 12 represents hydrogen or methyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
2. A compound according to claim 1, characterized in that R10 represents CVCe-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylmethyl, trimethylsilylmethyl, -amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (Ci-C-alkylamino) -2-oxoethyl or 2- (Ci-C4-alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylamino and [amino (imino ) methyl] amino, and wherein cycloalkyl, cycloalkylmethyl, phenyl, benzyl, heteroaryl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy , CVC-alkylamino, hydroxycarbonyl, Ci-C4-alkoxycarbonyl, aminocarbonyl and C1-C4-alkylaminocarbonyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
3. A compound according to claim 1 or 2, characterized in that R represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl or 3-pyridylmethyl, wherein benzyl, 2-pyridylmethyl and 3-pyridylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, R2 represents 2-methylprop-1-yl , 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl or 3-pyridylmethyl, where benzyl, 2-pyridylmethyl and 3-pyridylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, represents C4-alkyl, phenyl, benzyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, wherein phenyl, benzyl, 2-pyridyl, 3-pyridyl and 4-pyridyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl , trifluoromethoxy, dC -alkyl, C, -C -alcoxy, and CrQ-alkylamino, represents Ci-C6-alkyl, C3-C7-cycloalkylmethyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, where alkyl may be substituted with a hydroxy substituent, and wherein cycloalkylmethyl, benzyl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoro methyl, trifluoromethoxy, CV C4-alkyl, Ci-C4-alkoxy, (VC-alkylamino, hydroxycarbonyl, CrCi-alkoxycarbonyl, aminocarbonyl and dQ-alkylaminocarbonyl, represents Ci-C6-alkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, heteroarylmethyl of 5 or 6 members or trimethylsilylmethyl, wherein alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkylmethyl, phenyl, benzyl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, CVC-alkyl, CVC4-alkoxy and CrC4-alkylamino, represents C C6-alkyl, where alkyl is substituted with a substituent selected from the group consisting of amino, 1, 4,5,6-tetrahydropyrimidin-2-ylamino, [amino- (imino) methyl] amino, 2-pyridyl, 3-pyridyl and 4-pyridyl, represents CVCe-alkyl, C3-C7-cycloalkylmethyl, phenyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl, wherein alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and where cycloalkylmethyl, phenyl, benzyl and heteroarylmethyl may be substituted with from 1 to 4 substituents selected from independently of each other between the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, CVC4-alkyl, CVCValkoxy and d-CValkylamino, represents C Ce-alkyl, C3-C7-cycloalkylmethyl, benzyl, 5- or 6-membered heteroarylmethyl or trimethylsilylmethyl , wherein alkyl may be substituted with a hydroxy substituent, and wherein cycloalkylmethyl, benzyl and heteroarylmethyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy , C C4-alkyl, CrCj-alkoxy, Ci-C4-alkylamino, hydroxycarbonyl, CVC-alkoxycarbonyl, aminocarbonyl and CVC-alkylaminocarbonyl, represents hydrogen, CVCValkyl, C3-C7-cycloa alkyl, phenyl, trimethylsilylmethyl or 2-amino-2-oxoethyl, wherein methyl may be substituted with a substituent selected from the group consisting of hydroxy, amino and mercapto, and wherein cycloalkyl and phenyl may be substituted with from 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C-C4-alkyl, C-C4-alkoxy and CrC ^ alkylamino, R10 represents hydrogen, CrCValkyl, C3-C7-cycloalkyl , phenyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1-hydroxy-2-oxoethyl, (aminosulfonyl) (hydroxy) methyl, 2- (C4-alkylamino) -2-oxo-ethyl or 2- (Ci-C4-alkylamino) -1-hydroxy-2-oxoethyl, where alkyl may be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2 -ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl and phenyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C < C4-alkyl, C4-C4-alkoxy and CrC4-alkylamino, R11 represents methyl or ethyl, where methyl and ethyl can be substituted with a substituent selected from the group consisting of hydroxy, amino, mercapto, 1, 4, 5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, or one of the salts thereof, the solvates thereof, or the solvates of the salts thereof, except the compounds of the formula (la), wherein R 1 represents 2-methy1prop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl or 3-pyridylmethyl, wherein benzyl, - pyridylmethyl and 3-pyridylmethyl can be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, R2 represents 2-methylprop-1-yl, 2,2-dimethylprop-1 - ilo, 2,2-dimethylbut-1-yl, trimethylsilylmethyl, benzyl, 2-pyridylmethyl or 3-pyridylmethyl, where benzyl, 2-pyridylmethyl and 3-pyridylmethyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, and R 12 represents hydrogen or methyl, or one of the salts thereof , the solvates thereof or the solvates of the salts thereof.
4. A compound according to claim 3, characterized in that R1 represents 2-methylprop-1-yl, 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or benzyl, where benzyl may be substituted with 1 or 2 substituents independently selected from the group consisting of halogen, trifluoromethyl and methyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
5. A compound according to claim 3 or 4, characterized in that R3 represents phenyl, benzyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, where phenyl, benzyl, 2-pyridyl, 3-pyridyl and 4-pyridyl may be substituted with between 1 and 4 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, C1-C4-alkyl, d-Gt-alkoxy and CrCi-alkylamino, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
6. A compound according to any of claims 3 to 5, characterized in that R10 represents C6-alkyl, C3-C7-cycloalkyl, phenyl, trimethylsilylmethyl, 2-amino-2-oxoethyl, 2-amino-1- hydroxy-2-oxoethyl, (aminosulfonyl) - (hydroxy) methyl, 2- (C 1 -C 4 alkylamino) -2-oxoethyl or 2- (C 1 -C 4 -alkylamino) -1-hydroxy-2-oxoethyl, where alkyl can to be substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mercapto, 1,4,6,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, and wherein cycloalkyl and phenyl may be substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, C- | - C - alkoxy and CpC - alkylamino, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
7. A compound according to any of claims 1 to 6, characterized in that R1 represents 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, R2 represents 2 , 2-dimethylprop-1-yl, 2,2-dimethylbuM-yl, trimethylsilylmethyl or 3-pyridylmethyl, R 3 represents CVC 4 -alkyl, 3-pyridyl or phenyl, where 3-pyridyl or phenyl may be substituted with a selected substituent among the group consisting of halogen, cyano, methyl, methoxy, dimethylamino and diethylamino, R 4 represents -CH (OH) -CrC 5 -alkyl or -CH (OH) phenyl, where -CH (OH) phenyl may be substituted with 1 and 3 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, d-C4-alkylo, Ci-C4-alkoxy and (4-dialkylamino, R5 represents C Ce-alkyl , C3-C7-cycloalkylmethyl, benzyl or trimethylsilylmethyl, R6 represents C2-C-linear alkyl, where alkyl is substituted with a substitute selected from the group consisting of amino, 1, 4,5,6-tetrahydropyrimidin-2-ylamino and [amino (imino) methyl] amino, R7 represents C Ce-alkyl, C3-C7-cycloalkylmethyl, benzyl or trimethylsilylmethyl, R8 represents C4-alkyl, -CH2-OH, -CH (OH) -CrC5-alkyl or -CH (OH) -phenyl, where -CH (OH) phenyl may be substituted with between 1 and 3 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, CrC4-alkyl, Ci-C4-alkoxy and CVC4-dialkylamino, and R9 represents hydrogen, CrCe-alkyl, hydroxymethyl or 2-amino-2 -oxoethyl, R 0 represents hydrogen, CVC 4 -alkyl, 2-amino-2-oxoethyl or 2-amino-1-hydroxy-2-oxoethyl, where CrC ^ alkyl may be substituted with a substituent selected from the group consisting of amino and hydroxy, with the exception that R10 is not 4-aminobut-1-yl, R represents methyl, where methyl is substituted with a substituent selected from the group consisting of hydroxy and amino, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof , except compounds of formula (la), wherein R 1 represents 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, R 2 represents 2,2-dimethylprop-1 - ilo, 2,2-dimethylbut-1-yl, trimethylsilylmethyl or 3-pyridylmethyl, and R12 represents hydrogen or methyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
8. A compound according to claim 7, characterized in that R1 represents 2,2-dimethylprop-1-yl, 2,2-dimethylbut-1-yl or trimethylsilylmethyl, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof.
9. A compound according to claim 7 or 8, characterized in that R2 represents 2,2-dimethylprop-1-yl or 3-pyridylmethyl, or one of the salts thereof, the solvates thereof or the solvates of the you come out of it
10. A compound according to any of claims 7 to 9, characterized in that R3 represents phenyl, wherein phenyl may be substituted with a substituent selected from the group consisting of halogen, cyano, methyl, methoxy, dimethylamino and diethylamino, or one of the salts thereof, the solvates thereof or the solvates of the you come out of it A compound according to any of claims 7 to 10, characterized in that R8 represents -CHIOOHJ-d-Cs-alkyl or -CH (OH) phenyl, where -CH (OH) phenyl may be substituted with between 1 and 3 substituents independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, Ci-C4-alkyl, CrC4-alkoxy and C1-C4-dialkylamino, and or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. 12. A compound according to any of claims 7 to 11, characterized in that R10 represents methyl, ethyl, 2-amino-2-oxoethyl or 2-amino-1-hydroxy-2-oxoethyl, where methyl and ethyl can be substituted with a hydroxy substituent, or one of the salts thereof, the solvates thereof or the solvates of the salts thereof. 13. Method for preparing a compound of formula (I) according to claim 1, characterized in that [A] a compound of formula wherein R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings indicated in claim 1, is first reacted with a compound of formula wherein R1 and R2 have the meanings indicated in claim 1, Y1 represents fer-butoxycarbonyl or benzyloxycarbonyl, and X1 represents halogen, preferably bromine, chlorine or fluorine, or hydroxy, and then with an acid and / or hydrogenolysis, or [ B] a compound of formula wherein R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings indicated in claim 1, is reacted in p wherein R1, R2 and R3 have the meanings indicated in claim 1, and Y1 represents io-butoxycarbonyl or benzyloxycarbonyl, and then in a 4-step synthesis a) with a fluoride reagent such as tetrabutylammonium fluoride, b) with an acid, c) with a dehydrating reagent, when appropriate in the presence of a base, and d) by hydrogenolysis. The method according to claim 13, characterized in that the compound of the formula (II) is prepared by reaction of a compound of the formula wherein R 4, R 5, R 6, R 7, R 8, R 9, R 10 and R 11 have the meaning indicated in claim 1, first with a compound of the formula wherein R 3 has the meaning indicated in claim 1, and R 13 represents cyanomethyl, p-nitrophenyl, o-nitrophenyl, 2,4-dinitrophenyl, 2,4,5-trichlorophenyl, pentachlorophenyl, pentafluorophenyl (Pfp), N-hydroxyphthalimidyl, N-hydroxysuccinimidyl (O-Su), 1-hydroxypiperidinyl or 5-chloro-8-hydroxyquinolinyl, and then in a 3-stage synthesis a) with an acid, b) with a dehydrating reagent, when appropriate in the presence of a base, and c) by hydrogenolysis. 15. The compound according to any of claims 1 to 12 for the treatment and / or prophylaxis of diseases. 16. Use of a compound according to any of claims 1 to 12 for the preparation of a medicament in the treatment and / or prophylaxis of diseases. 17. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament in the treatment and / or prophylaxis of bacterial infections. 18. A medicament comprising a compound according to any of claims 1 to 12 in combination with an inert excipient, non-toxic, acceptable for pharmaceutical use. 19. A medicament according to claim 18 for the treatment and / or prophylaxis of bacterial infections. A method for controlling bacterial infections in humans and animals by administering an antibacterial effective amount of at least one compound according to any of claims 1 to 12, of a medicament according to claim 18 or a medicine obtained according to the claim 16 or 17.